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SUMMARY
Tuberous sclerosis (TSC) is a dominantly inherited disorder with a high spontaneous 
mutation rate and a birth incidence of 1 in 10,000. It is a systemic disorder characterised 
by the growth of hamartomas, which in turn give rise to the clinical manifestations, for 
example, epilepsy and learning difficulties. Although some patients with TSC are only 
mildly affected and lead a normal life with typical life expectancy, there is an immense 
amount of morbidity associated with this disease. In addition, for the majority of patients 
there is reduced life expectancy. The purpose of this thesis is to look at the clinical 
factors that contribute to the morbidity and mortality seen in TSC and examine means of 
reducing the impact of these factors on long-term outcome. It reports a longitudinal 
population study of a small but defined group of patients looking at the epidemiology and 
natural history (the morbidity and mortality) suffered by in this population. It investigates 
the current treatment regimes for the types of epilepsy (infantile spasms and non- 
convulsive status epilepticus) known to be associated with the highest risk of learning 
difficulties in order to determine the most efficacious treatment for the seizures 
potentially reducing long-term psychomotor delay. A cochrane review of the treatment of 
infantile spasms was performed. This thesis also examines the effect of exogenous 
melatonin on sleep disorders (one of the major causes of morbidity) in tuberous sclerosis 
and the natural circadian rhythms in patients with sleep disorder in TSC and compares 
them with the normal population. Two important causes of premature mortality in TSC 
patients are respiratory and renal failure. This thesis examines the prevalence and 
underlying causes of end stage renal failure in adults with TSC and reviews the literature 
of LAM (in patients both with and without TSC) investigating further the natural history 
and treatment of LAM in TSC.
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Statement of Authors Contribution
This thesis contains a combination of research techniques including the collection of 
epidemiology data, systematic reviews and original research.
Epidemiological data collection
Chapter two looked at the epidemiology, mortality and morbidity of the tuberous sclerosis 
(TSC) population in the Bath Health District. It involved the retrieval and examination of 
the relevant medical records and reports, scrutiny of the Bath TSC data base and 
examination of the individual patients when they attended clinic or were visited for other 
research projects. It was undertaken solely by the author (ECH).
Systematic reviews
There are several systematic reviews included in this thesis.
The first review undertaken by the author was looking at the use of steroids and ACTH in 
the treatment of infantile spasms. This was a simple review using a single database and 
only considering studies published in English, the second review looking at vigabatrin in 
the treatment of infantile spasms in patients with TSC used two databases but again only 
considered studies published in English. A third review searched the English literature for 
all cases of lymphangioleiomyomatosis again used two data bases. All three of these 
reviews were performed solely by ECH.
A fourth review was the cochrane review looking at the treatment of infantile spasms. This 
involved searching several databases, in all languages, corresponding with colleagues, 
authors and drug companies for which ECH was fully responsible and appeals at 
international conferences for which JPO was responsible. ECH was also responsible for 
developing the protocol design, the database of the studies, data collection and extraction, 
data analysis and presentation of the results. JPO and PM had joint responsibility for the 
protocol, data extraction and agreement of results.
Original research
The following pieces of original research have been included in this thesis;
1. The treatment of infantile spasms with high dose oral prednisolone. ECH was 
responsible for developing the study design, collecting eligible patients, retrieving
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and reviewing the medical notes, extracting the relevant data, data analysis and 
presentation of the results.
2. The United Kingdom Infantile Spasms Study. This is a multicenter randomised trial 
looking at the treatment of infantile spasms. ECH was responsible, under JPO’s 
supervision for developing the triai design, protocol and trial packs which were put 
to the trial steering committee for comment and approval. ECH remains closely 
involved with the trial as a member of the trial steering committee. Management of 
data, developmental assessment and analysis are the responsibility of another 
research fellow of Prof. Osborne, Dr Andrew Lux.
3. Oral treatment of non-convulsive status epilepticus in tuberous sclerosis. ECH was 
responsible for developing the study design, collecting eligible patients, retrieving 
and reviewing the medical notes, extracting the relevant data, data analysis and 
presentation of the results.
4. Lymphangioleiomyomatosis and tuberous sclerosis: patient ascertainment. ECH 
was responsible for developing the study design, recruiting patients, retrieving and 
reviewing the medical notes and examining the patients (with the exception of three 
patients (who were seen by Sue Thompson) extracting the relevant data, data 
analysis and presentation of the results.
5. End stage renal failure in adults with the tuberous sclerosis complex. ECH was 
responsible for reviewing the results and writing up the data for this study. The 
study design, data collection and initial assessment were done by Dr Antonia 
Clarke.
6. The effect of melatonin dosage on the sleep disorder in tuberous sclerosis. ECH 
was responsible for developing the study design, including the diaries for data 
collection, recruiting patients, data analysis and presentation of the results.
7. Melatonin excretion in normal children and tuberous sclerosis with sleep disorder 
responsive to melatonin. ECH was responsible for developing the study design, 
including data collection forms, recruiting eligible patients and controls, data 
analysis and presentation of the results.
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Tuberous sclerosis (TSC) is a dominantly inherited disorder with a high spontaneous 
mutation rate and a birth incidence that may be as high as 1 in 10,000\  It is now known to 
be a systemic disorder characterised by the growth of benign tumours (hamartomas), which 
may arise in almost any organ of the body with the possible exceptions of striated muscle, 
the peripheral nerves, the meninges and the thymus gland. Although TSC is an inherited 
disorder it may not always manifest in childhood and clinical features may develop at any 
age. The severity of the disease varies considerably, not only between individuals but also 
within families. This makes genetic counselling particularly difficult as a mildly affected 
parent with normal intellect is at risk of having an affected child who may either be mildly 
affected or have severe learning difficulties, extreme behavioural problems and refractory 
epilepsy.
Over the past century and a half our knowledge of the clinical manifestations and the 
natural history of this condition has increased substantially. Whereas TSC was thought to 
be exceptionally rare, causing severe handicap and early demise, it is now known to be 
relatively common, affecting patients in a wide variety of ways, although it is still 
associated with a high incidence of morbidity and mortality. It is, therefore, imperative that 
clinicians continue to improve their understanding and treatment of this condition, not only 
to maximise longevity but also to allow individuals to achieve their maximum potential.
The very first reference to TSC is probably the illustration drawn by Pierre Rayer in 1835 
representing the facial angiofibroma (see figure one) of TSC. Von Recklinghausen gave 
the first description of TSC in 1862 when he described sclerotic areas in the brain and 
cardiac rhabdomyomas in a stillborn child, who he thought had neurofibromatosis. In 1880 
Boumeville named the condition after accurately describing the potato-like (tuberous) hard 
(sclerosis) cerebral lesions pathognomonic of the disease. Over the following decade 
dermatologists such as Balzer, Menetrier and Pringle made the association between the
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facial rash and mental retardation in individuals found to have the cerebral lesions o f TSC 
at post-mortem.
■  Figure one -
At the beginning of the 20th century pathologists had started to recognise other lesions 
associated with these tubers, in the heart, kidneys and skin and Vogt described the clinical 
triad o f angiofibroma, severe epilepsy and mental retardation as a means o f recognising 
TSC clinically in patients whilst alive; previously the diagnosis had only been able to be 
made posthumously. Unfortunately, this gave rise to the misconception that all three 
features had to be present for the diagnosis to be made, which not only led to under 
recognition o f this disease but failure to recognise (and therefore to treat) the other 
complications o f TSC. However, over the latter half o f the past century it has gradually 
become apparent that the disease is more complex than that originally recognised and can 
affect almost any part o f the body.
In 1920 Berg noted the hereditary nature of TSC and it was soon realised that some 
relatives had the skin lesions without the mental handicap and over the following decades, 
other manifestations o f TSC have been documented. However it was not until Gomez’s 
study in 1967 that it became clear that as many as half o f affected individuals had normal 
intelligence and only one third had the complete Vogt’s triad. This led Gomez2 to publish a 
set o f criteria in 1979, updated by Osborne in 19883, on which the disease could be 
recognised. These diagnostic criteria were divided into three groups.
Diagnostic criteria for the diagnosis of TSC2,3
Primary criteria
These are diagnostic of TSC even in the absence of any other stigmata of TSC
1. Angiofibroma
2. Retinal phakoma
3. Multiple subependymal nodules
4. Multiple cortical tubers
5. Forehead fibrous plaque
6. Shagreen patch
Diagnostic criteria with a first degree relative
1. Subependymal giant cell astrocytoma
2. Cardiac rhabdomyoma
3. Single cortical tuber
4. Single retinal phakoma
Secondary diagnostic criteria
These can occur in unaffected individuals but a combination of two or more implies a diagnosis of TSC 
because of the low risk of more than one occurring in an unaffected individual.
1. Hypomelanic patches
2. Bilateral polycystic kidneys
3. Lymphangioleiomyomatosis of the lung
4. Cardiac rhabdomyoma
5. Renal angiomyolipoma
In 1998 the clinical diagnostic criteria were revised once more by the Tuberous Sclerosis 
Complex Consensus4, yet again reflecting the increasing knowledge and understanding of 
this disorder. It had become apparent that some features previously thought to be 
pathognomonic of the disease, for example cortical tubers could occur in patients without 
TSC, as could renal angiomyolipoma and lymphangioleiomyomatosis. It was also known 
that when these individuals had no other signs of TSC, they did not have children who 
inherited the disorder. Studies of families with a known gene mutation also showed that 
where an individual had a disease causing mutation, they always had convincing signs of 
the disorder and that those with no signs were always unaffected. Penetrance was 
therefore high. The only reclassification in UK families following more traditional 
analysis involved individuals with one possible hamartoma -  usually white patches or a 
single ungula fibroma. Improving the criteria required for diagnosis, would also highlight 
the potential complications of the disease to the clinicians at the time of diagnosis, 
hopefully improving long-term follow up and reducing morbidity and mortality from the 
disease. It was therefore decided;
“A definite diagnosis of TSC should be reserved for patients with two or more distinct types of hamartomas 
rather than multiple lesions of the same type in the same organ system” 4_____________________________
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For the purpose of this definition renal angiomyolipoma and pulmonary 
lymphangioleiomyomatosis are considered as one hamartoma since some individuals with 
these two hamartomas but without other signs of TSC do not pass TSC onto their children. 
It is likely that the clinical criteria for TSC will become less important with the discovery 
of two genes for TSC: it is probable that diagnosis by genetic testing will be available for 
the vast majority of individuals in the near future: it is already possible for up to 70% of 
individuals in the best laboratories.
The diagnosis of TSC was also made easier (and is often made at an earlier age) as the 
result of the introduction of new imaging techniques particularly computerised 
tomography (CT) (1973) and magnetic resonance imaging (MRI) (1980’s). Before such 
techniques were available TSC could often only be recognised clinically if the patient 
developed the skin lesions that are pathognomonic of TSC, for example angiofibroma and 
shagreen patches, or became symptomatic from the hamartomas, for example developed 
seizures, haematuria, or pneumothoracies. With the advent of CT, MRI etc it has become 
apparent that hamartomas may be present in many organs e.g. brain and kidney without 
giving rise to symptoms. For example, it is now known that the vast majority of patients 
with TSC have subependymal calcifications (within the brain) that are easily recognisable 
on CT scan, are present from birth (but may only calcify in the first year of life) and rarely 
occur in the absence of TSC. Before CT scanning was available, if an affected individual 
had a child, or if for example a child developed infantile spasms, only a skull X-ray or air 
encephalogram could be undertaken to look for intracranial lesions. It is also possible to 
perform echocardiography to look for rhabdomyomas: a positive finding would help 
confirm the diagnosis but a negative finding would not help exclude the diagnosis. Only 
30 -50% of TSC patients have rhabdomyomas at birth and they often regress over the first 
few months of life. Likewise ophthalmology confirmation of a retinal phakoma would 
help substantiate the diagnosis, but they are not present in all patients. Nowadays a CT 
brain scan can be undertaken; if subependymal nodules are present it is highly probable 
that the child has TSC. Unfortunately, even with these more advanced imaging techniques, 
it is not always possible to make a definitive diagnosis of TSC. Other conditions such as 
neurofibromatosis type one and some congenital infections can give rise to calcification 
on imaging and grey matter heterotopia (including an autosomal dominant variant 
associated with epilepsy) can give an appearance similar to the non-calcified lesions seen 
in TSC.
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Similarly, many patients with TSC have cysts and/or angiomyolipomas in their kidneys 
but only some have symptoms such as pain or bleeding. Ultrasound scan is a non-invasive 
but useful tool for diagnosing these lesions and in combination with other scanning 
techniques may help to make a diagnosis in a patient who has few clinical manifestations 
of TSC, but it can mislead: “AML” may not be found on further investigation. Renal cysts 
can also be found in normal individuals, it is estimated that approximately 1 in 40 people 
at 40 years of age will have one or more renal cysts.
Note: the majority of the cutaneous manifestations of TSC are not present at birth and may not develop until 
adulthood or rarely may never develop at all.
Genetics
Berg first noted the hereditary nature of TSC in 1920 and it was then recognised to be an
autosomal disorder by Gunther and Penrose in 1935. However, the condition has a high
spontaneous mutation rate accounting for about 60% of affected individuals5. A gene
locus was discovered on chromosome 9q34 (TSC1) by Fryer6 in 1987, but it soon became
apparent that a second gene existed. This was located, by linkage studies, on chromosome
16pl3 (TSC2) in 1992 by Kandt7, and was cloned a year later by Nellist8 who found that
the TSC2 gene lies close to the PKD1 gene. The TSC1 gene was cloned in 1998 by
Young et al9. The exact functions of the two gene products, hamartin (TSC1) and tuberin
(TSC2) are still being researched but both are thought to act as tumour suppressor genes.
A number of tumour suppressor genes are now recognised and molecular studies have shown them to play an 
important role in the regulation of the normal cell cycle. For a tumour suppressor gene to exert a pathological 
influence on a cell, both alleles must be inactivated; the Knudsen10 two hit theory explains why inheriting a 
defective copy of a tumour suppressor gene leads to an individual with multiple tumours. Normally for a 
tumour to arise (in an individual without an inherited or early embryonic defect), two independent somatic 
mutations are required, explaining why sporadic tumours can occasionally arise in a single tissue later in life. 
But, individuals who have already inherited an inactivated tumour suppressor gene only need one further 
somatic mutation to lose both alleles explaining why in TSC the tumours often occur earlier (as early as in 
utero) and tend to be multiple. This may also explain why clinical expression is extremely variable even 
within families, if chance affects the number and timing of second hits. The hypothesis that TSC genes were 
tumour suppressor genes was developed following the demonstration of loss of part of the normal gene in the 
hamartomas of individuals with TSC -  a phenomenon known as loss of heterozygosity.
The TSC1 gene is 8.6kb in length and codes for a protein of at least 1164 amino acids 
called hamartin. The TSC2 gene is larger in size, 45kb in length and codes for a similar 
sized protein, tuberin, 1807 amino acids in length. Both proteins have regions similar in 
structure to the GTPase-activating proteins (GAP) human GAP3 and murine GAP. GTP is 
an energy source required for normal cell growth. GTPase-activating proteins break down 
GTP to GDP, an inactive form, thus inhibiting normal cell growth. It is therefore
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postulated that hamartin and tuberin have a comparable effect to GAP proteins i.e. act as a 
growth suppressor gene. Consequently, if either hamartin or tuberin are deficient or do not 
function correctly there is uninhibited cell growth thus giving rise to the hamartomas seen 
in TSC.
Defects in either gene produce a remarkably similar phenotype, so that at present it is not 
possible to clinically detect which gene is affected in any affected individual, except in the 
rare cases where there is also early onset polycystic kidney disease (PKD) due to a deletion 
on chromosome 16 affecting both the TSC2 and the PKD gene7. However, there have been 
recent suggestions that TSC2 mutations may be seen more commonly in sporadic cases of 
TSC and may be associated with more severe handicap than TSC1 mutations, but further 
research is required in order confirm this hypothesis.
The rapidly increasing knowledge and understanding of molecular genetics may be 
beneficial in aiding diagnosis in this group of patients, but it also introduces new 
dilemmas. Pre-natal diagnosis is now available for families where a disease causing 
mutation has been identified but there is no reason to believe that the test will be able to 
predict the severity of affected individuals. This can lead to increased anxiety when 
choosing whether or not to opt for pre-natal testing and subsequent termination of an 
affected foetus. If the family opt for pre-natal testing, the mutation must be identified 
before the pregnancy and counselling given with preferably both partners together. Pre­
natal testing can also be considered in subsequent pregnancies in individuals with apparent 
new mutations because of the risk of gonadal mosaicism even though the recurrence risk is 
less than about 2%. There is also then the dilemma of whether and when to test apparently 
unaffected individuals within a family. If found to be affected, not only can this be a 
constant source of worry in itself but it can also have financial implications, making it 
difficult, for example to acquire life insurance or a mortgage. On the other hand the 
individual may not want to risk having an affected child, and may opt to be tested as late in 
adult life as possible.
Prevalence
Earliest studies (Critchley and Earl11 1935 and Gunther and Penrose12 1935) investigating 
the prevalence and morbidity in TSC concentrated on small samples of institutionalised 
patients estimating TSC to be a rare disorder affecting 1 in 30 mentally handicapped
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patients. Gunther and Penrose12 also estimated 1 in 1,000 of the population to be 
handicapped giving a prevalence of TSC around 1 in 30,000. By the 90’s, it was well 
known that TSC could present in a multitude of guises and not all sufferers had moderate 
or severe learning difficulties. Consequently several population-based prevalence studies 
were performed in the attempt to provide more accurate information. Unfortunately four of 
the studies involved only small numbers of patients: Wiederholt et al13 1985 gave a 
prevalence of 1 in 10,000 based on only eight patients; Umpathy14 et al 1989 gave a 
prevalence of 1 in 34,000 based on 14 patients, Shepherd15 et al 1991 a prevalence of 1 in 
13,000 based on 12 patients and Ahlsen16 et al 1994 a prevalence of 1 in 13,000 based on 
32 patients.
The first epidemiological study to look at prevalence in different age groups was 
performed by Hunt and Lindenbaum17 in 1984 reporting on 68 patients in the Oxford 
region giving an overall estimated prevalence of 1 in 30,000. They found decreasing 
prevalence with increasing age; 1:10,000 at birth, 1:15.000 under 5 years and 1:20,000 
under 30 years of age. A further study carried out by Sampson et al in Scotland 198918 
looked at 101 patients giving a similar overall prevalence of 1 in 27,000. In 1996 the 
largest population based study to date was published by Webb19 et al totalling 131 known 
affected individuals from a population of 3,400,000 people, most of whom were examined 
for the review, unlike previous studies. They estimated a birth incidence of 1 in 10,000. 
They found only 40% of their patients to have learning difficulties giving a prevalence of 1 




1. Facial angiofibroma (figure one, page eight) affecting the cheeks, nasal folds and chin 
but often sparing the upper lip rarely occur before 2 years, but most often become 
apparent before adolescence and progressively increase in number and prominence. 
They are reported to occur in about 90% of patients with TSC. They result from 
proliferation of the normal dermal tissue with a vascular component giving rise to 
telangectatic nodules, while more fibrous lesions appear skin coloured. Either type 
may become pedunculated20 21.
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2. Shagreen patches (figure two) are usually found in the lumber region of the trunk and 
are a roughened raised area o f skin, often slightly pigmented with a leathery 
consistency. They occur in 20-80%21 of patients and vary considerably in size from a 
few inches to as much as a foot in diameter. They have an irregular edge. Some 
patients wili have a number of smaller, so called “satellite” lesions either in isolation 
or surrounding a shagreen patch.
Figure two -  Shagreen patch
3. Hypomelanic macules (figure three) are best seen with an ultraviolet light (W ood’s 
light), are the commonest and often earliest skin sign of TSC, but are not unique to 
TSC and may occur in healthy individuals3 20. As a general rule the greater the number 
o f hypopigmented patches the higher the risk o f TSC, and the USA consensus 
conference4 felt three was a significant number. Depigmentation may also affect the 
hair (known as poliosis -  figure four) and iris, or occasionally causes a confetti type 
pattern (figure five) usually seen on the proximal limbs. Pathologically, there is an 
absence o f melanosomes within a normal number o f melanocytes (unlike vitiligo). It is 
not clear that these lesions are hamartomas.
Figure three -  Hypomelanic macule
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F ig u re  fo u r  -  Poliosis
F igure  five -  confetti dep igm enta tion
4. Forehead fibrous plaques (figure six) are raised reddish areas o f skin occurring on the 
forehead or scalp and occasionally the face. Unlike the shagreen patch, which has a 
roughened texture, these tend to have a smooth surface3 21. They may be the first skin 
signs o f TSC. Histologically they are angiofibromatous.
5. Fibromas (figure seven) are flesh-coloured nodules commonly occurring in up to 70% 
of patients and may occur around the nails, more commonly the feet than the hands 
(ungual fibromas) or gums. They are a result o f over proliferation o f the dermal
'X 0  1
connective tissue and tend to re-grow after excision
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Figure six -  Fibrous forehead plaque
Figure seven -  Fibroma of nail
Pathological neurological manifestations
1. Cortical tubers (figure eight) are present in almost all cases o f TSC and are traditionally 
shown on T2 weighted images but may be best visualised on flare sequence MRI 
scanning. Macroscopically, the tubers are prominent thickened gyri with an appearance 
not unlike a potato and they may feel hard (sclerotic), hence Boumville's description in 
1880. Histologically they contain dysplastic cells resembling neurones and astrocytes21. 
The number and location o f tubers varies widely and although it appears as though 
there is a relationship between the number o f tubers, the risk o f epilepsy and learning 
difficulties22 23 this does not hold true for an individual. There may also be a correlation 
between position o f the tubers and the clinical manifestations; for example, it has been 
suggested that there is a link between temporal lobe tubers and autistic tendencies24.
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Figure eight -  Cortical tuber (MRI 
FLAIR)
2. Subependymal nodules (figure nine) are best seen on CT imaging although they may 
be missed in the first few months of life before calcification takes place3. They range 
from small nodules to larger or multiple lesions, which may produce a candle-guttering 
effect on the ventricular surface, and are nearly always but not universally present in 
all patients with TSC. Histologically they consist o f a collection o f giant astrocytes and 
look like giant cell astrocytomas, but many have calcified and do not grow.




1. Epilepsy (see later) is a common presenting feature in TSC affecting approximately 
60% 19 25 o f individuals most often beginning in the first two years of life, but can also 
occur in aduits for the first time. Infantile spasms account for about half o f the initial 
seizures with partial and generalised seizures making up the rest26.
2. Severe learning difficulties (SLD) are seen in about 40% o f patients19 25 but rarely in 
the absence of fits1926. Many are also lacking in verbal skills.
3. Behavioural problems are also common in these patients with hyperactivity, associated 
with poor sleep patterns and autistic behaviour predominating27. Self-injury is also 
seen.
4. Giant cell astrocytomas (figure ten) are much more common in TSC patients than the
ORgeneral population and there is a continuing debate as to whether they arise de novo 
or from pre-existing subependymal nodules. They most commonly arise near to the 
Foramen o f Munro and are essentially slow growing and benign but may lead to 
hydrocephalus and raised intracranial pressure if  untreated. They commonly enhance 
with contrast injection on CT scan, unlike subependymal nodules, which do not often
3 • • •enhance . However, if  raised intracranial pressure does occur some larger 
subependymal nodules (usually >l-2cm ) may enhance, leading to arbitrary radiological 
criteria to label such lesions as “GCA pre-symptomatically” .
Figure ten -  Giant cell astrocytoma (CT scan)
The kidney
1. Polycystic kidney disease (PKD) (figure eleven) is more common in patients with TSC 
than the general population. In these patients, the kidneys are bilaterally enlarged with
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numerous cysts from birth and these patients require careful follow up through life as 
they commonly develop hypertension and chronic renal failure. Early onset PKD is 
linked to the TSC2 gene on chromosome 167 and has not been reported in patients 
carrying mutation in the TSC1 gene.
Figure eleven -  Polycystic kidney (USS)
2. Angiomyolipoma (AML) (figure twelve) are highly vascular benign tumours consisting 
o f smooth muscle and adipose cells occurring in 40-80%29 o f patients with TSC. They 
can occur at any age. Many patients remain asymptomatic but in others they may cause 
frank haematuria, pain, give rise to life threatening haemorrhage or occasionally cause 
renal failure.
Figure twelve -  Single renal 
angiomyolipoma (arrowed) (CT scan)
3. Cysts occur separately from PKD in approximately 30%29 of patients with either TSC1 
or TSC2. They may occur independently or coexist with AML. They may arise at any 
age and have been known to resolve spontaneously. They may give rise to similar 
problems as AML.
4. Renal cell carcinomas may be more common than in the general population, and are
considered to arise de novo and not from pre-existing AML29. Their significance in
TSC was highlighted by the discovery that the Eker rat (an animal model for renal cell
carcinoma) has an inherited mutation in the rat TSC 2 gene30.
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The heart
1. Cardiac rhabdomyomas (figure thirteen) occur relatively frequently (30-50% of
2 1 # # 
cases ) but rarely cause symptoms. If  they do, it is usually in infancy when they can
cause cardiac failure (and even death) from arrhythmia or obstruction. Unlike the other
clinical manifestations o f TSC that become more common with increasing age, these
seem to shrink in size and even disappear with time, often disappearing rapidly, within
weeks or months o f birth. They can be demonstrated by echocardiography3 and larger
lesions may even be visualised in utero, usually in the third trimester. They can arise
anywhere in the heart and may grow up to several centimetres in size as smooth but
firm benign tumours. Histologically they are composed o f large myocardial cells with
large intracytoplasmic spaces .
1 0  B B /n iJ
Figure thirteen -  Cardiac 1 large square = 0.2 sec
Rhabdomyoma (Echo) (arrowed) in Figure Fourteen -  WPW (ECG) 
right ventricle. LV = left ventricle
2. W olff Parkinson White syndrome (WPW) can also occur in TSC, though it is rare. It has
a typical electrocardiogram ECG pattern with a short PR interval and a wide QRS 
complex that begins as a slurred upwards deflection known as the delta wave (figure 
fourteen). WPW may predispose to supraventricular tachycardias, which in turn may 
lead to heart failure or sudden death.
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The lung
Changes resembling pulmonary lymphangioleiomyomatosis (LAM) have been described 
as occurring in about 1% o f TSC sufferers. LAM is a rare cystic lung disease (figure 
fifteen) that is usually considered generalised and progressive. It can be extremely difficult 
to treat and is generally considered to have a poor prognosis. It is almost exclusively 
reported to occur in women o f childbearing age, the commonest presentation being 





Retinal phakoma (figure sixteen) are benign astrocytomas arising from the retina. They 
often calcify with age but rarely cause problems unless they occur in the macular region.




Bony changes include cysts and sclerosis, but the incidence is unknown as they are usually 
asymptomatic.
Epilepsy
In its simplest form an epileptic seizure (fit or convulsion) can be defined as an abnormal 
paroxysmal electrical discharge of cerebral neurones. However, in reality epilepsy 
encompasses a vast array of clinical symptoms and signs with poorly understood 
underlying pathophysiology. As a consequence the many attempts to classify epileptic 
seizures and syndromes over the past century have often been confusing and misleading. 
The current classification, Commission on Classification and terminology of the 
International League Against Epilepsy31 (ILAE), is based on the clinical manifestations of 
the seizures experienced together with findings from electroencephalogram (EEG) 
investigation and, whilst this classification does assist in communication between 
professionals in both the clinical and research setting, it is less helpful in determining the 
cause, prognosis or how the patient is best treated. It is likely that with time, as our 
understanding of the underlying pathophysiological processes that take place in epileptic 
seizures improves, particularly with regard to the chemical substrates involved, the 
classification will evolve and become more useful in determining which treatments are 
most likely to benefit the patient.
A further sub-classification divides epileptic seizures into three main groups; partial, 
generalised and unclassified. The first two groups are then further sub-divided. However 
this classification fails to make use of all the information available to physicians to 
describe epileptic seizures and a second classification has been devised by the ILAE31. 
This defines syndromes that are epileptic disorders characterised by a cluster of signs and 
symptoms occurring together, are often age related, may be inherited, and may have 
characteristic histories and results on investigation.
Although most types of epileptic seizures can occur in patients with TSC the most common 
are infantile spasms, partial seizures, tonic clonic seizures, and myoclonic seizures. 
Akinetic and drop attacks, status epilepticus and non-convulsive status epilepticus also 
occur in these patients. True three per second spike and wave absence seizures (previously 
called petit mal epilepsy) are very rare, probably arising in those with TSC only by chance.
22
It is probable that in TSC all seizure types are partial in onset (with many becoming rapidly
secondarily generalised), with the cortical tubers acting as epileptigenic foci, whatever the
•  •  00seizure semiology. Even in infantile spasms it has been suggested by Curatolo that the
seizures may arise in one frontal lobe but spread so fast that ordinary EEG methods 
suggest the seizure arose in both hemispheres simultaneously.
Infantile spasms (also known as West’s syndrome)
This is an age related epileptic syndrome, usually but not exclusively, comprising the triad; 
clinical manifestation of spasms, psychomotor retardation and hypsarrhythmia (see chapter 
three). The onset of spasms is almost exclusively during the first year of life with a peak 
between four and seven months. The spasms consist of a brief and sudden stiffening of the 
body. Most commonly there is flexion of the head, bending of the knees and abduction of 
the arms. However extensor spasms also occur as well as more subtle spasms that might 
for example affect the head only. Each individual spasm usually lasts clinically for less 
than a second but they tend to occur in batches ranging from a few, to hundreds of spasms 
occurring in quick succession. They often take place as the infant is waking or falling 
asleep and may be associated with a cry. Hypsarrhythmia is the term given to a 
characteristic highly chaotic, high voltage pattern seen on EEG pathognomonic for this 
syndrome. There are many underlying etiological factors that may predispose to the 
development of infantile spasms but in as many as 30% of cases no cause in found. The 
vast majority of infants diagnosed as having infantile spasms will develop psychomotor 
retardation. Treatment of the spasms has been notoriously difficult with steroids and 
benzodiazepines forming the mainstay of treatment over the past fifty years or so. More 
recently, vigabatrin, one of the new generation of anticonvulsants has been shown to be 
efficacious in treating spasms in a large proportion of these patients. Refractory epilepsy of 
other seizure types is common in this group and there is increasing interest in the role of 
epileptic surgery in those patients shown to have an epileptic focus for the propagation of 
their spasms.
Partial seizures
Partial seizures are those that arise from a focal area of the brain (as opposed to generalised 
seizures which involve the whole brain simultaneously). It may be difficult to distinguish 
between focal seizures that rapidly become secondarily generalised and primary 
generalised seizures clinically but investigations such as EEG or telemetry (prolonged
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video EEG) may help to differentiate between the two. Some partial seizures do not 
generalise, or do so only slowly. Partial seizures have a range of manifestations; motor, 
sensory, behavioural or autonomic (previously called psychomotor or temporal lobe 
epilepsy). In simple partial seizures there is no significant loss of consciousness, whilst in 
complex partial seizures there is. Some or all types of partial seizures may be present in 
any one individual.
Typical simple partial motor seizures involve a limb or one half of the face and consist of a 
clonic movement (a sudden contraction, followed by slow relaxation of the affected 
muscle). The seizure may be confined to one area or appear to move along the limb -  a 
phenomenon known as a Jacksonian march. Weakness of the affected limb(s) may follow, 
lasting minutes to hours -  a phenomenon known as Todd’s paralysis.
Complex partial seizures are often (though not always) associated with a temporal lobe 
focus. In TSC in particular they are often frontal and can be occipital or parietal in origin 
(possibly reflecting the position of tubers). The clinical features are wide-ranging and often 
specific to the individual. They may include olfactory, auditory and even visual 
hallucinations, which are accompanied by automatisms such as chewing, swallowing, 
fumbling or doing repetitive movements whilst mumbling in a confused state.
Response to treatment is variable and resistance is not uncommon particularly in complex 
partial seizures. Surgery should be considered in those shown to have a single epileptigenic 
focus that continue to have refractory epilepsy.
Primary generalised tonic clonic seizures
These seizures affect the whole brain simultaneously. Clinically, onset is sudden and 
without warning, with a tonic phase during which the patient become rigid and may appear 
to stop breathing. This is rapidly followed by the clonic phase; the patient falls to the 
ground with jerking movements affecting the whole body symmetrically: there may be
associated urinary or faecal incontinence and an increase in secretions giving the
\
appearance of foaming at the mouth. This phase can last a variable amount of time and 
there is loss of consciousness throughout. The patient then regains consciousness but often 
falls asleep for a period of time: the post-ictal phase. A large choice of drugs is now 
available for this type of seizure, though many have adverse side effects. It is often a 
matter of trial and error to discover which treatment best controls the fits without causing 
unacceptable side effects in any individual patient. Surgery is not usually an option in these
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patients. Secondary rapidly generalised partial seizures are probably the usual aetiology of 
apparent generalised tonic clonic seizures in TSC and are best treated as such.
Myoclonic seizures
These are a type of generalised seizure (i.e. the whole brain is affected simultaneously). 
They have a sudden onset without warning, tend to be very brief and may affect any 
muscle group. Sometimes there is loss of consciousness associated with a sudden 
contraction of the muscles resulting in the patient been thrown to the ground with some 
considerable force. These are known as “drop attacks” and frequently result in injury, 
especially to the face and head. Treatment is problematic and it is not uncommon for these 
fits to be refractory to treatment. Akinetic attacks resemble drop attacks in as much as there 
is loss of consciousness and the patient drops to the ground, but in these seizures there is 
sudden and total loss of muscle tone rather than forceful contraction of the muscles.
(Convulsive) status epilepticus
This is usually defined either as convulsions lasting longer than a given time (most often 
thirty minutes) or successive convulsions such that the patient does not recover 
consciousness between them. This term encompasses any type of seizure but it most 
commonly presents as generalised tonic clonic seizures. Treatment of status epilepticus is a 
medical emergency requiring both resuscitation and support of the patient as well as 
pharmacological control of the fits.
Non-convulsive status epilepticus (NCSE)
Non-convulsive status epilepticus is a rare but severe type of epileptic seizure (see chapter 
six) in which there is ongoing seizure activity within the brain (this can be seen on the 
EEG recording), but it may not be obvious that the patient is having a seizure. For 
example, there may not be any visible jerking of the limbs and the patient may be partially 
aware of their surroundings, however on closer examination the patient may have clinical 
features such as drooling, dilating and/or constricting pupils, sweating and palpable jerks. 
NCSE most often occurs in patients who already have epilepsy that is difficult to control. It 
most commonly occurs in patients with other seizure types (past or current) such as 
infantile spasms or Lennox-Gastaut syndrome or other neurological conditions such as 
TSC. Long periods of NCSE can interfere with development, education and well-being.
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The traditional treatment is the intravenous administration of diazepam, which requires 
hospital admission.
Generalised 3/sec spike and wave
These are a type of generalised seizure consisting of momentary loss of awareness and 
responsiveness with a corresponding cessation of ongoing activity. There may be 
associated clonic movements of the eyelids (at three cycles per second) and more rarely of 
the face or a change in postural tone with either rolling of the eyes (increased) or slumping 
of the arms and shoulders (decreased). Automatisms are seen in about 60% of cases. They 
are often associated with triggering factors such as hyperventilation, tiredness or emotion. 
Recovery is quick and they are rarely associated with a post ictal phase. Diagnosis is often 
delayed because the events are put down to ‘day dreaming’, but once it has been made 
many respond to sodium valproate or ethosuximide. The vast majority also resolve with 
time and it is rare for them to continue into adult life (although other types of epilepsy may 
occur). They are usually due to childhood or juvenile absence epilepsy, both genetic 
syndromes. Typical absence seizures rarely occur in patients with TSC, as they are genetic 
in origin and are truly generalised seizures. They do not result from secondary 
generalisation from a focal epileptic focus whether acquired, e.g. head injury, or inherited 
or in TSC.
Morbidity and mortality in tuberous sclerosis
Although some patients with TSC are only mildly affected and lead a normal life with 
typical life expectancy (a few may never even be aware that they are affected) there is an 
immense amount of morbidity associated with this disease. In addition, for the majority of 
patients there is reduced life expectancy. The purpose of this thesis is to look at the clinical 
factors that contribute to the morbidity and mortality seen in TSC and examine means of 
reducing the impact of these factors on the long-term outcome.
There have been few studies investigating the morbidity and mortality in TSC. The two 
early studies by Critchley and Earl11 1932 and Gunther and Penrose12 in 1935 concentrated 
on small populations of institutionalised patients giving biased results. Over the past 15 
years population based studies have been performed but they have either been based on 
small numbers of patients (less than twenty) or have concentrated on issues other than 
morbidity and mortality. Two studies have been carried out looking at morbidity in a large
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geographically defined area with a known population of TSC sufferers: Shepherd et al 
1992 who looked at the prevalence of TSC in the West of Scotland and then more 
specifically at the associated seizures and intellectual disability; Webb et al19 1994 who 
looked at the prevalence of TSC in the Wessex region and the related morbidity, 
neurological and other. The largest study looking at the causes of death in TSC is that of 
the Mayo clinic (1991) who studied a series of 355 TSC patients32.
Both Shepherd26 and Webb19 25 found seizures and mental retardation to be the major 
inextricably linked causes of morbidity affecting up to 80% of the TSC population. There 
are only a few cases of patients who have learning difficulties without a history of epilepsy 
reported in the literature. In addition, the age of seizure onset correlates with long-term 
prognosis for psychomotor development. Children who have not developed epilepsy by the 
age of five rarely regress and are more than likely to have normal intellectual outcome. 
None of the patients studied by Shepherd26 or Webb19 25 who developed epilepsy over the 
age of five had psychomotor delay.
Seizure type is also an important prognostic factor for long term psychomotor 
development, with infantile spasms (IS) most commonly associated with a poor outcome. 
Webb19 25 et al found that 94% of infants who developed IS subsequently were shown to 
have severe learning difficulties. Likewise, Shepherd26 found that seventeen out of 
eighteen infants presenting with IS had impaired intellect as compared with thirteen out of 
thirty presenting with other seizure types. They also found that learning difficulty is more 
common in those that have poor seizure control. IS also account for over half of the 
primary seizure type in patients with epilepsy and TSC. Although it is not possible to 
change the age of onset (peak 4-7 months of age) it might be possible to reduce the long­
term psychomotor delay either by improving the treatment of these seizures (both in term 
of number of patients in whom control is attained and the speed at which this control 
occurs) or by preventing the onset of the spasms from occurring.
However, some believe that mental retardation and epilepsy are not so closely linked. They 
believe that it is the number and possibly, more specifically, the location of tubers which 
give rise to the cognitive defects in patients with TSC not the onset of epilepsy. One study 
has shown that nine patients with tuberous sclerosis considered to have normal intelligence 
(Average IQ = 99) were significantly more prone to having specific cognitive difficulties
27
on detailed neuropsychological testing than controls. Only three of their patients also 
suffered from epilepsy33. Nonetheless, this does not explain the developmental regression 
seen in those developing seizures although it is probable that in most cases it is the tubers 
that give rise to the epileptic foci.
Psychomotor regression is rarely seen in patients developing epilepsy after the age of five. 
This regression usually results from the development of NCSE that continues either 
unrecognised or untreated for long periods of time leading to prolonged periods of 
impaired consciousness that can interfere with development, education and well being. The 
problem is that the attacks are often frequently recurring and require hospital admission for 
treatment. Not only is there a delay whilst admission to hospital is arranged but the 
admission itself may result in interruption to education. If the parents could be taught to 
recognise the episodes of NCSE early and administer treatment at home that aborted these 
attacks, further regression might be prevented and improved education and well-being 
would result.
Also associated with TSC and learning difficulties is a high incidence of behavioural
•  17 •problems coupled with poor sleeping patterns. In a study, carried out by Hunt in 1993, 
60% of parents reported refusal to go to sleep, early wakening and nocturnal hyperactivity 
in children with learning difficulties as the hardest problems to cope with. A study 
performed in Sweden16 also found that most of the children had behavioural problems such 
as autistic traits, hyperactivity, poor sleep, aggression and self-harm. The main difficulty is 
that these children also respond poorly to traditional sedatives (often becoming even more 
hyperactive) or to behaviour modification techniques. Melatonin, a natural hormone that is 
available in synthetic form, has been shown to improve sleep in blind children with 
developmental delay and may therefore be of benefit in children with TSC.
In Shepherd’s32 review of the causes of death in 355 patients with TSC, forty had died 
from their disease (nine others died from unrelated causes). Renal disease was the 
commonest cause of death (twelve patients); seven died of renal failure, three of carcinoma 
and two of haemorrhage from angiomyolipoma. To date no study has been carried out in 
the United Kingdom (UK) to look at the incidence of end stage renal failure (ESRF) in 
TSC or its clinical presentation and no paper has reported the underlying pathology in 
these patients. Ten of Shepherd’s patients died as a result of brain tumours, four died of
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pulmonary complications (LAM) and two infants died as a result of cardiovascular disease. 
Of thirteen patients with severe handicap, nine died as a result of status epilepticus, the 
other four from bronchopneumonia. It is important, when interpreting these results to note 
that approximately 60% of patients with TSC have renal complications compared to only 1 
-3% of patients who are known to have pulmonary complications and as Shepherd 
concluded in his paper; “the prognosis associated with pulmonary TSC is less favourable 
than that associated with other organ involvement in TSC; a higher percentage of patients 
died of TSC with lung disease than with heart, kidney or brain involvement”. Despite this, 
there is very little in the literature about the pulmonary complications of TSC both in terms 
of its clinical presentation and association and in terms of treatment and long-term 
prognosis.
The causes of premature mortality also seem to be age related in TSC. Cardiovascular 
disease, usually arrhythmia or cardiac failure resulting from rhabdomyomas, less 
commonly WPW syndrome leads to death in the infant or young child. GCAs most 
commonly occur between the ages of ten and twenty whilst deaths from lung disease rarely 
occur under the age of forty. Death from renal disease is also rare under the age of ten and 
is again age related with respect to the underlying pathology; infants with PKD are often 
affected earliest with renal failure occurring in the first to second decade of life; AMLs 
causing haemorrhage become more frequent with increasing age and renal carcinomas tend 
to occur in older patients (though often at a younger age than the general population)34.
Aims
The aims of this thesis were:
1. To report a longitudinal population study in a defined group of patients looking at the 
epidemiology and natural history as well as the morbidity and mortality suffered by 
this population.
2. To investigate the current treatment regimes for the types of epilepsy (infantile spasms 
and NCSE) known to be linked with the highest risk of associated learning difficulties 
to try and determine which are most efficacious in treating the fits by;
> reviewing the treatment of infantile spasms with high dose prednisolone,
> reviewing the use of vigabatrin in the treatment of infantile spasms in TSC,
> setting up the United Kingdom Infantile Spasm Study (UKISS) to compare the efficacy
of steroids and vigabatrin in treating infantile spasms,
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> undertaking a Cochrane review comparing all medical treatments of infantile spasms in 
terms of seizure control,
> looking at oral treatments of non-convulsive status epilepticus in TSC.
3. To investigate whether any treatment regime is more efficacious at reducing the 
incidence of
long-term psychomotor delay in these patients by;
> setting up UKISS to compare the efficacy of steroids and vigabatrin in terms of long 
term developmental outcome,
> undertaking a Cochrane review: comparing all medical treatments of infantile spasms 
in terms of long-term developmental outcome.
4. To determine if any treatment regime might be used to prevent the onset of seizures 
and so prevent subsequent psychomotor delay and to develop a possible model for a 
prophylactic trial.
5. To investigate the effect of exogenous melatonin on sleep disorders in tuberous 
sclerosis by;
> reviewing the literature on the use of melatonin in sleep disorders,
> looking at the use of melatonin in treating the sleep disorder of TSC.
6. To investigate the natural circadian rhythms in patients with sleep disorder in TSC and 
compare them with the normal population by;
> examining at the rhythms of melatonin excretion in children with TSC and sleep 
disorder and to determine the normal excretion pattern of melatonin in children without 
TSC.
7. Two important causes of premature mortality in patients are respiratory and renal 
failure;
> to examine the prevalence and underlying causes of end stage renal failure in adults 
with TSC.
> to undertake a review of the literature of LAM in patients both with and without TSC.
> to investigate further the natural history and treatment of LAM in TSC.
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CHAPTER TWO
A Ten Year Review of the Epidemiology, Morbidity and Mortality of the 
Tuberous Sclerosis Population in the Bath Health District
In 1996 our group published the first large population based study19 of 3,400,000 people 
finding 131 known individuals with TSC in the Wessex region, most of whom were 
examined for the review, unlike previous prevalence studies. It was also the first review to 
look at both the epidemiology of this condition and the morbidity associated with TSC, 
other than seizures and learning disability, which had previously been described.
Aim
To report a longitudinal population study in a defined sub-group of the Wessex study to 
improve information about the epidemiology and the natural history of this condition, in 
particular the morbidity and mortality suffered by this population.
Patient selection
Index cases were identified as patients ordinarily resident, within the Bath Health District 
Authority between the 31st August 1986 and 31st August 1996. Gomez’s criteria2, updated 
by Osborne were used to confirm a diagnosis in those patients given a diagnosis of TSC 
on 31st August 1986, whilst the newer criteria of two hamartomas in two distinct organs4 
was used for those given a diagnosis of TSC on 31st August 1996 (see chapter one).
Method
Since 1985 patients suffering from TSC in the Bath district have been identified by one of 
us (JPO) and followed either regularly in clinic, or if they preferred, followed only if they 
developed symptoms. Those not seen in clinic have been reviewed by checking their notes, 
writing to their General Practitioners (GPs) as well as involving them in research studies. 
Initially in 1986 there was a systematic search as previously reported19: since then we have 
relied on the existence of the TSC clinic, which is well known in the district, as a source of 
referral. The patients’ progress is reported up to August 1996. Patient details include 
findings from at least one detailed history and examination, and where possible results 
from Woods light examination, direct fundoscopy, cranial CT or MRI scan, renal
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ultrasound scan (USS) and echocardiography, supplemented by further investigation as 
indicated.
Normal intellect was defined using Webb et al’s definition used in the original cohort of 
patients defined in 1996: patients able to talk, read, write and undertake self care e.g. 
dressing, feeding and toileting were assumed to have normal intellect19.
Results
Prevalence and incidence
In Webb et al’s ascertainment in 198619 there were 19 patients with TSC resident in the 
Bath district. Since that time:
• Three patients have had their diagnosis withdrawn as a result of the new diagnostic 
criteria. One patient has bilateral renal AML but no other stigmata of TSC. The other 
two patients belong to a large family with TSC affecting five generations. One had a 
single ungual fibroma (which has since disappeared) the other was thought to be an 
obligate carrier, but this is now known not to be the case; the other affected members 
of this family all have proven gene defects which these two individuals do not have35.
• Two patients who were present in 1986 have been subsequently ascertained.
• Five patients have been bom since 1986 and subsequently diagnosed as suffering from 
TSC; three had a strong family history (though one was a new mutation); two are 
sporadic cases.
• One patient has moved into the Bath district.
This brings the total number of known patients in the Bath district on 31st August 1996 to 
24, giving a total of 200 patient years of observation and 628 patient years of existence.




Known TSC patients in 1986 19 190 673
Diagnosis withdrawn -3 -30 -116
Diagnosed post 1986 2 8 34
Bom into Bath district 5 30 30
Moved into the Bath district 1 2 7
24 200 628
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Bath Health District covers a population of -417,000 people (1996) giving an estimated 
prevalence of TSC of 1:17,000 (5.3 per 100,000).
In the Bath district there are approximately 5,500 live births per annum giving an estimated 
birth incidence of 5:55,000 or 1:11000.
Population
The mean age has remained static at around 26 years over the ten-year period, but the age 
at diagnosis has decreased from 18.8 years to 15.5 years. There were no deaths recorded 
during the ten-year period.
In 1986 there was a predominance of affected females of 1.7:1 but in 1996 there were 
equal numbers of affected males and females.
Genetics (table one)
In 1986 ten patients had an affected parent (although nine of these were from one family) 
and nine were sporadic cases i.e. neither parent affected, this gives a spontaneous mutation 
rate of 47%. In 1996 nine patients had an affected parent (again eight were from the one 
family) and fifteen were sporadic cases, giving a spontaneous mutation rate of 63%.
Ideally for a diagnosis of TSC to be excluded in the parents, there should be absence of 
skin and eye signs and a normal CT Brain. At one time, a renal ultrasound was also 
performed but this is now thought to be unhelpful (due to regular normal occurrence of 
renal cyst(s) in adults) and is no longer routinely performed36. 46% of parents chose or for 
other reasons could not be examined and / or screened.
In Bath three patients have had the diagnosis of TSC withdrawn over the past ten years; 
one had bilateral renal AML and according to Osborne’s contemporary criteria3 fitted the 
criteria for TSC, but with the modification of these criteria, it is now recognised that 
bilateral renal AML can occur independently of TSC37 and with no other stigmata present 
















2 V V V V V V
3 V V V V V V V V
4 V V
5 Not screened Died before patient diagnosed
6 Not screened Not screened
7 V V V V V V V V
8 V V V V V
9 Not screened Not screened
10 Not screened Not screened
11 V V V V V V V V
12 V V V V V V
13 Patient adopted - not in contact with biological parents
14 Not screened Not screened
15 V V V V V
CT = computerised tomography, USS = ultrasound scan. 
Table showing how TSC was excluded in the parents of sporadic cases. For 
the diagnosis to be definitely excluded skin and ophthalmological and CT 
investigations should be performed but some parents declined.
The other two patients belong to a large family that was known to carry the TSC 2 gene in 
1988 (pedigree one).
Fryer et al first reported this family in 1987 as “a family where tuberous sclerosis has 
probably affected five generations, but where none of the members has been mentally 
retarded and there is no history of seizures”. At that time it was thought that TSC was 
caused by a single gene mutation and in the same year a gene locus was discovered on 
chromosome 9 (TSC l)6. Since then six children have been bom into the family.
In 1987 IV.3’s first son (V.l) was found to have echo dense lesions on his echocardiogram.
Initially it was thought that these were rhabdomyomas, placing him at high risk of
suffering from TSC. He was re-scanned a year later, and in retrospect, with the increased
experience and knowledge in this area, the lesions were not thought to be rhabdomyomas.
Although he has not undergone cranial imaging, he has no fits, learning difficulties or
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neurocutaneous manifestations of TSC and Woods light examination, renal USS and 
fundoscopy have all proved negative so far, making the diagnosis unlikely. He has now 
been shown not to have the mutation in TSC1 which his mother and brother have (JPO 
personal communication).
In 1988 IV.6 (previously thought to be unaffected) had her first child (V.4). At the age of 
13 months V.4 developed epilepsy following his measles, mumps and rubella (MMR) 
vaccination. He subsequently went on to develop severe learning and behavioural 
difficulties. On investigation he was found to have subependymal nodules, bilateral renal 
AML and retinal phakomas in both eyes. He has also developed angiofibroma and 
hypomelanic patches leading to the unequivocal diagnosis of TSC. IV.6 was extensively 
investigated: CT and MRI brain, renal USS, echocardiogram and examination of the skin, 
including Woods light were all negative. It was therefore reported that this family 
contained an individual (III.3) with minimal expression (under the diagnostic criteria in use 
at that time III.3 was thought to have TSC as he had a first degree relative and a single 
ungual fibroma: under the current criteria he would not be considered to suffer from TSC) 
and an individual with non-penetrance39. IV.5 has also subsequently been investigated as 
IV.6 and found to not be affected. V.4 was therefore the first member of this family now 
spanning at least six generations to suffer from epilepsy and learning difficulties. However, 
it had become apparent that a second gene existed and its location on chromosome 16pl3
7 ft(TSC2) was discovered in 1992 by Kandt, and was cloned a year later by Nellist. The 
TSC1 gene was then cloned in 19979. This family has since undergone DNA testing and all 
definitely affected members found to carry TSC1 mutation except V.4 who has been found 
to have a TSC2 mutation, IV.6 and her father (III.3) tested negative for both gene defects. 
We now believe V.4 to be a sporadic mutation occurring within this family carrying the 
TSC gene. Interestingly, the hypothesis that the clinical phenotype of TSC1 is not as 
severe as TSC2 is compatible with the information from this family.
IV.6 (in 1989) had another son (V.5) in 1989 who appears, as yet to be unaffected.
In 1990 V.2 was bom to IV.3. He was found to have three rhabdomyomas on 
echocardiogram at two weeks of age, a repeat echocardiogram at seven weeks showed 
them to have regressed without causing any symptoms, a phenomenon increasingly 
recognised in this condition. He has also subsequently been shown to have tubers on MRI
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imaging and AML on renal USS. He developed seizures and also has mild learning 
difficulties and behavioural problems, though not as severe as V.4.
In 1993 IV.3 had her third son V.3. He was admitted to the neonatal intensive care unit on 
the first day of life following a cyanotic episode on feeding. An ECG showed WPW 
syndrome coupled with SVT; echocardiology showed a rhabdomyoma on the aortic valve 
causing outflow obstruction. Initially he was successfully treated with diuretics and 
digoxin, but by two months of age continuing attacks of aortic obstruction required 
surgical removal of his rhabdomyoma which had not decreased in size. He has since gone 
onto develop a shagreen patch, confirming the diagnosis of TSC.
The sixth boy to be bom into this family is V.6. At the time of IV.6 pregnancy with V.6 it 
was still believed that she could be an obligate carrier. In the third trimester she 
experienced some abnormal foetal movements, which she described as repetitive jerking 
movements. Although fits starting in utero had not been previously described in TSC, with 
the family history, this was the concern. After lengthy discussion with the parents it was 
decided to undertake an antenatal MRI scan to try and establish whether or not the baby 
was likely to be suffering from TSC. It was performed at 36 weeks gestation. The foetus 
was sedated by giving IV.5, the mother, an oral sedative of lOmg diazepam approximately 
20 minutes before the scan. T1 weighted images of the foetal brain were obtained in axial, 
sagittal and coronal planes. Good quality images were obtained but (now unsurprisingly) 
no abnormalities were detected. V.6 is now eighteen months old and has no stigmata of 
TSC.
Referral patterns (table two)
The referral patterns are summarised in table two and are given for all 24 patients who 
have resided in the Bath district over the past ten years. In the last ten years, seven new 
patients have been diagnosed. Two were brothers bom into a family with a family history 
of TSC spanning five generations; both had skin stigmata confirming the diagnosis. In 
addition, the younger son also had a cardiac rhabdomyoma that was diagnosed on the first 
day of life. Four others presented with epilepsy and were found to have either skin stigmata 
and/or an abnormal brain scan (one also had a strong family history). The final patient was 




Other features Total (n=24)Referral Diagnosis
Affected relative 7 (29%) - - -
Incidental referral 1 (4%) - - -
Epilepsy 12 (50%) - 16 (67%) 16 (67%)
Abnormal brain scan - 7 (29%) 4 (17%) 11(46%)
Giant cell 
astrocytoma
- - 1 (4%) 1 (4%)
Developmental delay - - 10 (42%) 10 (42%)
Behavioural
problems
- - 8 (33%) 8 (33%)
Cardiac disease - 2 (8%) 2 (8%) 4 (17%)
Renal disease 2 (2%) 2 (8%) 12 (50%) 14 (58%)
Lung disease - 1 (4%) - 1 (4%)
Retinal phakoma - 3 (12.5%) 4 (17%) 7 (29%)
Skin signs 4 (17%) 23 (96%) 1 (4%) 24 (100%)
Table showing the referral patterns for the diagnosis of TSC (N.B. some 
patients may have had more than one reason for referral).
Skin stigmata (table three)
All 24 patients in Bath have skin signs, but this was not always true at presentation. The 
most common dermatological features are facial angiofibroma, hypomelanic macules, 
shagreen patches and ungual fibroma.
Table three
1986 (n=I9) 1996 (n=24)
Facial angiofibroma 16 (84%) 22 (92%)
Hypomelanic macules 10 (53%) 15 (63%)
Forehead plaque 7 (37%) 10 (42%)
Shagreen patch 9 (47%) 12 (50%)
Confetti 2(11%) 3 (13%)
Poliosis 2(11%) 4 (17%)
Nail fibroma / ridging 12 (63%) 14 (58%)
Gum fibroma 2(11%) 2 (8%)
Table showing the skin lesions experience by the 24 patients. All 24 patients 
had skin stigmata of TSC. The two patients who did not have angiofibroma 
both had a shagreen patch.
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Retinal phakoma
Nineteen patients have had their retina examined by fundoscopy, eight (42%) of whom 
were found to have retinal phakoma. One patient was also found to have amblyopia, which 
may have arisen as a result of his phakoma overlying the macula and interfering with the 
development of vision. Another patient is known to have a squint.
Seizures (table four)
In 1986 eight (42%) patients had suffered from epilepsy, by 1996 fourteen patients (58%) 
had a diagnosis of epilepsy. Equal numbers of males and females are affected.












F 12 Weeks GTC CPS, Absence, 
NCSE, Drop
Y Refractory Y
F 4 Months IS GTC, CPS Y ~ 2 / year Y
F 4 Months IS Focal N Stopped N
F 11 Months GTC None Y Stopped N
F 5 Years CPS GTC N Controlled N
F 5 Years GTC None N Controlled N
F 18 Years CPS None N Stopped N
M 1 Month Focal IS, GTC, Absence, 
Drop, NCSE
Y Refractory Y
M 6 Months IS GTC, Absence Y Refractory Y
M 7 Months IS Absence Y Controlled Y
M 8 Months GTC Focal N ~2 / year N
M 9 Months IS None Y Stopped Y
M 13 Months GTC Absence Y Refractory Y
M 18 Months Absence None Y Refractory Y
LD = moderate I severe learning difficulties, IS = infantile spasms, GTC = 
generalised tonic clonic, CPS = complex partial seizures, NCSE + non- 
convulsive status epilepticus, Y = Yes, N = No.
Table showing patient gender, age at onset of seizures, the type of seizure at 
onset, other seizure types experienced, presence or absence of moderate or 
severe learning difficulties and behavioural problems and the outcome of 
the seizures.
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There were many seizure types recorded with many patients experiencing more than one 
type. In total five patients had infantile spasms (IS), five had primary generalised tonic 
clonic seizures (GTC), one had atypical absence, two had complex partial (CPS), and one 
focal seizures as their first seizure type.
Outcome of seizures (table four)
Five patients had IS as their primary seizure type with onset under one year of age. All 
these patients developed further seizure types and all but one have severe learning 
difficulties.
In total eleven patients had onset of seizures before the age of five. Nine have moderate to 
severe learning difficulties. The three patients in whom the seizures started after the age of 
five, and the ten patients who have never suffered from fits, all have normal intellect (as 
defined by Webb).
Seven females have suffered from epilepsy, in five the fits have either stopped or are 
completely controlled by anticonvulsants, one continues to suffer the occasional fit only 
and the seventh patient continues to have poorly controlled fits with multiple seizure types. 
Three have learning difficulties. Seven males have suffered from epilepsy. In one the fits 
have stopped and in one they are controlled on vigabatrin. One other patient continues to 
have occasional fits off anticonvulsants. The other four all continue to have poorly 
controlled epilepsy despite anticonvulsant therapy. Six have learning difficulties.
Two children developed episodes of NCSE. Both have been successfully treated with oral 
diazepam.
Learning difficulties and behavioural problems (table four)
In 1986, four patients had learning disabilities and three behavioural problems. In 1996 
nine had learning disability and eight behavioural problems. All patients with behavioural 
and/or learning disability suffered from epilepsy.
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Other neurology
One patient known to have TSC developed symptoms of raised intracranial pressure and 
was diagnosed as having a giant cell astrocytoma (GCA), which was successfully removed 
without sequelae. One other patient has a mild hemiplegia.
Renal disease
Twenty-two patients have undergone at least one renal USS. Thirteen of these patients 
were shown to have at least one renal lesion. Five patients had cysts; three unilaterally, one 
bilaterally and one had adult type PKD. Eleven had renal AML, seven of which were 
bilateral. One patient had a renal carcinoma.
Only three patients experienced symptoms of haematuria and pain; all three were known to 
have large bilateral AML, and CT scanning confirmed renal haemorrhage arising from an 
AML in each case. They were all successfully treated by selective renal artery 
embolisation. The renal carcinoma was detected on a research scan; the patient had been 
entirely asymptomatic. The diagnosis was confirmed by biopsy and the patient had a left 
nephrectomy performed.
Cardiac disease
Twelve patients have had an echocardiogram. Three patients under the age of one and one 
adult patient had evidence of rhabdomyomas. One had hypertrophy probably secondary to 
his long-standing essential hypertension. The others were all normal. Two of the three 
infants showed complete resolution of the rhabdomyomas, on repeat echocardiograms.
One patient (who also had a large cardiac rhabdomyoma causing outflow obstruction) was 
found to have Wolff-Parkinson-White Syndrome.
Lung disease
Only one patient has been diagnosed as suffering from pulmonary 
lymphangioleiomyomatosis (LAM) in the Bath district in the past ten years. She presented 
with a pneumothorax at the age of 21 years treated by pleurectomy, which has not 
recurred, but she continues to have exercise induced dyspnoea and episodes of 
haemoptysis despite treatment with methyl-progesterone. Her spirometry shows a reduced 
vital capacity of 35% predicted, an FEVj of 38% predicted and a peak flow of 95%
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predicted. High Resonance CT (HRCT) scanning showed multiple thin walled cysts and 
peripheral bullae confirming the diagnosis of LAM.
The chest X-rays of three other patients (performed for other reasons) were reported as 
normal.
Discussion
Although patients with TSC may have a normal life span, and one patient in Bath is now in 
his ninth decade and has suffered no serious complications, it is a disease associated with 
high morbidity and early mortality. As discussed earlier it can affect almost any tissue in 
the body, although the most troublesome complications arise from involvement of the 
neurological, renal, cardiovascular and respiratory systems.
The disease also has important genetic implications. It is an autosomal dominant condition, 
thus, any patient diagnosed with TSC will have a 1 in 2 risk of passing the disease to each 
of their off spring. Although it may be possible that the TSC1 phenotype is not as severe as 
the TSC2 phenotype, severity of disease does not run in families (there are many cases of 
only mildly affected patients having children who are severely affected) and it is 
impossible to predict who will be most affected. About half of patients with TSC have 
severe learning difficulties and epilepsy25 26. Therefore, a patient with TSC will have 
approximately a 1 in 4 chance of having a child with TSC and epilepsy and severe learning 
difficulties.
It is important, to make the correct diagnosis, not only because of the possible 
complications that might arise in the affected individual, but also so that accurate genetic 
counselling may be given. Presently, it is not possible to routinely test DNA from 
individuals with TSC (research has isolated TSC1 and TSC2 gene defects in approximately 
half of affected families) but it is possible to detect TSC on chorionic villus sampling or 
amniocentesis when a parent has a known mutation. Even though prenatal diagnosis will 
be possible for the majority in the near future it is unlikely that a test will be available that 
will predict the severity of the disease in an affected foetus. Therefore, the diagnosis is still 
frequently a clinical one and the diagnostic criteria need to be modified accordingly as our 
knowledge of the disease improves to allow both accurate diagnoses and exclusion to be 
made.
42
Over the past ten years the age of diagnosis has gradually decreased. This may be 
explained in part by the fact that three patients had a known family history, so that the 
family and health professionals were aware of their risk of inheriting the disease. It is also 
possible that greater awareness of this disease and improving technology have contributed 
to earlier diagnosis. However, these figures must be treated with caution, as the number of 
patients is small.
The most common causes of morbidity in the Bath TSC population over the last ten years 
were seizures and learning difficulties coupled with behavioural problems. Both 
Shepherd26 and Webb19 also found seizures and mental retardation to be the major causes 
of morbidity affecting up to 80% of the TSC population. There also appears to be a close 
relationship between seizures and severe learning difficulties. There are only a few cases of 
patients who have learning difficulties without a history of epilepsy reported in the 
literature and in those that do it may be some other mechanism other than the TSC that 
accounts for their impaired intellect. None of our patients who were seizure free had 
learning difficulties. In addition the age of seizure onset correlates with long-term 
prognosis for psychomotor development. Children who have not developed epilepsy by the 
age of five rarely regress and are more than likely to have normal intellectual outcome. 
None of our patients who developed epilepsy over the age of five had psychomotor delay.
Seizure type at onset is also an important prognostic factor for long term psychomotor 
development with infantile spasms (IS) associated with the highest risk of severe learning 
difficulties (SLD). In our group the most common seizure type at onset was IS, followed 
by generalised tonic clonic (GTC) and then partial seizures. Four out of five patients with 
IS had SLD, and interestingly the one patient who had normal intellect was the only patient 
in whom the spasms were rapidly controlled (although the electroencephalogram (EEG) 
did not show hypsarrhythmia bringing the diagnosis into doubt, it was obtained after 
treatment had been initiated which might have lead to resolution of the hypsarrhythmia). 
Because of the long-term psychomotor implications of early onset epilepsy in this group of 
patients, it is of paramount importance that fits are recognised quickly, accurately 
diagnosed and treated promptly. Though no study has been undertaken to show that early 
intervention will improve outcome in these children, many clinicians believe that the 
quicker the fits (particularly when they are IS) are controlled the better the long-term
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prognosis for development. Any infant who is known to suffer from TSC or is at high risk 
(i.e. has a first-degree relative) must be closely monitored for the development of fits 
especially IS. If any concerns arise they should be admitted to hospital the same day for 
observation and EEG monitoring. If the diagnosis is confirmed, treatment should be started 
immediately. The treatment of IS in the past has been notoriously difficult, but early 
studies have suggested vigabatrin to be particularly efficacious in treating patients with 
TSC, controlling the spasms in over 90% of patients40. Vigabatrin is also effective in 
treating partial seizures (the second commonest type of seizure at onset) in these infants41.
Gender may also be an important prognostic factor for outcome of seizures. Although our 
numbers are very small and the observation will have to be repeated on larger populations, 
girls might have a more favourable outcome than boys. Equal numbers of males and 
females suffered epilepsy but only one girl continues to have refractory epilepsy as 
compared with four boys. Likewise only three females have moderate to severe learning 
difficulties compared to six males.
Behavioural problems commonly occur in children with learning difficulties and/or 
epilepsy. They often exhibit autistic traits and are commonly hyperactive with poor 
sleeping patterns. In a survey carried out in 199427 parents complained that one of the most 
difficult aspects to looking after their children with TSC was the hyperactivity and poor 
sleeping. It is also known that these children respond badly to traditional sedatives (often 
becoming more hyperactive) and behavioural therapies are often ineffective.
Giant cell astrocytomas are another recognised neurological complication of TSC and 
occur more commonly than in the general population. There is controversy as to whether 
they arise from subependymal nodules or occur de novo. They most commonly occur 
around the Foramen of Munro, frequently occurring around adolescence and are rare over 
the age of thirty years. They usually present with raised intracranial pressure: headache, 
vomiting, ataxia, drowsiness, diplopia and papilloedema. Treatment is surgical removal. 
Unlike other forms of brain tumours, the prognosis is excellent. The Bath patient was not 
typical of patients with TSC who develop astrocytomas, as she was 37 years old. She had 
long-standing epilepsy, though was taking no treatment. She complained of increasingly 
severe intermittent headaches, episodes of loss of consciousness and weakness of her legs 
on head movement. A CT brain scan confirmed a GCA obstructing the Foramen of Munro
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causing obstructive hydrocephalus. The operation and post-operative period were 
uneventful and she was discharged home on anticonvulsant medication. She remains well 
and symptom free seven years later. This case illustrates the need for vigilance when 
reviewing patients with neurological symptoms and a diagnosis of TSC.
The only other neurological complication recorded in this group was a hemiplegia. This 
patient was diagnosed as having IS at the age of four months. Treatment with prednisolone 
was commenced with resolution of the spasms, but then she developed right-sided fits that 
continued until the patient was three years old when they resolved spontaneously. Over the 
ensuing years it became apparent that she had a mild right-sided hemiplegia although in all 
other aspects she had made excellent progress and had normal intellect. We can only 
speculate as to whether the hemiplegia is secondary to the right-sided fits or is another 
neurological manifestation of the TSC, possibly due to the location of a tuber.
Two thirds of the Bath population are known to have renal lesions, but the majority remain 
asymptomatic. The patients in our survey represented the wide spectrum of renal disease 
seen in TSC, most commonly AML and/or cysts with, more rarely PKD and 
adenocarcinoma. As discussed above the TSC2 gene is close to the PKD1 gene. Although 
PKD1 mutations do not underlie the cytogenesis in all patients (cysts can occur in TSC1 
and TSC2), early onset bilateral PKD occurs with a contiguous deletion of both TSC2 and 
PKD1. Only one patient in our survey has PKD -  she is known to be mosaic for a deletion 
on chromosome 16 affecting both genes. AMLs also occur in both TSC1 and TSC2. The 
severity of renal disease between the individuals also varies widely. Many patients with 
AML with or without cysts have remained asymptomatic with normal renal function 
throughout their life, whilst others have suffered from haematuria, anaemia, pain and 
haemorrhage (which can be life threatening)34.
Over the past ten years four of our patients (13%) have undergone treatment for renal 
complications. Three suffered haemorrhage from large AMLs requiring embolisation and 
one was found to have a renal carcinoma which was removed surgically. Selective arterial 
embolisation should now be now the treatment of choice for patients suffering from 
haemorrhage from renal lesions. In the past nephrectomy was frequently performed but, as 
in our patients, both kidneys are often involved. When bleeding then occurs in the 
remaining kidney, this may result in a second nephrectomy (either because of catastrophic
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haemorrhage or if embolisation is not successful) leaving the patient reliant on dialysis 
unless they are fortunate enough to receive a successful kidney transplant. Although none 
of our patients suffer from ESRF, it does contribute a significant degree of morbidity and 
mortality within the TSC population as a whole42. DMSA scanning and creatinine 
excretion following selective embolisation does show the remaining part of the treated 
kidney to be contributing significantly to renal excretion and therefore function. 
Nephrectomy still remains the treatment of choice for renal carcinoma.
Cardiovascular complications can also occur in TSC and may be life threatening. Cardiac 
rhabdomyomas are the commonest cardiac manifestation. Three patients in our survey 
were found to have rhabdomyomas in early infancy, in two of which the lesions were 
shown to regress and eventually disappear on echocardiology. The other patient was noted 
to have a large rhabdomyoma in adult life. It is generally accepted that, unlike other 
hamartomas in TSC which tend to become more numerous and larger with increasing age, 
rhabdomyomas generally regress, becoming smaller and less common with age. However, 
the size and position of the rhabdomyoma in this older patient makes it unlikely that it was 
present in infancy, as she had experienced no symptoms. This raises the possibility that 
some rhabdomyomas may increase in size after birth; whether arising de novo or from a 
smaller congenital rhabdomyoma is not known. One possible explanation for the changing 
size of rhabdomyomas is that they are under the influence of oestrogens. It has been 
postulated that other manifestations of TSC such as AMLs and LAM are affected by 
oestrogens (see chapter seven) and it is possible that rhabdomyomas are similarly affected. 
It could be hypothesised that as oestrogen levels increase during pregnancy, growth of the 
rhabdomyomas is stimulated so that they reach their maximum size at birth. After 
parturition, as oestrogen levels fall, the growth of the rhabdomyomas is no longer 
stimulated and their size regresses, so that they can no longer be detected on 
echocardiology. Likewise if in later life a patient is exposed to high levels of oestrogens 
(e.g. ovarian tumour) then a rhabdomyoma may either increase in size once again, or even 
develop de novo. It is not known whether or not our patient was exposed to high levels of 
oestrogens.
The majority of rhabdomyomas remain asymptomatic but they can cause heart failure if 
they arise in a position that causes obstruction to the flow of blood within the heart, or as in 
one of our patients, syncope due to acute but intermittent obstruction. A less common
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problem is the development of WPW syndrome and associated SVTs. It nearly always 
occurs in conjunction with rhabdomyomas and usually presents within the first year of life, 
with approximately half presenting on the first day of life. It responds well to medical 
treatment and will often resolve in later life43.
Only one patient had been symptomatic and therefore diagnosed as having LAM. She 
presented at the age of 21 years with sudden onset of chest pain and shortness of breath as 
a result of a pneumothorax. Pulmonary involvement in TSC is undoubtedly rare. It is 
difficult to estimate the true incidence, partly because the few studies that have attempted 
to do so have generally used small numbers of patients from biased groups and partly 
because it is unknown how many patients with pulmonary complications become 
symptomatic and therefore recognised. We now know of at least one other patient who 
may have had asymptomatic LAM during this 10 year period, but only came to light later 
when she became symptomatic. At present we have no proven method of screening our 
TSC population for asymptomatic LAM. Previous studies have estimated 1 -  3 % of 
patients to be affected44. It predominately affects females of child bearing age although 
rare cases occurring in men and children have been reported45 46. The commonest 
presenting symptoms are dyspnoea and pneumothorax, as in our patient. Other symptoms 
include chronic dry cough, haemoptysis, wheeze, and chest pain. Development of cyanosis, 
respiratory failure and cor-pulmonale can also occur44. Our patient is currently receiving 
monthly injections of methyl progesterone and, though she remains symptomatic she has 
not suffered any further pneumothoracies and has had a moderate improvement on 
pulmonary function testing. This complication is reviewed in detail in chapter seven.
Skin lesions are nearly universally present in patients with TSC. All the patients in the 
Bath district had skin lesions that are pathognomonic for TSC. All but two have facial 
angiofibroma and they both have a shagreen patch. One of these patients is seven, the other 
four years and it is well recognised that angiofibromas most commonly develop after the 
age of five and may even arise in adult life. On the other hand hypomelanic patches (best 
visualised by a Woods ultraviolet light) are often, though not always, present at birth. They 
can arise later. One patient was examined at the age of 13 months with a Woods lamp; four 
hypopigmented lesions were noted and documented. Two years later he was re-examined 
with the Woods light and was found to have twelve new hypopigmented lesions (sixteen 
lesions in all). The neurocutaneous lesions do not contribute to the potentially lethal
47
morbidity of this condition, but many of the lesions are unsightly and are of great cosmetic 
concern to the patient. Treatment for the facial angiofibroma has progressed dramatically 
over the past ten years due to the introduction of laser treatment. Though blistering of the 
superficial layers of the skin does occur immediately after the laser treatment permanent 
scarring is rare. It was also thought that if the treatment was carried out at a young age the 
lesions would recur, but this does not appear to be the case so that the major limiting factor 
for age at which treatment can be undertaken is the ability to lie still. A general anaesthetic 
can be used, but several treatment sessions are required.
No deaths occurred in our population: this might be accounted by both the small numbers 
and the relatively young age of the population.
Conclusion
Although there were no deaths in the Bath TSC population over the past ten years there is a 
high rate of morbidity with seizures, associated learning difficulties and behavioural 
problems affecting two thirds of the population. Symptomatic renal disease affected over 
10% of our population necessitating either selective embolisation or nephrectomy. 
Although renal failure requiring renal replacement therapy had not yet intervened in any of 
our patients it remains an important cause of premature mortality in TSC. Lung 
complications (LAM) do appear to be rare within the TSC population, becoming 
symptomatic in only a small minority of patients. Nonetheless, it is not known how many 
patients have asymptomatic lung involvement and whether screening patients might be 
beneficial. Theoretically, at least, anaesthesia and flying may precipitate pneumothoracies, 
respiratory failure and even death in some affected (but previously asymptomatic) patients. 
There is very little information available about the effectiveness of treatment and long-term 
outcome in this group of patients. Other complications contributing to morbidity within our 
group of patients included cardiac manifestations, GCA and hemiplegia and amblyopia.
This study has also shown that it is possible to undertake long-term studies that give us
improved understanding of the natural history of a disease. However, despite the large
number of patient years observed (628), a larger study is required to examine lower risk
complications such as LAM in more detail. Nonetheless, this study helps confirm that
epilepsy, learning difficulties and behavioural problems are the most frequent problems
encountered in TSC and occur in as many as two thirds of patients. This type of study also
allows observation of time patterns of the complications: for example, although the skin
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manifestations of TSC are almost universal, most patients do not develop angiofibroma 
until after the age of five and the number of hypomelanic patches may also increase with 
age. Another way to present this data so that the effect of age, time and cohort can be 
simply visualised would be the use of a modified Lexus diagram.
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CHAPTER THREE
Epilepsy and Learning Difficulties
As discussed previously and shown in chapter two, seizures and the associated learning 
difficulties are two of the most important causes of morbidity in TSC affecting over half of 
the population. About two thirds of affected patients will develop their epilepsy within the 
first year of life. The most common seizure type at onset is infantile spasms (IS) 
accounting for about 40% of cases, followed by partial seizures and then secondarily 
generalised seizures. Nearly all patients who experience IS will go on to have learning 
difficulties, as will many of those suffering from partial seizures. Age at seizure onset as 
well as type at onset and possibly gender are other important prognostic factors for long­
term developmental outcome. It is also believed, though scientific evidence is lacking, that 
early, good control of the seizures may also improve long term outcome.
Infantile spasms: recognition, treatment and prognosis
159 years ago Dr West wrote a letter to the Lancet describing “a peculiar type of 
convulsion” occurring in his four month old son, so documenting the first case of IS or 
what has become known as West’s Syndrome. IS are a clinical seizure type which include 
a peculiar type of seizure and psychomotor retardation, usually with a characteristic 
electroencephalogram (EEG) pattern known as hypsarrhythmia. There are numerous 
causes of IS which do not share a known common underlying pathophysiological process, 
although TSC accounts for 10-20% of cases. There are too many other causes to list them 
all exhaustively but as a general rule any process that affects brain development or 
metabolism can cause IS.
Examples of other underlying aetiological factors for infantile spasms include:
• Abnormal brain development e.g.: Neurofibromatosis, Sturge Weber Syndrome, neuronal migration 
disorders, agenesis corpus callusom, hemi-megalenencephaly.
• Chromosomal disorders e.g.: Down Syndrome (-10%), Cri du Chat (trisomy 13).
• Congenital infections e.g.: maternal rubella, CMV infection.
• Infection e.g.: meningitis.
• Hypoxic -Ischemic encephalopathy whether incurred at birth, antenatally, postnatally or due to pre-term 
birth.
• Metabolic e.g.: phenylketonuria, organic acidurias, pyridoxine dependency.
• Degenerative brain disease, leukodystrophies (rare).
• Trauma
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Despite the huge advances that have been made in medicine IS still remain a poorly 
understood entity. Although with newer imaging techniques we are more often able to 
elicit the underlying causes of these spasms, still little is known about their 
pathophysiological basis and treatment remains problematic.
Epidemiology
IS (from all causes) have an estimated incidence of 0.16 -  0.4247 48 49 50 per 1000 live 
births. Little is known about the geographical distribution, but two studies from the USA47 
48 , one from Denmark49 and one from Finland50 showed incidence rates of 0.16, 0.25, 
0.25-0.33 and 0.42 per 1000 live births respectively. Studies have reported either equal sex 
incidence or a slight preponderance of males ranging from 1:149 to 1:450 (only one has 
found an excess of females51). Age of onset of the spasms has been reported to occur 
between 1 day and 6 years of age52, however the vast majority begin within the first year of 
life, after which alternative diagnoses including infantile myoclonic epilepsy, are more 
likely. There is a peak age of onset between four and seven months. One of the main 
difficulties in estimating the age of onset is the time taken to make the diagnosis. There is 
often a significant delay between the start of the spasms and their eventual diagnosis: 
parents may not recognise that there is something amiss; often if they do seek professional 
advice the spasms are mistaken for colic or a natural startle reflex. In a review by Bobele 
and Bodensteiner53 the average lead-time to diagnosis was 3.5 months, but it is well known 
that this can vary greatly and it is possible that some cases are never recognised.
Genetics
It is rare to have more than one affected member in any family, unless there is another 
inherited underlying cause for the spasms such as TSC, except in a small number of 
families where it has been described as having X-linked inheritance54. It is more likely that 
the spasms are a symptom of underlying disease (just as haematuria is a symptom of 
disease, but can also be idiopathic).
Classification
IS can be classified into three groups;
Symptomatic group: the underlying cause is known prior to the onset of the spasms, for 
example an infant diagnosed as having Down syndrome or TSC who then subsequently 
develops IS.
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Cryptogenic group: the underlying cause is only discovered following the onset of the 
spasms for example, a normally developing infant who after the onset of IS, is investigated 
and then found to have TSC.
Idiopathic group: no underlying cause is found despite investigation.
Unfortunately this classification has led to confusion, as it does not depend on the 
underlying cause. For example one child with TSC may fall into the symptomatic group, 
whilst another falls into the cryptogenic group. In addition, with better imaging techniques 
and diagnostic tools, patients who would have previously been in the idiopathic group, 
now fall into either the cryptogenic or symptomatic group. Some authors also cause 
confusion by calling all infants in whom a cause is eventually found as symptomatic and 
the rest either cryptogenic (assuming there must be a cause) or more correctly idiopathic.
The spasms
No good term has yet been given to this phenomenon that is brief yet fully descriptive. In 
1841 West described the sudden forward jerking movement of his son as a Salaam spasm; 
lightning major convulsions55, Blitz -  Kramp and Jack Knife convulsions56 have also been 
used. The problem with these terms is that they only describe the flexor type of spasm.
c n
Other terms have been misleading for example, propulsive petit mal suggesting similarity 
to benign petit mal epilepsy or Pallidum epilepsia58 falsely implying that the source of the 
spasm is known. Names that fully describe the spasms such as that used by Gastaut in 
195959 1 Encephalopathic myoclonique infantile avec hypsarrhythmie" are long and 
cumbersome and are unlikely to be used in English speaking countries. Gibbs and Gibbs60 
coined the phase “infantile spasms” in 1952. Although this is still the best and most 
commonly used term it is not strictly accurate: not all cases start in “infancy” and a spasm 
implies to some an abnormal muscle contraction rather than epileptic activity. It has 
however fallen into general use over many years.
Infancy: this can be defined as “in the first year of life” as infancy is now usually alluded to e.g. infant 
mortality is death before one year of age, although infant is less precisely defined in the Oxford dictionary as 
a “child during earliest period of life” thus giving rise to terms such as “infant school”
The commonest type of spasm is the flexor spasm, consisting of sudden generally bilateral
and symmetrical contractions of the neck, trunk and extremities. The extent and degree of
muscle involvement varies between individuals so that in some, the whole body bends at
the waist, the arms are flung upwards and outwards and then brought down, hence the
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terms salaam and jack knife, whilst others have only involvement of the neck resulting in 
head bobbing61. Extensor spasms have a predominance of extensor muscle contraction 
producing an abrupt extension of the neck and trunk with extensor abduction or adduction 
of the arms and legs62. Many infants will have a combination of flexor and extensor spasms 
during the course of their epilepsy. Kellaway et al 1979 found that approximately 34% of 
infants have flexor spasms, 23% extensor spasms and 42% mixed flexor-extensor spasms 
Although the vast majority of infants have symmetrical spasms a small minority ~1% have 
asymmetrical spasms often adopting a tonic neck reflex position.
Each spasm is only visible for a brief duration lasting a few seconds, though persisting 
EEG changes for a single spasm may last as long as 106 seconds62. They tend to run in a 
series or in batches or clusters ranging from just a few to as many as one hundred, with 
many studies quoting averages of between 30 and 50 spasms in each batch. The spasms 
may also be triggered by certain stimuli, the most common being waking or falling asleep63 
though feeding64 has also been implicated. Some earlier studies suggested that external 
stimuli such as noise and touch can provoke the spasms but this has only been reported 
rarely since.
An association of a cry with the attacks is common and has been frequently reported, 
usually during or after the attack, more rarely before. It may be this cry that leads to the 
misdiagnosis of colic or intussusception, or the observer to believe the child is in pain64. A 
few authors have reported other phenomena such as tears, hiccups, a laugh or a giggle63.
It is difficult to evaluate whether consciousness is lost or maintained during these events 
because of the age of the patients, the brevity of the fit and the frequently associated 
learning difficulties.
Electroencephalogram (EEG)
Hypsarrhythmia is the most important EEG pattern associated with IS (figure seventeen). It 
is important to note that this EEG appearance is not present at all times and tends to be 
modified by both the natural course of the disease and treatment therapy60. Synchrony 
between the hemispheres and between spike and wave components often appear in the later 
stages of the disease, a pattern termed modified hypsarrhythmia. Hypsarrhythmia is most
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commonly seen as the child falls asleep and wakes, but interestingly the EEG often returns 
to normal during rapid eye movement (REM) sleep65.
Figure seventeen -  EEG showing hypsarrhythmia
Definition of hypsarrhythmia; Gibbs and Gibbs 195260 “Very high voltage, random, slow waves and spikes 
in all cortical areas. The spikes vary from moment to moment in duration and location; at times they seem to 
come from another focus, or possibly from multiple foci. Occasionally the spike discharge is generalised but 
it is never rhythmically repetitive or highly organised as in petit mal or petit mal variant. The chaotic 
appearance of this abnormality gives the impression of a nearly total disorganisation of cortical voltage 
regulation".
The presence of a focal abnormality within the hypsarrhythmia is not uncommon, and 
when persistent may suggest a focal lesion within the brain. In patients with TSC such a 
focus may be the result o f an underlying tuber. With the pioneering advances in epilepsy, it 
may be that in the future this group of patients will be potential candidates for epilepsy 
surgery.
Developmental delay
The most devastating association o f IS is with psychomotor development. Studies in the 
past have estimated the risk o f mental retardation o f 80% - 90%66 67 68 69. Admittedly, many 
of the affected infants already have an underlying disorder, which predisposes them to 
having psychomotor delay, for example Down syndrome or cerebral palsy. Nonetheless, 
even the children with these types o f problems will stop developing as quickly and even 
regress after the onset of the spasms. Infants with TSC usually follow a pattern of
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development within the normal range until such a time that they develop IS after which 
they show signs of arrested development or regression.
Although it is impossible to predict which children will be most severely affected, good 
prognostic factors include:
• idiopathic aetiology66 67 68
• later age of onset68
d 'X• single spasms (rather than batches)
• no other fits67 68
• absence of focal abnormalities on EEG66
• short lag time between onset of spasms and treatment
• a good response to treatment67 68
It is not known whether any particular therapeutic agent is superior to the others with 
regard to long-term outcome (seizure control or psychomotor development).
There is a definite pattern to the developmental delay. Social skills, such as smiling are lost 
first. The infant then becomes lethargic, floppy and apathetic and no longer seems aware of 
or interested in their surroundings: this sometimes leads to concerns about vision and 
hearing. Motor skills such as grasping and reaching are usually the last to be affected, but 
gross motor skills can be affected and a few children never learn to walk65.
In a minority of cases, development is not arrested or may return to normal after the 
cessation of spasms.
Diagnosis and investigations
Diagnosis is by clinical observation and EEG. Clinical observation is not always easy and 
can be missed by parents and less experienced nursing and medical staff. It is simple 
enough when an infant presents with the typical salaam spasms occurring in long batches 
many times a day, but in the infant with infrequent or single spasms they can readily be 
mistaken for colic or a startle reflex. The younger the infant, the more difficult it is to 
detect abnormal movement or delayed development.
It is important that whenever IS are suspected the child is admitted for close clinical 
observation by experienced staff. An EEG should then be undertaken and if
hypsarrhythmia is not seen, a sleep EEG performed, since hypsarrhythmia may only be 
present as the infant is falling asleep or waking. Where there is any doubt video and 
polygraphic recordings may help. Occasionally, it may not be possible to confirm the 
diagnosis with an abnormal EEG, however, if IS are clinically certain, treatment should be 
considered because of the poor prognosis of this condition. Some of these infants, with a 
normal interictal EEG will have a relapse later with severe psychomotor retardation but 
their management at presentation is controversial, because benign infantile myoclonus 
does not require treatment and is clinically similar, but without the risk of associated 
psychomotor retardation: their EEG is normal. In all infants in whom there is no other 
known cause for their spasms a diagnosis of TSC should be excluded. Brain imaging (CT 
and/or MRI), examination of the skin with Woods light (for hypomelanic patches) and 
fundoscopy (for retinal phakomas) should be undertaken as a minimum. Renal USS and 
echocardiography should also be considered.
Treatment
At least 30 drugs have been tried since Dr West wrote his letter in 1841. Most 
anticonvulsants have been tried, many with no effect and no treatment has been shown to 
be successful in treating the spasms in more than about half of the patients, except steroids, 
valproate and vigabatrin.
The first recorded treatment, after West, was by Gibbs et al in 195469, who reported 
favourable results using chlortetracycline, 113 years after West's letter. It is unclear from 
the literature whether this delay was due to the fact that IS were not being readily 
recognised and therefore treated, or whether in fact no treatment had previously been found 
to have any effect.
Steroids and hormonal treatments have been used in the treatment of seizure disorders 
since the early 1950’s. In 1958 Sorel and Dusaucy Bauloye70 reported a dramatic response 
to ACTH therapy in children suffering from IS. Not only did the spasms stop and the EEG 
improve, often becoming normal, but they claimed that mental improvement occurred if 
treatment was started within a few weeks of the onset of the spasms.
Following this first report there have been many studies which have frequently confirmed 
the effect of steroid/hormonal therapy claiming to stop seizures in just over half of the
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patients supporting the suggestion that steroid/hormonal therapy is effective in a significant 
proportion of children with IS. A literature review of the English Language using Medline 
between 1950 and 1995 found eleven studies and a further review of three studies (fourteen 
in total) investigating the effect of ACTH and steroids on IS. There were three randomised 
RCT trials71 72 73 , eight open prospective trials 74 73 76 77 78 79 80 and three retrospective trials 
8182 (see table five). Out of a total of 784 patients treated there was complete cessation of 
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relapses Cross over No of 
patients
Baram 1996(71) RCT Clinical spasms 
Hypsarrythmia 











14 II 13 N/AN/A PrednisoneACTH 28
Hrachovy 1994 (72) RCT Clinical spasms 
Hypsarrythmia 





IM 3 weeks (tap) 26 13 N/A 13 N/A N/A N/A
ACTH 
low dose
20 - 30 U/day 
tor two weeks
IM 2 weeks (tap) 24 14 N/A 14 N/A N/A N/A
Hrachovy 1983 (73) RCT Clinical spasms 
Hypsarrythmia 







2 - 4 weeks (tap) 








4 II PrednisoneACTH 78
Glaze 1988 (74) Prospective Clinical spasms 
Hypsarrythmia 
No prior steroid treatment
64 ACTH
Prednisone




2 - 4 weeks 





Hrachovy 1979 (75) Prospective Clinical spasms 
Polygraph Ic-video 
No prior steroid therapy
12 Prednisone 2mg/kg/day Orally 4 -  6 weeks (tap) 12 2 1 2 0 N/A N/A
Hrachovy 1980 (76) Prospective Clinical spasms 
Modified hypsarrythmia 
No prior steroid therpsy
5 ACTH 20U/day IM 6 weeks (tap) 6 5 0 5 2 N/A N/A
Kuaaa 1993(77) Prospective Clinical spasms 
Hypsarrythmia 
Pychomotor delay
18 ACTH 0.8mg IM 4 weeks (tap) 18 6 5 6 N/A N/A N/A
Snead 1996 (78) Prospective Clinical spasms 
(modified) hypsarrythmia
15 ACTH l50U/m2/day IM 1 week (tap) 16 14 0 14 5 N/A N/A
Matsumoto 
1987(79)


















Prospective Clinical spasms 
hypsarrythmia 
No prior steroid therapy 












70 N/A N/A 6 ACTH 15
(9 exclude
Haines 1994 (81) Retrospective Clinical spasms 
Hypsarrythmia
191 ACTH 2-4U/kd/day IM 1 week (tap) 191 113 N/A 80 N/A N/A N/A
Retrospective Clinical spasms 
Hypsarrythmia
25 ACTH N/A N/A N/A 25 22 N/A 21 N/A N/A N/A


















Singer 1980 (82) Retrospective Clinical spasms 55 ACTH 40U/dsy IM 1 week (tap) 55 42 N/A 42 18 N/A N/A
Table showing the results of the literature search for the treatment of infantile spasms with steroids.
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The mechanism of action of hormonal therapy in infantile spasms remains poorly 
understood. Baram et al71 has proposed that “stress” increases adreno-corticotrophin 
releasing hormone (CRH) activity causing infantile spasms during a time when brain 
maturation is occurring, explaining why infantile spasms are age specific. They argue that 
ACTH acts by suppressing ARH synthesis. ACTH may also act directly by membrane 
stabilisation, improving the integrity of the blood-brain-barrier and stimulating myelin 
formation. Steroids such as hydrocortisone and prednisolone have metabolic, anti­
inflammatory and immunosuppressive effects that may play a role in spasm suppression 
but also act directly by inhibiting anterior pituitary and hypothalamic secretion, including 
ARH.
The problem with steroids are the side effects: potentially life threatening problems include 
depression of the immune system (leading to overwhelming sepsis) and electrolyte 
imbalances. There have been few studies investigating the side effects of steroids when 
used for the treatment of IS. One such study , investigating the risk of infection with 
ACTH therapy in 27 infants, identified 75 febrile episodes, four of which had confirmed 
bacteraemia and three deaths occurred. However IS occur at an age when febrile episodes 
are common. The deaths occurred in children who had received large doses (over 100 units 
ACTH given 2 times a week over three weeks). Less serious side effects, for example 
hypertension, are often transient but nevertheless cause a certain amount of morbidity. It is 
difficult to estimate the frequency of these side effects as the study by Riikonen and 
Donner shows. In their study only 17 out of 64 had their blood pressure routinely 
measured. Minor side effects, estimated to occur in two thirds of patients, include 
behavioural changes especially irritability, changes in appetite, weight gain and alteration 
in sleep patterns. In addition some forms of steroids e.g. ACTH and synacthen involve 
daily or alternate daily intramuscular injections.
In view of the devastating effect that IS can have on the patient, it is not surprising that 
most anticonvulsants have been tried for their treatment at one time or another. Sodium 
Valproate, used over the past 1 5 - 2 0  years84 85, has been one of the most successful. 
Sodium valproate inhibits the breakdown of GABA, a neurotransmitter, thus increasing its 
availability. It is also thought to have membrane stabilising properties. Siemes et al 
conducted a trial of valproate therapy in 22 infants with IS. The dose ranged from 45mg to 
lOOmg/kg i.e. much higher doses than those generally recommended in children for the
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treatment of epilepsy (30-40mg/kg). Abolition of seizures was obtained in 65% of children 
within three months of commencing therapy. There are potential problems with valproate 
therapy and side effects are common. Hepatotoxicity and pancreatitis, although rare, can 
occur and be life threatening. It may be that the higher than normal doses required and 
fears of these serious complications, but particularly the length of time to obtain a response 
(usually weeks or months rather than days), have limited the use of valproate in this 
disorder.
Vigabatrin, one of the new generation anticonvulsants, is rapidly gaining popularity in 
view of both its efficacy and its favourable drug profile. It also acts on the GABA 
pathways, by inhibiting GABA transaminase (an enzyme involved in the metabolism of 
GABA) thus increasing CSF concentration. It was first brought to clinicians’ attention in 
1991 by Chiron87 et al who reported complete cessation of seizures in 43% of patients. The 
effect was seen rapidly, often within one week. Subsequently there have been preliminary 
trials, open and uncontrolled, on the use of vigabatrin in IS showing similar control to that 
seen with steroids. There is also increasing evidence that vigabatrin is particularly
o o
efficacious in the treatment of IS in the group of children suffering from TSC. Acairdi 
found in his review of 192 patients that out of the 28 patients with TSC, 27 (96%) had
O A
complete cessation of their spasms. There has also been one study comparing vigabatrin 
with steroid therapy specifically in this subgroup of patients. They found that 11/11 
responded to the vigabatrin and only 5/11 to hydrocortisone. Again they concluded that 
vigabatrin might be particularly effective in treating children with both IS and TSC.
Although vigabatrin has only been used in the treatment of IS for a few years, it had been 
thought to have few side effects. The most commonly reported problems were drowsiness, 
vomiting and behavioural changes, all of which resolve on discontinuing the drug. There 
had also been one reported event of myoclonus, though it is not clear whether this was an
o o
effect of the vigabatrin or the child’s underlying neurological disorder .
However, more recently there have been reports of both asymptomatic and symptomatic visual field defects 
with loss of peripheral vision to varying degrees in adults treated with vigabatrin90 (see later).
Second line drugs include:
Benzodiazepines, for example, nitrazepam and clonazepam, have been shown to be 
effective in treating IS but are rarely used as first line monotherapy, they are more
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commonly used in addition to, or after failure of other drugs. They are thought to act by 
acting directly on GABA receptors at chloride channels within the brain. Driefuss et al91 
were the first to report the use of nitrazepam in a controlled study against steroids in 1986, 
although it had been in use for many years before. They reported that both treatments 
resulted in a significant reduction in seizures but that the difference between treatments 
was not significant. The main problems with benzodiazepines that have limited their use 
are; sedation, excess bronchopulmonary secretions and the development of tolerance in a 
significant proportion of infants.
Intravenous gammaglobulins came into vogue in the early 1990s. With the knowledge of 
the favourable effect of steroids it was postulated that there might be an immune 
mechanism at work and IV gammaglobulins were tried92. But in view of their expense, 
inconvenience and potential problems with infection (contamination with HIV and Hep C 
was of great contemporary concern) as well as failure of any studies to prove their efficacy, 
they are now rarely used.
Thyrotropin-releasing hormone (TRH) is widely distributed throughout the brain acting 
as either a neurotransmitter or neuromodulator. A Japanese study, carried out in 198779 
showed that just over half of the patients responded to TRH - similar results to those 
achieved by ACTH. They also noted a lower incidence of side effects in the TRH group. 
Despite these preliminary findings, it is not yet routinely used in the treatment of IS. The 
mode of administration (intravenously) and cost (approximately seven times that of 
ACTH) make the treatment unattractive.
Pyridoxine under went several studies93 94 during the late 80’s to assess it’s validity in 
treating IS following the successful treatment of vitamin B6 - dependent seizures in the 
new-born with high doses of pyridoxine and whilst there is no doubt that it is effective in a 
small number of cases, none of the studies proved that it has such a benefit as to deserve 
consideration as first-line monotherapy in this disorder. It is however used in Japan as first 
line treatment.
Epilepsy surgery: Alongside the increased use of vigabatrin for IS there has also been a 
steady rise in the number of patients undergoing epilepsy surgery. Although the numbers 
have been small, early results have been promising. In one study95 of 23 patients only four
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failed to respond to surgery. However, these patients were selected on strict criteria 
suggesting a focal cause and in many children with TSC there are multiple active or 
potential epileptic foci such that surgery is not thought to be an option. In addition long­
term follow up studies have not been undertaken, but in surgery used for other forms of 
epilepsy the relapse rate is high.
Table six -  summary of the pharmacological treatment of infantile spasms
Drug Comments
First line drugs
Vigabatrin If the infant is known to have TSC, or is at high risk i.e. has a first- 
degree relative with TSC, at the time of onset of the spasms then 




Infants who are commenced on steroid therapy should be admitted 
for the initial 48 hours of treatment. During this admission their 
blood pressure should be measured twice daily and their urine 
dipsticked to exclude the development of hypertension and diabetes 
respectively. They should then be reviewed on a weekly basis to 




Valproate BEWARE of thrombocytopenia at high dosage.
Trial of 
Pyridoxine
A test dose should be given intravenously alongside EEG monitoring. 
If the hypsarrhythmia resolves then oral pyridoxine should be tried to 
see if the spasms resolve.
Prognosis
The long-term prognosis is poor. Few studies have specifically looked at long term out­
come. In a study carried out by Riikonen96 looking at adults with a history of IS, only 17% 
attended mainstream school, and less than 10% were married, had children or were 
employed. One fifth had progressed to developing Lennox Gastaut syndrome with severe 
epilepsy and a further third of patients had continued to have seizures in adult life.
07Another study looking at the long term prognosis in 162 patients, found mental 




Although the improvement of diagnostic techniques has led to better recognition of the 
underlying causes and pathology of IS, response to treatment remains disappointing. Even 
with the best therapies available abolishment of seizures only occurs in two thirds of 
patients at best, with a high risk of relapse of spasms and other seizure types and the long­
term prognosis is appalling. There are many questions that remain with regard to 
determining the best treatment for IS.
• Is one treatment better than another in reducing the long-term morbidity of IS? It could be argued 
that long-term psychomotor development is the most important outcome factor for these children. 
Although the spasms may be distressing in themselves, in a significant minority they resolve 
spontaneously if left untreated, though many children will go on to develop other types of epilepsy. 
However, the vast majority will develop severe learning difficulties. Although it is thought that earlier 
control of the spasms may improve outcome, no study has specifically considered this and no study has 
set out to compare different therapies with regard to long-term outcome.
• Is there an optimum steroid dosage regime? There is currently no widely accepted dosage regime for 
steroid dose, frequency, duration or type of steroid used in the treatment of IS. The studies in the 
literature have used many different regimes but none have been large enough to give reliable results.
• Is vigabatrin really the drug of choice for patients with TSC or for those at a high risk of TSC at 
the time of diagnosis their spasms? Only one study89 to date has considered the use of different drug 
regimes in the treatment of the subgroup of patients who have IS as a result of TSC. Their results 
suggested that vigabatrin was more efficacious in this group than steroids, however their numbers were 
small (22 in total).
• Finally, if IS can be prevented from occurring in infants with TSC will this reduce the incidence of 
severe learning difficulties and the development of other seizure types in this subgroup?
In order to try and answer the first question it was decided that a large trial needed to be set 
up to look at the effect of treatment in terms of both seizure control and more importantly 
long-term psychomotor outcome. It was decided that this would be a pragmatic drug trial 
comparing the two drug treatments currently in widespread use in the UK; adreno-corticoid 
or hormonal treatments which I will call “steroids” for convenience and vigabatrin. 
However, it is possible that adrenocorticotrophin hormones work not by production of 
steroid hormone through stimulation of the adrenal cortex but by direct negative feedback 
on the hypothalamus reducing ARH products. This theory promoted by Dr Baram suggests 
that ARH is epileptogenic at a critical period in brain development. This brought up the 
next two important questions; which steroid dosage regime should be used in the trial? and
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if there were enough evidence to suggest that patients with TSC had a better response to 
vigabatrin, should this sub-group be excluded from the trial?
There are currently two preparations of steroids widely used in the treatment of IS in the 
UK
• Prednisolone given orally.
• Adrenocorticotrophin hormone (synacthen) given as an intramuscular (IM) injection.
It was decided that both drugs would be used in the trial as many doctors who would be 
recruiting into the trial expressed that they thought one type to be superior to the other, 
although these opinions are not founded on evidence based medicine. There has only been 
one double blind, randomised crossover trial comparing ACTH and prednisolone. This 
study by Hrachovy73 used lower doses of both ACTH (20u/day) and oral prednisolone 
(2mg/kg/day) than usually used in the UK and found no significant difference between the 
two different types of steroids. Five out of twelve patients responded to the ACTH and four 
out of twelve to the prednisolone, but the numbers of patients enrolled into this study were 
small and will have been insufficient to detect a clinically important difference in response. 
The next question to be addressed was the dosage to be used for each of the steroids. Again 
only one controlled trail comparing high dose versus low dose ACTH had been reported72 
and the numbers were small but no difference was found between the two groups. We 
therefore had a dilemma; if we were going to conduct a large clinical trial we wanted to 
ensure that we were using an adequate dose of ACTH; one which would give us the best 
clinical response, but on the other hand high dose steroids may be associated with more 
frequent serious side effects. In the one paper that had looked at the side effects of ACTH
•  •  •  f t luse m IS in detail all the deaths had occurred in children who had received very large 
doses i.e. over 100 units ACTH given two times a week. It was therefore decided that a 
reasonable dose of ACTH would be 40 units on alternate days increasing to 60 units if no 
response was seen within a week, a dosage regime currently in widespread use in the UK, 
but the duration of treatment was restricted to 2 weeks since length of treatment as well 
dosage seemed to bear a significant relation to the incidence of side effects.
Deciding the dose of prednisolone to be used proved more problematic. Again we wanted 
to ensure that we were using an adequate dose that would give us the best clinical response 
but without causing serious side effects. Historically, large doses of prednisolone have 
been used when treating children. In the 1970’s doses were reduced, often to 2mg/kg body
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weight probably as a result of a wish to be logical over the treatment and because of 
concerns over the systemic side effects, although there was no scientific data to suggest 
that a reduction was necessary or that a dose on a per kg basis was logical. Large doses of 
steroids have been given for many years to pregnant women with no known ill effect to the 
foetus. High doses well above 2mg/kg are used in acute asthma attacks in children, albeit 
for only a few days. There are several pathophysiological mechanisms to explain why it 
might be safe to give relatively large doses of steroids to young children, including a 
relatively large volume of distribution. In the adult and older child only the kidney 
inactivates cortisol and prednisol. In the infant they are metabolised in every organ of the 
body, thus giving an extensive first pass metabolism effect throughout the first year which 
tails off after the first three months of life (personal communication). It was therefore 
thought that although 2mg/kg was the most widely reported dose of prednisolone for 
infantile spasms it might be inadequate. Baram71 et al in a single blinded study used a high 
dose of ACTH (150u/m2/day) against a low dose of oral prednisolone (2mg/kg/day), 
concluding that ACTH was more effective in terminating infantile spasms. Fourteen out of 
fifteen patients responded to the ACTH whereas only four out of fourteen responded to the 
relatively low dose prednisolone perhaps suggesting that when smaller doses of the 
steroids were used fewer patients responded. We would suggest that if these studies were 
to be repeated on a larger population using higher doses of prednisolone a greater 
proportion of infants might show a response. Their response to ACTH also helped to 
justify a high dosage regime.
Higher doses of oral prednisolone had been in use at the Royal United Hospital (RUH) 
during the previous thirteen years. We decide therefore to look at the patients who had 
been treated with prednisolone for infantile spasms during this time in order to try and 
assess the efficacy and safety of high dose oral prednisolone (usually 20mg tds for two 
weeks, regardless of weight or age) in the treatment of IS.
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The treatment of infantile spasms with high dose oral prednisolone: a retrospective
review.
Aims
In this retrospective study, the aims were to identify the frequency and type of side effects 
suffered by infants being treated with high dose oral prednisolone, in particular those that 
could be considered to be potentially serious or life threatening, and to observe the effect 
of the high dose prednisolone on the spasms themselves.
Patients and methods
The study group comprised all patients who had been admitted to the RUH between 
January 1983 and August 1996 with a diagnosis of IS. Patients were collected by two 
methods. Those who had been admitted between August 1987 and August 1996 were 
located via a database at Bath Health Information Services and those admitted prior to 
August 1987 were located via the EEG departmental records.
The medical notes were then retrieved and reviewed. Both a clinical description of the 
spasms and an EEG recording compatible with West syndrome (i.e. hypsarrhythmia or 
modified hypsarrhythmia) were required to fulfil the criteria for a diagnosis of IS. The 
following information was then sought for each patient;
• predisposing factors,
• age at diagnosis of IS,
• the apparent time delay from onset of spasms to diagnosis,
• time to start of treatment,
• dose and duration of steroids and the effect of treatment on spasms.
The notes, including nursing profiles, observation charts etc. were then scrutinised for any 





21 patients in total were identified has having IS during the period of January 1983 to 
August 1996. In our study there were 10 girls and 11 boys.
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There were four sets of notes in which the nursing observation charts had been lost and one 
further set only had the clinic letters available for the period of time that the patient 
suffered the IS (patient 21).
The age at diagnosis of the spasms ranged from three to 18 months with a mean of eight 
months and a median of seven and half months; no significant age difference was seen 
between girls and boys. In seven of the patients, no underlying cause was found. There 
was a wide range of predisposing factors in the remaining fourteen patients (table seven).
Table seven
Predisposing factors Number of patients 
n = 21
Symbol denoting this 
diagnosis in table 8
None (Idiopathic) 7 *
Neonatal hypoxic ischaemic 
encephalopathy
5 A
Down Syndrome 2 B
Tuberous Sclerosis 1 C







Idiopathic but time related to 
Pertussis Vaccination
1 I
One third of the patients had no cause underlying their IS i.e. they were 
idiopathic in type. Five of the patients had a history of birth asphyxia and 
one of developmental delay prior to the onset of spasms.
14/21 of the patients received 20mg prednisolone tds the other seven received slightly 














1.* 9 months 1 week 20mg tds 1 month 
then stopped
3 days None None
2. f 5 months 2 months 20mg tds 2 weeks 
then weaned off
8 days None None
3.* 5 months 5 days 20mg tds 2 weeks 
then weaned off
3 weeks None None
4 .b 5 months 6 weeks 20 mg tds 2 weeks 
then weaned off
2 weeks None None
5.* 8 months 5 weeks 20mg tds 2 weeks 
then stopped
1 day None None
6 .d 7 months 4 days lOmg tds 2 weeks 
then weaned off
5 days None None
7 .8 4 months 3 days 15mg tds 2 weeks 
then weaned off
2 weeks None None
8. * 8.5 months 3 weeks 10 mg tds 2 weeks 
then weaned off
2 weeks None None
9.* 9 months 9 months 10 mg bd 2 weeks 
then weaned off
reduced N/A Nitrazepam
10. * 6 months 3 months 20mg tds 2 weeks 
then weaned off
Reduced N/A Nitrazepam
11. h 6 months 2 months 20mg tds 2 weeks 
then stopped
Reduced N/A Vigabatrin, clonazepam, 
Valproate
12.* 15 months 8 months 20 mg bd 4 weeks 
then weaned off
Reduced N/A Nitrazepam, CMZ
13.* 8 months 2 months 20mg tds I month 
then weaned off
1 day Yes Vigabatrin, Nitrazepam, 
Valproate, Pyridoxine, 
Biotin
14.* 3 months 1 month 20mg tds 2 weeks 
then weaned off
10 days Yes Vigabatrin, Valproate
15.c 7 months 4 months 20mg tds 1 month 
then weaned off
2 days Yes Vigabatrin
16.* 10 months 6 weeks 20mg tds 2 weeks 
then stopped
3 days Yes Clonazepam, CMZ
17.c 6 months 1 month lOmg qds 1 month 
then weaned off
6 weeks Yes Nitrazepam
18.* 5 months 1 week 20mg tds 2 weeks 
then weaned off
4 days Yes Steroids repeated fits 
stopped next day, no further 
relapse
19. b 11 months 6 months 20mg tds 2 weeks 
then stopped
Didn’t N/A Vigabatrin, Valproate, 
Nitrazepam
20.* 11 months Unknown 20 mg a day 2 weeks 
then stopped
Didn’t N/A Valproate, Nitrazepam, 
CMZ
Clonazepam, ethosuximide
21.e 18 months Unknown 20mg tds 2 weeks 
then weaned off
Reduced N/A Steroids repeated, 
Vigabatrin and 
Valproate
• idiopathic, a birth asphyxia, b Down syndrome, c tuberous sclerosis, d head 
injury, e developmental delay, f polymicrogyria, 9 lisencephaly, h unknown, 
'pertussis vaccination. See table seven for diagnoses.
• In patient 17 it is not clear whether the cessation in spasms was directly due to 
the steroid therapy or nitrazepam but analysis was performed on an intention to 
treat basis.
Table to show the age at which the infantile spasms were diagnosed and the delay 
from onset of the spasms to their diagnosis. The dose and duration of oral 
prednisolone, the effect it had on the spasms and any other drugs used.
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Nineteen (90%) of patients showed either a reduction in the number (5) or complete 
cessation of their spasms (14) as a result of prednisolone treatment with four of the 
fourteen receiving less than 20 mg tds. Two patients had no response to the prednisolone, 
both were treated with a wide variety of drugs, with no response and both went on to 
develop further types of fits. Six of those that responded subsequently relapsed after 
stopping the prednisolone, one initially receiving lOmg tds only: one was given and 
responded to a second course of prednisolone.
In five patients the number of fits were reduced by prednisolone, in two of the patients the 
fits were further reduced by the addition of nitrazepam and in one by vigabatrin, the 
remaining two received a variety of drugs including vigabatrin, clonazepam and valproate 
with no beneficial effect.
Side effects
In eight of our patients no side effects were reported. Irritability was by far the commonest 
problem experienced by eight of the patients, drowsiness, changes in appetite and poor 
sleeping were also experienced. Diarrhoea and vomiting occurred in two of the patients 
requiring oral rehydration only. No other infections were reported during the use of 
steroids. A transient mild rise in blood pressure was noted in three patients but no medical 
intervention was required and in each case the blood pressure returned to normal after the 
course of steroids was completed. In a fourth patient (patient 21) the blood pressure was 
noted to be high 150/90 at follow up: this child’s notes were missing but in subsequent 
letters the systolic pressure is recorded as 100 after the steroids had been tailed off.
Table nine
Side effects (n=21) No. Of patients
Irritability 8
Drowsiness 3
Transient rise in BP 3 + (l)





In eight patients no side effects were reported, in the remaining 13 patients 
one or more side effects were experienced.
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No glycosuria was recorded at any time in any of the patients. Finally cushingnoid features 
were noted in three of the infants, two of these patients had received two courses of 
steroids (table nine).
Discussion
This was a small retrospective study and is therefore prone to bias. It is possible that cases 
were missed the collection method and it is possible that those patients may have had a 
worse outcome. The estimated incidence of IS ranges from 0.16 - 0.42 per 1000 live births 
per year50 51 52 53. In the Bath district there are just over 5000 live births per annum. We 
would therefore expect to see on average one to two cases a year (i.e. 13 -26 cases over the 
13 year period). We believe that using our search strategy we are unlikely to have missed 
many cases. In addition the study is prone to selection bias (see chapter five), that is 
patients who might respond less well to steroids may have been given an alternative 
treatment. Finally the numbers are small, thus the power of the study is small.
The side effects of steroids are well known. One of the aims of this study was to ascertain 
the frequency of serious side effects with the use of high dose oral steroids. In our small 
study of 21 patients none suffered serious complications of steroid therapy. There are the 
less serious side effects that are often transient but nevertheless cause a certain amount of 
morbidity such as hypertension. In our group we had three patients who had a mild 
transient rise in blood pressure (95/50 to 155/80, 100/60 to 140/80 and 105/70 to 160/70), 
fortunately with no serious sequele. The hypertension was usually seen after the patient 
had been discharged from hospital, whilst being followed up in the out patient clinics. 
Hypertension is often overlooked and as a result the amount of information available in the 
literature is lacking. In the study carried out by Riikonen and Donner83 looking specifically 
at the side effects of ACTH only 17 out of 162 patients had their blood pressure routinely 
measured and in a review of the treatment by child neurologists of infantile spasms by 
Bobele and Bodensteiner53 only two thirds measured blood pressure on a weekly basis 
during treatment. In our study the blood pressure had been monitored in all patients for 
whom the full medical notes and nursing observation charts were available. In our study 
two thirds of the patients complained of minor side effects although none were sufficiently 
severe to prevent continuation of the therapy.
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Control of fits occurred in the majority of our patients and of the patients in whom fitting 
was not controlled by a course of prednisolone, other anticonvulsants including vigabatrin 
also failed. We would speculate that our success rate of 70% complete remission may be 
due to our larger than generally accepted dose of 20mg three times a day, regardless of age 
or weight (however the lower doses used in some patients were also effective). This 
finding has not been previously published but does show, importantly, that higher doses of 
prednisolone are effective.
It is interesting to note that in our study the patients who had idiopathic infantile spasms 
(denoted by * table eight) faired no better or worse in terms of outcome of seizures. The 
one patient known to have TSC showed a good response to steroids initially but 
subsequently relapsed and was successfully treated with vigabatrin.
In retrospect many of the patients were thought to have had the spasms for some time prior 
to diagnosis. The time delay to diagnosis ranged from one week to nine months (table 
eight). Often this was because the spasms had been misdiagnosed, for example as colic, but 
in others the parents had not sought medical advice. In one patient, the spasms were 
diagnosed when the patient attended clinic for a different reason at the age of nine months. 
The mother stated that the spasms had been present from birth but that she thought they 
were normal for her child. This highlights the great difficulty in diagnosing this syndrome 
early.
Conclusion
In conclusion, we found high dose oral prednisolone to be an effective treatment for IS, 
stopping seizure activity in two thirds of the patients treated. In addition, life-threatening 
complications did not occur with high dose prednisolone in our group suggesting that they 
may be infrequent in this effective regime for West syndrome. Although minor side effects 
are commonly experienced these are transient and cause no long-term morbidity. We 
therefore decided that it was justified to use high dose oral prednisolone in order to achieve 
maximum effect in our trial. The core group decided on a dosage regime of 40mg / day 
increasing to 60mg / day if no effect was seen after one week, in the hope that not all 
infants would need 60/kg/day and that starting at a lower dose would encourage 
participation by parents and doctors in the trial.
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A review of vigabatrin in the treatment of infantile spasms in tuberous sclerosis 
complex.
The next question to be addressed was whether patients known to have a diagnosis of TSC 
at the onset of their spasms should be included or excluded from the trial. We therefore 
undertook a review of the English literature to examine the efficacy and safety of 
vigabatrin in the treatment of IS in infants suffering from TSC.
Methods
A Medline and Embase search dating back to 1990 of the English literature for all studies 
investigating the effect of vigabatrin on IS was performed. Vigabatrin was first brought to 
clinicians attentions by Chiron in 1991 and it is unlikely that there are any relevant trials 
published prior to 1990. All references in the articles cited were then examined for further 
references. Studies that did not distinguish which infants had an underlying diagnosis of 
TSC were excluded.
Results
Fifteen studies investigating the effect of vigabatrin on IS were found in total. Of these, ten 
studies gave a breakdown for the effect in patients with TSC in addition to the overall 
results. Two of these studies98 99 were then rejected because the patients were all included 
in a further publication100.
Table ten
Study Type of study No patients M:F
Chiron et al 19901W1 Single Blind 45 Not given
Chiron et al 19918̂ Open add on 70 33:37
Appleton et al 1993 100 Retrospective 21 10:11
Vies et al 199310i Open 6 2:4
Schmitt et al 1994103 Open 17 Not given
Vigevano et al 1995104 Open randomised 21 Not given
Aicardi et al 199688 Retrospective 192 109:83
Chiron et al 199789 Open randomised 18 5:6
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Table of authors of the studies reviewed, the type of study, the total number 
of patients treated with vigabatrin and the male to female ratio of patients, 
presented chronologically.
There were five open prospective studies, two retrospective studies and one single blinded 
study. The total number of patients in each study ranged from as few as six to as many as 
192. The male to female ratio was only included in five of the studies and overall showed a 
slight male preponderance of 1.1:1.0 (table ten).
The average age at treatment was given for five of the eight studies with an overall average 
of 9.9 months. In five of the studies the patients had received therapy prior to the 
vigabatrin and in three of these studies the patients continued with concurrent therapy 
alongside the vigabatrin. The dose of vigabatrin varied from 50 to 200mg/kg/day (table 
eleven).
Overall there were 390 infants treated with complete cessation of spasms occurring in 242 
i.e. 62%. Of these 77 had a known underlying diagnosis of TSC, the remaining 313 had IS 
due to other causes or no cause found at the time of the study. 73 (94%) of the patients 
with TSC had complete cessation of their seizures as compared with 169 (54%) of the 
remaining patients (table twelve).
Table eleven






Dose of vigabatrin 
(mg/kg/day)
Chiron et al 19901U1 26 Yes Yes 50-200
Chiron et al 199187 Not given Yes Yes 50-200
Appleton et al 1993100 8.5 No No 80-120
Vies et al 199310i 4.75 Yes No 50-100
Schmitt et al 1994103 Not given Yes Yes Up to 150
Vigevano 1995104 4 -9  months No No 100-150
Aicardi et al 199688 5.8 No No 20 -  400 (Av 99)
Chiron et al 199789 7.25 Yes No 150
Table showing the average age at treatment, whether previous treatment had 
been given, whether concurrent treatment was given and the range of doses 
of vigabatrin administered.
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Three 101 102 103 of the papers did not specify the time taken to achieve cessation of the 
spasms and a further paper87 specified that cessation had occurred within a month of 
commencing the vigabatrin. Appleton100 reported that control occurred within seven days 
and Vivevano104 reported control within eight days. Aicardi88 and Chiron89 both reported 
an average of 4 days for control of spasms in those patients who responded to vigabatrin.
Table twelve
Study





Total number Number of 
responders
Chiron 1990 8 7 37 9
Chiron 1991 14 12 56 29
Appleton 1993 3 3 18 14
Vies 1993 1 1 5 3
Schmitt 1994 2 2 15 5
Vigevano 1995 3 3 18 6
Aicardi1996 28 27 164 104
Chiron 1997 18 18 0 0
Total 77 73 (94%) 313 170 (54%)
Table showing the response rate to vigabatrin in all the patients, those 
without tuberous sclerosis and those with tuberous sclerosis. A responder 
is defined as a patient in whom there was total cessation of spasms.
Table thirteen


















Drowsiness 5 2 15 3 25
Behavioural 1 12 3 16
Insomnia 3 5 8
Hypotonia 4 1 4 1 10
Diarrhoea 1 1
Weight gain 4 1 5
Vomiting 0
Other 12 2 3 4 1 22
Total 12* 18 2 2 None
reported
3* 42 8 87
*9 children reported adverse events of hyperkinesia, weight gain and 
drowsiness 
# specific side effects not stated.
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Table showing the number and type of side effects I adverse reactions 
reported in each study (there were 390 patients in total).
In total 87, adverse events, from the 390 patients were noted (table thirteen). The majority 
of these were transient and none were reported to continue after stopping the vigabatrin. In 
all the studies only seven patients were reported as having the vigabatrin withdrawn due to 
intolerability. The reasons for withdrawal were: hypertonia, hypotonia, hyperactivity, 
irritability and myoclonus. There were no reported deaths attributable to vigabatrin.
Discussion
This review found a male : female ratio of 1.1:1. The average age of treatment was 9 
months, which reflects that many of the patients had been tried on more traditional 
therapies such as steroids before vigabatrin was used. Interestingly, in past studies TSC has 
accounted for approximately 10% of patients with IS. In these studies it accounted for 20% 
of the patients. This may be due to biased selection of patients (as most of the studies were 
either open or retrospective) or alternatively with improving imaging and diagnostic 
techniques, it may be that more patients are being diagnosed as having TSC. It may be a 
chance finding.
The group of patients with TSC treated with vigabatrin had a 94% response rate. This 
response rate was seen in spite of resistance to other treatment and delay in commencing 
therapy. In contrast, in the group of patients in whom there was no history of TSC, the 
overall response rate (i.e. total cessation of spasms) to vigabatrin was 54%, similar to 
steroids but, it must be remembered that many of these patients treated with vigabatrin 
were not newly presenting and had previously failed to have their spasms controlled by 
other therapies.
Many children who suffer IS ultimately go on to have further seizures. The second 
commonest seizure type in young children with TSC is partial seizures. Although partial 
seizures are generally considered to be resistant to treatment with vigabatrin, a recent study 
by Nabbout et al 1997105 suggested that in children with TSC vigabatrin may be effective 
in treating partial seizures in up to 85% of patients.
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Various dose regimes were used, but the core group decided to use the licensed dosage 
regime:
50mg/kg/day orally in two divided doses for 24 hours (i.e. a total of two doses), increasing 
to lOOmg/kg/day orally. If seizure control is not achieved then the dose can be further 
increased to a maximum of 150mg/kg/day in two divided doses.
Although vigabatrin has only been in clinical use for a few years, it appeared to have few 
serious side effects. Although a total of 87 adverse events were reported in the studies 
reviewed, only seven patients had their vigabatrin stopped and no side effects were 
reported to persist after withdrawal of the vigabatrin. (The reasons for withdrawing the 
vigabatrin were only given for five of the seven patients and were: hypotonia, hypertonia, 
hyperexcitability, irritability and myoclonus).
Earlier primate studies in dogs and rats had suggested a risk of intramyelinic oedema with 
vigabatrin, but serial evoked potential studies and reports of brain histology in treated 
patients have not supported this effect in humans106. However, since this work was 
completed there have been reports of both asymptomatic and symptomatic visual field
• 1H7defects with loss of peripheral vision to varying degrees in adults treated with vigabatrin
l08. It appears to occur most commonly in patients who have been treated with vigabatrin
for several years and more recent research, at least in adults, suggests that it is not
reversible on withdrawing the vigabatrin109. Out of approximately 140,000 adults treated
with vigabatrin between its introduction in 1989 and 1997 there had been 28 reports of
visual defects - a frequency of less than O.l90 107 108 109. The main difficulty in infants is that
they cannot be tested or monitored for visual field defects (a child needs to be at least
eleven to be able to co-operate and complete the test). However, on balance the devastating
effects of IS probably outweigh the risks of developing visual field defects (which may be
asymptomatic): a paediatric advisory group110 have recommended that vigabatrin should
still be prescribed for IS, and the medicine licence in the UK remains. In addition it must
be remembered that refractory epilepsy may cause visual defects itself, for example by
disseminated intravascular co-agulation (DIC) occurring with prolonged seizure activity111
and other anticonvulsants such as sodium valproate and phenytoin have also been
110associated with visual defects . In some patients with infantile spasms, their underlying 
disease may also cause visual field defects. Further research into the effects of vigabatrin 
on visual fields in this group of children is required. Unfortunately, because of the
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difficulty in testing visual fields in young children, it may be necessary to wait several 
more years until infants treated with vigabatrin for infantile spasms become old enough to 
co-operate with such testing. In addition, because of the devastating effect that the spasms 
can have on development many of these children may never be able to perform visual field 
testing.
Unfortunately only tw'o of the studies gave a breakdown for the effect of vigabatrin on 
cessation of spasms due to other underlying aetiologies (e.g. cerebral dysgenesis, birth 
asphyxia), a total of only 15 patients, so it is not possible to comment on the efficacy of 
vigabatrin in these other subgroups. Neither is it possible to discuss the effect of vigabatrin 
on EEG appearance in this review as the papers did not contain sufficient information. It is 
also known that abolition of hypsarrhythmia on EEG can lag behind the clinical response, 
and some of the studies only had a relatively short follow up period.
Conclusion
We conclude that vigabatrin should be considered the drug of choice for patients with IS 
and either a known diagnosis of TSC, or at high risk of TSC before investigations are 
complete i.e. those with a first degree relative with TSC because of its efficacy, speed of 
onset and relatively safe drug profile. Paradoxically, steroids despite the side effects may 
be a better choice for the remainder, but further information is required and a randomised 
controlled trial clearly justified.
On the basis of this review it was decided that it would be unethical to randomise patients 
with, or at high risk of TSC to steroids and they would therefore be excluded from the trial.
77
CHAPTER FOUR
The United Kingdom Infantile Spasms Study (UKISS)
Appendix one -  protocol and trial pack
A core group (appendix two) was identified to propose a study design to investigate the use 
of “steroids” and vigabatrin in the treatment of infantile spasms to try establish the most 
effective initial treatment regime for this serious disorder. At the time of designing the 
study the two “steroid” preparations in widespread use in the UK were ACTH 
(adrenocorticotrophin hormone) and prednisolone. ACTH was a natural product derived 
from a bovine source and as discussed above was administered as a daily intramuscular 
injection with a commonly accepted dosage regime of 40-60iu/day. However, with the 
existing concerns surrounding bovine spongiform encephalopathy (BSE) ACTH was 
withdrawn from the market. It was replaced with synacthen depot, a synthetic analogue of 
ACTH with a dose equivalent of 0.5-0.75mg/altemate days.
Infantile spasms are relatively uncommon and in order to be able to recruit the numbers 
required to give the study reasonable power, the trial would need to recruit infants from a 
large population such as the whole of the UK rather than just a few health districts. In order 
to try and minimise selection bias it was decided that the trial should be a randomised 
controlled trial with concealment of allocation (see chapter five). Ideally, in order to 
minimise performance bias (see chapter five) the trial should also be blinded so that the 
patients (parents/guardians) and medical staff administering the treatment and measuring 
outcome would be unaware as to which treatment the subject had been randomised. 
However, this would be problematic because synacthen depot can only be given by 
intramuscular injection whilst prednisolone and vigabatrin are administered orally; 
nowadays it is generally considered unethical to administer placebo injections to young 
infants. In addition, the side effects of steroids are easily recognised by both clinicians and 
parents so that it was likely that the treatment that had been assigned would become 
apparent in a significant number of cases. The final dilemma was that few placebo 
controlled trials have been performed and those that have contain insufficient number of 
patients to provide adequate power to the study, so that we do not know if any one 
treatment is more effective than no treatment at all. However, many would argue that 
delaying treatment (which might worsen the outcome) by administering a placebo
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treatment is also unethical. It was therefore decided that this should be a national, 
multicentre, randomised, parallel-group, open clinical trial.
The trial centre would be in Bath and one Paediatric Neurologist in each of the old Health 
Regions would be identified and recruited to help promote the study. It was hoped that 
every health district within the UK would participate. Papers dealing with the 
epidemiology of IS put the incidence between 1 in 2380 and 1 in 6250 births (see chapter 
three). The average UK birth rate is approximately 800,000 per year. Therefore it should 
be possible to recruit between 130 and 340 new cases per year. Taking into account 
exclusions the scheduling of the study presumed a recruitment rate of approximately 200 
per year. Assuming recruitment of 250 children over an 18 month period, with 
approximately 125 randomised to vigabatrin and 125 to “steroids” and assuming 
approximately 50% would achieve cessation of seizures in the “steroid” group, the trial 
would have 90% power to detect an improvement in cessation of seizures to 70% in the 
vigabatrin group. The consensus of the core group was that an improvement of at least 
20% in cessation of spasms would be required to persuade clinicians to change their 
clinical management of these patients. Central randomisation by telephone call would 
register the child into the trial, report baseline information and allocate initial treatment 
(concealed in sealed envelopes). Patients would be allocated to one of two treatment 
groups: vigabatrin or steroids. The steroid group would then be further randomised to 
receive synacthen or prednisolone. To try and reduce selection bias further, patients would 
be stratified before entry according to sex, age and whether they belong to symptomatic or 
non-symptomatic groups (see later).
We envisaged minimal problems with compliance and loss to follow up. This is a serious 
disorder with profound sequele. The motivation for clinicians and parents of patients to 
participate in treatment is high. The workload to be imposed on attending physicians 
would be little more than constitutes good clinical practice. The workload to be imposed 
on parents is small. Patients known to be likely to move outside the country during the trial 
period would be excluded at entry. As this would be a national study, movement within 
the UK should not lead to loss of contact. Patient's NHS number would be recorded on 
entry to the trial thus making subsequent identification easier. In a previous multicentre 
follow-up study conducted from Bath of 276 children, the investigators achieved 97%
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follow-up at 3 years and 9 months. It was hoped that we could achieve a similar or 
improved rate of follow-up in the UKISS trial.
To maximize the amount of information gathered during the trial it was decided to set the 
drug trial within an epidemiological report of all cases of infantile spasms occurring within 
the UK. This would allow us to collect further information on the epidemiology and 
natural history of infantile spasms, including those infants who would be excluded from 
the drug trial for whatever reason. It was decided therefore that we would ask that all cases 
of infantile spasms would be reported to the trial centre even if the individual patient was 
not to be recruited into the drug trial. This would also be helpful in allowing us to ascertain 
how representative our trial population was compared to the whole UK population. Brief 
clinical details would be requested.
In order to be recruited into the drug trial the patient would have to be between 2 
completed calendar months and 1 year of age (up to but not including their first birthday) 
at the onset of their spasms. Below the age of two months infantile spasms are rare and can 
be difficult to diagnose. It was therefore decided that infants under the age of two months 
would only be eligible for entry into the epidemiology part of the study. It was decided that 
one year of age would be the upper age limit for drug trial entry for two reasons; firstly, 
measurement of long-term psychomotor development (see later) would be undertaken 
when the infant reached 12-14 months; secondly, after the age of one other possible 
diagnosis should be considered, for example infantile myoclonic epilepsy, that can be 
easily mistaken for infantile spasms. Infants would be excluded from the drug trial (but not 
the epidemiology trial) if they were either known to suffer from tuberous sclerosis (TSC) 
or who were at high risk i.e. a presumptive diagnosis of tuberous sclerosis because of; 
known affected parent, previously diagnosed cardiac rhabdomyoma, hypomelanic macules, 
a forehead fibrous plaque or shagreen patch noted, a retinal phakoma seen, or were known 
to have polycystic kidneys. We recommended that first line therapy in these infants should 
be vigabatrin (see chapter three). Infants would also be excluded from the drug trail if they 
had received previous treatment for infantile spasms or had been treated with vigabatrin or 
steroids within 28 days of the first diagnosis of infantile spasms for any other reason. This 
was because the aim of the trial was to establish the most effective initial treatment for 
infantile spasms. Other exclusion criteria included; infants with a contra-indication to 
vigabatrin or steroids; infants with a lethal or potentially lethal other condition; inability of
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parents or guardians to give informed, signed consent; inability of parents or guardians to 
know when spasms stop - to the nearest whole day; infants expected to leave the UK 
within one month of randomisation and finally any infants enrolled in a concurrent trial 
that either uses therapy that might affect the outcome measures of the UKISS trial or one 
that is time/effort consuming for the patients/guardians or the infants’ medical 
practitioners.
The trial would then be discussed with the parents or guardians and their consent requested 
for participation in the trial. If consent was refused for entry into the drug trial or the 
infant was excluded for any reason given above then consent would be requested for entry 
into the epidemiology trial only. If consent into the drug trial was successfully obtained 
then an EEG (or video EEG) would be obtained as quickly as possible to confirm the 
diagnosis of infantile spasms and allow randomisation into the drug trial. If the EEG was 
normal the child would be excluded from the drug trial (but not the epidemiology trial). 
Prior to randomisation for entry into the study the children would be stratified for; gender, 
male or female; by age, 60 to 119 days, 120 to 179 days, 180 to 239 days, 240 days and 
over; whether the infant belonged to a symptomatic or non-symptomatic group. The 
symptomatic group consisted of those infants known to have an underlying diagnosis such 
as a proven chromosomal abnormality, a syndrome diagnosis, cerebral palsy or a diagnosis 
of neonatal encephalopathy with seizures, and those with a diagnosis of delayed 
development having already been made by either a medical practitioner or health visitor 
before the onset of the spasms. The non-symptomatic group includes all infants who had 
no known underlying diagnosis at the time of diagnosis and who had normal development 
prior to onset of the spasms. The purpose of pre-randomisation stratification was to balance 
the treatment groups with respect to factors, which were identifiable at randomisation that 
might affect the outcome measures.
All children eligible for the trial would then be randomised into the two treatment groups; 
vigabatrin or “steroids” and all patients randomised to receive "steroids" would undergo a 
second randomisation; to receive either synacthen depot or prednisolone. The only 
pharmacological intervention for the infantile spasms for the initial trial period of two 
weeks would be the drug to which each patient had been randomised. Those randomised to 
receive vigabatrin would be given the dosage regime recommended by the manufacturers: 
50mg/kg/day orally in two divided doses for 24 hours (i.e. a total of 2 doses); then to
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increase to 100mg//kg/day orally in two divided doses in all patients; if at 96 hours seizure 
control has not been achieved then the dose should be further increased to 150mg/kg/day 
orally in two divided doses; they would then continue on this dose (100 or 150mg/kg/day) 
until the time of their final developmental assessment around 12-14 months of age unless 
no response or relapse occurred (see below). As ACTH gel was no longer available in the 
UK, synacthen depot was substituted at the equivalent dosage; 0.5 mg on alternate days 
(equivalent to 40iu/day of synacthen) intramuscularly (regardless of age or weight) for two 
weeks. If at the end of the first week seizure control had not been achieved then the dose 
would be further increased to 0.75 mg on alternate days (equivalent to 60iu/day of 
synacthen) intramuscularly. This is a relatively high dosage regime, but one that is widely 
accepted by clinicians in the UK. It is important that exogenous steroids are not stopped 
suddenly, especially if they have been administered at high doses, as sudden withdrawal 
can lead to an Addisonian crisis.
Addisonian Crisis
Addisonian crisis is acute adrenocortical failure that may occur as the result of sudden withdrawal of 
exogenous steroids, and is a critical medical emergency. Delay in treatment may result in death. The patient 
usually presents with abdominal pain, vomiting, diarrhoea, pyrexia, dehydration and profound hypotension 
and later with collapse and coma. Laboratory parameters show low sodium, bicarbonate, glucose and cortisol 
levels and high potassium, urea and endogenous ACTH. Immediate management consists of resuscitation and 
intravenous hydrocortisone. All patients on steroid treatment should be advised not to alter their drug regime 
except on medical advice and should carry a medi-alert card.
This group would therefore tail on oral prednisolone over 15 days. Those on 0.5 mg on 
alternate days of synacthen depot would receive 30mg of oral prednisolone for 5 days, then 
20mg for 5 days then lOmg for five days and stop. Those on 0.75 mg on alternate days of 
synacthen depot would receive 40mg of oral prednisolone for 5 days then 20 mg for 5 days 
then lOmg for 5 days then stop.
Those randomised to prednisolone would be given lOmg qds. orally (regardless of age or 
weight) for two weeks; if at the end of the first week seizure control had not been achieved 
the dose should be increased to 20mg tds. orally. The dosage regime is higher than that 
frequently used by clinicians in the UK but was chosen for the reasons outlined in chapter 
three. This group would also tail on oral prednisolone over 15 days. Those on 40mg (10 
mg qds.) would reduce to 30mg for 5 days, then 20mg for 5 days then lOmg for five days 
and stop. Those on 60mg (20 mg tds.) would reduce to 40mg for 5 days then 20 mg for 5 
days then 1 Omg for 5 days then stop.
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Primary outcome measure
The primary outcome measure would be the number of patients who achieve complete 
cessation of spasms for at least 48 hours up to and including the end of the 14th day of 
treatment.
At enrolment the parents/guardians would be given their copy of a ‘fit diary’ and its use 
fully explained to them. The parents/guardians would be asked to make a once daily entry 
for the first 4 weeks of the trial and a once weekly entry thereafter, until the time of the 
final developmental assessment (12 -14 months), with a final 7 day daily entry for those 
still having seizures.
Responders are defined as those in whom there is total cessation of spasms for at least 48 hours up to and 
including the end of the 14th day of treatment.
Relapse: a single spasm in a responder constitutes a relapse.
If a child relapses within the initial two week period then the lead clinician would be 
expected to increase the dose of the initial therapy up to the maximum recommended dose 
as per protocol.
The patient should be seen by the enrolling physician at two weeks post-trial entry to 
confirm their progress. If the infant has responded the patient will continue on the same 
therapy as above. The trial will be analysed by intention to treat at the time of 
randomisation; in order to minimise the effects of a multitude of different subsequent 
treatments if a response has not occurred after 2 weeks, the lead clinician will be asked to 
change to the alternative therapy i.e. either steroids after vigabatrin (the lead clinician to 
choose which steroid -  synacthen depot or prednisolone) or vigabatrin after steroids. This 
alternative treatment will continue for the third and fourth weeks (a full 14 days) at the 
same dose as recommended for the first two weeks. If both treatments fail, the clinician 
will be left to choose the most appropriate treatment.
If the patient relapses after the initial two week trial period we suggest that if the child is 
on vigabatrin to increase the dose in parallel with the child’s weight gain (if increase is 
more than 1 kg) or if on lOOmg/kg/day increase to 150mg/kg/day; If on steroids repeat the 
course once even if tailing. If these measures fail after a full 14 days treatment change to
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the alternative therapy i.e. either steroids (synacthen depot or prednisolone) after
vigabatrin, or vigabatrin after steroids.
Secondary outcome measures
ft was decided that the time taken to complete cessation of all spasms for at least 48 hours 
would be measured as many clinicians believe that the quicker the spasms are brought 
under control the better the long-term outcome. If one treatment does bring the spasms 
under quicker control and also improves long-term psychomotor development then this 
would support the above hypothesis. In addition the spasms may be distressing to the 
infant and parents; if both treatments were found to be equally efficacious then it might be 
preferable to use the treatment that works most quickly.
Any reduction in the number of spasms suffered by non-responders would also be 
measured. If the duration of spasms is linked to long-term psychomotor development then 
likewise the number of spasms may also be important in determining long-term 
development. In addition if the spasms are distressing to the infant a treatment which 
reduces their frequency may be preferable to one that has less effect.
Relapse rates; clearly even if one treatment stopped the spasms in a greater proportion than 
the other, if remission of the spasms could not be maintained then if the number of patients 
who remained in remission in the other group was higher it might be considered to be the 
most efficacious treatment overall.
The precise relationship between clinical spasms and hypsarrhythmia is not clear 
especially with regard to long-term outcome. To be eligible for entry into the drug trial 
hypsarrhythmia had to be present on the entry EEG. An EEG was then to be repeated at the 
end of the initial two week period. It was hoped this might allow us to determine whether 
or not resolution of the hypsarrhythmia has any impact on the long term outcome. Patients 
who did not have hypsarrhythmia on the entry EEG would be asked to participate in the 
epidemiology trial, this would allow us to hypothesize whether patients without 
hypsarrhythmia at time of diagnosis have a better/worse/similar outcome to those who do 
have hypsarrhythmia.
It is known that in the majority of patients the natural history of the spasms is that they will
resolve with time, even if the patient is untreated. Nonetheless, many patients will continue
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on to develop other forms of seizures and epilepsy. It is not yet known whether controlling 
the spasms effectively bears any relationship to the risk of developing other seizure types. 
It was therefore decided that subsequent seizure types would be regarded as a long-term 
outcome in our group of patients and would be measured at the time of the follow up for 
psychomotor development. The type and frequency of seizures other than spasms suffered 
by the infant in the month preceding the developmental assessment at 12-14 months would 
be recorded.
Long term psychomotor development may be the most important outcome for this group of 
patients. Many would argue that any treatment proven to be most beneficial with respect to 
developmental progress should be used in preference to any other medication regardless of 
its effect on the other outcomes listed above. Developmental progress would be assessed at 
the time of trial entry and again at 12 -14 months of age. This would allow at least 2 
months of recovery following treatment and is an age at which some language 
development has occurred. It is believed that delaying the assessment to a greater age will 
give little advantage and would have the disadvantage of increasing the impact of 
environmental factors. The Vineland Adaptive Behavioural Scales were chosen after 
lengthy consideration as the tool of choice for assessing developmental outcome in our 
group of patients.
The Vineland Adaptive Behaviour Scales have been developed and validated in the U.S.A. to measure 
“adaptive behaviour” defined as the performance of the daily activities required for personal and social 
sufficiency. The Vineland has four domains (communication, daily living skills, socialisation and motor 
skills) and these combine to give an Adaptive Behaviour Composite: each of these has a standard score of 
100 with a standard deviation of 15 and each can be expressed as an age equivalent (developmental age).
One of the main benefits of the Vineland is that it can be easily adapted to be performed as a questionnaire 
that can be administered over the phone by a trained researcher who would be based in Bath either to the 
enrolling physician or parent/guardian. In addition it concentrates on the usual response, not the best response 
to any task. It has been validated in greater detail on larger numbers of children (3000) and has been used in 
the U.K. for other developmental follow-up studies. It achieves construct validity, content validity and has 
been compared to other scales in both normal and handicapped children. It has been shown to have internal 
consistency, test-retest and inter-rater reliability. It has also been designed to minimise the influence of 
physical handicap.
Finally side effects and deaths in each group would be recorded as these are considerations 
which in clinical practice often dictate the acceptability of a treatment to the 
clinician/patient//parent /guardian. Should an infant suffer unacceptable side effects during 
the trial then the treatment should be discontinued and the trial centre informed 
immediately. The lead clinician may then choose his own alternative treatment, but we
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suggest the lead clinician change to the alternative therapy i.e. either steroids (synacthen
depot or prednisolone) after vigabatrin, or vigabatrin after steroids.
Investigations
In order to understand more about the associations and aetiologies of infantile spasms we 
choose to collect information on the results of any investigations undertaken on any patient 
enrolled into the trial. As part of normal clinic practice it was anticipated that the following 
investigations would be undertaken on all subjects.
1. MRI or CT of the brain.
2. Urine metabolic screen for amino acids.
3. Ophthalmoscopy (either direct or indirect).
4. Ultraviolet light examination (Woods light).
We requested that the results of these tests should be forwarded to the trial centre. The 
following tests might also have be considered appropriate in some cases and, if performed, 
the results of these and any other tests would be requested.
1. Urea and electrolytes.
2. Liver function tests.
3. Chromosomes.





9. Pyridoxine response - if pyridoxine is to be given we would recommend that 
pyridoxine is given one month after the start of the trial (after both the 
randomised treatment and first alternate treatment have been given in a child 
who continues fitting).
Finally, at present it is not thought that infantile spasms are genetically determined, but 
there are rare reports of X-linked cases in the literature54. To investigate the possibility of a 
genetic predisposition we requested that if venesection was performed for any clinical 




A Data Monitoring Group has been set up (appendix two) that will analyse and assess the 
results independently of the trial investigators (the Trial Steering Committee, appendix 
two) for the duration of the trial at a frequency to be recommended by the chair.
There will be post-randomisation stratification for potential confounding variables not 
accounted for in pre-randomisation. These include EEG appearance (i.e. hypsarrhythmia vs 
atypical vs normal awake, normal asleep) and diagnostic sub-groups (i.e. cerebral 
dysgenesis on cranial scanning, chromosomal abnormalities or other syndromes and other 
diagnosis such as metabolic disease). Social factors will include birth order and maternal 
age at school leaving.
It may be possible to see if any trends in outcome are repeated within subgroups of the trial 
population. The largest subgroup should be infants where development was delayed (as 
shown by pre-randomisation stratification data and as shown separately by the 
developmental history). Smaller subgroups, e.g. those diagnosed with cerebral palsy on 
clinical examination, cerebral dysgenesis on cranial imaging, normal awake and sleep 
EEGs, are unlikely to be large enough for separate analysis. However, the data will be 
examined in case there is a dramatic difference in outcome, or a consistent trend.
We are aware that the pattern of developmental age in the two groups may be bimodal. A 
direct comparison of the developmental age (total score and subsets) of the two groups will 
be undertaken, but we will also determine the proportion of individuals in each group 
whose development is one, two and three standard deviations below the mean for the 
Vineland.
Ethical approval was then sought and granted from the Multicentre Research Ethics 
Committee (MREC). Investigators are continuing to be recruited and Local Research 
Ethics Committees (LREC) approached. Enrolment of patients into the trial began June 
1999.
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REPORT ON STUDY STATUS TO THE END OF SEPTEMBER 2002
Local ethical approval had been granted in 150 centres across the UK.
Enrollment
One hundred and five infants have been enrolled into the randomised controlled drug trial 
and the epidemiology study.
Eighty eight infants have been enrolled into the epidemiology study only.
A further fourty four infants have been notified to the trial centre but were not eligible for 
inclusion into the trial.
Duration of study
Due to unforeseen delays in recruiting centres and obtaining local ethical approval, the rate 
of recruitment into the trial has failed to reach the above estimates. Additional funds have 
been granted to allow the UKISS study to continue until the end of 2002 to allow us to aim 
to reach an adjusted target recruitment of 125 patients into the randomised controlled drug 
trial, this will give us an 80% power to see a 25% difference in cessation of spasms 
between the two groups.
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CHAPTER FIVE
The Cochrane Collaborative: a systematic review comparing the medical 
treatments of infantile spasms (West syndrome) in terms of long term 
developmental outcome, seizure control and treatment side effects.
Whilst searching the literature for information on trials and studies that had previously 
investigated the effect of drug treatments on IS it became clear that although there was a 
wealth of literature on this subject there were the following problems in trying to assess the 
validity, applicability and implications of the results of these studies:
1. There were few randomised controlled trials (RCTs), the majority of reports were 
either prospective non-randomised or retrospective studies. The main problem with 
non-randomised controlled trials is that they are open to selection bias: i.e. systematic 
differences between comparison groups in prognosis or responsiveness to treatment.
2. Many of the studies contained only small numbers of subjects with the result that they 
have little or no power.
3. The studies were located by traditional methods only i.e. through the electronic 
databases usually Medline only. The problem with this method is that only 30 -  80% of 
published trials can be located via any one database. In addition unpublished trials were 
not sought leading to publication bias: studies in which an intervention is not found to 
be effective are far less likely to be published thus traditional reviews tend to 
overestimate the true effect of an intervention.
4. Only studies published in the English language were considered, again studies in which 
an intervention is not found to be effective are less likely to be published in English 
leading to language bias.
In order to try and minimise the above problems and determine if any one treatment for IS 
was better in terms of long-term outcome, seizure control and side effects a systematic 
review in conjunction with the Cochrane Collaboration was undertaken. Although a 
conventional review of the literature on the treatment of IS had shown that few studies had 
considered the long-term outcomes (i.e. psychomotor development and progression to 
other seizure types) when investigating the effect of medical therapies on IS, one of the 
aims of this review was to set a “Gold Standard” for future studies.
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It was decided that there are four important factors that must to be considered when 
choosing a therapy for treatment of any infant diagnosed with IS;
1. Development
Any effect on long-term psychomotor development: arguably the most important 
factor.
2. Subsequent epilepsy
Many patients continue to have other forms of epilepsy into adult life and about 
20% will progress to Lennox Gastaut syndrome . These patients will therefore 
require anticonvulsants and will continue to suffer the effects of epilepsy often for 
life.
Definition: Lennox Gastaut syndrome;
The Lennox-Gastaut syndrome is an age specific epileptic encephalopathy, characterised by epileptic 
seizures, slow spike-waves in the waking electroencephalogram (EEG) and fast rhythmic bursts during 
sleep, psychomotor delay and personality disorders. Its incidence is not known but it has been estimated 
to account for 1-10% of all childhood epilepsies. It occurs more frequently in males and onset is usually 
before the age of eight with a peak between three and five years
The following seizure types and EEG findings are associated with Lennox-Gastaut syndrome;
• Atypical absence seizures: these occur in the majority of cases and are frequently subtle. Loss of 
consciousness may be incomplete allowing the patient to continue ongoing activities. However they are 
often accompanied by loss of muscle tone, myoclonic jerks and drooling. EEG shows irregular diffuse 
slow spike-wave activity at 2 - 2.5hz.
• Tonic seizures: these are commonly seen and may be axial, appendicular or global, they may be 
symmetrical or unilateral. They consist of flexion of the neck and body, extension of the arms and legs 
and contraction of the facial muscles. There may be associated apnoea, eye rolling and facial flushing. 
Consciousness is usually impaired. They are usually brief, lasting seconds. The EEG shows discharges 
of fast bilateral bursts predominately anteriorly or on the vertex.
• Myoclonic and atonic seizures: these are less common and consist of a sudden head drop or fall to 
the ground and are associated with polyspikes and slow waves, or diffuse spike waves, or fast rhythms 
with an anterior predominance on the EEG.
• Status epilepticus and non-convulsive status occurs in approximately two thirds of patients and 
usually consists of continuous absence seizures punctuated by recurring tonic seizures and may be 
difficult to recognise.
• The waking EEG is abnormal in the vast majority of cases showing 2 to 2.5hz slow spike-wave 
discharges over both hemispheres with multifocal spikes and spike waves predominating in the frontal 
and temporal areas.
Psychomotor delay and neuropsychiatric symptoms occur in 90% of patients with Lennox-Gastaut 
syndrome. Language is frequently affected with both slowness in ideation and expression in addition to 
difficulties of motor dysfunction. Severe behavioural disorders and personality disorders are nearly 
always present. There is also a tendency for psychosis to develop with time. The long-term prognosis is 
poor; although the epilepsy often improves, complete seizure freedom is rare and conversely the mental 
and psychiatric disorders tend to worsen with time.113
3. Response: control of the spasms
The spasms are certainly distressing for parents and may well be distressing to the
infant. It is also possible that the spasms are directly linked to the development of
SLD as it is generally thought by clinicians (anecdotal evidence only) that the
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earlier the spasms are brought under control the better the outcome. It may of 
course be that those with a better prognosis have seizures that are easier to control. 
It was therefore decided to look at control of spasms in terms of;
• complete cessation of spasm
• time taken to achieve cessation of spasms
• reduction in total number of spasms
• relapse rates
• resolution of hypsarrhythmia
The exact relationship between clinical spasms and hypsarrhythmia on the EEG is not 
entirely clear. Not all infants with spasms have classical hypsarrhythmia on the EEG, 
and in those in whom it is present it is not always present all of the time65. It is not 
known whether presence or absence of hypsarrhythmia affects long-term outcome.
4. Side effects
These must always be taken into account. Any drug with unacceptable side effects will 
not be used in clinical practice. Likewise if two drugs show similar beneficial effects 
then the one with the safer drug profile should be used in preference.
The following review was undertaken under the aegis of the Cochrane Collaboration, it 
strictly adheres to the guidelines set out in the Cochrane Collaboration Handbook and was 
compiled and analysed using the Revman Package provided by the Cochrane collaboration.
Reviewers
Dr Eleanor Hancock (ECH), Prof. John Osbome(JPO), Prof. Phillip Milner (PLM). 
Contribution of reviewers
ECH was primarily responsible for all aspects of this review including protocol design, 
undertaking the searches, the database of studies, data collection and extraction, data 
analysis and presentation of the results.
JPO and PLM agreed and approved the review at all stages and independently evaluated 
which studies should be included and excluded from the review and also independently 
extracted the data from the included studies.
Background
There have been numerous clinical trials looking at different treatment regimes in the past 
(discussed in detail in chapter three). The main problem is that few of the trials have been
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randomised controlled trials and that the drug under investigation has frequently been used 
long after the onset of seizures and in addition to or after other anticonvulsants. There is 
wide variation in the drug dosages used and the duration for which the drugs are used. As a 
result it is confusing when looking at the literature to know which is the best treatment for 
this disorder with the consequence that many different treatment modalities are currently in 
use.
A conventional review of the literature on the treatment of infantile spasms carried out by
o  1
Haines and Casto in 1994 concluded that the results of previous studies were widely 
varying and that well-designed, blind, prospective clinical trials are needed to answer many 
questions regarding the treatment of infantile spasms.
Objectives
The aim was to compare the effects of single pharmaceutical therapies used to treat 
infantile spasms in terms of long-term psychomotor development, subsequent epilepsy 
rates, control of spasms and side effects.
The following hypotheses were tested:
A. Therapy vs placebo
1. Therapy A* will give improved long term psychomotor development compared with placebo treatment.
2. Treatment of infantile spasms with therapy A* will reduce subsequent epilepsy rates compared with 
placebo treatment.
3. Therapy A* is more effective in controlling infantile spasms (in terms of spasm cessation, reduction in 
total number of spasms and relapse) than placebo treatment.
4. Therapy A* is more effective in resolving hypsarrhythmia than placebo treatment.
B. Therapy vs no treatment
1. Therapy A* will give improved long term psychomotor development compared with no treatment.
2. Treatment of infantile spasms with therapy A* will reduce subsequent epilepsy rates compared with no 
treatment.
3. Therapy A* is more effective in controlling infantile spasms (in terms of spasm cessation, reduction in 
total number of spasms and relapse) than no treatment.
4. Therapy A* is more effective in resolving hypsarrhythmia than no treatment.
C. Comparisons between therapies
1. Therapy A* will give improved long term psychomotor development compared with any other single 
pharmaceutical therapy.
2. Treatment of infantile spasms with therapy A* will reduce subsequent epilepsy rates compared with any 
other single pharmaceutical therapy.
3. Therapy A* is more effective in controlling infantile spasms (in terms of spasm cessation, reduction in 
total number of spasms and relapse) compared with any other single pharmaceutical therapy.
4. Therapy A* is more effective in resolving hypsarrhythmia compared with any other single pharmaceutical 
therapy.
♦Therapy A = ACTH** or Hydrocortisone or Prednisone / Prednisolone or
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Carbamazepine or Ethosuximide or Gabapentin or Lamotrigine or Phenobarbitone or 
Phenytoin or Topiramate or Vigabatrin or Valproate or Clonazepam or Diazepam or 
Nitrazepam or Pyridoxine (Vitamin B6) or any other single therapeutic agent studied in the 
literature.
** ACTH At the time of undertaking this review there were two "ACTH" preparations in 
widespread use; ACTH (adrenocorticotrophin hormone) and tetracosactrin. ACTH is a 
natural product derived from a bovine source administered as a daily intramuscular 
injection. However, in the UK, with the existing concerns surrounding bovine spongiform 
encephalopathy (BSE) ACTH has been withdrawn from the market.
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of the administration of drug therapy to infants 
and children with infantile spasms were included in this review, including trials which 
compared a therapy with none or placebo and trials that compared one drug with another.
Definition of RCT: trials in which participants are prospectively allocated to treatment groups by a random 
(e.g. random number generation, coin flips) or quasi random (e.g. by date of birth) process.
If the study was not an RCT it was not included in the review: the existence of such studies 
was documented.
We considered studies looking at drug therapy as second line therapy as well as those 
studies looking at drug therapies as first line therapy.
Types of participants
Any infant or child treated for infantile spasms, regardless of whether or not EEGs were 
performed or whether therapy had been given prior to trial entry.
As the majority of published studies on infantile spasms did not give a definition of infantile spasms used for 
their participants, for the purpose of this review, we assumed a clinical diagnosis had been made for any 
participant that was entered into a trial. We documented any definitions which were given, and considered 
whether differences in definition might account for between study variation.
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Types of interventions
1. Any trial that compared at least one therapy against placebo treatment
2. Any trial that compared at least one therapy against no therapy
3. Any trial that compared at least one therapy against another therapy
Therapies included:
1. "Steroids"; ACTH, Tetracosactrin, Hydrocortisone, Prednisone/prednisolone.
2. Antiepileptic drugs; Carbamazepine, Clonazepam, Diazepam, Ethosuximide, 
Gabapentin, Lamotrigine, Nitrazepam, Phenobarbitone, Phenytoin, Pyridoxine, Sodium 
Valproate, Topiramate, Vigabatrin.
3. Methysergide and methylparatyrosine.
4. Any other single therapeutic agent studied in the literature.
Any dose regime of the above therapies was included.
Types of outcome measures
1. Long term psvchomotor development
This was to be analysed in months as a measure of the deviation from the chronological 
age. It was to be measured at 3 months post entry into the trial and where possible at 5 
years of age. It was measured as a continuous variable.
2. Subsequent epilepsy rates
The diagnosis of any other epileptic seizure type other than infantile spasms after the 
commencement of therapy constituted subsequent epilepsy. It was to be measured at three 
months post entry into the trial and where possible at five years of age. Any seizure type 
plus each seizure type (e.g. primary generalised, partial etc.) was to be measured as a 
dichotomous variable (i.e. present / absent) over the previous one month at three months 
post entry and over the previous six months at five years of age.
Because of the difficulty of defining epileptic seizures in children we would use the 
original authors1 diagnosis.
3. Cessation of spasms
This was defined as total cessation of spasms for at least 48 hours after commencing 
therapy, but occurring within a month of commencement of therapy. It was measured as a 
dichotomous variable (i.e. ceased / continuing). Time taken from commencement of 
therapy to cessation of spasms was also to be measured as a continuous variable (measured
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in days).
4. Quantitative reduction of spasms
This was measured as the number of spasms occurring before treatment was commenced 
compared with the number occurring following treatment and was to be measured as a 
dichotomous variable (i.e. greater than 50% reduction or less than 50% reduction in the 
number of spasms occurring / day over the seven day period before trial entry and over a 
seven day period at one month of commencing therapy).
5. Relapse rates of spasms
A single spasm occurring by one year of age or within the study period, but after cessation 
of spasms constituted a relapse. It was measured as a dichotomous variable (i.e. relapse 
occurred / no relapse occurred). Time taken from cessation of spasms to relapse was also to 
be measured as a continuous variable (measured in days) in those patients in whom spasms 
had ceased.
6. Resolution of hypsarrhythmia
Patients were divided into those who had a normal EEG prior to entry into a study and 
those who did not. In the group that did not have a normal EEG on entry, the EEG 
appearance after treatment was divided into those in whom the EEG remained abnormal 
and those in whom it became normal. It was measured as a dichotomous variable (i.e. 
normal / abnormal).
7. Side effects
Only side effects that were considered severe enough to warrant discontinuation of the test 
treatment were measured. They were measured as a dichotomous variable i.e. therapy 
stopped vs therapy not stopped. They were also qualitatively summarised.
8. Deaths
All deaths were measured. They were measured as a dichotomous variable (i.e. alive / 
deceased).
Search strategy for identification of studies
In addition to searching the central trials register of the Cochrane Epilepsy Group (see 
group module) we searched:
1. MEDLINE Database (1960 to 2001) according to the search strategy used by the 
Cochrane Epilepsy Group.
2. EMBASE Database (1981 to 2001).
3. The reference lists of both the Randomised Controlled Trials and rejected articles were
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scanned (by ECH) to identify possible articles missed by the computerised search.
4. Correspondence with colleagues to try and identify unpublished data. Correspondence 
with authors of review articles has not yet been undertaken.
5. Correspondence with drug companies to try and identify unpublished data.
6. Appeals at international conferences to delegates to try and identify unpublished data 
and studies not published in English.
Methods of the review
Relevant publications were reviewed independently by the three reviewers (Dr Hancock, 
Professor Osborne and Professor Milner). Discrepancies were resolved by discussion. 
There was no blinding of authorship or results. All randomised controlled trials were 
considered. All non-English studies were also considered.
1. Exclusion criteria
• Any trial that was not a RCT was excluded from analysis but was documented.
• If a clinical definition for infantile spasms was given; in any trial in which there 
was doubt about the clinical diagnosis, the trial was excluded from analysis, but 
was documented.
2. Assessment of methodological quality
• Selection bias: the studies were assessed as to whether allocation concealment was 
adequate, unclear or inadequate.
• Performance bias: The studies were assessed as to whether recipients and those 
measuring outcome were unaware of the assigned therapy (However we accepted 
that the majority of the studies in this review would not be double blinded trials)
• Attrition bias was assessed as to whether there was loss of patients to follow up.
Using the above criteria studies were then divided into (1) those with a low risk of bias (2) 
those with a moderate risk of bias and (3) those with a high risk of bias. (See Cochrane 
Handbook section 6.7.1)
In studies where it was unclear if the above criteria have been met then the reviewers are 
endeavouring to obtain additional information by contacting the first author on up to three 
occasions. This will be documented.
96
The following data was extracted independently by the three reviewers (Dr Hancock, 
Professor Osborne and Professor Milner) and discrepancies resolved by discussion.
1. Participants (i.e. those characteristics of the population that may affect outcome 
regardless of treatment):
• age at spasm onset, diagnosis and start of treatment (mean, median and range measured to 
the nearest completed week of age).
• time taken from onset of spasms to initiation of treatment (mean, median and range 
measured to the nearest completed week).
• sex (male, female).
• previous treatment (e.g. prednisolone, ACTH, vigabatrin, valproate).
2. Interventions:
• type of pharmaceutical agent used (e.g. prednisolone, ACTH, vigabatrin, valproate).
• dose (measured in the internationally accepted units i.e. mg for prednisolone, IU for 
ACTH).
• frequency (measured as the number of times the pharmaceutical agent is given in a 24 
hour
period).
• route of administration (i.e. oral, intramuscularly, intravenously).
• treatment length (measured to the nearest completed day).
3. Outcome measures:
• psychomotor development.
• subsequent epilepsy rates.
• cessation of spasms and the time taken to cessation of spasms.
• reduction in spasms.
• relapse rates and the time taken to relapse.




1. Study quality: this was done by a table of met / unmet criteria for selection, performance 
and attrition bias.
2. Dichotomous data: for each item of data requiring dichotomous analysis the following
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was recorded; no. of patients who experienced the event (or outcome) in each group for 
each comparison and the total number in each group. They were analysed using Peto odds 
ratios in the Cochrane RevMan Package.
3. Continuous data: for each item of data requiring continuous data analysis, except 
psychomotor development the following were recorded; number of patients in each group, 
the mean value for the outcome in each group and the standard deviation. They were 
analysed using weighted means in the Cochrane RevMan Package
4. When data for the same outcome is presented in some studies as dichotomous and in 
others as continuous data then we are endeavouring to obtain continuous data from the 
investigators. If it is not possible to obtain continuous data, for example because it was not 
recorded then the data will either be analysed as dichotomous data with a "cut off' point 
agreed by the three reviewers or a mixture of dichotomous and continuous data will be 
analysed using two separate tables.
5. We looked for sources of heterogeneity between trials of methodological and clinical 
differences, including previous treatment for spasms, age at trial entry, single underlying 
cause. We also looked for subgroup analysis of clinical features, for example; 
developmental delay prior to onset of spasms, differences in drug dosages, timing and 
length of treatment and specific underlying diagnosis such as tuberous sclerosis.
Description of studies
The literature search of the central trials register of the Cochrane Epilepsy Group found 13 
potential studies. The literature search of MEDLINE (1960-2001) found 33 potential 
studies, and the literature search of EMBASE (1981-2001) found 14 potential studies. 
Some studies were identified from more than one database. From these three databases a 
total of 43 potential studies were identified. The references of these 43 studies were then 
scanned by Dr Hancock and a further 9 possible studies identified. Direct correspondence 
with colleagues and appeals at international conferences (Seattle September 2000 and 
Tokyo February 2001) also identified two of the above (Appleton 1999 and Vigevano 1997 
pre-publication) randomised controlled trials (and two ongoing trials). Correspondence 
with drug companies did not identify any further trials. This brought the total to 52 studies 
to be evaluated for inclusion into this review (see appendix three for references). We 
intend to continue correspondence with authors, colleagues and drug companies and to 
regularly update our literature searches of the above databases, so that we may update this 









40 patients with a clinical 
definition of infantile spasms 
and hypsarrhythmia on EEG.
Vigabatrin
Placebo
Cessation of spasms 







29 patients with a diagnosis 
confirmed on video EEG







2 2  patients with a clinical 
diagnosis of infantile spasms 
or hypsarrhythmia on EEG







52 patients with a diagnosis ACTH Reduction in 





17 patients with a clinical 
definition of infantile spasms 








24 patients with a clinical 
definition of infantile spasms 








24 patients with a clinical 
definition of infantile spasms 





Cessation of spasms 
Reduction in spasms
Hrachovy
1 9 9 4 8
Randomised 
controlled trial
59 patients with a clinical 
definition of infantile spasms 
and hypsarrhythmia on EEG.
ACTH high Cessation of spasms 
dose Relapse rates 





42 patients with a diagnosis 














26 patients with a diagnosis 










Table showing the characteristics of included studies
Review o f the studies eliminated 3611'46 studies because they were not randomised 
controlled trials, a further four4 7 *5 0  because the subjects did not suffer from infantile spasms 
and one paper51 was excluded because the data referred to the effects o f hormonal
treatment on the brain when imaged using computerised tomography, it did not report any
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other outcome measure. This left a total of eleven papers1'10 52, in one of these; Vigevano 
199452 all the data was included in a further paper Vigevano 1997. This gave a total of ten 
randomised controlled trials1"10 looking at the treatment of infantile spasms, with a total of 
335 patients. These ten studies looked at eight different pharmacological agents for the 
treatment of infantile spasms; vigabatrin, ACTH (including six different treatment 
regimes), prednisone, hydrocortisone, nitrazepam, sodium valproate, methysergide and 
alpha-methylparatyrosine (see table fourteen).
• Appleton 19991
This was a short term randomised, double-blind, placebo-controlled multicentre trial of 40 
patients. Inclusion criteria included patients aged between 1 and 20 months with newly 
diagnosed and previously untreated infantile spasms in whom the EEG demonstrated either 
classical or modified hypsarrhythmia. A spasm was defined as a sudden, generally bilateral 
and symmetric contraction of the muscles of the neck, trunk and extremities (flexor, 
extensor or mixed). The principal exclusion criteria was the use of any medication, 
including steroids, that could be considered to be an antiepileptic drug within a 2-month 
period before entry into the trail. The trial consisted of a 5-day double-blind phase during 
which patients received either vigabatrin or placebo. Twenty patients received vigabatrin 
and twenty placebo. The initial starting dose was 50 mg/kg/day for 24 hours, if spasms did 
not cease completely, the dose was increased to 100/mg/kg/day and maintained for a 
further 48 hours. The dose could then be increased further to 150/mg/day. Randomisation 
was pre-determined by a code held by the pharmacy department of each participating 
hospital. Both the recipients and assessors were blinded. Outcomes reported were cessation 
of spasms, reduction in spasms, resolution of hypsarrhythmia and relapse rates. Some 
patients were lost to follow up, but not during the double-blind phase.
• Baram 19962
This was a randomised single-blinded single-centred trial of 29 patients. Infants with 
clinical infantile spasms were considered for the study and underwent 24-hour video-EEG 
to ascertain hypsarrhythmia and clinical spasms. The trial consisted of a two week period 
during which 15 patients were treated with ACTH, 150 units/m.squared/day, 
intramuscularly in two divided doses and 14 patients treated with prednisone 2 mg/kg/day 
given orally in two divided doses. A computer-generated random-number list determined 
treatment, and concealment of allocation was not clearly stated, but has been confirmed by 
Dr Baram (direct correspondence). Blinding of recipients was not done, but blinded 
assessment of outcomes was performed. Outcomes reported were, subsequent seizure rates 
(short term only), cessation of spasms, resolution of hypsarrhythmia, relapse rates and 
development of other seizure types within the follow-up period.
• Chiron 19973
This was a randomised multicentre trial of 22 patients with infantile spasms all of whom 
had tuberous sclerosis. Inclusion criteria included epileptic spasms recorded on EEG or 
seen by an experienced clinician, diffuse interictal paroxysmal activity and age ranging 
from 1 month to 2 years. Patients were excluded if they had been previously treated with 
steroids or vigabatrin, but not other anticonvulsant medications. The trial consisted of a 
one month period during which 11 infants received vigabatrin at a dose of 150 mg/kg/day 
and 11 infants received hydrocortisone at a dose of 15 mg/kg/day. The method of
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randomisation was not stated. Neither recipients nor assessors were blinded. Outcomes 
reported were cessation of spasms, resolution of hypsarrhythmia and relapse rates.
• Dreifuss 19864
This was a randomised multicentre trial of 52 patients. Inclusion criteria included patients 
aged between 1 and 24 months of age with infantile spasms documented by a 
hypsarrhythmic or modified hypsarrhythmic pattern on EEG. None of the patients had 
received steroids or nitrazepam prior to entry into the trial. The trial consisted of a four 
week period during which 27 patients received nitrazepam and 25 patients ACTH. 
Nitrazepam was started at 0.2 mg/kg/day in two divided doses or 1 mg twice daily, 
whichever was greater and was adjusted twice weekly by increments of 0.3 to 0.4 
mg/kg/day. Maintenance dosage ranged from 4.8 to 9 mg/day. ACTH was given as a once 
daily intramuscular injection of 40 units. A computer-generated randomisation code 
determined treatment, but concealment of allocation was not clearly stated. Blinding of 
recipients was not done, but blinded assessment of outcome was performed. The only 
outcome reported was reduction in spasm frequency. There was a discrepancy between the 
reviewers over the assessment of how many patients were lost to follow up in this trial, this 
discrepancy arose because the authors are unclear in their paper as to how many patients 
were lost to follow up. We are intending to contact the author in order to clarify this point 
so that it may be included in a future update of the review, in the meantime it remains 
unclear as to the number of patients lost to follow up.
• Dyken 1985s
This was a randomised, placebo-controlled-cross-over single-centre trial of 17 patients. 
Inclusion criteria included patients aged between 8 and 83 months of age with a clinical 
diagnosis of infantile spasms and hypsarrhythmia on EEG, who had previously failed to 
respond to steroids. Many patients had received other anticonvulsant medication. The trial 
compared sodium valproate against placebo but the length of the trial and dosages used 
were not given. A computer-generated random numbers table was used to allocate patients, 
but concealment of allocation was not clearly stated. Blinding of recipients and blinded 
assessment of outcome were performed. They only reported reduction in spasm frequency 
as an outcome. Four patients were lost to follow up.
• Hrachovy 19836
This was a randomised single-centre trial (using a double-dummy technique) of 24 
patients. Inclusion criteria included patients with infantile spasms and hypsarrhythmic 
EEG patterns on serial 24-hour video and polygraphic monitoring. No patient had been 
previously treated with steroids, but some had received other anticonvulsant medications. 
Twelve patients received ACTH 20-30 units/day for two weeks, which was then tapered 
over one week if a response was seen. If a response was not seen, they received a further 
four weeks before the dose was tapered. These patients also received a prednisone placebo. 
Twelve patients received prednisone, 2 mg/kg/day for two weeks, which was then tapered 
over one week if a response was seen. If a response was not seen, they received a further 
four weeks before the dose was tapered. These patients also received an ACTH gel 
placebo. The method of randomisation was not given. Blinding of recipients was done but 
it was unclear if blinded assessment of outcome was performed. Outcomes reported were 
complete cessation of spasms and relapse rates.
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• Hrachovy 19897
This was a randomised trial of 24 patients. Inclusion criteria included newly diagnosed 
patients with infantile spasms and hypsarrhythmic EEGs. The trial consisted of a three 
week period during which, twelve patients were treated with methysergide, 2 
mg/m.squared/day for the first seven days, then 5 mg/m.squared/day for the next 14 days 
and twelve patients were treated with alpha-methylparatyrosine 500 mg/m.squared/day, 
increasing by 150 mg/m.squared/day on day two and thereafter until a maximum dosage of 
1,250 mg/m.squared/day was reached. The method of randomisation was not given. It was 
not clear that recipients and assessors were blinded. They reported cessation of spasms, a 
reduction in the number of spasms (and developmental status at 3 weeks) as outcome 
measures.
• Hrachovy 19948
This was a randomised controlled trial of 59 patients. Inclusion criteria included infants in 
whom a diagnosis of infantile spasms had recently been made, who had hypsarrhythmic 
EEG findings. They were excluded if they had previously received steroids. Thirty patients 
received 150 units/m.squared of ACTH per day for three weeks with a tapering dose over a 
further nine weeks, and twenty-nine patients received 20-30 units/day of ACTH for two to 
six weeks, tapering over one week. The method of randomisation was not stated. Blinding 
of recipients was not done, but blinded assessment of outcomes was performed. Outcomes 
reported were complete cessation of spasms, resolution of hypsarrhythmia and relapse 
rates. They had loss of follow up of nine patients.
• Vigevano 19979
This was a randomised (response mediated, cross-over) single-centre trial of 42 patients. 
Inclusion criteria included patients with newly diagnosed and previously untreated infantile 
spasms diagnosed according to the ILAE classification. Twenty three patients received 
vigabatrin at 100-150 mg/kg/day and nineteen received ACTH at 10 units/day. The method 
of randomisation was not stated. Blinding of recipients was not done and it was not clear if 
the assessors of outcome were blinded. Outcomes reported were cessation of spasms, 
resolution of hypsarrhythmia, (and short term effects on subsequent epilepsy rates and 
cognitive function).
• Yanagaki 199910
This was a randomised single-centre trial of 26 patients. Inclusion criteria included patients 
with infantile spasms and hypsarrhythmia on video EEG. Patients were excluded if they 
had received previous steroid or intravenous gamma globulin treatment. Thirteen patients 
received 1 unit/kg/day of synthetic ACTH for two weeks tapering over a further two weeks 
and thirteen patients received 0.2 units/kg/day of synthetic ACTH for two weeks tapering 
over a further two weeks. The method of randomisation was not stated. It was not clear 
whether recipients and assessors were blinded. Outcomes reported were cessation of 
spasms, resolution of hypsarrhythmia, relapse rates (and the short term effect on 
development). One patient was lost to follow up.
Methodological quality of included studies
Overall, methodological quality of the included studies was poor. All the studies had small
•  finumbers of participants, the largest having only 59 patients (although results were only 
given for 50 of these patients), subsequently the power of each individual study was low.
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There were only two placebo-controlled trials1 5 (one further trial used a double dummy 
technique6). Although all the studies stated that they were randomised controlled trials, 
only four gave the method o f randomisation, and only two stated that concealment of 
allocation had been performed. Blinding o f recipients occurred in only three studies, did 
not take place in five studies and was unclear in the remaining studies. Six studies clearly 
stated that those measuring outcome were unaware o f  the assigned therapy. At least four 
studies had loss o f patients to follow up. Three o f the studies were multicentre trials, four 
studies recruited patients from a single centre and it was unclear in the remaining three 
studies how many centres were involved in recruiting patients. O f the ten RCTs considered 















follow up Risk of bias
Appleton
1999' 40 Yes Yes Yes yes No
Low
Baram
19962 29 No Yes
no yes no moderate
Chiron
19973 2 2 No not clear No No no High
Dreifuss
19864 52 No
not clear no yes yes
high
Dyken
19855 17 Yes not clear yes yes yes
high
Hrachovy
19836 24 Yes not clear yes yes no high
Hrachovy













1 9 9 9 1 0 26 No not clear Not clear Not clear yes high
Table showing methodological quality of included studies
Results
Participants, those characteristics of the population that may affect outcome regardless of 
treatment (see table sixteen).
The male: female ratio was given for six of the studies and was 1:1.
The age at spasm onset was given in four studies and ranged from 20 to 30 weeks.
The age at which diagnosis of spasms was made was not given in any study.
The age at trial entry (i.e. the age at which the trial treatment was started) was given in six 
studies and ranged from 22 to 41 weeks.
The time delay between onset of spasms and start of treatment was given in three studies 
and ranged from 3 to 16 weeks.
In two studies other treatments had been previously tried, in two studies other treatments 
had not been used, and in six studies it was unclear.
We had also planned to look for heterogeneity according to different diagnostic groupings 
for example tuberous sclerosis and Down's syndrome and also looking at whether patients 
had developmental delay prior to the onset of spasms. Unfortunately, for the majority of 
the studies this information was not available and could not, therefore be analysed.
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T a b le  s ix teen
S tudy  ID In terven tion M alerFem ale Age a t 
onset
Age a t 
diagnosis
Age a t 
tr ia l e n try
Delay to 
trea tm e n t
Previous
trea tm e n t
Appleton 
1999 1
Vigabatrin 11:9 30 weeks
Not
available
35 weeks 6 weeks No
Placebo 8:12 26 weeks
Not
available




















Vigabatrin 5:6 25 weeks Not
available
29 weeks 3 weeks Not available
Hydrocortisone 5:6 26 weeks
Not
available




























































































































ACTH (high-dose) 8:5 20 weeks
Not
available
28 weeks 7 weeks yes
ACTH (low-dose) 7:5 23 weeks
Not
available
41 weeks 16 weeks yes
Table showing the characteristics of the population that may affect outcome 
regardless of treatment
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VIGABATRIN VERSUS PLACEBO 
There was one study Appleton 19991.
• Effects on psychomotor development was not reported as an outcome in this study.
• Effects on subsequent seizure rates was not reported as an outcome in this study.
• Effects on cessation of spasms: Appleton 1999 had 40 patients and showed 
complete cessation of spasms in seven of twenty (35%) of patients treated with 
vigabatrin compared with two of twenty (10%) treated with placebo, Peto odds 
ratio 4.1 (95% Cl 0.9 to 17.5).
• Effects on time taken to achieve cessation of spasms was not reported as an 
outcome in this study.
• Effects on reduction in the number of spasms: Appleton 1999 showed an >70% 
reduction in spasms in 40% of the group treated with vigabatrin compared with 
15% in the group treated with placebo. However, it is not clear from the paper to 
what proportion of the two groups of patients these figures apply, whether the 
figures apply to the whole group or just those patients in whom complete cessation 
of spasms was not achieved.
• Effects on relapse rates: Appleton 1999, four out of seven patients who responded 
to vigabatrin relapsed and all the patients successfully treated with placebo 
relapsed.
• Overall only three patients treated with vigabatrin and no patient treated with 
placebo treatment remained spasm free within the four week study period, Peto 
odds ratio 8.2 (95% Cl 0.8 to 84).
• Effects on time taken to relapse was not reported as an outcome in this study.
• Effects on resolution of hypsarrhythmia: Appleton 1999, five of the seven patients 
who were spasm free with vigabatrin showed resolution of hypsarrhythmia on 
EEG, compared with one of the two patients who had become spasm free on 
placebo, Peto odds ratio 2.4 (95% Cl 0.1 to 54.6).
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in this study.
• No side effects severe enough to warrant stopping treatment were reported in this 
study.
• No deaths were reported.
SODIUM VALPROATE VERSUS PLACEBO
There was one study Dyken 1985s
• Effects on psychomotor development was not reported as an outcome in this study.
• Effects on subsequent seizure rates was not reported as an outcome in this study.
• Effects on cessation of spasms was not reported as an outcome in this study.
• Effects on time taken to achieve cessation of spasms was not reported as an 
outcome in this study.
• Effects on reduction in the number of spasms: Dyken 1985 used a spasm index: S.I. 
= (spasm frequency x spasm duration / total observation time) x 1000 to calculate 
the mean reduction in spasm frequency from the baseline. At the end of the four 
week treatment period, the valproate treatment was found to have a lower mean 
spasm index than placebo, when valproate was administered first (p<0.04). There 
was no significant difference between placebo and valproate during the second 
level of treatment. It is not possible to calculate a Peto odds ratio.
• Effects on relapse rates was not reported as an outcome in this study.
• Effects on time taken to relapse was not reported as an outcome in this study.
• Effects on resolution of hypsarrhythmia was not reported as an outcome in this 
study.
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in this study.
• Side effects were not reported as an outcome in this study.
• Deaths were not reported as an outcome in this study.
VIGABATRIN VERSUS HYDROCORTISONE
There was one study Chiron 19973
• Effects on psychomotor development was not reported as an outcome in this study.
• Effects on subsequent seizure rates was not reported as an outcome in this study.
• Effects on cessation of spasms: Chiron 1997 comparing vigabatrin (150 mg/kg/day) 
and hydrocortisone (15 mg/kg/day) in twenty-two infants with infantile spasms due 
to tuberous sclerosis, found in the initial phase, eleven of the eleven patients 
(100%) treated with vigabatrin to be spasm free as compared to five of eleven 
patients (45%) treated with hydrocortisone. Peto odds ratio 13.8 (95% Cl 2.21 to 
86.35).
107
• Effects on time taken to achieve cessation of spasms: Chiron 1997; on average the 
11 responders to vigabatrin took 4 days (range 0.5-14 days, median 2 days) to 
achieve complete cessation of spasms, whilst the 5 responders to hydrocortisone 
took an average of 13 days (range 3-30 days, median 23.5 days), WMD = -8.8 (- 
19.2 to 1.6).
• Effects on reduction in the number of spasms was not reported as an outcome in 
this study.
• Effects on relapse rates: Chiron 1997, ten of the eleven patients who responded to 
vigabatrin remained spasm free, this information was not given for the five 
responders to hydrocortisone.
• Effects on time taken to relapse was not reported as an outcome in this study.
• Effects on resolution of hypsarrhythmia was not reported as an outcome in this 
study.
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in this study.
• Side effects: Chiron 1997 reported that hydrocortisone had to be stopped in one 
patient, no reason was given.
• No deaths were reported in this study.
VIGABATRIN VERSUS ACTH
There was one study Vigevano 19979
• Effects on psychomotor development: Vigevano 1997 stated that there was no 
apparent difference in cognitive development between the two groups during 
follow up which ranged from 9 to 44 months. They did not state how they assessed 
development or quantify it any further, and this comparison was confounded by the 
fact that some infants initially randomised to receive vigabatrin went on to receive 
ACTH, and vice versa, within the follow up period. They did not consider long­
term developmental status at 5 years of age.
• Effects on subsequent seizure rates: Vigevano 1997 found an incidence of other 
types of epileptic seizures to be 25% in both groups during follow up of 9 to 44 
months. Again they did not consider subsequent epilepsy rates at 5 years of age. 
Again, this comparison was confounded by the fact that some infants initially 
randomised to receive vigabatrin went on to receive ACTH, and vice versa, within 
the follow up period.
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• Effects on cessation of spasms: Vigevano's 1997 trial of forty-two patients showed 
cessation of spasms in eleven of the twenty-three patients randomised to vigabatrin 
compared with fourteen of the nineteen patients randomised to ACTH. Peto odds 
ratio 0.4 (95% Cl 0.1 to 1.2)
• Effects on time taken to achieve cessation of spasms: Vigevano 1997, the 11 
responders to vigabatrin took between 1 and 14 days to achieve complete cessation 
of spasms, whilst the 14 responders to ACTH took between 2 and 12 days.
• Effects on reduction in the number of spasms was not reported as an outcome in 
this study.
• Effects on relapse rates was not reported as an outcome in this study.
• Effects on time taken to relapse was not reported as an outcome in this study.
• Effects on resolution of hypsarrhythmia: Vigevano 1997, resolution occurred in 
four out of eleven patients responding to vigabatrin and eleven out fourteen patients 
responding to ACTH. Peto odds ratio 0.2 (95% Cl 0.0 to 0.9).
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in this study.
• Side effects: Vigevano 1997 stopped vigabatrin in one patient because of excessive 
irritability and ACTH in one patient, no reason given.
• Deaths: One patient in Vigevano's 1997 study died, but the cause was not given 
and it is unclear to which treatment group they had been randomised.
ACTH VERSUS PREDNISONE
There were two studies Baram 19962 and Hrachovy 19836. The doses of ACTH used in 
these two studies differed, so the results should be interpreted with caution.
• Effects on psychomotor development was not reported as an outcome in these 
studies.
• Effects on subsequent seizure rates: Baram 1996 in their study comparing ACTH 
with prednisone found seven (-50%) patients in both groups to have developed 
other seizure types over the period of follow up of 2 to 48 months. However, this 
comparison was confounded by the fact that some infants initially randomised to 
receive prednisone went on to receive ACTH within the follow up period. They did 
not report subsequent epilepsy rates at 5 years of age.
• Effects on cessation of spasms: Baram 1996 compared fifteen patients treated with 
ACTH (150 units/m.squared/day) with fourteen treated with prednisone (2
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mg/kg/day). and showed ACTH to be superior to prednisone with cessation of 
spasms in thirteen of fifteen (87%) patients and four of fourteen (29%) patients 
respectively. Hrachovy 1983 compared twelve patients treated with ACTH (20 -30 
units/day) with twelve patients treated with prednisone (2 mg/kg/day). In the initial 
phase of the trial five of twelve (42%) patients treated with ACTH had complete 
cessation of spasms and resolution of hypsarrhythmia on their EEG compared with 
four of twelve (33%) treated with prednisone. Combining the two studies, ACTH 
stopped the spasms in 67.5% of patients compared with prednisone in 31% of 
patients, Peto odds ratio 4.2 (95% Cl 1.4 to 12.4).
• Effects on time taken to achieve cessation: Baram 1996; on average the 13 
responders to ACTH took 3.2 days (range 1-7 days, median 2 days) to achieve 
complete cessation of spasms, whilst the 4 responders to prednisone took an 
average of 4 days (range 2-7 days, median 3.5 days), WMD = -0.8 (95% Cl -3.3 to 
1.7).
• Effects on reduction in the number of spasms was not reported as an outcome in 
these studies.
• Effects on relapse rates: Baram 1996, two of the thirteen patients who responded to 
ACTH relapsed and none of the four responders to prednisone relapsed. Hrachovy 
1983, three of the five patients who responded to ACTH relapsed and one of the 
four responders to prednisone also relapsed.
• Overall, Baram 1996, eleven patients who responded to ACTH remained spasm 
free and the four responders to prednisone also remained spasm free. Hrachovy 
1983, two patients successfully treated with ACTH remained spasm free and three 
successfully treated with prednisone remained spasm free within the study period. 
The combined Peto odds ratio for these two studies is 2.6 (95% Cl 0.8 to 8.1).
• Effects on time taken to relapse was not reported as an outcome in these studies.
• Effects on resolution of hypsarrhythmia: Baram 1996, this study showed ACTH to 
be superior to prednisone with resolution of hypsarrhythmia in thirteen of fifteen 
patients treated with ACTH compared to four of fourteen of patients treated with 
prednisone, Peto odds ratio 10.1 (95% Cl 2.4 to 43.2). Hrachovy 1983, five of 
twelve patients treated with ACTH had resolution of hypsarrhythmia but this was 
not reported for the group treated with prednisone.
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in these studies.
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• Side effects were not reported as an outcome in these studies.
• No deaths were reported in these studies.
HIGH DOSE ACTH VERSUS LOW DOSE ACTH
• There were two studies Hrachovy 19948 and Yanagaki 199910. Hrachovy used 
natural ACTH and Yanagaki used synthetic ACTH. This makes direct comparison 
difficult. Yanagaki states that the dose equivalent of 1 IU of natural ACTH is 
0.025 IU of synthetic ACTH, but the results must be interpreted with caution.
• Effects on psychomotor development: Yanagaki 1999 in their study comparing 
high-dose ACTH with low-dose ACTH used the Japanese Tsumori scale to 
evaluate developmental status at entry into the trial and in 17 responders who were 
followed up for more than one year. They found no significant difference in 
developmental quotient between the two groups at the end of the follow up period. 
However, they only considered psychomotor development in the responders which 
gives rise to biased analysis and this should be interpreted with caution. They did 
not consider long-term developmental status at 5 years of age.
• Effects on subsequent seizure rates was not reported as an outcome in these studies.
• Effects on cessation of spasms: Hrachovy 1994 randomised thirty patients to high- 
dose ACTH (150 units/m.squared/day for three weeks with a tapering dose over a 
further nine weeks), and twenty-nine patients to low-dose ACTH (20-30 units/day 
for two to six weeks, tapering over one week). Of the thirty patients treated with 
high dose therapy thirteen (50%) had complete cessation of spasms and of the 
twenty-nine patients treated with low dose therapy fourteen (58%) had complete 
cessation of spasms. Yanagaki 1999 randomised thirteen patients to receive 1 unit 
/kg/day (equivalent to 40 units/ kg/ day of natural ACTH) for two weeks tapering 
over a further two weeks and thirteen patients to receive 0.2 units/kg/day 
(equivalent to 8 units/kg/day of natural ACTH) for two weeks tapering over a 
further two weeks. Of the patients treated with high-dose ACTH, spasm cessation 
occurred in eleven of thirteen patients compared with nine of thirteen treated with 
low dose ACTH. Combining these two studies, "high-dose" ACTH stopped the 
spasms in 79.5% patients compared with "low-dose" ACTH in 76.5% of patients, 
Peto odds ratio 1.1 (95% Cl 0.4 to 2.6).
• Effects on time taken to achieve cessation of spasms was not reported as an 





• Effects on reduction in the number of spasms was not considered as an outcome in 
these studies.
• Effects on relapse rates: Hrachovy 1994, two of the thirteen patients who responded 
to "high-dose ACTH" relapsed and two of the fourteen patients who responded to 
"low-dose ACTH" also relapsed. Yanagaki 1999, three of the eleven patients who 
responded to "high-dose ACTH" relapsed and three of the nine responders to "low- 
dose ACTH" relapsed.
• Hrachovy 1994, eleven patients who responded to high-dose ACTH remained 
spasm free and twelve patients who responded to low-dose ACTH also remained 
spasm free. Yanagaki 1999, eight patients who responded to high-dose ACTH 
remained spasm free and six patients who responded to low-dose ACTH remained 
spasm free. Combining these two studies gives a Peto odds ratio 0.8 (95% Cl 0.3 to 
1.9).
• Effects on time taken to relapse was not considered as an outcome reported in these 
studies.
• Effects on resolution of hypsarrhythmia: Hrachovy 1994, three out of thirteen 
responders to high-dose ACTH showed resolution of their EEG and three out of 
fourteen responders to low-dose ACTH showed resolution of their EEG. Yanagaki 
1999, eight out of thirteen treated with high-dose ACTH showed resolution of their 
EEG and seven out of twelve treated with low-dose ACTH showed resolution of 
their EEG. Combining these two studies gives a Peto odds ratio 1.9 (95% Cl 0.6 to 
6.2)
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in these studies.
• Side effects were not reported as an outcome in these studies.
• No deaths were reported in these studies.
NITRAZEPAM VERSUS ACTH 
There was one study Dreifuss 19864.
• Effects on psychomotor development was not reported as an outcome in this study.
• Effects on subsequent seizure rates was not reported as an outcome in this study.
• Effects on cessation of spasms was not reported as an outcome in this study.
• Effects on time taken to achieve cessation of spasms was not reported as an 
outcome in this study.
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• Effects on reduction in the number of spasms: Dreifuss 1986 showed an >50% 
reduction in spasms in 66% of the group treated with nitrazepam compared with 
50% in the group treated with ACTH, Peto odds ratio 2.0 (95% Cl 0.7 to 5.9).
• Effects on relapse rates was not reported as an outcome in this study.
• Effects on time taken to relapse was not reported as an outcome in this study.
• Effects on resolution of hypsarrhythmia was not reported as an outcome in this 
study.
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in this study.
• Side effects: Dreifuss 1986 had to withdraw ACTH in six patients, hypertension 
and maleana were given as two causes for withdrawal.
• Deaths: Dreifuss 1986 had one patient in their ACTH group who died, but no cause 
was found at autopsy.
METHY SERGIDE VERSUS ALPHA-METHYLPARATYROSINE
There was one study Hrachovy 1989
• Effects on psychomotor development: Hrachovy 1989 used the Denver 
Developmental Screening Test to evaluate developmental status at entry into the 
trial and at 3 weeks post entry into the trial. They stated, in their results section, that 
two patients in each group showed developmental improvement but did not 
quantify this further. They did not report developmental status at 3 months post trial 
entry or at 5 years of age.
• Effects on subsequent seizure rates was not reported as an outcome in this study.
• Effects on cessation of spasms: Hrachovy 1989 found only one patient (8%) treated 
with methysergide and two (16%) treated with alpha-methylparatyrosine responded 
to therapy, Peto odds ratio 0.5 (95% Cl 0.1 to 5.2).
• Effects on time taken to achieve cessation of spasms was not reported as an 
outcome in this study.
• Effects on reduction in the number of spasms: Hrachovy 1989 showed a >50% 
reduction in spasms in 25% of the group treated with methysergide compared with 
17% in the group treated with alpha-methylparatyrosine, Peto odds ratio 1.6 (95% 
Cl 0.2 to 11.2).
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• Effects on relapse rates: no patient treated with methysergide remained spasm free 
and only one of the two patients successfully treated with alpha-methylparatyrosine 
remained spasm free. Peto odds ratio 0.14 (95% Cl 0.0 to 6.8).
• Effects on time taken to relapse was not reported as an outcome in this study.
• Effects on resolution of hypsarrhythmia was not reported as an outcome in this 
study.
• Effects on time taken to achieve resolution of hypsarrhythmia was not reported as 
an outcome in this study.
• No side effects severe enough to warrant stopping treatment were reported in this 
study.
• No deaths were reported in this study.
Discussion
Infantile spasms were first described 160 years ago in a letter that Dr West wrote to the 
Lancet. Since that time at least 30 drugs have been tried and reported in the literature, but 
treatment remains problematic and the long-term prognosis remains poor for both 
psychomotor development and subsequent development of other seizure types. Despite the 
wealth of literature on this subject there have been only a few RCTs and the majority of 
studies have been either open prospective or retrospective trials. The RCTs that have been 
undertaken contain only small numbers of subjects with the result that they have little or no 
power and have used widely varying dosage regimes and outcome measures, making meta­
analysis difficult to perform. In addition, only eight drugs out of all those used in the 
treatment of infantile spasms have been subjected to RCTs. We found no RCTs comparing 
forms of therapies, such as phenobarbitone or pyridoxine, despite the fact that these are 
often first line therapies in some countries. Some therapies (for example gamma-globulins, 
pyridoxine, lamotrigine) have been reported as case reports or in uncontrolled trials. We 
have not considered these therapies in this review. In addition many different "steroid" 
preparations have been used in the available RCTs. This is partly due to the availability of 
different compounds in different countries, for example in Europe and Japan synthetic 
ACTH is usually available, whilst in the USA natural ACTH derivatives are normally 
used. ACTH can only be given as an injection, intramuscularly, intravenously or into the 
peritoneal cavity, infants find this distressing and many centres use oral preparations such 
as prednisone or hydrocortisone in preference. This makes analysis of the efficacy of 





Despite an extensive literature search we found only ten RCTs and the overall reported 
methodology was poor. Only one study had considered the number of patients required to 
determine whether one treatment was more efficacious than another; they based their 
calculations on the assumption that the trial drug would be 50% more efficacious in 
stopping the spasms than the comparative drug; their trial did not find such a difference. 
Although all the studies claimed to be randomised, less than half stated how randomisation 
had been performed and only two studies stated that adequate concealment of 
randomisation had taken place. Ideally to minimise performance bias trials should be 
double-blinded, although perhaps it is not surprising that only two such trials have been 
performed. Blinding the recipients (or parents) and staff administering the therapies 
remains problematic. ACTH can only be given by intramuscular injection, whilst the other 
drugs used in the above RCTs are administered orally and nowadays it is generally 
considered to be unethical to administer placebo intramuscular injections to young infants. 
In addition, many of the side effects of steroids are common and easily recognised, for 
example weight gain and hypertension, making blinding difficult. Some would also argue 
that it is possible that the spasms are directly linked to the development of severe learning 
difficulties and it is generally thought (though not proven) that it may be possible that the 
earlier the spasms are brought under control the better the outcome. Thus delaying 
treatment (for example by administering placebo alone) is also usually thought to be 
unethical. Finally five studies had loss of patients to follow up and the remaining studies 
did not clearly state that all patients entered into the trials had been successfully followed 
up for the duration of the study. We had also planned to look for possible sources of 
clinical heterogeneity between the studies, for example, sex, age at spasm onset, age at trial 
entry, delay to treatment and whether or not participants had received previous treatment. 
Unfortunately, this information was not available for the majority of the included studies 
and we are unable to draw any conclusions. However, it is possible that some of these 
sources of heterogeneity are important in determining outcome. For example, the study 
Baram 1996 found ACTH to be more efficacious than prednisolone but had three times as 
many girls than boys in the ACTH group and roughly equal numbers in the prednisone 
group. It is possible therefore, that if girls have a better outcome than boys that this may 
have contributed to the differences seen in response between their two groups.
When developing our protocol we had tried to provide definitions for terms such as 
infantile spasms, cessation of spasms, relapse etc. We had planned to try and establish
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whether different definitions used by authors for infantile spasms might affect which 
participants would be included into a trial, thereby affecting outcome. It became clear from 
our review of the literature that few authors clearly define the term infantile spasms and it 
was clear that some trials using entry criteria that defined the need for hypsarrhythmia in 
fact entered infants who did not have this. It is theoretically possible that either some 
patients entered into these trials did not have infantile spasms or that different trials were 
investigating different populations. Therefore, for the purpose of this review we accepted 
that any RCT stating that their participants had "infantile spasms" would be included, but 
the results should be interpreted with caution. Likewise, we had also tried to define 
outcome measures such as cessation of spasms and what constituted a relapse, so that we 
could accurately compare the outcomes of each individual study. Again, the majority of 
studies did not define such outcomes and meta-analysis of these outcomes should again be 
interpreted with caution.
Infantile spasms are associated with a poor long-term prognosis. The majority will also 
have severe learning difficulties, with high cost implications not only to the patients and 
the families and their quality of life, but also on health services. Therefore, if any one 
treatment was proven to improve long-term psychomotor development and to reduce the 
risk of further seizure types then it would probably be considered to be more efficacious 
than other treatments regardless of the effect on the spasms themselves or the 
hypsarrhythmia. Although, with time the spasms will resolve, many patients continue to 
have other forms of epilepsy into adult life and about one fifth will progress to Lennox 
Gastaut syndrome. These patients will therefore require anticonvulsants and will continue 
to suffer the effects of epilepsy, often for life. However, no study has considered these 
factors as long term outcome measures beyond 44 months post trial entry, and currently 
there is no standard agreement on the timing or means of measuring these outcomes.
The spasms themselves are certainly distressing to parents and carers. It is possible that 
they are also distressing to the infant as many will cry immediately following a spasm or 
appear to be in pain and distressed, so much so, it is not uncommon for the spasms to be 
mistaken for colic. Whilst the long-term benefits of different therapies remain uncertain, 
we tried to establish if any one therapy was more efficacious in stopping the spasms 
themselves. One small study looking at patients with infantile spasms and an underlying 
diagnosis of tuberous sclerosis found vigabatrin to be more efficacious than hydrocortisone
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in stopping the spasms in this group of patients, a finding also found in some open 
studies . However, it is not clear that vigabatrin is more efficacious than steroids in 
treating infantile spasms in patients without tuberous sclerosis. One underpowered RCT 
showed a trend that vigabatrin might be more efficacious than placebo. Two small studies, 
Baram 1996 and Hrachovy 1993, did show ACTH to be more efficacious than prednisone 
in stopping the spasms, however their dose of prednisone of 2mg/kg/day would be 
considered too low a dose by some and it is therefore possible that higher doses of 
prednisone may be as efficacious as ACTH54. Further trials are required. We found no 
other RCTs comparing other forms of therapies, such as sodium valproate, 
benzodiazepines, pyridoxine or phenobarbitone, in terms of cessation of spasms. Although 
four studies did consider reduction in the number of spasms, it is not at all clear as to 
whether a reduction in spasms is of major benefit to a patient. Complete control of spasms 
has to be the main objective. Some open, prospective trials have suggested that vigabatrin 
might control spasms more quickly than steroids. Only three RCTs considered the time 
taken to cessation of spasms and there was no significant difference between vigabatrin 
and hydrocortisone or ACTH.
The exact relationship between clinical spasms and typical or even modified (or atypical) 
hypsarrhythmia on the EEG is not entirely clear. Not all infants with clinical evidence of 
infantile spasms have hypsarrhythmia, and in those in whom it is present it is not always 
present all of the time. It is not known whether the presence or absence of hypsarrhythmia 
affects long term outcome. Again we had hoped that by collecting and combining data 
from the studies, it might help clarify these areas of uncertainty. Unfortunately, few studies 
contained sufficient data to draw any conclusions.
We had also planned to look at subgroup analysis of clinical features, but unfortunately, 
because of lack of trials this was not possible. It was possible to consider patients with an 
underlying diagnosis of tuberous sclerosis as a subgroup in one underpowered study. This 
study, Chiron 19973 showed vigabatrin to be more efficacious than hydrocortisone in 
stopping the spasms in this group of patients. All their patients treated with vigabatrin had 
complete cessation of spasms and only one patient relapsed within the study period. 
However, the numbers are small - only eleven patients in each group and these results 
should be treated with caution, even though this result mimics the findings of open studies. 
Further trials are required with larger numbers of patients to confirm (or refute) the
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findings of this study.
Side effects must always be taken into account. Any drug with unacceptable side effects 
will not be used in clinical practice. Likewise if two drugs show similar beneficial effects 
then the one with the safer drug profile should be used in preference. Within these studies 
few side effects or deaths were reported. However, both steroids and vigabatrin have 
potentially serious side effects. The problem with steroids are potentially life threatening 
problems which include depression of the immune system and modified response to 
infection leading to overwhelming sepsis. Less serious side effects, for example 
hypertension, are often transient but nevertheless have the potential to cause morbidity. 
Minor side effects, estimated to occur in two thirds of patients, include behavioural 
changes especially irritability, changes in appetite, weight gain and alteration in sleep 
patterns. In addition some forms of steroids (e.g. ACTH) involve daily intramuscular 
injections. However, there have been reports of both asymptomatic and symptomatic visual 
field defects with loss of peripheral vision to varying degrees in adults and children treated 
with vigabatrin. It appears to occur most commonly in patients who have been treated with 
vigabatrin for more than six months but it does not appear to always be reversible on 
withdrawing the vigabatrin. The main difficulty in infants is that they cannot be tested or 
monitored for visual field defects (a child needs to be at least eleven to be able to co­
operate and complete a reliable test). However, on balance the devastating effects of 
infantile spasms probably outweigh the risks of developing the severe side effects of these 
therapies.
Implications for practice
The optimum treatment for infantile spasms remains uncertain. No study to date has shown 
any one drug to be more efficacious than any other in terms of long term psychomotor 
development or subsequent epilepsy rates. Vigabatrin may be more efficacious than 
placebo, and ACTH may be more efficacious than low doses of prednisone in stopping the 
spasms. Vigabatrin may be more effective than hydrocortisone in stopping the spasms in 
the group of patients who also have tuberous sclerosis. We found no one treatment to be 
more efficacious than any other with regard to reduction in number of spasms, relapse rates 
or resolution of hypsarrhythmia. Both steroids and vigabatrin have potentially serious side 
effects but the risks of these should be considered against the potential benefits, when 
considering treatment of infantile spasms.
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Implications for research
There is still little evidence available on the optimum treatment for infantile spasms. 
Further trials with improved methodology, standardised valid outcome measures, larger 
numbers of participants and longer follow up are required. As stated previously infantile 
spasms are a relatively rare disorder, so that in order to be able to recruit large numbers of 





Oral treatment of non-convulsive status epilepticus in tuberous sclerosis
Age of seizure onset is one of the most important prognostic factors for long-term outcome 
in patients suffering from TSC. It is rare for patients who have normal development and 
intellect at the age of five who subsequently develop epilepsy to regress. In the review of 
the patients in the Bath region over the past ten years no patient who developed fits over 
the age of five had impaired intellect. One unusual cause of regression after the age of 5 
years in TSC is the development of non-convulsive status epilepticus (NCSE). The 
epilepsy in TSC is often refractory to treatment and NCSE is regularly seen in those whose 
seizures are most difficult to treat. In addition these patients are liable to suffer recurrent 
attacks of NCSE.
Dr Frank Besag, National Centre for Young People with Epilepsy, has treated his patients 
with NCSE with oral diazepam for many years. He recommended this treatment to JPO 
who also had success with oral diazepam treatment of NCSE in some of his TSC patients. 
A literature search of the English Language failed to find any studies looking at this form 
of treatment or comparing it with conventional intravenous benzodiazepine administration.
NCSE is an infrequent but severe epileptic seizure disorder. It is characterised by a patient who has 
continuous or almost continuous epileptic activity both clinically and on EEG but the clinical signs of an 
epileptic seizure disorder may be extremely subtle. Usually, but not always in a patient with NCSE, there is a 
history of a previous overt seizure disorder, frequently severe. This can include IS and other difficult to 
control epileptic syndromes including Lennox-Gastaut syndrome. Clinically there is no clonic jerking of the 
limbs and although the patient may have some awareness of their surroundings, impaired consciousness is the 
main clinical feature. The onset may either be so subtle as to suggest a dementia or may be abrupt. Lack of 
awareness may extend to loss of appetite with significant weight loss. Patients may cycle from periods of 
complete unresponsiveness to one of partial responsiveness. Frequent brief, but small, myoclonic jerks can 
often be felt but not seen: they are random in time and site and are effectively detected clinically by a light 
handshake. Often there are associated autonomic features such as excessive salivation, sweaty palms and 
pupils that are rapidly dilating and constricting for no obvious reason.
Aim
Prolonged periods of impaired consciousness can interfere with development, education 
and well-being. The traditional treatment, effective in the majority of cases of idiopathic 
primary generalised NCSE, is the intravenous administration of benzodiazepines 114, which 
requires hospital admission and is inappropriate for those with frequently recurring attacks.
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Therefore, the aim of this study was to evaluate the use of oral diazepam in aborting 
attacks in those with recurrent episodes of NCSE.
Method
The notes of all the patients seen in the Bath Tuberous Sclerosis Clinic in 1996 (including 
patients outside the Wessex region) were examined to identify those patients who had a 
history of NCSE. The diagnosis of NCSE was made on clinical grounds at the time of 
attending the clinic as defined above; palpable myoclonic jerks, evidence of autonomic 
dysfunction and impaired consciousness were all required before NCSE was diagnosed. 
Those notes were then examined further to ascertain the patient details, information about 
their epilepsy and the treatment received. No patients were excluded from the study 
because of lack of data in the medical notes.
Results
Eight patients had a history of NCSE, including the two patients reported in chapter two, 
five males and three females. All eight patients had presented with IS by the age of seven 
months. They all subsequently developed secondarily generalised tonic-clonic seizures, 
absence seizures and drop attacks.
The age of onset of the NCSE varied from six to 18 years. The clinical nature of the 
episodes varied greatly. For example the parents of case four described a picture of being 
‘limp, lethargic, lying around, dribbling, often staring and gazing with pupils dilated, hands 
sweating, unusual circulation and jerky movements of the limbs’. Case three had an 
insidious onset over three to four months during which time he had changed from being 
independently mobile to becoming wheelchair bound. On occasions when he did walk, he 
would walk into doors. He also became disinterested in food during this period, lost weight 
and was thought to be terminally ill when referred. He was given lOmg oral diazepam and 
within an hour was alert and had a normal appetite. The dose was repeated when NCSE 
recurred; on average every five days, with the same effect and speed of action.
Seven were treated successfully with oral diazepam (table seventeen) and in only one (case 
number five) was drowsiness, lasting about three hours, noted to be a problem. No other 
side effects were recorded. The dose of diazepam required varied considerably and bore no 
relationship to either the child’s age or weight, but was the dose required to produce
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clinical evidence of the abolition of NCSE (a return of consciousness, an absence of both 
myoclonic jerks and signs of autonomic dysfunction) as determined by the parents or 
carers. Confirmation, of the diagnosis of NCSE and of its abolition on EEG was only 
available by direct observation and investigation for one of the patients who was 







Effect of diazepam Prophylactic anti­
convulsant treatment 
(total / day)
Case 1 6 years Female 30 Markedly reduces 
time of NCSE (from 
days to hours)
Sodium Valproate 1200mg 
Phenobarbitone 90mg
Case 2 9 years Male 5 Aborts NCSE Sodium Valproate lOOOmg* 
Carbamazepine 1800mg
Case 3 13 years Male 10 Aborts NCSE within 
1 hour
None 4
Case 4 14 years Female 1 0 -
20
Aborts NCSE Sodium Valproate 1800mg 
Nitrazepam 7.5mg
Case 5 16 years Male 10 Aborts NCSE Carbamazepine 1200mg 
Vigabatrin 2.5g
Case 6 18 years Female 5 Markedly reduces 





Case 7 27 years Male 20-40 Aborts NCSE Sodium Valproate 800mg 
Carbamazepine 1200mg 
Lamotrigine 200mg
Case 8 3 years Male Not known -  
admitted in non- 
convulsive status 
elsewhere and given 
iv diazepam
Sodium Valproate 900mg 
Vigabatrin lg
* This boy was later inadvertently given 4000mg sodium valproate I day and 
his NCSE recurred, responding to a reduction in dose to 1000mg/day
# This boy had not been on any anticonvulsants for 8 weeks prior to 
treatment for his NCSE as he was considered “terminally ill” . Previously he 
had been tried on at least 8 different anticonvulsants to try and control his 
seizures, without obvious benefit.
This table shows the outcome of treatment with oral diazepam in the seven
patients. One patient did not receive an oral dose.
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The eighth patient diagnosed as having episodes of NCSE, from the parent’s description in 
clinic, was prescribed 5 mg oral diazepam to be given at the onset of the next episode to 
see if it would abort the attack. He was then admitted to his local hospital with NCSE 
before the oral diazepam was given (he too had the clinical diagnosis of NCSE confirmed 
by EEG). After successful treatment with IV diazepam he was discharged and to date 
(three years later) has had no further episodes: his other seizures have also reduced in 
frequency.
Discussion
These eight patients with TSC all had a severe recurrent epileptic seizure disorder and were 
on regular prophylactic anticonvulsant treatment. We do not know if their EEG would have 
supported a diagnosis of primary generalised or secondarily generalised NCSE except in 
two patients. However we agree with Aicardi115 that a generalised EEG in these patients 
who at other times have focal EEG changes and who have tubers causing focal structural 
lesions makes it difficult to decide on classification. Our diagnoses were made on clinical 
grounds and it was not possible to further validate this: there must therefore be some doubt 
about the diagnosis of NCSE and of its abolition. However we believe these diagnoses are 
usually reliable clinically and the response to treatment would support this. An EEG is 
preferable but was usually not possible in our cases: it would be required if the diagnosis 
were in doubt. Our patients were usually recognised as having episodes of NCSE between 
attacks when in clinic either on history alone or history supported by examination at the 
time. Carers were taught what to look for so that the diagnosis could be confirmed during a 
telephone consultation. These latter are a common practice in our TSC clinic because of 
the need for frequent feedback concerning the epilepsy and the great distance some people 
travel to visit the clinic.
Little has been published about NCSE and many paediatricians are unfamiliar with its 
clinical signs, diagnosis or management. In most publications intravenous diazepam is the 
usual treatment for NCSE, effective in 80-100% cases of primary NCSE but only 15 -  59% 
of secondary NCSE116: this is not convenient when the patient suffers recurrent attacks, 
because of the severity of their epileptic seizure disorder, despite appropriate regular 
anticonvulsant treatment. Oral diazepam is not normally considered for antiepileptic 
treatment since it is not effective for the termination of primary generalised tonic-clonic
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seizures or for prophylaxis because an inability to achieve adequate blood levels. Oral 
diazepam has been used to prevent febrile convulsions and other agents, buccal or nasal, 
midazolam most frequently, have more recently been used for primary generalised status 
epilepticus. Why it might work in NCSE is unclear. We have found it to be effective in 
patients with TSC for recurrent attacks of NCSE that the parents and carers can learn to 
recognise, so allowing prompt treatment to be given without necessitating hospital 
admission. It is likely to be equally or more effective in primary generalised NCSE.
Side effects were only seen in one patient. Effective management of NCSE in these 
patients has allowed planned alteration to regular anticonvulsant treatment without 
admission to hospital, making it easier for carers to consider trying alternative prophylactic 
anticonvulsant management. In one patient the inadvertent administration of large doses of 
sodium valproate (>100mg/kg) re-precipitated recurrent attacks of NCSE, which resolved 
on return to the prescribed dose: no other associations between NCSE and prophylactic 
treatment were noted. Precipitation of NCSE by a rapidly increasing dosage of sodium
1 17valproate in an adult patient has been previously described 
Conclusion
Oral diazepam is a safe and effective treatment for termination of NCSE in patients with 
TSC. If parents and carers can be taught to recognise episodes of NCSE early in their 
evolution so that early intervention with oral diazepam can be undertaken thus abolishing 
the attacks then the outcome may be improved and regression avoided. Unfortunately all 
the patients in this series had suffered severe fits from a young age and had severe learning 
difficulties at the time of onset of their NCSE and it is difficult to ascertain whether further 
regression has been avoided in these patients.
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CHAPTER SEVEN
Lvmphangioleiomvomatosis and Tuberous Sclerosis
Lymphangioleiomyomatosis (LAM) is thought to occur as a complication in approximately 
1% of patients with TSC. Although Lutembacher first described LAM in association with 
TSC in 1881, he mistook the cystic and nodular changes for metastasis from renal 
fibrosarcoma, in the lungs of a 36 year old woman who died from bilateral 
pneumothoracies. It wasn’t until 1939 that Berg and Vejilens gave the first accurate and 
clear description of the clinical and radiological features of pulmonary tuberous sclerosis. 
It is difficult to estimate the true incidence of LAM in TSC, other than it is undoubtedly 
rare, partly because the few studies that have attempted to do so have generally used small 
numbers of patients from biased groups and partly because it is unknown how many 
patients with pulmonary complications become symptomatic and are therefore recognised.
1 i o
In 1971 Dwyer et. al. described three cases and reviewed the literature on a further 31 
cases and in 1995 Castro et al.44 produced a retrospective study of nine patients seen at the 
Mayo Clinic in the previous 43 years. The other reports have all been of only a few 
patients.
LAM is a rare cystic lung disease that is usually generalised and progressive, can be extremely difficult to 
treat and has generally been considered to have a poor prognosis. It has almost exclusively been reported to 
occur in women of childbearing age, the commonest presentation being dyspnoea and pneumothorax, after 
which many patients follow a relentless deterioration. Although LAM is a rare complication of TSC it causes 
a significant amount of morbidity and mortality.
LAM predominately affects females of childbearing age119. The commonest presenting symptoms are 
dyspnoea and pneumothorax but other symptoms include chronic cough, haemoptysis, chylothorax, wheeze 
and chest pain. Cyanosis, respiratory failure and cor- pulmonale also occur44118 . Asymptomatic cases have
also been described, with radiographic changes being the only clue to pulmonary involvement118. Pulmonary 
function tests tend to show an obstructive pattern although a restrictive pattern has been noted in some 
patients120.
Treatment of LAM is difficult, and historically it has been treated symptomatically, for example, drainage of 
pneumothoracies, conventional inhalers for wheeze and oxygen therapy for respiratory failure. More recently 
hormone manipulation has been tried with variable success44,121 The long-term prognosis is considered poor 
with many patients following a relentless deterioration after the onset of their symptoms’18.
Aims
Despite the fact that LAM has been recognised as a complication of TSC for over 80 years 
and is the third commonest cause of premature mortality, after renal disease and brain 
tumours , it is probably under recognised, its epidemiology and natural history remains 
poorly understood and there is little data on the effectiveness of treatment or the value of
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screening. Therefore, the aim was to try and highlight those patients at greatest risk of 
developing LAM in TSC and to try and provide further guidance for both the screening 
and the treatment of this entity.
Methods -  To ascertain patients with LAM in TSC
Patients suffering from the pulmonary complications of TSC were identified from several 
sources;
1. The Bath TSC clinic, research and epidemiological studies: clinical information was 
available on 145 patients known to suffer from TSC in the Wessex region and on 
approximately 250 other TSC patients from outside the Wessex region.
2. By contacting all the respiratory physicians in the Wessex region asking them to notify 
us of any patients with LAM who might also have TSC.
3. The Tuberous Sclerosis Association (TSA).
4. The medical genetics department in Cardiff.
5. The renal department in Brighton, where a TSC clinic is held.
Patients were classified as having LAM on the following criteria;
1. A definite diagnosis
(a) Pathological confirmation by lung biopsy.
(b) Pathological confirmation at post mortem.
2. A probable diagnosis
(a) Typical findings on HRCT scan i.e. the presence of multiple thin walled cysts.
(b) Honeycombing +/- pneumothorax on CXR.
(c) Fine reticular shadowing +/- pneumothorax on CXR.
3. A possible diagnosis
_______ (a) pneumothorax only on CXR._______________________________________________________
Patients were accepted as having TSC according to strict interpretation of the recently 
revised criteria for clinical diagnosis: i.e. at least one hamartoma present in each of a 
minimum of two different organs (but excluding the lung for the purpose of this study)4.
The following information was then collected by visiting each patient (other than those 
deceased), studying their clinical notes and obtaining copies of the relevant investigations;
• Age of diagnosis of TSC.
• Diagnostic criteria for TSC.
• Family history of TSC.
• Age at presentation of lung disease.
• Age at diagnosis of lung disease.
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• Mode of presentation.
•  Pulmonary symptoms and complications.
•  Chest X-ray (CXR), high resolution computerised tomography (HRCT) and biopsy 
findings.
• Any disturbance in spirometry.





Three patients from Wessex had been diagnosed as having LAM, two of who were 
deceased.
22 out of the 23 (96%) respiratory physicians in the Wessex region replied, but only one 
had a patient with both LAM and TSC and this was the live patient that had been identified 
from above.
The TSA was then contacted for the names of any patients suffering from the lung 
complications of TSC and an advertisement placed in SCAN, the association’s publication. 
Thirteen additional patients were contacted in this way including the names of two patients 
who had died from their disease.
Three patients were known to the medical genetics department in Cardiff.
A renal physician in Brighton, who knew of our interest, then gave us the names of two 
further patients bringing the total to twenty-one.
Confirmation of diagnosis
Definite LAM: We gave ten of our patients a definite diagnosis of LAM. These included 
the four patients (patients 1-4) in whom a pathological diagnosis of LAM was confirmed at 
post-mortem and the six patients (patients 5-10) who underwent open lung biopsy. In these 
patients the histology was reported as consistent with LAM (i.e. proliferation of smooth 
muscle), honeycomb lung or as having multiple cysts and bullae.
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Probable LAM: Six patients (patients 11-16) had HRCT of the chest with findings 
consistent with LAM. Three other patients had abnormal CXRs suggesting LAM, two 
(patients 17 & 18) had a honeycomb appearance and one (patient 19) fine reticular 
shadowing and on the grounds of this together with the clinical history were given a 
probable diagnosis of LAM.
Possible LAM: The remaining two (patients 20 & 21) had evidence of pneumothoracies 
but no other abnormality on CXR and therefore were given a diagnosis of possible LAM 
only.
TSC: All our patients, other than patient 21, had facial angiofibroma (a hamartoma 
considered pathognomonic of TSC) plus the presence of at least one hamartoma in another 
organ (for example renal AML, retinal phakoma, giant cell astrocytoma, or subependymal 
nodules) and had a definite diagnosis of TSC. Patient 21 had two hypomelanic macules 
together with a strong family history of TSC: both her sister and son had been diagnosed as 
having definite TSC (and her mother who had not been screened was known to have 
ungual fibromata) thus making her a likely obligate carrier. Unfortunately the patient 
herself had not undergone fundoscopy, renal or cranial imaging in order to prove the 
diagnosis of TSC and was therefore given a diagnosis of probable, rather than definite 
TSC.
Population characteristics (table eighteen)
There were 18 females and 3 males.
The median age of diagnosis of TSC was 17 years with a range of 6 weeks to 37 years. 
Three (patients 7, 9 and 10) had a diagnosis of TSC made as a result of their respiratory 
disease; the others had a variety of reasons. Seven had a family history of TSC, five of 
whom had the diagnosis of TSC made as a result of a child being diagnosed. This gives a 
spontaneous mutation rate of 66%.
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Table eighteen
Patient Sex Age at diagnosis 
of TSC







Patients with a definite diagnosis of LAM
1 Female 16 years Retinal phakoma 25 years Pneumothorax (bilateral)
2 Female 4 years Facial angiofibroma 
CT brain
18 years Pneumothorax
3 Female 2 years Infantile spasms 
CT brain
18 years Pneumothorax (bilateral)
4 Female 3 years Epilepsy 
CT brain
19 years Pneumothorax
5 Female 9 months Facial angiofibroma 7 years Dyspnoea
6 Female 37 years Investigated following 
diagnosis of son
Teenager Dyspnoea and chest pain
7 Male 6 months Pulmonary TSC 6 months Thick pulmonary 
secretions
8 Female 18 months Infantile spasms 
CT brain
21 years Pneumothorax (bilateral)
9 Female 34 years Pulmonary TSC 10 years Dyspnoea and weight loss
10 Female 30 years Pulmonary TSC 30 years Pneumothorax (bilateral)
Patients with a probable diagnosis of LAM
11 Female 21 years Investigated following 
diagnosis of daughter
34 years Dyspnoea
12 Female 11 months Infantile spasms 
CT brain
19 years Pneumothorax
13 Female 5 years Facial angiofibroma 
CT brain
32 years Pneumothorax
14 Female 35 years Renal haemorrhage 38 years Chylothorax
15 Female 17 years Investigated following 
diagnosis of son
17 years Pneumothorax (bilateral)
16 Female 37 years Ungual fibroma on feet 
Angiofibroma
23 years Pneumothorax
17 Female 24 years Investigated following 
diagnosis of son.
20 years Pneumothorax
18 Male 6 weeks Epilepsy 
CT brain
8 years Dyspnoea and dry cough
19 Male 21 years Epilepsy 
CT brain
32 years Pneumothorax
Patients with a possible diagnosis of LAM
20 Female 6 years Facial angiofibroma 20 years Pneumothorax




Table showing the sex of each patient, the age at which TSC was diagnosed 
and the reason for diagnosis of TSC, the age of onset and the presenting 
features of the pulmonary disease, stratified by definite, probable and 
possible diagnosis of LAM.
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Pulmonary disease
The average age of onset of pulmonary symptoms was 19 years with a median of 20 years 
and a range of birth to 34 years. The average age of diagnosis of pulmonary tuberous 
sclerosis was 25 years with a median of 25 years and a range of six months to 38 years. On 
average there was a delay of six years between the onset of respiratory symptoms and the 
eventual diagnosis of LAM.
The commonest presenting feature was pneumothorax, which occurred in 14 of the 
patients, five of whom presented with bilateral pneumothoracies. Five patients had a 
history of gradual onset dyspnoea. One patient presented with a chylothorax. The final 
patient had thick bronchopulmonary secretions requiring suction as an infant: a lung biopsy 
at the age of six months gave the diagnosis of LAM (table eighteen).
Pulmonary symptoms: 19 patients complained of dyspnoea, 15 had a cough with six 
having haemoptysis at times, 13 patients experienced pain usually, though not always, in 
conjunction with proven pneumothoracies and 11 patients noticed wheezing at times (table 
nineteen).
Complications
In total 17 of the 21 patients suffered pneumothoracies. There were 12 right sided, five left 
sided and six bilateral pneumothoracies. Four patients suffered from chylothoraces, one 
had a pericardial effusion and one died from pulmonary haemorrhage (table nineteen).
Four patients died as a result of their respiratory disease:
The first patient had sudden onset of pain and shortness of breath at the age of 25 
years. She was diagnosed as having bilateral pneumothoracies requiring bilateral 
pleurodesis. There was then a gradual deterioration over the following 20 years 
with increasing shortness of breath, a productive cough and cyanosis. She was 
initially treated with home oxygen but was later admitted to a long stay hospital 
where she developed cor-pulmonale and died at the age of 47 years from her lung 
disease. She was considered for a lung transplant but it was decided that, because of 
her history of pleurodesis and her general medical condition by that stage, she 
would be unable to tolerate the operation.
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The second patient had had a history of a left pneumothorax, aged 18 years, which 
was treated by pleurodesis. Three years later she had bilateral pneumothoracies, 
which were again treated by pleurodesis. Approximately a year later she 
complained of shortness of breath and started suffering from recurrent chest 
infections. She then developed respiratory failure requiring increasing amounts of 
oxygen therapy. Although hormonal treatment was tried it was ineffective and at 
the age of 26 years she too was considered for a lung transplant. Unfortunately by 
that time she was so weak it was felt that she would not be able to tolerate the 
physiotherapy required. In addition there were technical concerns because of the 
pleurodesis. She died a year later.
The third had been admitted for investigation of indigestion and vomiting and 
underwent gastroscopy under general anaesthetic. During the procedure she 
developed bilateral pneumothoracies and required admission to intensive care. The 
pneumothorax on the right failed to resolve and chemical pleurodesis was 
performed. Following this her urinary output deteriorated and she went into renal 
and respiratory failure, dying one week later.
The fourth patient was a 19 year old girl with a history of severe renal involvement. 
She had a one week history of dyspnoea and dry cough (following two recent 
airplane flights) and had been treated by antibiotics before presenting to casualty 
with a left-sided pneumothorax. She was treated conservatively and allowed home 
to await HRCT and review. Two days before her review she suffered an acute fatal 
pulmonary haemorrhage whilst asleep.
One other patient also had a history of respiratory failure with two respiratory 
arrests as a result of developing pneumonia after a 10 year history of gradually 
increasing shortness of breath. She was treated in hospital with oral steroids and 
oxygen. She was not ventilated because there were concerns about the possibility of 
not being able to wean her off a ventilator. She has since made a remarkable 
recovery and just six months later has returned to work.
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Table nineteen
Patient SOB Cough Haem Pain Wheeze Complications CXR HRCT Biopsy / histology
Patients with de inite LAM
1 ✓ ✓ ✓ 1 Bil. P. P. Not performed “lung involvement”
2 ✓ ✓ 1 Bil. P. P. Unavailable Appearance of LAM
3 Developed bilateral pnuemothoracies under GA and diec whilst ventilated 7 days later. P. Not performed LAM
4 V 1 Lt P, 1 Chy, 1 Pul. Haem. P. Not performed LAM
5 S s ✓ ✓ 2 Rt P. P. RS. Multiple cystic spaces Proliferation of immature muscle.
6 ✓ ✓ ✓ 2 Rt P. 1 Lt P. P. Not performed Small cysts in the lung tissue
7 V ✓ H. Not performed Appearance is that of LAM.
8 ✓ s s 1 Bil. P, 1 Chy P. Not performed. Proliferation of smooth muscle.
9 ✓ s 1 RtP, 1 Chy, 1 CE. Emph. Emphysema Opinion is of honeycomb lung.
10 ✓ ✓ 1 Bil P. P. Consistent with LAM Proliferation of smooth muscle.
Patients with a probable diagnosis of LAM
11 S ✓ s H Thin walled cysts. Not performed
12 S ✓ s 1 RtP. P. Lung cysts and bullae. Not performed
13 S s ✓ 1 RtP. P. Honeycomb pattern Not performed
14 S 1 Chy P. Eff. Cystic changes of TSC Not performed.
15 s ✓ s 1 Bil P. P. Thin walled cysts. Not performed
16 s s ✓ s 1 Rt P, 1 Lt P. H. Thin walled cysts Not performed
17 s V ✓ ✓ s 2 RtP, 1 Lt P. H. Not performed Not performed
18 V s ✓ H. Not performed Not performed
19 ✓ ✓ 1 RtP. RS Not performed Not performed.
Patients with a possible diagnosis of LAM
20 s 1 RtP. P. Not performed. Not performed
21 1 LtP. P. Not performed Not performed
SOB = dyspnoea, Haem = Haemoptysis, CXR = chest Xray, HRCT = high resolution computerised tomography scan of chest. 
Rt P. = right pnuemothorax, Lt P. = left pnuemothorax, Bil P. = bilateral pnuemothorax, Chy = Chylothorax, Pul Haem = pulmonary 
haemorrhage, CE = cardiac effussion, 
P. = pnuemothoxax, R.S. = reticular shadowing, Emph = emphasema, Eff = pleural effusion. 
Table showing the symptoms and the complications experienced and the investigations undertaken on each patient.
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Investigations (table nineteen)
All four patients who died as a result o f their lung disease had post-mortem examination of 
their lungs. In all cases the histology was consistent with a diagnosis of LAM and TSC.
Six patients underwent open lung biopsy reported as being consistent with LAM.
Nine patients had undergone HRCT all o f which demonstrated the well-defined thin wall 
cysts characteristic o f LAM (see figure eighteen).
Figure eighteen: HRCT chest of patient 
with LAM
All 21 patients had undergone CXR during the course o f their illness. Seventeen had 
evidence of pneumothoracies and four showed pleural effusions. In addition six 
demonstrated a picture of nodular shadowing or honeycombing, and two had fine reticular 
shadowing (figure nineteen).
Figure nineteen: CXR showing 
honeycombing in a patient with LAM
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It was not possible to perform spirometry on ten of the patients; four who had had died, 
five who had severe learning difficulties and were unable to co-operate with the test and 
the spirometer was not available at the time of the visit of one further patient. Lung 
function tests in the remaining patients were normal in two, showed an obstructive picture 
in three and a restrictive pattern in the other six.
Treatment (table twenty)
Drainage of the pneumothoracies and chylothoraces was undertaken in the acute phase 
when necessary. Nine patients underwent pleurodesis and four pleurectomy for recurrent or 
severe pneumothoracies.
Five patients were prescribed conventional inhalers with little or no improvement in 
symptoms.
Four patients received progesterone therapy;
Patient two suffered her first pneumothorax at the age of eighteen, which was treated 
by pleurodesis, three years later she had bilateral pneumothoracies, again treated by 
pleurodesis. A year later aged 22 years she began to suffer from increasing dyspnoea 
and recurrent chest infections. She was commenced on progesterone tablets but her 
condition continued to deteriorate and the progesterone was discontinued after one 
year. She later died aged 27 years.
Patient ten had bilateral pneumothoracies aged 30 years requiring pleurodesis. She was 
then started on depot provera, which she has continued to the present day (five years 
follow up). Since starting the progesterone she has remained well with mild dyspnoea 
and wheeze on exertion and an occasional cough (no haemoptysis) only.
Patient twelve suffered her first pneumothorax aged twenty one requiring pleurectomy. 
Over the following 16 years she had slowly worsening dyspnoea with episodes of 
haemoptysis. At the age of 35 years a HRCT of the chest confirmed the diagnosis of 
LAM and depot provera was commenced. Over the following year her exercise 
tolerance improved and she also showed an improvement in spirometry. She remains 
well on the depot provera.
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Table twenty
Acute / surgical 
treatment
Long term Medical 
treatment
Disease Course (follow up)
Patients with a definite diagnosis of LAM
1 Drainage
Pleurodesis
Oxygen therapy Died from cor-pulmonale whilst waiting 






Died from cor-pulmonale, too ill for 
transplant (~ 10 years after onset of 
symptoms)
3 Drainage and ventilation None Died from respiratory and renal failure 
(~ one week after onset of symptoms)
4 None None Died from massive pulmonary 




None Stable (3 years)
6 Drainage
Pleurectomy
None Remains well (25 years)
7 None Inhalers (no benefit) Improved (23 years)
8 Drainage
Pleurectomy
None Remains well (6 months)
9 Lobectomy None Remains well (38 years)
10 Drainage
Pleurodesis
Progesterone Remains well (6 years)
Patients with a probable diagnosis of LAM
11 None Atrovent (little benefit) Stable (13 years)
12 Drainage
Pleurectomy
Progesterone Improved (18 years)
13 Drainage
Pleurodesis
Atrovent (some benefit) Remains well (2 years)
14 Drainage Progesterone Remains well (1 year)
15 Drainage
Pleurodesis
None Progressive deterioration (10 years)
16 Drainage
Pleurodesis
Inhalers (no benefit) Progressive deterioration (30 years)
17 Drainage
Pleurodesis
Progressive deterioration (31 years)
18 None Inhalers (little benefit) Improved slowly (6 years)
19 Aspiration None Remains well (2 years)
Patients with a possible diagnosis of LAM
20 Drainage
Pleurodesis
None Remains well (17 years)
21 Drainage None Remains well (5 years)
Table showing acute surgical and medical treatment, long term medical treatment, 
disease course and time of follow up.
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Patient fourteen suffered a renal haemorrhage at the age of 35 years, which was treated 
conservatively by transfusion. She was then commenced on depot provera but four 
years later suffered a pneumothorax and chylous effusion, treated by drainage. She 
continues with hormonal treatment.
A course of steroids (dexamethasone / prednisolone) was prescribed for two patients with 
no discernible effect on the progression of their disease. Though a third patient suffering 
from acute respiratory failure made a remarkable recovery after treatment with oxygen and 
steroids.
The two patients who died from cor-pulmonale received home oxygen therapy and courses 
of antibiotics when appropriate. Both these patients were also considered for lung 
transplantation.
Follow up (table twenty)
Two patients died within a few weeks of developing respiratory symptoms.
The remaining patients were followed up for an average of 14 years and a median of 10 
years (range 6 months to 38 years).
Five patients have shown a progressive deterioration, a further two dying from their 
disease. Three patients have improved slowly whilst two have remained stable. The other 
nine patients have remained well with no further symptoms occurring after treatment of 
their presenting symptoms.
Skin manifestations
All the patients had skin manifestations of TSC. Twenty patients had facial angiofibroma, 
19 hypomelanic patches, 12 ungual fibromas, 11a shagreen patch, eight a fibrous forehead 
plaque, eight nail ridging, five skin tags, three had poliosis and three confetti 
depigmentation.
Renal manifestations (table twenty-one)
Twelve (57%) patients had a clinical history of renal involvement; of those who did not 
only three had undergone imaging of the kidneys of whom one was found to have
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angiomyolipomas (AML). Post mortem examination of a patient who had also been 
entirely asymptomatic also showed evidence of renal disease. One patient died as a result 
of a combination of renal and respiratory failure.
In total five patients suffered from proven haemorrhage, one underwent nephrectomy, one 
had embolisation performed and one required both embolisation and then nephrectomy.
The other two patients were treated conservatively, one by transfusion the other with 
analgesia and antibiotics.
In addition two patients had embolisation, and one a nephrectomy performed for pain 
relief. One patient had a presumed renal carcinoma removed that was subsequently shown 
to be an AML on histology.
Neurological manifestations
Epilepsy was the commonest neurological manifestation occurring in 18 (86%) of our 
patients at some time. Ten (48%) patients had associated learning difficulties, but in three 
it was very mild and they had been able to attend mainstream school. Six (29%) patients 
had associated behavioural problems -  autistic tendencies and hyperactivity. Two patients 
had a GCA diagnosed with associated hydrocephalus requiring tumour excision and shunt 
insertion. One patient had a mild hemiplegia.
Other clinical associations
Four patients (patients 7,11,18,19) had scoliosis, two were fixed and two were mobile, 
none had undergone surgery or bracing. All four patients have had a relatively mild course 
of LAM. Pulmonary function was only possible in one patient. He had a mild restrictive 
defect, so although scoliosis is known to affect pulmonary function, it is difficult to assess 
what part it has played in the respiratory disease of these four patients.
Four patients were also incidentally noted to have hepatic haemangioma on USS or CT 





Age of onset 
of symptoms
Pain Haematuria Haemorrhage USS / CT result Treatment
Patients with a definite diagnosis of LAM
1 Asymptomatic Not done
2 Pain 11 years Yes Yes Yes Not known Embolisation and nephrectomy
3 Pain, ARF 15 years Yes Multiple AML
4 Pain 16 years Yes Yes Multiple AML Embolisation
5 UTIs Unknown Yes Multiple AML
6 Asymptomatic Not done
7 Asymptomatic Normal
8 Asymptomatic AML and cysts AML removed
9 Asymptomatic Not done
10 Asymptomatic Not done
Patients with a probable diagnosis of LAM
11 Pain, UTIs Childhood Yes AML & cysts
12 Pain 20 years Yes Multiple AML Embolisation
13 Asymptomatic Not done
14 Pain 35 years Yes Yes Bilateral AML Transfusion
15 Pain Not known AML & cysts
16 Pain 21 years Yes Normal R kidney Nephrectomy
17 Haemorrhage 14 years Yes Yes Yes Cysts R kidney Analgesia and antibiotics
18 Asymptomatic Not done
19 Pain 32 years Yes AML & cysts Embolisation
Patients with a possi )le diagnosis of LAM
20 Pain, UTIs 11 years Yes Yes Yes AML & cysts Nephrectomy
21 Asymptomatic Normal
Table showing the renal symptoms, complications and investigations of our group of patients.
Methods - Literature search (see appendix four for references)
A search of the English literature for all cases of LAM, both with and without associated 
TSC, was performed from 1939 to 1997 using the Medline database and from 1981 to 1997 
using the EMBASE database. The references of all retrieved papers (including those 
discounted after review) were searched for additional references.
The cases were then divided into four groups on the following criteria:
TSC: the paper either stated that a diagnosis of tuberous sclerosis had been made in the individual(s) or gave 
enough features in the individual(s) to fulfil the diagnostic criteria for tuberous sclerosis (for example the 
combination of epilepsy, mental retardation and renal angiomyolipoma).
Possible: the paper did not state whether the individual(s) did or did not have tuberous sclerosis but described 
some features suggesting the possibility that they might have TSC (e.g. renal angiomyolipoma or mental 
retardation).
Unlikely: the paper did not state that the diagnosis of tuberous sclerosis had been excluded and did not 
describe any features of tuberous sclerosis in the individual(s).
Not TSC: The paper clearly stated that the individual(s) did not have any features of tuberous sclerosis. How 
this was done was not always stated.
Results
In total there were 183 papers citing a total of 445 individual cases of LAM.
83 cases had TSC, 119 were possible cases, 174 cases were unlikely and 69 definitely 
were not TSC.
Population characteristics
There were 435 females, 9 males and in one case the gender was not given.
78 females and 5 males had TSC, 117 females and 2 males had possible TSC, 172 females, 
1 male and one other patient (gender not stated) were unlikely to have TSC and 68 females 
and 1 male were stated as not having TSC.
Pulmonary disease
The average age of onset of pulmonary symptoms was given for 365 / 445 (82%) cases and 
was 32.7 years with a range of 4 years to 70 years.
TSC: Given for 75 patients, Average = 30.4 years (range = 8 - 5 7  years, SD = 9.2 years). 
Possible: Given for 74 patients, Average = 27.5 years (range = 4 - 5 9  years, SD = 10.7 
years).
Unlikely: Given for 148 patients, Average = 35.6 years (range = 4 - 7 0  years, SD = 11.5 
years).
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Not TSC: Given for 68 cases, Average = 34.6years (range = 9 - 6 2  years, SD = 11.9 
years).
The average age of diagnosis of LAM was given for 273 / 445 (61%) cases and was 36.2 
years with a range of 4 -  72 years.
TSC: Given for 59 patients, Average = 36.6 years (range = 1 3 - 7 2  years, SD = 10.7 
years).
Possible: Given for 50 patients, Average = 34.3 years (range = 4 -6 1  years, SD = 13.4 
years).
Unlikely: Given for 135 patients, Average = 36.6 years (range = 1 4 - 7 2  years, SD = 10.7 
years).
Not TSC: Given for 29 cases, Average = 36.6 years (range = 8 - 6 8  years, SD = 12.7 
years).
Therefore on average there was a delay of 3.5 years between the onset of respiratory 
symptoms and the eventual diagnosis of LAM.
The presenting features were given for 320 / 445 (72%) patients (see table twenty two) and 
there was a wide range of pulmonary symptoms described in all groups (also summarised 
in table twenty two). Pneumothorax and chylothorax were the commonest reported 
complications. Pleural effusions were also reported but it was not always stated whether 
these were serous, chylous or bloody.
Investigations and confirmation of diagnosis of TSC
Only two thirds of the papers stated how a diagnosis of LAM was confirmed. In the papers 
that did, the majority were confirmed either histologically (post mortem or biopsy) or by 
CT scan. Lung function testing was only performed on / given for approximately half of 









Not TSC  
n = 69
Dyspnoea any time: 67% 66% 85% 91%
Dyspnoea at presentation: 38% 46% 59% 20%
Pneumothorax any time: 47% 56% 36% 67%
Pneumothorax at presentation: 29% 35% 21% 68%
Cough any time: 24% 43% 42% 35%
Cough at presentation: 0% 3% 11% 0%
Chylothorax any time: 10% 27% 27% 33%
Chylothorax at presentation: 2% 8% 4% 2%
Haemoptysis any time: 19% 20% 23% 32%
Haemoptysis at presentation: 0% 5% 1% 3%
Respiratory failure any time: 0% 0% 0% 0%
Respiratory failure at presentation: 0% 0% 0% 2%
Pain (without proven pneumothorax) any time: 6% 8% 2% 2%
Pain (without proven pneumothorax) at 
presentation:
0% 0% 0% 0%
Other any time: 2% 1% 13% 3%
Other at presentation: 6% 0% 1% 2%
Asymptomatic 25% 3% 4% 3%
Table showing the symptoms suffered at any time by, and the presenting 












Post mortem 9 (10%) 0 17(10%) 8 (12 %)
Biopsy 18 (21%) 48 (40%) 84 (48%) 16 (23%)
Chest CT 15(18%) 9 (8%) 61 (35%) 7 (10%)
CXR 9 (10%) 15 (13%) 2 (1%) 4 (6%)
Pulmonary function tests
Normal 5 (6%) 3 (3%) 9 (5%) 4 (6%)
Obstructive 18 (22%) 18 (15%) 46 (26%) 16 (23%)
Restrictive 3 (4%) 3 (3%) 19(11%) 1 (1%)
Mixed 0 0 10 (6%) 33 (48%)
Abnormal 8 (10%) 0 4 (2%) 2 (3%)
Table showing the investigations undertaken (and method of diagnosis) and 
the pulmonary function tests.
Treatment and outcome
Where stated most patients were treated symptomatically, pneumothoracies and effusions 
were drained when clinically necessary and pleurodesis and pleurectomies were frequently 
reported. Many patients received courses of antibiotics and those in respiratory failure 
were treated by oxygen.
Hormonal manipulation was tried in a total of 187 / 445 (42%) of patients with variable 
success (table twenty-four).
Unfortunately progression of the disease was only given for 95/258 (37%) of patients 
who did not receive hormonal manipulation as treatment and even fewer gave an indication 















Improved 6 (33%) 2 (6%) 19 (20%) 2 (5%) 29 (16%)
Stable / 
unchanged
5 (27%) 1 (3%) 27 (28%) 9 (21%) 42 (22%)
Worsened / 
died
6 (33%) 26 (81%) 47 (50%) 23 (55%) 102 (55%)
Unknown 1 (5%) 3 (9%) 2 (2%) 8 (19%) 14 (7%)
Total 18 32 95 42 187
Average 
follow up
5 years 10 years 4 years 8 years











Improved 0 2(11%) 1 (3%) 1 (7%) 4 (5%)
Stable / 
unchanged
6 (24%) 3 (17%) 12 (32%) 3 (20%) 24 (25%)
Worsened / 
died
19 (76%) 13 (72%) 24 (65%) 11 (73%) 67 (70%)
Total 25 18 37 15 95
Average follow up not given for this as data not available
Table showing the effects of hormonal manipulation on the course of the 




We divided our group of patients into those who we felt had a definite (patients 1 -10), a 
probable (patients 11- 19) and a possible (patients 20& 21) diagnosis of LAM. Although 
our numbers were small there were no discernible differences between these three groups
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in terms of presentation, clinical course and outcome. Unfortunately, when searching 
through the literature it was not always clear as to how the diagnosis was reached or how 
unequivocal the diagnosis was. For the purpose of our review we have assumed that the 
diagnosis of LAM is correct in all the literature cases. However it must be borne in mind 
that some cases may have been misdiagnosed and therefore suffer from other diseases such 
as fibrosing alveolitis that have similar clinical and radiological appearances.
It is also interesting to note that papers have used the terms lymphangiomyomatosis and 
lvmphangioleiomvomatosis synomonously to describe the changes in the lung. 
Histologically, there is proliferation of irregularly arranged, spindle-shaped smooth muscle 
cells surrounding the lymph channels and blood vessels within the lung parenchyma. There
1/ i a  1 0 T  1 0 /1  1 0 <  1 0 /v
is no evidence of fat cells or collections in the lesions , therefore this
condition is most appropriately described as lvmphangioleiomvomatosis.
Diagnosis of TSC
We divided our group of patients into those who had a definite diagnosis of TSC, 
according to the strict criteria given above, and those who had a probable diagnosis only. 
For the purpose of the literature review we divided the patients on the information given by 
the individual paper. For example, if a paper stated that the patient had TSC then they 
would be classified as having TSC. Again it must be borne in mind that some cases may 
have been misdiagnosed.
Prevalence
The Bath epidemiology study knew of 147 patients on 1st January 1997 with a diagnosis of 
TSC in the Wessex region. The population of the Wessex region obtained from the Office 
of Population Census and Surveys is 3,400,000. This gives a prevalence rate within the 
Wessex region of 1:23,500 and this figure is similar to that found by other studies 
estimating the prevalence of TSC. We know we are likely to have missed some cases of 
TSC1 19, but within our population we are less likely to have missed symptomatic LAM. 
On 1st January 1997 there was only one live TSC patient in the Wessex region, known to 
have LAM, giving a prevalence rate of 0.66%, but patient four who was also alive at that
1151time had asymptomatic LAM. This is similar to previous studies. Dwyer et. al. and 
Torres et al127 (found 3 cases out of 403 patients reviewed) estimated that symptomatic 
LAM occurs in less than 1% of patients with TSC. Castro et. al.44 believe their series
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shows the incidence to be slightly higher at around 2.3%. However, incidental findings of 
LAM have been described on the CXRs and CT scans of entirely asymptomatic patients118. 
No study has been undertaken to screen TSC patients for LAM and it is likely that the true 
prevalence is higher than 1%.
Population characteristics
LAM predominately affects females of child bearing age although cases occurring in
1 ? o  1 0 0  n o  i o imen and children have rarely been reported. In many cases symptoms start or
1 0 0  1 0 0are exacerbated during the menstruation period or in the course of a pregnancy 
Patients have also reported onset of symptoms following the menopause, or after 
commencing the oral contraceptive pill134 135.
We had 18 females and three males in our group of 21 patients. All the female patients 
developed symptoms prior to the menopause. One (patient ten) had onset of respiratory 
symptoms during her first pregnancy when she suffered bilateral pneumothoracies. Two 
developed respiratory symptoms prepubertally at the age of seven (patient five), with 
dyspnoea, pain haemoptysis and pneumothoracies, and at ten (patient nine) with dyspnoea, 
pain, wheeze, pneumothorax and chylothorax (both started their menses in their teens). 
Both these patients subsequently had open lung biopsy performed with a definite diagnosis 
of LAM, so confirming that LAM in TSC is not confined to females of childbearing age.
In the literature out of 360 female cases in whom an age of onset was given there were five 
cases of onset in childhood (4, 9, 9, 12 and 13 years). In total 7 / 378 cases presented in 
childhood: approximately 2%.
We also had three phenotypic males in our group who exhibited signs of lung disease. Two 
of the males developed symptoms at an early age: six months and eight years.
The first boy had a very unusual presentation; from birth he suffered from 
thick pulmonary secretions requiring frequent suction and recurrent chest 
infections. At the age of 6 months he underwent lung biopsy that was reported 
as showing LAM. The combination of this result with the history of epilepsy 
and developmental delay led to the diagnosis of TSC. During childhood he 
continued to have recurrent chest infections requiring antibiotic treatment but
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since going through puberty his infections have become far less frequent. He 
has never suffered from pneumothoracies, chylothoraces or haemoptysis. 
Unfortunately, the lung biopsy is no longer available for repeat analysis in 
order to confirm the diagnosis and he is not sufficiently co-operative to 
undergo HRCT. His unusual course must throw some doubt on the diagnosis.
The second male patient had suffered from episodes of dyspnoea and wheeze 
from the age of eight years. He was originally diagnosed has having asthma, 
but asthma medication did not relieve his symptoms and a CXR showing 
honeycombing confirmed the diagnosis of LAM. He has never suffered from 
pneumothoracies, chylothoraces or haemoptysis. He has never had 
confirmation of LAM made by HRCT or open lung biopsy.
The third male had been entirely asymptomatic until the age of 32 years when 
he suffered a spontaneous pneumothorax, which required treatment with 
drainage only, he has had no recurrence (follow up 4 years), nor suffered any 
other respiratory symptoms. His HRCT showed thin walled cysts and his CXR 
reticular shadowing of the lung fields suggestive of LAM. Interestingly on 
testing his chromosomes his genotype was 47XXY (Klienfelters syndrome). 
This may give an explanation of his presentation of a lung disease that is 
normally limited to females.
Looking through the literature there are five reported cases46 118 129 136 of LAM in 
TSC males and a further possible two cases128 137’. Their clinical, radiographic 
and histology details are summarised in table twenty- five.
Case one: had CXR findings compatible with a diagnosis of LAM and a lung 
biopsy reported as “consistent with TSC”.
Case two: had CXR findings that were not typical of LAM and had not had CT 
or biopsy performed. It is therefore possible that this patient did not have LAM. 
Case three: had findings typical of LAM on his CXR, but the authors did not 
state whether the biopsy showed smooth muscle proliferation.
Case four: although given a definite diagnosis of TSC, in the text the only 
features described were skin tags and cafe au lait spots: we would not accept
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these as confirming the diagnosis of TSC, so this diagnosis should be accepted 
cautiously.
Case five: given that HRCT is highly sensitive at showing the thin walled cysts 
associated with LAM, the presence of a normal result should make the diagnosis 
unlikely.
In case six the authors stated that the biopsy was consistent with LAM but 
described a proliferation of lymph vessels rather than smooth muscle hyperplasia. 
These findings may be compatible with a diagnosis of lymphangioma rather than 
lymphangioleiomyomatosis.




CXR CT Scan Biopsy
Patients diagnosed as having TSC
Case l 118 Dyspnoea Extensive reticular 
changes
Not given Consistent with 
TSC
Case 211* Dyspnoea 111 defined opacity 
plus a cyst





Not given Thickened 
pleura and cysts
Case 4‘" Dyspnoea and 
cough
Not given Not given Cysts, empty or 
filled with fluid




Patients with a possible diagnosis of TSC





Case 7U7 Pleural effusion, 
pneumothorax
Not given Not given Not given
Table showing possible cases of LAM in males in the literature
It is therefore difficult to estimate the true frequency of LAM in TSC males, 
other than it must be extremely rare. In any male in whom the diagnosis is 
suspected, other pulmonary diagnoses must be considered and excluded and
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chromosomal analysis undertaken. Patients should have HRCT at the very least 
and preferably lung biopsy performed to confirm the diagnosis.
Although the numbers are small, the findings hint at the possibility that the 
clinical course of LAM in TSC is milder in males than females.
The average age of diagnosis of TSC in our group of patients was 17 years, slightly older 
than that usually seen for TSC. This may be a chance finding because of the small 
numbers, but it may also back previous observations that patients with pulmonary TSC 
generally suffer milder forms of TSC often delaying diagnosis. For example; Singerland et
1 'Ifi •  •al. found TSC patients without LAM to have intellectual impairment in 46% of cases 
and seizures in 93%. In the patients with LAM 20% had intellectual impairment and 62% 
had seizures.
Pulmonary disease
We found the average age to onset of pulmonary symptoms, and the subsequent diagnosis 
of LAM to be earlier than that cited in the literature although the delay between onset and
n o
diagnosis was similar. With regard to Dwyer’s data this difference may be explained, at 
least in part, by improved diagnostic imaging and increased awareness over the past 25 
years that lung complications do occur in TSC. However Castro44 et al had similar findings 
to Dwyer118 in their review just two years ago (though they only had nine cases). The 
average age of onset of pulmonary symptoms in our group of patients was 19 years and 
diagnosis 25 years. This compares to an average of 30.4 and 36.6 years in the patients with 
TSC in the literature. In both groups there is a delay of about 6 years between onset and 
diagnosis. Therefore, the earlier age of diagnosis found in our small group of patients may 
just reflect a chance finding of earlier age of onset.
Comparing LAM in patients with TSC to those without TSC there is a later age of onset of
symptoms (30.4 and 34.6 years respectively) and shorter period of delay between onset and
diagnosis in the group without TSC. This difference might be explained by the Knudson
two hit therory10: normally for a tumour to arise (in an individual without an inherited
defect), two independent somatic mutations are required, explaining why sporadic tumours
in those without TSC can rarely arise in a single tissue later in life. But individuals who
have already inherited an inactivated tumour suppressor gene only need one further
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somatic mutation to lose both alleles, explaining why in TSC the tumours often occur 
earlier.
Histologically the lungs show perivascular and perilymphatic smooth muscle throughout 
the lung fields. The proliferation of the smooth muscle gives rise to the different clinical 
manifestations depending on its site. For example, around the airways it leads to 
obstruction and air trapping contributing to the obstructive picture on lung function testing 
and also causes bullae formation leading to pneumothoracies and a restrictive picture on 
lung function testing. Around the pulmonary venules it leads to venous congestion with 
consequent haemoptysis and around the arterioles it may precipitate pulmonary 
hypertension and cor-pulmonale, whilst involvement of the lymphatics may lead to 
chylothorax. In addition there is also proliferation of fibrous tissue which probably 
contributes to the diffusion impairment seen in the most affected patients whilst, shunting 
and V.Q. mismatching may increase the degree of hypoxia44 139.
As alluded to above, pulmonary tuberous sclerosis can present in a multitude of guises. 
Presentation can range from mild exertional dyspnoea to sudden acute severe respiratory 
distress with marked hypoxia and collapse. One common scenario is that described by 
Slingerland138 in his case presentations of a 21 year old daughter and her 45 year old 
mother. Progressive dyspnoea begins in the 2nd or 3rd decade of life accompanied by a 
chronic non-productive cough and haemoptysis; this is then followed by the onset of 
increasing number of lower respiratory tract infections associated with worsening 
hypoxemia and an obstructive respiratory picture. Death can occur within years as a result 
of respiratory failure and cor-pulmonale. In another case presentation of a 21 year old girl 
by Uzzo et al140, the patient had been entirely asymptomatic from a respiratory point of 
view until 2 weeks prior to scheduled surgery for renal angiomyolipoma. She then 
presented as an emergency with a massive left pneumothorax and bilateral chylothorax 
eventually requiring several chest drains and bilateral pleurectomies.
We also found a wide range of presentation from gradual onset of shortness of breath to 
sudden bilateral pneumothoracies, thick pulmonary secretions to chylothorax. The 
commonest presenting symptoms were pneumothorax and dyspnoea. Other symptoms 
included; chronic dry cough, haemoptysis, wheeze, and chest pain. Development of
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cyanosis, respiratory failure and cor-pulmonale was also common. These corresponded to 
the findings in the literature.
Chylothoracies may occur less commonly in patients with TSC, 10% of cases with proven 
TSC compared to 33% in patients in whom TSC has been definitely excluded. A possible 
explanation may be differences found histologically as the smooth muscle proliferation in 
LAM seen in TSC is more frequently described as being predominantly peri-vascular; in 
LAM without TSC it is peri-lymphatic122 123 124 125 126. The reason for these differences is 
not clear. Pneumothoracies seem to be equally common in both forms of the disease.
We also report two rare manifestations of LAM. The first is the occurrence of a pericardial 
effusion (patient nine). This patient presented at the age of ten with dyspnoea and weight 
loss. She subsequently developed recurrent pleural effusions, a persistent right 
pneumothorax and a pericardial effusion. She was treated by lobectomy after which all her 
symptoms resolved and she has remained well since. There has only been one other case141 
reported in the literature in a patient without TSC. She had a history of dyspnoea and 
recurrent pneumothoracies and had been diagnosed as having LAM on biopsy. She then 
presented with cardiac tamponade and was found to have a haemopericardium, which was 
successfully treated, by a subdiaphragmatic window. The second rare manifestation was 
patient four who suffered a massive pulmonary haemorrhage resulting in sudden death. To 
our knowledge this has not been previously reported in the literature.
Lymphangioleiomyomatosis is described as a generalised lung disease affecting all zones 
of the lung equally142. However, we believe that, in patients with TSC at least, there is 
evidence that it can occur as a focal entity. This is best demonstrated by the clinical history 
of two of our patients. Patient nine (described above) had severe persistent disease for 
several years until she underwent a lobectomy, following which her symptoms resolved. 
She has received no other treatment and has remained asymptomatic for 38 years. Patient 
six also had a two year history of severe persistent disease with dyspnoea, haemoptysis, 
pain and recurrent pneumothoracies. She then underwent pleurectomy, has had no other 
treatment, and has developed no further symptoms in 25 years of follow up.
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Investigations
A CXR is the first investigation, showing any pneumothoracies, chylothoraces and 
effusions and excluding other causes: it may show prominent interstitial markings with 
obvious cysts sometimes forming a honeycomb pattern and in milder cases may show a 
microreticulonodular pattern often greatest in the lower lobes118 139. Nevertheless, in the 
early stages the CXR may be unhelpful.
In these cases, HRCT is more sensitive and more precise at demonstrating the well-defined 
cysts that tend to have smooth thin walls. The architecture of the intervening lung tissue is 
normal. Occasionally focal markings due to lymphatic oedema in the alveoli and 
intralobular septa secondary to lymphatic involvement are also seen143 144. HRCT also has 
the advantage of correlating better with lung function than plain radiography145; disease 
extent as rated independently on a scale 0%-100% of involvement on HRCT, correlated 
significantly with impairment in gas exchange (using carbon monoxide diffusion). There 
was no significant correlation between the number of opacities seen on CXR and the 
results of any of the pulmonary function tests. It is frequently stated that HRCT is highly 
sensitive in diagnosing LAM and in combination with a clinical history and examination, 
open lung biopsy to confirm the diagnosis may only rarely be required146. Also there have 
been two reports147 148 of diagnosis made on cytology following aspiration of chylous 
effusion. In both cases immature smooth muscle cells and surface cells from the 
endothelium were demonstrated, suggesting that the LAM tissue had ruptured into the 
thoracic cavity. In both cases the diagnoses were later confirmed by open lung biopsy.
Only one case has been cited in the literature on the use of magnetic resonance imaging 
(MRI) in LAM. King149 reported on a 33-year-old woman who underwent MRI because of 
the possibility of chest wall recurrence of breast cancer. An incidental finding was focal 
areas of low signal intensity surrounded by thin walls. HRCT gave a diagnosis of LAM, 
which was later confirmed by open lung biopsy. There is no reference in the literature as to 
the use of MRI either in the diagnosis or as a marker of response to treatment in pulmonary 
tuberous sclerosis.
Spirometry
Spirometry shows wide ranging of patterns from normal to obstructive through mixed to 
restrictive. This variation is unsurprising when the underlying pathogenesis is considered.
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Initially there is proliferation of smooth muscle cells around the bronchi leading to 
narrowing of the lumen, as seen in asthma, giving rise to an obstructive picture. Unlike 
asthma the narrowing is not due to bronchospasm but rather hyperplasia, and the 
obstruction is not readily reversible. With time, air trapping in the alveoli leads to an 
emphysematous picture with the formation of cysts and bullae giving rise to a restrictive 
picture. As the disease progresses with more smooth muscle cells surrounding both the 
airways and the blood vessels, diffusion becomes impaired, cor-pulmonale and respiratory 
failure develop.
Clinical associations
Because very few studies (none of them large) of patients with LAM in TSC have been 
described in the literature it is difficult to accurately summarise its associations with the 
other clinical stigmata of TSC. Some authors have suggested that pulmonary TSC tends to 
develop in patients with less severe disease, especially when considering seizures and 
learning difficulties44 118 138. In Castro’s44 study eight out of nine of patients suffered from 
severe renal disease with haemorrhage into AML prior to diagnosis of their lung 
complications, suggesting a possible association between symptomatic renal disease and 
LAM.
We carefully looked for other clinical associations of TSC in our 21 patients and compared 
them with the 250 patients known to have TSC in the Wessex region to see if there was 
any phenotype at high risk of developing LAM. If this proved to be the case it might form 
a basis for screening high-risk patients. There was no significant difference between the 








We also took blood from all our patients in order to analyse whether genotype correlates 
with lung disease but this data will not be available for some time. We therefore propose, 
that at the present time, there are no prognostic factors that assist in predicting which
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individuals with TSC are at greatest risk of developing lung disease, but that it is rare in 
men and children.
Treatment
Again, because of the rarity of this condition few studies have been performed to assess 
long-term treatment and indeed few therapeutic measures have been undertaken in order to 
ameliorate the course of the disease. Instead treatment is symptomatic, treating the 
complications as they arise. Pneumothoracies and chylothoraces are treated in the acute 
phase by drainage, though pleurodesis is often required, as they are frequently recurrent. 
Chest infections are treated with the appropriate antibiotics and haemoptysis, if severe, 
occasionally requires iron supplements. The cough and wheeze are difficult to control as 
they are generally caused by the proliferation of the smooth muscle, (though undoubtedly 
some patients do have an element of bronchospasm), with the result that conventional 
inhalers are often ineffective. In those patients with a chronically deteriorating course, 
continuous oxygen therapy will be required towards the terminal stages of the respiratory 
failure and cor-pulmonale.
The presence of hormone receptors in the lung tissue of patients with LAM and TSC’150 151, 
the suggestion that exacerbations can occur at times of hormonal fluctuation for example 
during pregnancy and in association with the oral contraceptive pill, and the relative 
absence of LAM in males have, not surprisingly, led to attempts to ameliorate the disease 
by hormonal manipulation121 152 153 154 155.
In the literature review just under half of patients were tried on hormonal therapy. They 
used a wide range of therapies including oophrectomy, radioablation of the ovaries, 
progesterone administration and androgens with varying results. The best results are seen 
in those patients with TSC. One third of patients with TSC tried on hormonal therapy 
showed improvement compared with none showing improvement without hormonal 
treatment, although the numbers are small and consist mainly of individual cases in open 
studies.
1̂1In 1989 Eliasson et al undertook a meta-analysis of the hormonal treatment of LAM. 
They identified 30 cases of LAM treated by hormonal manipulation. Unfortunately many
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of the cases lacked information on dosage, timing and duration of therapy making them 








Progesterone alone 8/13 5 5/9
Oophrectomy alone 5/9 2 5/7
Tamoxifen alone 2/7 4 1/3
Androgen alone 0/1 0 0/1
Oophrectomy + progesterone 3/5 3 2/2
Oophrectomy and tamoxifen 0/1 1 0
Progesterone + tamoxifen Vi 2 0
Oophrectomy, progesterone + 
Tamoxifen
1/3 1 1/2
Reported regimens of treatment before and after meta-analysis.
*ln sequential evaluation of each case, ten case were excluded because 
therapy was started too late in the course of disease; six additional cases 
were excluded due to lack of data on dosage; and of cases remaining, two 
were excluded due to insufficient data to judge outcome of therapy
The remaining studies showed oophrectomy alone or in combination with progesterone to 
be the most successful therapeutic option with seven out of nine cases showing 
stabilisation or improvement. Progesterone alone was successful in five out of nine 
patients. None of the other regimes showed any significant benefit. Although this review 
suggests that hormonal manipulation might be beneficial in some patients the results need 
to be treated with caution. It is not clear if any of the thirty cases reviewed suffered from 
TSC and it is not yet known whether LAM with TSC and LAM without TSC are similar in 
their response to treatment. In addition it appears that the natural history of LAM in TSC is 
extremely variable. Finally, we would not recommend radioablation of the ovaries as a 
means of hormonal manipulation in patients with TSC: the genes involved in TSC are 
tumour suppressor genes so there is a theoretical risk (at least) that exposure to 
radiotherapy may increase the incidence and development of hamartomas. Our series 
would not alter these findings.
Angel Ferdnandez-Gonzalez156 suggested in 1993 that lung transplantation should be
considered in patients in view of poor survival after the onset of respiratory symptoms.
Sadly, previous pleurectomies and the presence of systemic disease (cor-pulmonale,
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hypertension etc), not to mention lack of donors, limits the number of patients in whom 
this is a viable option. It is also impossible to predict at the onset of symptoms, which 
patients will follow a relentless deteriorating course, which patients will remain relatively 
stable or even improve spontaneously and those who will respond to hormonal treatment. 
In addition, there have been reports of LAM recurring in transplanted lungs157 158.
Outcome
LAM is an important cause of mortality in TSC. In the review undertaken by Charles 
Shepherd et. al. at the Mayo Clinic in 1991 lung disease was the fourth commonest cause 
of early mortality in TSC, accounting for four out of 49 deaths, despite it only affecting 1 -  
2.5 % of all TSC sufferers.
It was previously thought that there was a relentless and severe deterioration after the onset
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of the disease. Average duration of survival was reported to be 4.8 years in 1971 . More
recent studies estimate survival times to be nearer to 10 years and some reports have even 
told of spontaneous resolution of the disease. In our experience the clinical course in TSC 
is extremely variable, with death occurring within days of the onset of symptoms in some 
patients, whilst others may remain asymptomatic for years.
Screening
Screening for LAM in patients with TSC remains controversial. We had hoped to highlight 
those patients at greatest risk of developing LAM and propose a screening model for this 
complication; however this has not been possible. The criteria required for a good 
screening programme include (as taken from Health For All Children edited by David Hall 
-  please see box below 203*204):
1. A recognisable latent or early symptomatic stage; this does not appear to be the 
case with LAM. Fourteen of our patients presented acutely with pnuemothoracies 
having been previously asymptomatic, two died within a short period of time.
2. That the natural history of the development of the disease from latent to 
symptomatic disease should be understood; further research is required for this.
3. There should be a suitable test for detecting the disease at an early or latent stage, 
which should be acceptable to the population; HRCT is likely to be the most 
sensitive tool for recognising LAM but it is not clear that changes are seen on 
HRCT before the development of symptoms and it may be unwise to screen all
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females approaching childbearing age in view of the radiation dose administered in 
patients with TSC who already have one mutation of their tumour suppressor gene; 
we had considered if lung function testing, spirometry or oxygen saturation, could 
be used for screening, these are simple non-invasive tests that can easily be 
performed in a clinic setting, however even in our small cohort of patients with 
symptomatic disease there was wide variation in lung-fimction suggesting that it is 
unlikely to be helpful as a screening tool.
4. There should be an acceptable form of treatment available for the disease, which if 
administered at the presymptomatic stage of the disease should favourably 
influence its course and prognosis; as discussed above further research is required 
to assess the efficacy of treatments such as progesterone in this group of patients, 
before it could even be considered to be given in pre-symptomatic patients.
However, it may be worth considering assessment in female patients of child bearing age 
for lung disease before they undergo anaesthesia or fly as these may precipitate onset of 
symptoms.
Criteria for screening programmes203,204
1. The condition being sought should be an important health problem for the individual and the 
community.
2. There should be an acceptable form of treatment for patients with recognizable disease or some 
other form of useful intervention should be available (e.g. genetic counselling).
3. The natural history of the condition, including its development from latent to declared disease, 
should be adequately understood.
4. There should be a recognisable latent or early symptomatic stage.
5. There should be a suitable test or examination for detecting the disease at an early or latent 
stage, which should be acceptable to the population.
6. Facilities should be available for diagnosing and treating patients uncovered by the programme.
7. there should be an agreed policy on whom to treat as patients.
8. The treatment at the pre-symptomatic stage of the disease should favourably influence its 
course and prognosis.
9. The cost of case finding which should include the cost of diagnosis and treatment, should be 
economically balanced in relation to (a) possible expenditure on medical care as a whole and 
(b) the cost of treatment if the patient does not present until the disease reaches a symptomatic 
stage.
10. Case finding should be a continuing process, not a once and for all project.
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Conclusion
LAM is a rare but important cause of morbidity and mortality in patients with TSC. 
Importantly, the only risk factor we found both in our cohort of patients that it almost 
exclusively occurs in female patients of childbearing age. It may rarely occur in 
prepubertal girls, the diagnosis should strongly be questioned in males. We found no other 
prognostic factors to identify those female patients at greatest risk of developing the 
disease, but some authors have suggested an association between symptomatic renal 
disease and LAM. We did not find any other clinical manifestations to be more common in 
our group of TSC patients compared with the overall population of TSC patients. LAM is 
usually generalised but may be focal in some patients and has a highly variable clinical 
course and again we found no prognostic factors to predict how the disease will progress in 
any individual, or those patients who will benefit from treatment. However, it does appear 
that hormonal manipulation may be beneficial in as many as one third of patients and 
further clinical trials are needed to fully evaluate the efficacy of such treatments. At 
present there is no evidence that screening the whole TSC population would be beneficial; 
nevertheless there is some evidence that flying and anaesthesia may precipitate 
symptomatic LAM in some patients. It may therefore be prudent to undertake chest HRCT 
before an anaesthetic is administered in high risk patients. Screening before flying is more 






There were twenty-four patients with TSC in the Bath district; twenty-two underwent renal 
ultrasound scanning. Nearly two thirds (13/22) were found to have renal involvement and 
13% (3/22) had been symptomatic. AML were most frequently found lesions, occurring in 
half of the patients screened. Five patients had cysts, one of whom had polycystic kidney 
disease. One patient was found to have a renal carcinoma. None of the rarer complications 
e.g. sarcoma were found in our group of patients.
Renal involvement is common in TSC with a wide diversity of renal disease most commonly 
angiomyolipoma (AML) and/or cysts with, more rarely adenocarcinoma, but oncocytomas, sarcomas, 
interstitial fibrosis and glomerulosclerosis have all been reported34. The severity of renal disease also varies 
widely. Many patients with AML with or without cysts will remain asymptomatic with normal renal function 
throughout their life, whilst others may suffer pain, haemorrhage, end stage renal failure (ESRF) and 
ultimately death from their lesions29.__________________________________________________________
Three patients who were all known to have large bilateral AML experienced symptoms of 
pain and haematuria, requiring treatment with selective arterial embolisation. The patient 
with the renal carcinoma had been asymptomatic and the lesion discovered on routine 
scanning. The diagnosis was confirmed initially by CT scan and then by biopsy, the patient 
then underwent nephrectomy and is currently being followed up. None of our patients 
have died from their renal disease but renal complications are an important cause of
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premature mortality in patients with TSC. In the study carried out at the Mayo Clinic 
looking at the cause of death in 40 patients with TSC, renal disease was the leading cause 
of mortality accounting for eleven of the deaths. Seven patients died of renal failure, two of 
renal carcinoma and two of haemorrhage from AML. The paper was not clear about the 
underlying pathology in the seven patients with renal failure.
End stage renal failure in adults with the tuberous sclerosis complex
To date no study has been carried out in the UK to look at the incidence or prevalence of 
ESRF in TSC or its clinical presentation and no paper has reported the underlying 
pathology in these patients. Therefore, the aim of this study was to examine both the 
prevalence and underlying causes of ESRF in patients with TSC.
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Method
This study was based on a questionnaire sent to the 170 UK members of the European 
Dialysis and Transplant Association in September 1993. The questionnaire asked if they 
currently had any patients with TSC in their renal replacement program. For those that did, 
the following clinical information was requested:
• Sex.
• Age of diagnosis of TSC.
• Age of diagnosis of renal disease.
• Age of onset of ESRF.
• The reason for diagnosis of TSC and whether the patient was a familial or sporadic
case.
• They were also asked if the patient had ever suffered from epilepsy, learning 
difficulties, giant cell astrocytomas or pulmonary lymphangioleiomyomatosis.
• In addition, information was collected on the presenting features of the renal disease,
including the presence or absence of hypertension, the underlying lesions, the
confirmation of diagnosis and renal function at presentation.
• Finally, we asked about the treatment the patient received for their renal disease 
including the need for nephrectomy.
Results
Of the 170 members contacted, 142 (84%) replied with a total of ten patients being 
identified. At least one reply was received from each unit.
There were eight females and two males. The average age at diagnosis of TSC was 21.2 
years (range <1 year to 34 years). Three patients had TSC diagnosed as a result of then- 
renal disease (table twenty seven), the average age of diagnosis of TSC in these patients 
was 32 years compared to an average age of 16 .7 years in the other seven patients who
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had TSC diagnosed on other criteria including skin lesions, epilepsy and family history 
(table twenty-seven). Six patients were known to be sporadic cases of TSC and two were 
known to be familial. Eight patients had a history of epilepsy and four had learning 
difficulties (one mildly) but none had a history of giant cell astrocytomas or pulmonary 
disease (table twenty-seven).
The average age of presentation of renal disease was 31 years (range 18 -50  years). Only 
one patient (case 10) was known to have renal involvement prior to presentation of renal 
disease as a result of screening at the age of 18 months when he was diagnosed as having 
TSC. He had then remained asymptomatic until 26 years of age.
Table twenty-seven







1 F 32 years Family history Familial No
2 F <1 year Infantile spasms Sporadic Yes
3 F About 12 years Epilepsy NK No
4 F 29 years Skin lesions Familial No
5 F NK Skin lesions Sporadic Yes
6 F 20 years Skin lesions, Epilepsy NK No
7 F 34 years NK Sporadic Yes
8 F 17 years Renal Haemorrhage Sporadic No
9 M 5 years Skin lesions, Epilepsy Sporadic No
10 M 18 months Infantile spasms Sporadic Yes
LD = learning difficulty, NK = not known 
Table showing the age and sex of the patients, the age at which TSC was 
diagnosed and the reason for diagnosis, whether the inheritance was 
sporadic or familial and the presence I absence of learning difficulties.
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The presenting features varied widely (table twenty-eight). Seven had impaired renal 
function at the time of presentation, five had renal masses, four had raised blood pressure, 














1 29 years Renal
masses
38 Carcinoma Histology NK No
2 20 years ESRF 20 NK NK ESRF Yes
3 32 years Renal
failure
32 SK and cysts USS NK Yes
4 32 years Haematuria 48 AML and 
cysts
IVP Normal No
5 44 years Acute on 
chronic 
renal failure
49 PKD USS ARF No
6 26 years Pain
Renal
masses
26 SK and cysts USS CRF Yes
7 34 years Pain, renal 
masses and 
haematuria
40 PKD CT CRF Yes





9 50 years UTI
Renal
masses
55 PKD USS CRF No
10 26 years Pain
Haematuria
26 PKD USS ESRF Yes
ESRF = end stage renal failure, UTI = urinary tract infection, NK = not known, 
Cr = creatinine, SK = small kidneys, USS = ultrasound scan, PKD = 
polycystic kidney disease, CT = CT scan, CRF = Chronic renal failure (all had 
high creatinine at presentation).
Table showing the age of presentation of renal disease and age of ESRF, 
presentation of renal disease, the underlying lesions, method of 
confirmation of the diagnosis, renal function at time of presentation of renal 
disease and the presence I absence of hypertension.
There was a range of underlying pathology; four patients were noted to have PKD, one 
patient had AMLs and cysts, two were noted to have small kidneys with cysts and one
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patient had AML alone, one patient had bilateral adenocarcinoma and in one patient the 
underlying pathology was not clear (table twenty-eight). The underlying pathology was 
confirmed by ultrasound in five patients, CT scan in one, CT and histology in one, 
histology alone in one and one by intravenous pyelogram (IVP): in one patient it was not 
clear how the diagnosis had been confirmed (table twenty-eight). The average age of end 
stage renal failure was 35.3 years.
Nephrectomy had been performed in four patients. Two patients had undergone 
nephrectomy (one bilaterally) for carcinoma, one because of haemorrhage, and the fourth 
patient had surgery for symptomatic relief. Nine patients had dialysis, haemodialysis in 
five, peritoneal haemodialysis in three and a combination in one. Seven patients had a renal 
transplant, one without prior dialysis of which five were successful (table twenty-nine).
Table twenty-nine
Reason for Nephrectomy 
(if performed)
Treatment











6 Failed transplant 
Peritoneal dialysis
7 Symptomatic relief Haemodialysis






Table showing the treatment of ESRF in the patients in our survey.
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Discussion
The prevalence of TSC is 1:23,000 between 15-45 years and 1: 97,000 over 45 years: we 
would therefore expect 1,350 adults in the UK to have TSC of whom approximately half 
will have normal intelligence. It is possible that in the UK patients with intellectual 
disability (i.e. half of patients with TSC) are less frequently referred to a renal replacement 
program. We have identified 10 adults, six with normal intellect who have end stage renal 
failure and TSC in the UK giving a prevalence of 1% in those with normal intellect. There 
are other possible inaccuracies. Firstly, the response rate to our questionnaire was only 
84% and it is conceivable that there are patients with TSC who were not notified. It is also 
likely that some patients with ESRF due to TSC are not recognised because either they do 
not exhibit other overt signs of TSC or are only mildly affected. However recent analyses 
suggest the prevalence of TSC1 may be higher than previously recognised which would 
reduce the risk of ESRF in TSC. The approximate risk of ESRF in TSC may be different in 
those with learning difficulties -  recent studies have begun to suggest that TSC2 gene 
defects may produce a more severe phenotype than TSC1 disease at least as far as intellect 
and epilepsy is concerned with no data yet on renal disease, other than PKD. A study 
carried out in France42, making different presumptions, also found the prevalence of ESRF 
in adults with TSC to be 1 in 100. They do not state if this is the whole of the adult 
population with TSC or those with normal intellect only. No mention is made of the 
underlying causes.
In our survey there was a preponderance of females. A study carried out by Webb159 et al 
suggested asymptomatic renal involvement to be as common in males as females. The 
small numbers might account for this discrepancy, but it might reflect that females tend to 
have more severe disease than males. It is well documented in the literature that females 
have a higher probability of symptoms from the lung complications of TSC 
(lymphangioleiomyomatosis -  see chapter seven) than males. One explanation is that 
female hormones play a part in influencing the disease. This theory has been backed up by 
the finding of hormone receptors150 in affected lungs and that the course of the disease may 
be affected in some patients by hormonal manipulation (e.g. oophrectomy) or by natural 
changes in hormone levels (e.g. pregnancy132 and menopause134). It is therefore feasible 
that oestrogens and progesterone similarly influence the renal lesions as the lung lesions. 
The underlying histopathology is similar for most TSC lesions in that they arise as
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hamartomas from over proliferation of otherwise normal tissue as a result of inactivation of 
tumour suppressor genes.
Inheritance of TSC is autosomal dominant with a spontaneous mutation rate of about 60%. 
Only two patients in our survey had parents with TSC, six were known to be sporadic 
mutations and in two the mode of inheritance unknown.
The patients in our survey represented a wide spectrum of renal disease seen in TSC. As 
discussed before, the TSC2 gene is close to the PKD1 gene, but PKD1 mutations do not 
underlie the cytogenesis in all patients. Renal disease including cysts occurs in patients 
with both TSC1 and TSC2. Although polycystic disease was more common in our survey 
of TSC patients with renal failure than is found in the TSC population, PKD was the cause 
of ESRF in only four of our patients; PKD is a known cause of ESRF, it is to be expected 
that this cause would be significantly represented in our survey, the pathological causes of 
ESRF in the other patients are more interesting.
The underlying pathology probably contributes to the renal failure by a variety of 
mechanisms. There may be compression of the normal renal parenchyma by cysts, 
angiomyolipoma or carcinoma. There may be a reduction in the amount of normal tissue 
either as a result of direct invasion by tumour or resulting from surgery. In addition it has 
been hypothesised that cysts in particular cause hyperfiltration of the remaining glomeruli, 
creating focal glomerulosclerosis42.
Probably as a reflection of the range of underlying pathology our patients presented in 
many different ways from simple haematuria to massive intra-abdominal haemorrhage; 
from acute renal failure to insidious chronic renal failure. They all presented in adulthood 
with a mean age of 31 years progressing to ESRF at an average of 35.3 years.
Confirmation of renal disease was made by ultrasound in the majority of cases. 
Ultrasonography is particularly sensitive in detecting cysts and intramural or perinephric 
haemorrhage160, but the echodense pattern seen on ultrasound although suggestive of AML 
is not pathognomonic. Renal carcinoma tends to be echolucent on ultrasound. CT is highly 
specific for AML when fatty tissue can be demonstrated within the lesion161. If any doubt 
remains biopsy can be undertaken to exclude malignancy, but it can give very misleading
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results. Histology at the edge of AML may look like renal carcinoma but recent studies 
suggest that staining for HMB45, which is positive in AML and negative in carcinoma, can 
differentiate it162. CT has the disadvantage of radiation and the theoretical risk of inducing 
further hamartomas, but while MRI can demonstrate renal lesions it does not demonstrate 
fatty tissue well.
Treatment of the renal lesions may contribute to the development of ESRF as discussed 
above. Nephrectomy remains the treatment of choice for patients with carcinoma, but 
transcatheter embolisation of distal branches of the renal arteiy for haemorrhage or pain 
offers a more conservative form of treatment allowing greater preservation of parenchymal 
tissue, thereby either delaying or preventing the onset of ESRF. Once ESRF has occurred 
treatment consists of dialysis and transplantation. There is still controversy as to whether 
nephrectomy should or should not be performed in patients undergoing transplant. 
Advocates argue that the diseased kidney carries a risk of bleeding and malignancy and 
should therefore be removed at the time of transplantation. Others argue that the disease 
free part of the kidney may retain some function which will be of use to the patient should 
rejection of the transplanted kidney occur.
Screening for renal disease in patients with TSC also remains controversial (please see 
chapter seven for the criteria for a good screening programme).
Presymptomatic diagnosis of PKD is known to be advantageous, for control of 
hypertension, prompt treatment of urine infections, close monitoring of renal function and 
early treatment of renal bone disease, but other lesions are much more common. Unlike 
LAM a suitable screening tool is available; ultrasound can be used to detect PKD in the 
young infant. Ultrasound scanning is a safe non-invasive technique which is generally 
acceptable to patients and parents. It is generally accepted that once a diagnosis of TSC has 
been made in an infant or young child that a renal USS should be undertaken to allow 
diagnosis of associated PKD. However, for the other lesions seen in TSC many of the 
criteria for good screening discussed in the previous chapter can not be met.
Studies in the past have suggested that AML, which bleed, are likely to be greater than 3.5
1 f\*\-  4cm in diameter . Some would therefore advocate screening for AML so that when 
they reach such a size prophylactic treatment could be undertaken. Ultrasound can be used
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to detect small AML and to monitor their size. However, the natural history of progression 
from latent to established disease remains unclear; size is not always predictive of 
haemorrhage and some individuals with longstanding large AML have never suffered 
haemorrhage. It might be the rate of expansion or some other factor which causes 
haemorrhage; and whilst treatment (embolisation and / or surgery) is available it is not 
without risk and complications, for example pain, infection, loss of normal renal tissue and 
risk of embolisation elsewhere; neither is screening, for example it can force people to 
know they have a disease, and may highlight the presence of disease other than that for 
which they undertook screening164. Neither is it known that embolisation is curative. 
Others would therefore wait until the lesions become symptomatic before initiating 
treatment.
Likewise, screening for ESRF is not currently undertaken in the TSC population. At 
present there is no screening test available that is simple, easy to interpret and acceptable to 
the patients. In order to detect very early ESRF it is likely that regular renal function 
testing involving venesection and blood pressure monitoring would be required. Whilst the 
measurement of blood pressure in simple and non-invasive and should be routinely 
performed as good clinical practice, many patients are not keen to have venesection 
performed. In addition, at present it is not known how frequently renal function would 
need to be undertaken to detect a decline in renal function before the onset of ESRF, nor 
whether treatment will help. Further research is required to understand the natural history 
and other factors to determine the risks and benefits of screening in these patients.
Conclusion
ESRF is rare in patients with TSC but does contribute significantly to the premature 
mortality in this group. At present there are no clear prognostic factors that can be used to 
determine which individuals are at greatest risk of developing ESRF, other than it appears 
to be more common in females. Importantly it may be possible to delay, or even prevent 
renal failure in some patients by undertaking more conservative forms of management, 
such as embolisation rather than nephrectomy in the earlier stages of disease.
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CHAPTER NINE
Sleep Disorder In Tuberous Sclerosis Complex
Over the past decade, sleep disorder in TSC has become increasingly recognised as a 
frequent cause of morbidity and stress not only for the patients suffering from TSC, but 
also for the families caring for them. In 1993 Hunt165 undertook a postal survey of 300 
TSC patients; carers reported problems with settling in 60% and night waking in 62% of 
children with TSC. In an earlier study Quine and Pahl166 found that the sleep disorder 
experienced by children with neurological disabilities was one of the greatest contributing 
factors to stress experienced by the families of such patients.
Normal sleep patterns
Sleep can be defined as a state of altered or reduced consciousness from which a person can be aroused by 
appropriate sensory or other stimuli. During a normal nights sleep a person goes through two main types of 
sleep that alternate with each other; slow wave and rapid eye movement (REM) sleep. Slow wave sleep 
accounts for about three quarters of the total sleep time and is called so because the frequency of the EEG 
becomes progressively slower until it reaches a frequency of 2-3 waves a second (delta waves). This type of 
sleep is further divided into four phases. Stage one occurs when the person is initially falling asleep and the 
EEG shows low voltage waves interspersed with sleep spindles (short bursts of high frequency, high voltage 
activity on the EEG), in stage two the sleep spindles disappear and in the following stages the background 
EEG frequency gradually decreases. REM sleep occurs through out the night in a cyclical fashion and is 
associated with dreaming. It is thought that not only are both slow wave and REM sleep necessary for a 
restful nights sleep but also the cyclical alternation between the two.
In 1994 Hunt and Stores27 undertook a further questionnaire-based study looking at sleep 
disorder (and its relationship to epilepsy) in TSC in greater detail. This study looked at 
forty children with TSC (identified via the Tuberous Sclerosis Association (GB)); a sample 
representing 5% of the estimated total population of the children with TSC in the UK aged 
between two and fifteen years. They used two groups of non-disabled children as controls; 
the first group contained 22 siblings of the TSC group (aged three to seventeen years) and 
the second group 37 children attending mainstream school (who were each matched for 
gender and age with a child in the TSC group). The three pre-school aged children in the 
TSC group did not have matched controls.
Sleep disturbance was calculated using the Quine Sleep Index score , which looks at the 
four following areas in sleep disturbance:
1. Difficulties settling the child to sleep.
2. Night time wakening.
3. Parents /carers attendance to the child during the night.
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4. Parental sleep loss.
Each area is scored on a three point score (0 -2) dependant on the severity and frequency 
of each problem giving a total score 0-8.
They found the degree of sleep disruption in their group of children with TSC to be 
significantly greater (p < 0.001) than in the 22 siblings and 37 matched controls. The mean 
sleep index for children with TSC was 4.9 (SD 3.1), compared with 0.59 (SD 1.02) for the 
siblings and 0.41 (SD 0.68) for the matched controls, thus confirming that settling and 
night time waking was more common in children with TSC than either their siblings or 
other children attending mainstream school. Hunt and Stores do not state clearly how the 
study subjects were recruited and it is possible that their group of children with TSC 
represent the 5% with the greatest sleep difficulties and that the controls were chosen 
because they were known not to have any sleep disturbances. Nevertheless, this study does 
suggest that some children with TSC do suffer significant sleep disturbances.
Hunt and Stores also looked at the associations of sleep disturbance with epilepsy and 
behavioural problems. Behaviour was rated using the Developmentally Delayed 
Children’s Checklist (Einfeild and Tonge 1991), constructed specifically to include the 
most prevalent behaviours observed in children with learning difficulties. Again they found 
the scores for the children with TSC to be significantly higher (p < 0.001) than those 
without. The children with TSC were further divided into two groups; those with current 
seizures and those who had either been fit free for the six months preceding the study or 
who had never had seizures. The mean Sleep Index of the former group was 6.24 (SD 
2.44), and significantly higher than the mean 1.45 (SD 1.50) for the latter group (p < 
0.001).
1 ££Seizures are known to disrupt sleep patterns in many ways including ;
•  fragmentation by frequent awakenings,
•  reduced REM sleep,
•  increase in wakefulness after sleep onset,
•  instability of sleep stages.
The sleep disorder in TSC is more complex than this with other multiple contributory 





•  learning difficulties which in turn may affect the development of normal behavioural 
zeitgebers (e.g. bed time routines which can be powerful enough to enforce the natural 
circadian rhythms of melatonin secretion in the absence of light-dark cycles),
•  anticonvulsant medications; often prescribed in patients with TSC may affect sleep.
Sedatives often prescribed for children with sleep disorders are generally ineffective and 
clinical experience suggests that in children with TSC they are even less likely to be 
effective. In fact they often worsen the situation by increasing hyperactivity. Behavioural 
techniques are also of less benefit to many of these patients, because of the above 
contributory factors and because of the extreme exhaustion of caring for these children day 
and night.
Normal sleep-wake cycles
The underlying physiological process for normal sleep-wake cycles in not yet fully understood and is likely 
to be complex, involving the circadian secretion o f neurotransmitters and learnt behavioural patterns 
(zeitgebers). Early theories suggested that the reticular activating system and other parts o f the brain became 
‘fatigued’ over the period o f a waking day and therefore became inactive resulting in sleep. It was then 
thought that the raphe nuclei (situated in the brainstem), which produces serotonin, a neurotransmitter known 
to induce sleep was responsible. However, serotonin does not appear to be secreted in a circadian manner. It 
is now thought that Melatonin, a hormone secreted from the pineal gland plays a major role in the normal 
sleep-wake cycles. Melatonin is thought to synchronise sleep-wake patterns with the light-dark cycle o f the 
normal day, through pathways from the retina, via the hypothalamus, to the pineal gland. Decreased light 
intensity at the retina (i.e. darkness) leads to an increase in melatonin production, which in turn leads to 
drowsiness.
With the advancing interest in the treatment of sleep disorders in children, melatonin has 
become one of the forerunners as a potential therapy for disruptive sleep patterns. 
Melatonin was first used in its synthetic form in 1981 by Weitzman169 et al to regulate 
sleep patterns in shift workers. It was then shown to be successful in alleviating jet-lag in 
adults by Arendt et al170. First to show success in treating the sleep disorders of disabled
171children (both with and without visual impairment) were Jan et al in 1994.
177A study of nine girls with Retts syndrome (but no visual impairment) was then
undertaken by McArthur et al 1998. Wrist actigraphs and sleep diaries were used to
monitor the sleep patterns of the nine patients. There was a one-week baseline period
followed by a double blind, placebo controlled, crossover trial lasting eight weeks with a
one-week washout period between the two crossover periods. The dose of melatonin given
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was based on weight and ranged from 2.5mg to 7.5mg. Sleep-onset latency was 
significantly reduced by melatonin, reducing from 32 +/- 8.6 minutes during the placebo 
period to 19.1 +/- 5.3 minutes (p = 0.05) with melatonin treatment. They also found that 
melatonin increased the total sleep time in some patients but that this did not reach clinical 
significance. Melatonin did not alter the frequency of night-time awakenings in this group. 
Their group experienced no adverse effects.
The results of these studies led our group to assess the use of melatonin patients with TSC
171and sleep disorder . A randomised double blind, placebo-controlled crossover study 
comparing 5mg melatonin (regardless of weight) against placebo was carried out in seven 
patients with confirmed diagnoses of TSC and significant associated sleep disorders. There 
were three males and four females and the age range was two to twenty-two years (median 
eleven years). All the patients were epileptic and had learning difficulties. Three outcome 
measures were applied; total sleep time, time to sleep onset and number of awakenings. 
Patients when treated with melatonin had a significant improvement in total sleep time 
(mean improvement 0.55 hours, p < 0.05), and tended to have an improvement in sleep 
onset time, which was not significant. There was no significant decrease in sleep 
fragmentation. Although the improvement was modest it was of great significance to the 
carers; half an hour over seven nights is an extra three and half hours extra sleep a week.
However, there were still unanswered questions. Firstly, there was the question of 
optimum dosage, Jan et al171 used a dose of 2.5 -  lOmg in their study and McArthur et al172 
a dose of 2.5 -  7.5mg in their study, both with promising results. However, another study 
by Camfield et al174 had used smaller doses of 0.5 -lm g  with less benefit. It might be 
possible that the effect is dose related. Secondly, the mechanism by which melatonin 
improves sleep patterns in these patients remains unclear. There are many complex factors, 
which contribute to the normal wake-sleep patterns, and the relationship between 
melatonin production and onset of sleep is not a simple one. For example, populations 
living in Northern Europe and the Arties do not sleep throughout the winter months where 
there is darkness all of the day, and we all feel tired as the evening progresses despite the 
fact that our homes are lit by electricity. There are therefore other factors, including 
learned behavioural routines (zeitgebers) that also contribute to the normal wake-sleep 
cycles. It is possible that TSC patients, with learning and behavioural difficulties, do not
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acquire these normal social responses that aid the sleep-wake cycles. It is also possible that 
TSC patients may not have a normal pattern of melatonin secretion.
The Effect of Melatonin Dosage on the Sleep Disorder in Tuberous 
Sclerosis Complex
Aim
The aim of this study was to investigate whether there is a dose related response to 
exogenous melatonin when using a dose higher than 5mg in patients suffering sleep 
disorder associated with TSC.
Methods
Ethical approval for the study was obtained from the Bath Local Research Ethics 
Committee. Patients with a confirmed diagnosis of TSC and severe sleep problems were 
then identified through the Bath TSC clinic, research and epidemiological studies. A 
diagnosis of TSC was confirmed by the presence of at least one hamartoma present in each 
of a minimum of two different organs. A diagnosis of sleep disorder was confirmed by a 
Quine sleep index score of at least six out of a possible eight167. The Quine index focuses 
on four areas of sleep difficulties; difficulties settling the child to sleep, night time 
wakening, parents /carers attendance to the child during the night and parental sleep loss. 
Children were excluded from the trial if their sleep disorder proved to be situational (for 
example a child that scored six on the Quine questionnaire whilst at home, but two whilst 
at respite care would not be included in the trial).
This was a randomised double-blind controlled crossover trial comparing 5mg and lOmg 
of melatonin. Melatonin was supplied by Penn Pharmaceuticals Ltd. Melatonin 5mg and 
placebo (a sugar compound) were administered in identical capsules. The trial consisted of 
four parts; an initial two week baseline period during which the patients received no 
treatment, a two week period during which the patient received either 5mg or lOmg of 
melatonin, a two week wash-out period during which the patient received no treatment and 
a two week period during which the patient received the alternate dose of melatonin (i.e.
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5mg or lOmg). The parents / carers completed both sleep and seizure diaries (see appendix 
five) throughout to document the sleep disorder and seizure frequency.
Melatonin was administered approximately thirty minutes before the patients’ usual 
bedtime; each patient received two identical capsules, either 2 x 5mg of melatonin (i.e. 
lOmg in total) or 1 x 5mg plus 1 x placebo (i.e. 5mg in total). The patients, carers and 
researchers did not know which weeks they received lOmg of melatonin and which weeks 
they received 5mg of melatonin.
The sleep diaries were used to monitor the sleep latency (i.e. time taken to fall asleep), the 
total sleep time and the number of awakenings each night. The seizure diaries were used to 
monitor the frequency and type of seizures (if any) experienced by the patients during the 
study period. The carers were also asked to record any illnesses the child had or any 
possible side effects they suffered during the trial period.
Results were analysed using paired t-tests.
Results
Eight patients were recruited who satisfied the inclusion criteria. One patient completed the 
study but the diaries were lost in the post and we had not thought to ask to have them 
photocopied before they were posted to us. We present the results of the seven whose 
diaries are available. There were four males and three females with an age range of 18 
months to 31 years (median age 9 years). All patients were epileptic and on concurrent 
anticonvulsants, two of whom were well controlled. All had severe learning and 
behavioural difficulties.
The results are shown in table thirty and although there was a small improvement in sleep 
latency time in the lOmg group compared to the 5 mg group, it does not reach conventional 
levels of statistical significance (p = 0.4). Total sleep time was calculated for each of the 
seven patients during each two-week phase of the trial. There was no statistical 
significance between the two groups (p = 0.6). The mean number of awakenings was 
recorded for five of the patients, but was not recorded by the carers in the other two 
patients, again there was no statistical difference between the two groups in terms of sleep 
fragmentation (p = 0.5).
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Table Thirty




Total sleep time 
5mg






1 female 18 months 154 mins 105 mins 8 hours 51 mins 9 hours 25 mins 0.9 2.5
2 female 4 years 102 mins 128 mins 9 hours 7 hours 47 mins 0.9 1.0
3 female 9 years 53 mins 50 mins 8 hours 54 mins 8 hours 39 mins 0.2 .2
4 male 9 years 30 mins 46 mins 9 hours 28 mins 10 hours 29 mins 0.6 .2
5 male 11 years 11 mins 13 mins 9 hours 30 mins 9 hours 20 mins 1.2 1.2
6 male 19 years 208 mins 154 mins 8 hours 9 hours 36 mins
7 male 31 years 46 mins 36 mins 8 hours 55 mins 8 hours 38 mins
Mean 86 mins 76 mins 8 hours 57 mins 9 hours 4 mins 0.8 1.0
Table showing the mean sleep latency, total sleep time and sleep fragmentation after the administration of 5mg 
melatonin and10 mg melatonin.
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In the five patients who had seizures during the trial, the seizure diary showed no change in 
the frequency (or type) of seizures seen compared to the initial baseline period before 
melatonin treatment. Three patients were well controlled on their anticonvulsants and 
remained seizure free during the study (table thirty-one).
There were no adverse side effects reported by the carers during the trial period. 
Table thirty-one
Patient Age No. of seizures 
without melatonin
No. seizures on 5mg 
melatonin
No. of seizures on 
lOmg melatonin
1(f) 18 M None None None
2(f) 4 Y 23 / week 20 /week 20 / week
3(f) 9 Y None None None
4 (m) 9 Y 4 / week 3 / week 3 / week
5(m) 11 Y 5 / week 6 / week 6 / week
6 (m) 19 Y None None None
7 (m) 31 Y 73 / week 159 / week 40 / week
p = 0.38 p = 0.31
Table showing seizure frequency; without melatonin; after the 
administration of 5mg melatonin; and after the administration of 10mg 
melatonin.
Discussion
The best way to accurately monitor sleep and its disturbance is by polysomnography; this 
was not possible in our group of patients. We chose to use sleep diaries, which is an 
inexpensive method of monitoring sleep patterns. Although, reliant on the vigilance of 
already overburdened caregivers, they demonstrate symptoms and any bias in minimised 
by the double blind nature of the study. McArthur et al used wrist actigraphs in their 
study172 and found them to be more accurate than sleep dairies but they too have 
disadvantages; they are prone to mechanical failure and non-compliance, which may lead
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to total loss of data. The effect of nocturnal seizures on actigraphs is a further complication 
in patients with TSC since the assumption is that movement is an awakening when it might 
be due to a seizure.
Although only a few studies have been undertaken looking at the effect of melatonin on 
sleep disturbance in children with severe neurological difficulties with mixed results, the 
combined results suggest that the effect seen might be dose related. Studies using higher 
doses (2.5mg -  lOmg) demonstrated a response while those using lower doses (0.5mg -  
1 .Omg) did not.
The results from our previous study173 comparing the effects of 5mg of melatonin versus 
placebo, found increased total sleep time and a trend towards decreased sleep latency, but 
with varying responses between subjects. We also found a trend towards increased total 
sleep time and decreased sleep latency when comparing our baseline data (i.e. no 
melatonin) with administration of 5 mg melatonin; however we have not reported these 
findings since they were not blinded and are therefore prone to attrition bias. We have 
shown that the administration of 10 mg of melatonin did not further reduce the sleep 
latency, improve the total sleep time or reduce sleep fragmentation in our group compared 
with 5mg. One possible explanation for this lack of dose related response is that 5mg is 
already a supraphysiological dose.
The exact mechanism by which melatonin improves sleep patterns in these patients 
remains unclear, many hypothesis have been suggested; the simplest that melatonin has a 
straight forward sedative effect. This would explain the clinical effect seen in our patients 
i.e. reduced sleep latency. It is also known that melatonin is metabolised rapidly and that 
there is a large hepatic, first pass metabolism so that, in humans, peak plasma levels are 
reached within one hour and there is a half life of approximately 45 minutes (personal 
communication). This rapid metabolism may explain why total sleep time and sleep 
fragmentation remained unimproved.
Another hypothesis is a link with epilepsy. All our patients were known to suffer from 
seizures and were on concurrent anticonvulsants during the trial. It is known that epilepsy
175plays an important role in the sleep disturbance of TSC by disrupting the normal sleep 
physiology in a variety of ways. It has also been suggested that melatonin may influence
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1 H(\epileptic activity in humans, though the exact relationship remains unclear. In 1974 
melatonin was reported to improve seizure control in epileptic subjects, an observation also
177 17ftnoted in mice when used in large doses (i.e. >200mg/kg). In 1985 Maurizi showed 
melatonin to increase levels of serotonin in the brain thus raising the seizure threshold. In 
1994 Molina et al1/9 and in 1995 Schapel180 both demonstrated that patients with epilepsy 
had higher serum concentrations of melatonin than individuals without epilepsy suggesting 
the possibility of a physiological attempt to reduce seizure threshold in these patients. Only
l O I
Sheldon et al have suggested in an observational study reported m a letter to the Lancet 
that oral administration of melatonin in disabled children might paradoxically result in an 
increase in seizure frequency.
All our carers completed seizure dairies for the eight-week duration of the sleep trial. 
There appeared to be no significant effect of melatonin administration on seizure activity 
in any of our patients.
It is also possible that some patients with TSC have either abnormally low or disrupted
i ftnmelatonin secretion. Although previous authors have suggested that patients with 
uncontrolled epilepsy have increased nocturnal melatonin production, others have 
suggested that the circadian rhythm is disrupted with peak levels occurring earlier in the
170night than normal subjects . However, to our knowledge, no one has looked at the 
circadian rhythms of melatonin production in children and comparisons have been made 
against adult data. In addition no study has looked at melatonin production in patients with 
TSC and epilepsy. We have addressed this in a separate study.
This study did not find any detrimental effect on seizures. However, there were only seven 
patients and it is possible that we have insufficient power to detect a significant difference 
in response, or that individual patients might benefit from a higher dose. Since none of our 
patients reported any adverse effects whilst taking the melatonin, we would suggest when 
treating this group of children for sleep disorder that 5mg melatonin is used and lOmg is 
only considered if 5mg fails to be of any benefit. Further studies on the use of melatonin 
would be worthwhile -  looking further at dosage and tolerance over a prolonged treatment 
period.
None of our patients reported any adverse effects whilst taking the melatonin.
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Conclusion
In conclusion, whilst it seems likely that the administration of exogenous melatonin in 
patients with TSC and sleep disorder does reduce sleep latency and increase total sleep 
time, higher doses show no further benefit. The response to melatonin does seem to vary 
between individuals and we would propose that a trial of 5mg of melatonin given 30 
minutes before bedtime is worth considering in these patients and that the response should 
be monitored by both sleep and seizure diaries. If no beneficial response is seen within two 
weeks then, while there is no proven advantage in increasing the dose of melatonin to 
lOmg, this is unlikely to cause significant side effects if it is considered. More studies are 
required.
Melatonin excretion in normal children and tuberous sclerosis with sleep 
disorder responsive to melatonin
Trials have established the beneficial effects of exogenous melatonin in the treatment of 
sleep disorders in children, but the mechanism of action remains unclear. It has been 
postulated that some children might have aberrant endogenous melatonin secretion that can 
be corrected by giving exogenous melatonin.
Melatonin is excreted in the urine as 6-sulphatoxymelatonin (a relatively stable metabolite) 
that can be easily measured. The pineal output of melatonin is believed to be very stable 
from day to day so it is not necessary to collect urine over long periods of time. Total 
excretion, the time of maximal excretion (acrophase time) and the wave form of excretion 
over 24 hours (cosinor rhythm) can all be measured. A cosinor rhythm of less than 70% 
can be due to inaccurate collection while if over 90% an accurate collection with normal 
circadian rhythm can be inferred.
Aims
The aims of this study were firstly to measure the melatonin excretion in six children and 
one adult suffering from sleep disorder responsive to melatonin (all these patients also 
suffer from TSC) and secondly to measure melatonin excretion in healthy children to 




Six children and one adult suffering from sleep disorder and TSC were recruited for the 
study. All seven subsequently took part in a study comparing the effect of 5mg melatonin 
versus placebo and were shown to have a significant improvement in total sleep time and a
173tendency to decreased sleep latency when treated with melatonin . We also recruited 21 
healthy children (between the ages of 5 and 15 years) who had no sleep problems. There 
were two for each year of age, except for five years, where we were only able to recruit 
one because of difficulties with compliance. We asked them to collect their urine over a 
48-hour period in four hourly aliquots. The children were not woken in the night in order 
to collect samples, but if they woke naturally to pass urine then a specimen was taken. 
They were asked to pass urine, discard that first sample, note the time and then start the 48- 
hour collection, collecting at least one sample four-hourly whenever possible. Each time 
they subsequently passed urine they would note the time and the quantity passed. The 
specimens were then frozen until the time of analysis.
All specimens were sent to Stockgrand Ltd, affiliated to the School of Biological Sciences 
at the University of Surrey for analysis. Melatonin excretion was expressed as the total 6- 
sulphatoxymelatonin secretion, cosinor analysis and the acrophase time over each of the 
two consecutive 24-hour periods.
The results from the first 24-hours excretion of each healthy child were then analysed, both 
including and excluding any results with a cosinor analysis of less than 70% and were then 
compared with the second 24-hour excretion period to give an estimate of the repeatability 
of the results. Only the excretion data from the first 24-hour period were used to determine 
normal excretion.
The excretion data obtained from the patient group was then compared with the data 
obtained from the healthy children and normal adult data.
Results
Tables thirty-two and thirty-three show the total daily excretion of 6-sulphatoxymelatonin, 
the cosinor rhythm and the acrophase time for the healthy children and the patients
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respectively. For each individual, two results are given, one for each of the 24 hours of the 
48-hour collection. There were no significant differences or trends seen with age.
Table thirty-two
Controls Total 6SM Cosinor Acrophase
(age years) (nanograms) % Time
5 11,112 99.9 02.30
12,505 96.4 04.00
6 40,175 75.0 03.24
30,574 99.7 03.48
6 17,148 99.1 01.36
12,715 100.0 04.42
7 28,971 94.9 04.42
28,374 96.2 05.00
7 24,386 57.8 08.30
21,687 76.5 07.24
8 21,474 68.9 23.54
16,167 73.6 01.54
8 28,820 95.7 02.12
33,055 92.7 01.00
9 14,778 74.8 08.12
14,630 81.1 09.42
9 11,911 94.9 03.06
11,510 100.0 04.24
10 20,220 93.2 06.36
20,529 56.9 09.42
10 11,184 92.7 04.00
10,110 100.0 05.18
11 17,583 99.4 03.06
21,074 96.9 04.48
11B 15,175 83.5 10.42
9,368 82.8 09.24
12 21,690 52.9 07.36
18,644 100.0 03.36
12 16,820 99.9 05.42
18,753 98.4 05.48
13 11,266 96.8 04.12
11,915 100.0 05.36
13B 15,201 61.0 07.54
13,209 75.4 09.42
14 24,785 97.7 05.18
25,020 99.4 05.18
14 19,528 93.4 03.30
18,020 99.0 05.00
15 10,760 99.3 03.36
11,850 98.9 05.06
15 15,808 100.0 03.24
16,307 96.9 02.24
Table showing the total 6-sulphatoxymelatonin excretion, the cosinor 
rhythms and acrophase times for the healthy controls. The first 24 hour 
excretion is given above the second 24 hour excretion for each child.
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In the healthy children total daily excretion of 6-sulphatoxymelatonin in the first 24 hours 
ranged from 11,112 to 40,175 nanograms with a mean 18,991 nanograms (SD 7,384) and a 
median 17,148 nanograms. The cosinor rhythm ranged from 52.9% to 100%, with a mean 
of 87% (SD 15.5%) and a median of 94%. The acrophase time varied from 23.54 to 10.42 
with a mean of 05.54 (SD 04.48) and a median of 04.12.
From the healthy children, we then excluded the results with a cosinor rhythm of less than 
70%. Total daily excretion of 6-sulphatoxymelatonin ranged from 11,911 to 20,220 
nanograms with a mean of 18,591 nanograms (SD 8,027 nanograms) and a median of 
16,820. The acrophase time ranged from 03.06 to 05.18 with a mean of 04.30 (SD 02.20) 








1 13,100 95.9 02.00
(6) 13,100 69.1 23.24
2 13,500 98.6 02.36
(5) 11,500 96.8 01.18
3 600 51.9 10.36
(ID 1,200 93.2 02.36
4 40,500 97.9 02.48
(6) 45,800 93.7 01.54
5 26,600 93.2 04.30
(8) 30,800 93.8 04.48
6 32,300 67.8 05.24
(14) 32,300 69.0 05.36




7 8,000 99.5 05.36
(28) 8,500 97.9 04.30
Normal range for adults12 2,000-30,000 >90% Early morning
Table showing the total 6-sulphatoxymelatonin excretion, the cosinor 
rhythms and acrophase times for the TSC patients.
n the healthy children samples for 6-sulphatoxymelatonin and cosinor rhythm from the 
second 24 hours all fell above the 5th centile (11,112 nanograms and 57.8% respectively). 
The acrophase times all fell within the 5th and 95th centile (02.12 and 10.42) except for one 
that was at 01.00.
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In our group of patients with tuberous sclerosis and sleep disorder, there were six children 
and one adult. In the children, the total 6-sulphatoxymelatonin fell below the 5th centile in 
one patient and above the 95th centile in one patient. The cosinor rhythm fell below the 5th 
centile in one patient and the acrophase time fell before the 5th centile in three patients. The 
adult patient showed excretion within the normal range for adults182.
Discussion
For our healthy controls, we chose five years as the lower limit, as we anticipated that 
children below this age would be too young to co-operate. We took 15 years as the upper 
limit as we felt that by 16 years excretion rates were likely to be similar to adult excretion 
rates. We found no significant differences with age, although the very youngest children 
tended to have slightly earlier acrophase time -  perhaps because they go to bed earlier. 
This finding is compatible with the results of Sivan184 et al who found a very early 
acrophase time in normal infants. Adult data shows total daily excretion to be 2,000 to 
30,000 nanograms, with a cosinor rhythm of >90% and an acrophase time within the early 
hours of the morning . Our data is compatible with this and with the data of Sivan et al 
suggesting that melatonin excretion is in a recognisable circadian rhythm from an early 
age. This is also compatible with the data of Attanasio et al184 who showed a circadian 
rhythm to melatonin excretion by measuring serum melatonin levels from infancy to 
adolescence.
Melatonin excretion is not thought to vary greatly from day to day, but we chose to collect 
our samples over two days to not only help assess how accurate the collections were, but 
also to assess repeatability. Although a cosinor rhythm of 90% infers accurate collection, it 
is also dependant on having a circadian rhythm. Our hypothesis was that patients with 
sleep disorders might not have normal circadian rhythms as shown by a low (less than 
70%) cosinor value, therefore we could not rely on this value alone. We therefore also 
examined total 6- sulphatoxymelatonin excretion. Where the values from both 24-hour 
collections were similar it suggests that all the urine passed in the 48-hour period was 
measured and collected and no urine samples were “missed”. For example, it is possible 
that the second eleven year old failed to collect at least some urine, perhaps on both days, 
accounting for the low melatonin excretion and cosinor rhythms. A high cosinor value 
correlates with a good circadian rhythm, however it was felt that ethically it was not 
acceptable to wake the children in the middle of the night to ask them to pass urine, but
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only to collect the urine if they woke naturally. Failing to collect the urine at frequent 
intervals risks smoothing out the cosinor curve of a circadian rhythm and this might 
explain why some of our children had low values. We also had to rely on the family to 
correctly time and label the specimens, and any failures will have affected acrophase time 
and cosinor rhythm. However, such failures will also occur in clinical practice, and 
contribute to the “normal” range.
All our patients except patient three had 6-suphatoxymelatonin values that fell within the 
normal range. Interestingly, patient three, as an individual also had a poor response to 
exogenous melatonin. The fact that she did not respond to a “supraphysiological” dose of 
melatonin strengthens the hypothesis that exogenous melatonin does not act by correcting 
abnormal excretion patterns. This patient also had severe behavioural problems and this 
may explain in part, her poor sleep patterns and poor response to melatonin. All but one of 
the patients with TSC and sleep disorder had at least one cosinor value above 90% 
indicating strong circadian rhythms. The one who did not, had responded to melatonin as 
an individual with an improvement in total sleep time. The acrophase time is indicative of 
the time at which maximal melatonin excretion occurs. In adults this occurs in the early 
hours of the morning. In the majority of our controls the acrophase time also occurred in 
the early hours of the morning. In two controls (1 IB and 13B), one or both collections, in 
which the acrophase time was later than 9am, the cosinor values were also low suggesting 
the possibility of inaccurate collections. However, the 6-SM excretion, although low was 
better in the first 24 hours where the cosinor rhythm was no better. Full collection, but 
inaccurate labelling of the time could explain this but normal variation is a more 
reasonable explanation.
In the patients with sleep disorder, one patient had an acrophase time of 10.36am during 
the first collection with a cosinor value of 51.9. The following collection had a cosinor 
value of 93.2 and an acrophase time of 2.36am suggesting the possibility of inaccurate 
collection or timing of samples during the first 24-hour period, but confirming the normal 
excretion of melatonin in the second collection. Collecting two 24-hour samples from 
patients is a sensible precaution when attempting to show normal excretion of melatonin. 
Exogenous melatonin is usually administered shortly before the patient’s normal bedtime. 
However we know that endogenous melatonin reaches its peak excretion in the early hours 
of the morning; we also know that exogenous melatonin has a very short half life and is
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quickly excreted in the urine. It is therefore possible that the advantageous effect of 
exogenous melatonin occurs too early in the night to provide maximum benefit to the 
patient. Perhaps by repeating the dose, should the patient wake or by administering a slow 
release formula, the natural rhythm of endogenous melatonin secretion could be more 
closely mimicked, allowing further improvement of the sleep patterns in these patients.
Conclusion
Although our numbers of controls and patients are small the total daily volume of 6- 
sulphatoxymelatonin and acrophase time do not differ significantly between the two 
groups or from adult data. In addition, all but one (who had responded to melatonin) of the 
patients with sleep disorder showed a normal circadian rhythm of melatonin secretion, yet 
showed an improvement in total sleep time and sleep latency when treated with exogenous 
melatonin. These results suggest that the exogenous melatonin did not act by correcting 
abnormal endogenous melatonin secretion. We would propose that exogenous melatonin 
acts in these children by a simple sedative effect.
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CHAPTER TEN
Summary of Thesis and Final Discussion
It is important to study TSC because potential treatment is available and there are a number 
of unanswered questions about the natural history of the condition. It is likely that 
resolving some of these issues could result in an improved quality of life and even life 
expectancy. I chose to study this condition as the subject for my thesis because I have a 
particular interest in epilepsy and neuro disability which are key issues for many patients 
with TSC.
Epidemiology of the TSC population in the Bath Health District
The reason why I undertook this ten year review was to look at the natural history of TSC 
in detail and to establish which clinical factors contributed most to the morbidity (and 
mortality) of this population so that I might examine some of these problems in greater 
detail. The advantage of undertaking a longitudinal study rather than a cross sectional 
study is that it allowed me to examine the impact of such factors observed over time. A 
database has now been set up at Bath to be updated regularly with information retrieved at 
clinic appointments and from research studies, which I hope will allow a more detailed 
picture of the disease to be compiled, giving greater understanding of the less common 
complications such as LAM. I also hope that it will allow the impact of clinical 
intervention in these patients to be more fully assessed.
In addition, this review gave us an opportunity to assess how the introduction of the 
diagnostic criteria might change the overall prevalence of the disease4. There will be a 
number of patients who previously had a diagnosis of TSC who are no longer considered 
to do so. In our small population of just nineteen patients ascertained in 1986, three 
patients had their diagnosis withdrawn; these are small numbers but if representative of the 
whole population of TSC patients, this might mean that as many as 15% had an incorrect 
diagnosis. This would significantly reduce the prevalence of the disease. It is therefore 
important that with the introduction of new diagnostic criteria, large and detailed 
epidemiology studies are repeated in order to provide a clear picture of the prevalence and 
incidence of the disease.
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Epilepsy, its association with learning difficulties and its treatment
The seizure disorders of TSC are closely associated with the learning difficulties 
experienced by many of these patients. Infantile spasms are associated with the greatest 
degree of mental handicap in patients with TSC but the optimum medical treatment for 
infantile spasms remains uncertain. Steroids have been used for many years and my search 
of the literature found them to be effective in stopping the spasms in just half of all 
patients. One reason for the poor response to oral steroids might be that fears of serious 
side effects have resulted in inadequate doses being administered, so I undertook a 
retrospective review of the use of larger doses of oral prednisolone in patients with 
infantile spasms in Bath. This review found it to be effective in stopping the spasms in 
70% of patients with no serious adverse effects being reported; although small it provided 
reassurance that larger doses of oral steroids could be used safely in the treatment of 
infantile spasms and suggested that larger doses might be more effective in stopping the 
spasms. I would suggest that larger study would be required to assess its efficacy more 
fully. Assuming approximately 50% of patients would achieve cessation of seizures if 
treated with 2mg/kg of prednisolone, such a trial would need to recruit at least 250 
children, with approximately half randomised to “low dose (2mg/kg)” prednisolone and the 
other half to “high dose (60mg/day)” to attain 90% power to detect an improvement in 
cessation of seizures of 70% in the “high dose” group. Such a trial would require 
collaboration between many centres over a long period of time.
Vigabatrin, a relatively new anticonvulsant has also been used in the treatment of infantile 
spasms over the past 20 years, with similar results to steroids. However, recent studies had 
suggested that it might be particularly efficacious in the treatment of infantile spasms in 
tuberous sclerosis. I reviewed the English literature and found support for this theory, 
although the majority of the studies undertaken were non-randomised and had little power. 
Nonetheless, it suggested that vigabatrin should be the drug of choice for stopping the 
spasms in infants either with a known diagnosis of TSC or at high risk of TSC. 
Unfortunately although IS are associated with a high degree of mental handicap in patients 
with TSC none of these trials assessed the effect of vigabatrin on either long term 
psychomotor development or the onset of subsequent seizure types.
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United Kingdom Infantile Spasms Study -  A Stepping Stone to the Future
UKISS was a multicenter randomised trial set up to try and determine whether (if either) 
steroids or vigabatrin was most effective at stopping infantile spasms and whether either 
treatment was more efficacious with regard to the long-term outcome. I was responsible, 
under JPO’s supervision for developing the trial design, protocol and trial packs which 
were put to the trial steering committee for comment and approval. I also remain closely 
involved with the trial as a member of the trial steering committee.
Unfortunately, patients with known TSC or at a high risk of TSC have been excluded from 
this study since it was felt that it would be unethical to withhold vigabatrin as treatment 
from this group of patients. The problem is that previous studies have not looked at long­
term psychomotor development as an outcome. I therefore feel that it is important that 
further studies are performed specifically looking at the treatment of infantile spasms in 
this subgroup of patients, with particular respect to psychomotor development. If the 
UKISS trial does find vigabatrin to be more effective in stopping the spasms and giving 
improved development than steroids, it may be prudent to continue using vigabatrin as the 
“gold standard” against which newer treatments can be considered. If however, the UKISS 
trial finds no significant difference between the two groups or finds “steroids” to be more 
efficacious then there is a greater dilemma. Should a randomised controlled trial be then 
set up comparing steroids vs. vigabatrin in TSC -  I feel that this would now be deemed 
ethical (in light of the visual field defects associated with the use of vigabatrin), but others 
might argue that a better trial would be one comparing treatment with vigabatrin alone say 
against a combination of vigabatrin and ACTH? Side effects must be taken into 
consideration. Although steroids are associated with a risk of mortality, especially if they 
are used for long periods of time, their side effects are well known and can be closely 
monitored. Unfortunately, although vigabatrin initially promised to be a relatively safe 
drug there are increasing concerns about the potential visual field defects associated with 
its use. At present it is unclear how frequently children will be affected, whether this 
complication is related to dosage or length of administration or whether it is reversible on 
withdrawing the drug.
Even if the UKISS trial does show one treatment to be beneficial overall as compared with 
the others, I believe that there are still many other issues that need to be addressed. There is 
often a delay in the presentation and/or diagnosis of the spasms so contributing to the delay
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of initiating treatment. In the group of infants with TSC we hope that with improving 
diagnostic techniques (especially the possibility of genetic testing) diagnosis will be made 
at a younger age in many of these infants. It is important that both the parents (or carers) 
and the professionals looking after these infants are taught to recognise the onset of 
infantile spasms so that if they do occur treatment can be quickly initiated, preferably the 
same day as onset. It is possible that one of the reasons that infantile spasms have such a 
devastating affect on development is that their peak age of onset (4 -7 months) is also at a 
time when the brain is maturing rapidly. Obviously, it is not possible to change the natural 
history of the condition, but if the onset of infantile spasms could be delayed, or even 
prevented then it is possible that these patients will have an improved outcome. I would 
suggest that one way to prevent the spasms from occurring might be to treat young infants 
(within a few weeks of birth) known to have TSC and therefore be at high risk of 
developing the spasms from the time of diagnosis to say two years of age with a 
prophylactic therapy. However, such a therapy would have to be known to be safe and 
effective in treating the spasms (and even that would not guarantee that it would be 
effective at preventing the spasms (or the onset of learning difficulties) and must be safe to 
administer for long periods of time. At present there is no such treatment available.
A different approach to treatment of infantile spasms in infants with TSC might be 
epilepsy surgery. Some clinicians have suggested that it is the tubers that are responsible 
for the seizures and the learning difficulties suffered by these patients; others suggest that it 
is the seizures that are responsible for the delay or regression in psychomotor development. 
It is likely that the issue is more complex than this with many factors playing a role. In the 
10 year review of the TSC patients in the Bath area, no patient without seizures had 
moderate or severe learning difficulties, yet we know that many of our patients without 
seizures have multiple tubers. It may be that in TSC tubers are responsible for acting as 
foci for seizures and also cause subtle intellectual impairment, but that it is the effect of the 
seizures on the developing brain that is associated with the greater loss of cognitive 
function. Further research is required to define the exact relationship of the tubers with 
both seizures and learning difficulties. Ongoing research into the treatment of epilepsy by 
surgery may help in solving this conundrum, at least in part. Epilepsy surgery has been a 
tool for treating some of those patients who have intractable epilepsy, resistant to 
anticonvulsant medication. In the past it has usually been reserved as “a last resort” -  to be 
tried in those in whom all other treatments have “failed”, although it is often very
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successful in selected patients in stopping seizures. It has been less noteworthy in its 
impact on cognitive function, although there are anecdotal reports of patients improving 
mentally following such surgery. One reason why cognitive function may not improve 
after such surgery is that many patients are older and so the “damage” has already taken 
place in the developing brain. If patients with severe seizures are treated at an earlier age 
by surgery, it may be that their long term outcome may be improved. In the past, patients 
with tuberous sclerosis have not been considered “good” candidates for epilepsy surgery 
because they have multiple tubers each of which might act as a foci for seizures. As 
investigative techniques improve, for example EEG techniques, SPECT and functional 
scanning, may help in some patients. It might therefore be possible to set up a trial looking 
at the role of epilepsy surgery in the treatment of infantile spasms including patients with 
known TSC. Patients could be randomised to receiving either conventional treatment (i.e. 
steroids or vigabatrin) alone or both conventional treatment and surgery. Long term 
psychomotor development could then be measured. If patients treated with surgery had a 
higher rate of cessation of spasms and improved long term outcome, this would lend 
support to the theory that it is the affect of the seizure activity on the developing brain that 
has the greatest impact on intellect.
A Cochrane Review: an alternative approach to the evaluation of the medical 
treatments of infantile spasms.
The difficulty in setting up trials looking at the treatment of many of the complications 
seen in TSC is their relative rarity. Often the number of patients seen at any one centre is 
insufficient to give high enough power to an individual study, whilst collaboration relies on 
co-operation and often more importantly agreement between different centres. The main 
reason why lead clinicians declined to participate in recruiting patients into the UKISS trial 
was because they felt one treatment to be superior or safer to the other in treating the 
spasms and yet robust enquiry shows that there is no scientific data to substantiate these 
claims. One alternative way of overcoming such problems is to combine smaller studies by 
meta-analysis in order to increase the power of such studies. This was the reason that I 
chose to undertaking a Cochrane review on the medical treatment of infantile spasms. 
However, it is important to remember that the results that can be obtained from such a 
meta analysis are only as good as the studies included within the review. Unfortunately, the 
majority of studies that have previously been undertaken are not only small in number, 
looking at a large number of different therapies, but also of poor methodological quality,
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and more importantly did not use standardised definitions, dosage regimes or outcome 
measures. Disappointingly, our review has not yet answered the question as to which 
treatment is optimum for infantile spasms. However, the review is ongoing and will 
continue to be updated on a six to twelve monthly basis, including newer (and hopefully 
larger, better quality) studies as they are undertaken. This still does not solve the problem 
of the different definitions or outcome measures used. Now might be the time to try and 
agree an international consensus as to how terms should be defined and how outcome 
should be measured, so that future studies can easily be compared.
A different approach to investigating the optimum treatment for infantile spasms is to 
consider them as a symptom of many underlying aetiologies rather than as a single entity. 
Past trials have produced inconsistent and varying results. One possible reason for this is 
that trials have looked at patients with a wide range of underlying causes for their infantile 
spasms. Only one trial40 to date has considered the treatment of infantile spasms due to a 
single underlying cause (tuberous sclerosis), which suggested that vigabatrin was more 
effective in stopping the spasms in this sub-group of patients. Again the problem in trying 
to study single underlying pathophysiological causes of the spasms is the rarity of the 
problem. In order to be able to study the treatment of infantile spasms in this way, large 
collaborative trials will need to be set up. Other possible sources of heterogeneity also 
need to be considered in future trials. At present it is unclear as to whether factors such as 
sex or age of onset of spasms contribute to the outcome as there is little data on the long­
term outcome of untreated spasms. It may be, for example, that girls have a better outcome 
than boys regardless of treatment. In our small review of patients with TSC who suffered 
from epilepsy in the Bath region (many of whom had infantile spasms) there was a 
suggestion that the trend was for girls to have a better long-term outcome, both in terms of 
seizure control and psychomotor development.
Can Oral treatment of Non-convulsive status epilepticus improve long term outcome?
Other seizure types (generalised tonic clonic seizures, complex partial seizures etc.) are 
common in TSC but the precise relationship of these to the learning disabilities seen in 
TSC remains unclear. The knowledge that some infants can develop normally to over a 
year and even sometimes to two or three years of age before seizures commence when they 
then dramatically lose skills does not deter some from believing that it is the continuing 
seizure activity, which is usually present, which interferes with both the learning and the
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expression of and the testing of ability; but that if the seizure activity ceased, the child 
would resume learning. They believe that seizures do not cause permanent harm but that 
our inability to control the seizures prevents us from seeing that. It has also been proposed 
that the underlying brain lesions prevent further development at the same moment that the 
seizures begin -  a coincidence not likely to be explained by the site, or size, or number of 
lesions. The loss of skills is explained by the theoretical possibility that cortical 
development fails to take over from sub-cortical activity (akin, to the apparent loss of 
vision in those with cortical blindness when sub-cortical fixation ceases). However, parents 
and clinicians who have seen a perfectly normal child lose the majority of their skills often 
believe that it is the seizures themselves that cause harm in some way and that controlling 
the seizures (our only hope) might improve intellectual outcome. This is reflected in those 
who suffer episodes of non-convulsive status. With the onset of continuous seizure activity 
there is often a dramatic loss of skills, which are rapidly regained if the seizure activity is 
successfully terminated. However, if the episodes recur regularly or are not treated quickly 
then the patients do not always regain the skills they previously had. Also some adults do 
stop seizing but do not “wake up” and recover their skills. Obtaining evidence of the 
beneficial effect (if any) of seizure control or prevention is therefore an important issue for 
which evidence is currently lacking, partly because of the lack of effective interventions 
but also because of the difficulties of setting up clinical trials that are ethically sound in 
these patients. Nevertheless it is an issue that urgently needs addressing. I therefore looked 
at a small number of patients in order to assess the effectiveness of oral diazepam in the 
treatment of NCSE, this observational study suggested that it was effective in terminating 
such episodes. However, it did not address the issue of whether earlier abortion of the 
episodes prevented or ameliorated subsequent intellectual regression. I would put forward 
that a larger study needs to be undertaken with patients randomised to either receiving oral 
treatment for each of their episodes of NCSE or more conventional intravenous 
benzodiazepines. Again, because of the rarity of NCSE, such a trial would need to be 
collaborative. Patients could be enrolled during their first episode of NCSE. On admission 
to hospital an EEG could be performed to confirm the diagnosis of NCSE, the patient 
would be randomised to receive either oral or intravenous treatment, following which a 
second EEG could be performed to ensure that the NCSE has been successfully terminated. 
Those patients randomised to receive oral treatment would then have subsequent episodes 
treated by the carers at home, whilst those receiving intravenous treatment would be 
readmitted to hospital. Cognitive function could then be performed at regular intervals, say
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six monthly by a blinded assessor to try and establish whether or not there was a more 
rapid or severe decline in function in either group. This would then need to be compared to 
the amount of time spent in NCSE to see if there was a link between the two phenomena.
Lymphangioleiomyomatosis, a question of gender?
LAM is a rare complication of TSC. Our cohort of 21 patients is (to our knowledge) the 
largest in the literature to date. We had hoped to highlight those patients at greatest risk of 
developing LAM. We found that it does seem to be limited to females, mainly of child 
bearing age. We only found one male with a definite diagnosis of LAM (both in our series 
of patients and in the literature) and he was unusual because he also had a diagnosis of 
Kleinfelters syndrome. However we found no other definite risk factors. We had hoped to 
propose a model for screening those patients at high risk but further research is required to 
ascertain if change on HRCT or abnormal lung function is present in the presymptomatic 
stage of the disease. Our cohort of patients did provide useful information regarding the 
natural history of LAM in TSC. In the literature LAM has been described as a relentless 
disease with death occurring within years of the onset of symptoms. We found its course to 
be extremely variable in our patients with TSC. We also found some anecdotal evidence 
that it might occur as localised disease in patients with TSC rather than always being 
generalised, and that these patients responded well to conventional treatments such as 
lobectomy. We had hoped to study the effects of hormonal treatment on the course of 
LAM, but unfortunately our numbers were too small to provide any useful information. A 
search of the literature suggests that hormonal manipulation may well be beneficial in a 
significant proportion of patients, however this is based mainly on case reports. The effects 
of hormonal treatment on LAM needs to be investigated further. We would suggest that the 
natural history of LAM may be different in patients with TSC than those without and that a 
trial would need to be set up looking specifically at this group of patients. Because of its 
rarity such a trial would need to be multicentre or even international in order to recruit the 
numbers required. It would need to be a randomised blinded trial with one arm of the trial 
receiving placebo treatment since the natural history of the condition remains uncertain. 
One way forward would be to set up a central register, such as has been set up for patients 
with renal complications, this would at least allow accumulation of information about the 
natural history of the condition.
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Screening for End Stage Renal Fialure -  a Conundrum
Renal disease contributes a significant proportion of morbidity seen within the TSC 
population. Fortunately we found ESRF to be rare in TSC, only affecting approximately 
1% of the population. Although PKD (known to cause ESRF) was over-represented in the 
population of TSC with ESRF as compared with the whole of the TSC population it 
accounted for less than half of cases, making screening for the prevention of ESRF 
problematic. Screening for PKD is no doubt useful, and all infants or young children 
diagnosed with TSC should have renal USS performed to exclude the presence of PKD. 
Screening for other causes requires further thought and until such time routine USS should 
not be done, but patients with symptoms such as pain or bleeding should be thoroughly 
investigated.
Sleep Disorders in TSC and the Use of Melatonin
There are many behavioural problems associated with tuberous sclerosis; they most 
commonly arise in patients who also have epilepsy and learning difficulties. Many of these 
patients have autistic tendencies, hyperactivity and self-harm. Many have associated sleep 
disorders, which carers find the hardest to cope with. Melatonin had been shown to be 
beneficial in treating the sleep disorders in other patients in small studies. Our group 
looked at the effect of melatonin on the sleep disorders in TSC. In two small studies we 
found it to be most helpful in increasing the total sleep time and sleep latency and is less 
helpful in preventing the frequent night awakenings suffered by many of these patients. We 
found 5mg to be a beneficial dose but that lOmg did not improve sleep patterns further. It 
also looks as though melatonin has few side effects, does not interfere with the 
pharmacokinetics of concurrent anticonvulsants and does not affect seizure frequency. 
However, larger randomised controlled trials are required to confirm these findings and 
also to assess long-term efficacy. A study undertaken over a longer time period might also 
be helpful in determining why melatonin was more effective in some individuals than 
others. We know that melatonin excretion in “normal individuals” is relatively stable from 
day to day. We also know that as a group TSC patients with sleep disorder have melatonin 
excretion patterns that fit within the normal distribution but we do not know how stable 
melatonin secretion is day to day in this group of patients. It has been suggested that many 
blind patients also have circadian rhythms, but that they have a different “time frame” i.e. 
each co-sinor wave is longer/shorter than 24 hours with the result that on some days their 
peak melatonin excretion will occur at the “normal” time i.e. the early hours of the
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morning, but at other times it will occur at different periods of the day, e.g. mid-afternoon. 
It has been suggested that in these patients timing of commencement of melatonin therapy 
with respect to the individuals circadian rhythm is crucial in determining whether or not 
melatonin therapy is likely to be successful or not.
We also attempted to examine the mechanism by which melatonin has its effect. It had 
been suggested that exogenous melatonin worked by resetting the sleep-wake cycles. 
However we found normal circadian rhythms in our small cohort of patients suggesting 
that it works by a simple sedative effect. Again theses findings need to be confirmed by 
larger studies. Interestingly endogenous melatonin reaches its peak excretion in the early 
hours of the morning whilst exogenous melatonin is given late at night reaching its peak 
levels earlier in the night. A slow release preparation of melatonin is now available which 
might in theory prove to be more effective particularly with regard to total sleep time and 
number of awakenings. Further studies need to be undertaken comparing slow release 
preparations both against placebo and traditional preparations to establish whether they 
improve sleep patterns further.
Conclusion
Even though great advances have been made in our understanding of tuberous sclerosis 
since Von Recklinghausen first described it over a century ago, it is still associated with 
high morbidity and mortality. It is unlikely, even with the advances in genetics that the 
incidence of severely affected patients is likely to fall much in the near future. It is clear 
that collaborative efforts, using the best protocols, need to be made if clinicians are to 
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Glossary
Adrenocorticotrophin Hormone (ACTH): a synthetic steroid given as an 
intramuscular injection for the treatment of infantile spasms.
Allele: alternative form of a gene occupying the same locus on a particular 
chromosome.
Amblyopia: loss of the development of vision in one eye.
Amniocentesis: a needle is inserted through the abdominal wall into the amniotic sac to 
withdraw some of the amniotic fluid for diagnostic purposes: it may be carried out after 
fourteen weeks gestation.
Angiofibroma (AF): a characteristic facial rash pathonognomic for tuberous sclerosis 
see figure one.
Angiomyolipoma (AML): highly vascular benign tumours consisting of smooth 
muscle and adipose cells found in the kidneys, see figure twelve.
Autosomal dominant: a dominant gene is transmitted by an affected individual to half 
of his/her offspring.
Bath Health District Authority: covers a population of ~417,000 people and has ~ 
5,500 live births per annum.
Chorionic Villus Sampling: involves taking chorionic tissue (part of the placenta) for 
diagnostic purposes; it may be carried out from eight weeks gestation.
Chromosome: a structure containing DNA and protein, situated in the nucleus of the 
cell, carrying genetic information.
Chylothorax: accumulation of chyle (fat laden fluid) within the lungs.
Cochrane Collaboration: A group that focuses on systematic reviews of randomised 
controlled trials because they are likely to provide more reliable information than other 
sources of evidence on the differential effects of alternative forms of health care.
Cochrane Controlled Trials Registrar (CCTR): a database of references to controlled 
trial in health care.
Cochrane Database of Systematic Reviews (CDSR): a database containing all the 
currently available Cochrane reviews.
Cochrane Review Library (CRL): is a collection of databases containing the 
Cochrane Database of Systematic reviews, the Cochrane Controlled Trial Register, the 
Database of Abstracts of Effectiveness, the Cochrane Review Methodology Database 
and information about the Cochrane Collaboration.
Complex partial seizures (CP): (previously called temporal lobe epilepsy) vary 
considerably in their clinical features. There is often an aura preceding the attack, 
during which the patient may be fully conscious. The patient will often exhibit extreme
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of emotion during an attack for example anger or fear. They often exhibit purposeful 
movements such as seeking close contact or pacing. Autonomic phenomena are also 
frequent. Some patients can recall the whole episode, others suffer amnesia. 
Computerised Tomography (CT): imaging of deep structures of the body by 
recording the echoes of pulses of electrons reflected by tissue planes where there is a 
change in density.
Cor pulmonale: right sided heart failure secondary to pulmonary hypertension.
Cyanosis: a bluish discolouration of the skin and mucus membranes due to decreased 
oxygenation of haemoglobin.
Deoxyribonucleic acid (DNA): Genetic information is stored in the form of double 
stranded DNA. Each strand of DNA is made up of a deoxyribose phosphate backbone 
and a series of purine (adenine and guanine) and pyrimidine (thymine and cytosine) 
bases that are held together by hydrogen bonds.
Disseminated Intravascular Co-agulation: activation of co-agualtion factors leading 
to platelet consumption and secondary fibrinolysis. It results in widespread spontaneous 
bleeding into the skin, from the mouth and nose and into the brain and other organs.
Drop attacks: These are typically violent and sudden in onset consisting of a sudden 
brief violent contraction of the muscles of the neck and trunk, often with a jerk of the 
arms. They cause the patient to fall and hurt himself as they make no attempt to save 
themselves by putting out their arms.
Dyspnoea: shortness of breath
Echocardiogram: recording of the position and motion of the heart walls, internal 
structures of the heart and neighbouring tissue by the echo obtained from beams of 
ultrasonic waves directed through the chest wall.
Electrocardiogram (ECG): a graphic record of the variations in electrical potential 
caused by the electrical activity of the heart muscle as detected at the body surface. See 
figure fourteen.
Electroencephalogram (EEG): a graphic record of changes in the electric potential in 
various areas of the brain by means of electrodes placed on the scalp. See figure 
seventeen.
Embase: an electronic database citing published scientific studies from 1981.
Fibrous Forehead Plaque (FFP): raised reddish area of skin occurring on the forehead 
or scalp. See figure six.
Gene: part of a DNA molecule which directs the synthesis of a specific polypeptide 
chain.
Generalised tonic-clonic seizures (GTC): (previously called grand mal seizures)
These may be primary and generalised from the outset or occur secondarily from 
generalisation of a partial seizure. They consist of a tonic phase with generalised rigidity 
with sudden loss of consciousness, the patient falling if standing. This short phase is
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followed by the clonic phase with rapid generalised jerking movements. After a variable 
time the clonic phase ends and the patient becomes post-ictal often sleeping for a period 
of time. There may be apnoea with cyanosis and incontinence of urine and faeces.
Genotype: the genetic constitution of an individual.
Giant Cell Astrocytoma (GCA): a brain tumour composed of astrocytes of varying 
differentiation. They usually follow a relatively benign course in tuberous sclerosis, but 
surgical removal is necessary.
Haemoptysis: blood stained sputum.
Hamartoma: a benign tumour composed of an overgrowth of tissue cells normally 
present in the affected part, but often with one element predominating.
Hemiplegia: weakness of one side of the body.
Heterozygosity: the possession of two different alleles at the corresponding loci on a 
pair of chromosomes.
Homozygosity: the possession of two identical alleles at the corresponding loci on a 
pair of chromosomes.
Hypertonia: increased tone.
Hypomelanic Patch or White Patch: Patches of skin that appear pale in colour as a 
result of a decrease in melanosomes in the skin. The are best visualised with ultraviolet 
light and are not unique to patients with tuberous sclerosis. See figure three.
Hypotonia: decreased tone.
Hypsarrhythmia: very high voltage, random, slow waves and spikes seen in all cortical 
areas giving a totally chaotic appearance on the EEG, see figure seventeen.
Incidence: the number of new cases of a specific disease occurring during a given 
period of time.
Infantile spasms (IS): Spasms may be flexor, extensor, lightning or nods, but most 
commonly are mixed. Each individual spasm last seconds only but they commonly 
occur in batches of up to 100s in one run. There is often an associated cry and they 
commonly occur on waking or falling asleep.
Language bias: studies in which an intervention is not found to be effective are less 
likely to published in English.
Lennox Gastaut syndrome: manifests itself in children aged 1 to 8 years. The most 
common seizure types are tonic-axial, atonic and absence seizures, but other types such 
as myoclonic, generalised tonic clonic or partial are frequently associated with this 
syndrome. Seizure frequency is high and status epilepticus frequent. In general there are 
severe learning difficulties and the seizures are difficult to control.
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Locus: the site of a gene on a chromosome.
Lymphangioleiomyomatosis (LAM): a rare cystic disease of the lung that is usually 
generalised and progressive, can be extremely difficult to treat and is generally 
considered to have a poor prognosis. It is almost exclusively reported to occur in 
women of childbearing age. See figure fifteen.
Magnetic resonance imaging (MRI): imaging of deep structures of the body by 
recording electrons reflected by electrons as they pass through different tissue planes.
Medline: an electronic database citing published medical studies.
Mutation: a permanent transmissible change in the genetic material.
Non-convulsive status epilepticus (NCSE): characterised by a patient who has 
continuous or almost continuous epileptic activity both clinically and on the EEG but 
clinical signs of an overt seizure disorder may be extremely subtle. The onset may either 
be so subtle as to suggest dementia or may be abrupt. Lack of awareness may extend to 
loss of appetite with weight loss. Patients may cycle from periods of complete 
unresponsiveness to one of partial responsiveness. Frequent brief, but small, myoclonic 
jerks can often be felt but not seen. Often there are associated autonomic features such 
as excessive salivation and sweaty palms.
Penetrance: the proportion of individuals with a particular genotype who also have the 
corresponding phenotype.
Phenotype: the appearance of an individual resulting from the effects of both 
environment and genes.
Pleural effusion: accumulation of fluid within the lungs.
Pleurectomy: excision of a portion of the pleura.
Pleurodesis: fusion of the two layers of the pleura together (usually chemically).
Pneumothorax: air or gas in the pleural space, i.e. within the membrane that surrounds 
the lung.
Polycystic Kidney Disease (PKD): Inherited in an autosomal dominant manner, it 
manifests in infancy as tiny cystic lesions distributed throughout both kidneys. With 
advancing age the cysts enlarge at a variable rate resulting in loss of renal function.
Prevalence: the total number of cases of a specific disease in existence in a given 
population at a given point in time.
Randomised controlled trial (RCT): Trials in which participants are prospectively 
allocated to treatment groups by random (e.g. random number generation, coin flips) or 
quasi random (e.g. by date of birth) process.
Selection bias: systematic differences between comparison groups in prognosis or 
responsiveness to treatment.
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Selective arterial embolisation: therapeutic introduction of a substance into a vessel in 
order to occlude it.
Simple partial seizures or absence attacks: These generally consist of a sudden, brief, 
blank stare accompanied by unawareness and sometimes flickering of the eyelids or 
other automatism, lasting seconds or occasionally minutes only.
Suppressor gene: a gene that plays an important role in the regulation of the normal 
cell cycle. For a suppressor gene to exert its influence on a cell, both alleles must be 
affected i.e. loss of heterozygosity.
Ultrasound scan (USS): imaging of deep structures of the body by recording the 
echoes of pulses of ultrasound reflected by tissue planes where there is a change in 
density.
West syndrome: (also called infantile spasms) consists of a characteristic triad; 
infantile spasms, arrest of psychomotor development and hypsarrhythmia on the EEG, 
though one element may be missing.
Wolff Parkinson White Syndrome (WPW): This is caused be an abnormal 
myocardial connection between the atria and ventricles of the heart causing abnormal 
depolarisation of the ventricles. About half of those with WPW will suffer from 
tachycardias (abnormally fast heart rates), see figure fourteen.
Woods light: an ultraviolet light that is shone on the skin. Hypomelanic patches shine 
bright white under light.
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Abbreviations
1. ACTH Adrenocorticotrophin Hormone
2. AF Angiofibroma
3. AML Angiomyolipoma
4. Bd Twice Daily
5. CMZ Carbamezepine
6. CPS Complex Partial Seizures
7. CRF Chronic Renal Failure
8. CT Computerised Tomography
9. CXR Chest Xray
10. DIC Disseminated Intravascular Co-agulation




15.ESRF End Stage Renal Failure
16. FFP Fibrous Forehead Plaque
17. GCA Giant Cell Astrocytoma
18. GP General Practitioner
19. GTC Generalised Tonic Clonic Seizures
20.HMP Hypomelanic Patch or White Patch
21.HRCT High Resolution Computerised Tomography
22. IM Intra-muscularly
23. IS Infantile Spasms
24. Iv Intra-vascular
25.IVP Intra-venous Pyelogram
26. JPO Professor John P Osborne
27. LAM Lymphangiomyomatosis
28. MMR Measles, Mumps and Rubella Vaccination
29. MR Mental Retardation
30.MRI Magnetic Resonance Imaging
31. N/A Not Available / Applicable
32.NCSE Non-Convulsive Status Epilepticus
33. Od Once Daily
34. PKD Polycystic Kidney Disease
35. Qds Four Times Daily
36. RCT Randomised Controlled Trial
37. REM Rapid Eye Movement (sleep)
38. RUH Royal United Hospital
39. SLD Severe Learning Difficulties
40. SVT Supraventricular Tachycardia
41. Tds Three Times Daily
42. TLE Temporal Lobe Epilepsy
43.TRH Thyroid Releasing Hormone
44. TSC Tuberous Sclerosis Complex
45. UK United Kingdom
46. USS Ultrasound scan
47.UTI Urinary Tract Infection
48. VGB Vigabatrin
49. WPW Wolff Parkinson White Syndrome
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Tables for thesis
Chapter two -  A ten year review of the epidemiology, morbidity and mortality of the 
tuberous sclerosis population in the Bath Health District.
Table one: page 34: Table showing how TSC was excluded in the parents of sporadic cases 
ofTSC.
Table two: page 38: Table showing the referral patterns for diagnosis ofTSC.
Table three: page 38: Table showing the skin lesions of the patients in the epidemiology 
study.
Table four: page 39: Table showing patient gender, age at onset of seizures, the type of 
seizure at onset, other seizure types, presence or absence of learning difficulties and 
behavioural problems and the outcome of seizures.
Chapter three -  Epilepsy and learning difficulties.
Table five: page 58: Table showing the results of a literature review of the treatment of 
infantile spasms with steroids.
Table six: page 62: Summary of the treatment of infantile spasms, first and second line 
drugs.
Table seven: page 67: Table showing the underlying aetiologies for patients with infantile 
spasms treated with high dose prednisolone.
Table eight: page 68: Table showing the age at which the infantile spasms were diagnosed 
and the delay from onset of the spasms to their diagnosis. The dose and duration of oral 
prednisolone, the effect it had on the spasms and any other drugs used.
Table nine: page 69: Table showing the side effects experienced with high dose 
prednisolone.
Table ten: page 72: Table of authors of the studies reviewed for the treatment of infantile 
spasms with vigabatrin in TSC, the type of study, the total number of patients treated with 
vigabatrin and the male to female ratio of patient.
Table eleven: page 73: Table (of the studies reviewed for the treatment of infantile spasms 
with vigabatrin in TSC) showing the average age at treatment, whether previous treatment 
had been given, whether concurrent treatment was given and the range of doses of 
vigabatrin administered.
Table twelve: page 74: Table showing the response rate to vigabatrin (in the studies 
reviewed for the treatment of infantile spasms with vigabatrin in TSC) in all the patients, 
those without tuberous sclerosis and those with tuberous sclerosis
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Table thirteen: page 74: Table showing the number and type of side effects / adverse 
reactions reported in each study (reviewed for the treatment of infantile spasms with 
vigabatrin in TSC).
Chapter Five — Cochrane review
Table fourteen: page 99: Table of the characteristics of studies included in the cochrane 
review
Table fifteen: page 103: Table showing the methodological quality of included studies in 
the Cochrane review.
Table sixteen: page 105: Table showing details of the participants of the included studies 
Chapter Six — Non-convulsive status epilepticus
Table seventeen: page 122: Table showing the outcome of treatment with oral diazepam 
for NCSE
Chapter Seven -  Lymphangioleiomyomatosis and tuberous sclerosis.
Table eighteen: page 129: Table showing the sex of each patient, the age at which TSC 
was diagnosed and the reason for diagnosis ofTSC, the age of onset and the presenting 
features of the pulmonary disease, stratified by definite, probable and possible diagnosis of 
LAM.
Table nineteen: page 132: Table showing the pulmonary symptoms and the complications 
experienced and the investigations undertaken on each patient.
Table twenty: page 135: Table showing acute surgical and medical treatment, long term 
medical treatment, disease course and time of follow up of patients with LAM.
Table twenty-one: page 138: Table showing the renal symptoms, complications and 
investigations in our group of patients with LAM.
Table twenty two: page 141: Table showing the symptoms suffered by the patients with 
LAM in the literature (both with and without TSC).
Table twenty three: page 142: Table showing the investigations undertaken (and method of 
diagnosis) and the pulmonary function tests in the patients with LAM in the literature (both 
with and without TSC).
Table twenty-four: page 143: Table showing the effects of hormonal manipulation on the 
course of LAM (compared with patients who did not receive hormonal manipulation).
Table twenty-five: page 147: Table showing possible cases of LAM in males in 
the literature
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Table twenty-six: page 154: Reported regimens of hormonal treatment for LAM 
before and after meta-analysis.
Chapter Eight -  Renal disease.
Table twenty-seven: page 160: Table showing the age and sex of the patients, the age at 
which TSC was diagnosed and the reason for diagnosis, whether the inheritance was 
sporadic or familial and the presence / absence of learning difficulties in patients with end 
stage renal failure.
Table twenty-eight: page 161: Table showing the age of presentation of renal disease and 
age of ESRF, presentation of renal disease, the underlying lesions, method of confirmation 
of the diagnosis, renal function at time of presentation of renal disease and the presence / 
absence of hypertension.
Table twenty-nine: page 162: Table showing the treatment of the patients in our ESRF 
survey.
Chapter Nine -  Sleep disorder in tuberous sclerosis complex.
Table thirty: page 173: Table showing the mean time to sleep onset, total sleep 
time and sleep fragmentation; after the administration of 5mg and 10 mg.
Table thirtv-one: page 174: Table showing seizure frequency; without melatonin; 
after the administration of 5mg melatonin; and after the administration of lOmg 
melatonin.
Table thirty-two: page 179: Table showing total melatonin secretion, the cosinor values 
and acrophase times in normal children.
Table thirty-three: page 180: Table showing total melatonin secretion, the cosinor 
values and acrophase times in patients with the sleep disorder ofTSC.
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Figures for thesis
Figure one Angiofibroma - page 8
Figure two Shagreen patch - page 14
Figure three - Hypopigmented lesion - page 14
Figure four Poliosis - page 15
Figure five Confetti depigmentation - page 15
Figure six Fibrous forehead plaque - page 16
Figure seven - Fibroma of finger - page 16
Figure eight - MRI scan of cortical tubers - page 17
Figure nine CT scan of subependymal nodules - page 17
Figure ten Astrocytoma - page 18
Figure eleven - USS of polycystic kidneys - page 19
Figure twelve - CT of angiomyolypoma of kidney - page 19
Figure thirteen Echo of cardiac rhabdomyoma - page 20
Figure fourteen - ECG of Wolff Parkinson White syndrome - page 20
Figure fifteen Lymphangioleiomyomatosis - page 21
Figure sixteen Retinal phakoma - page 21
Figure seventeen - EEG of hypsarrhythmia - page 54
Figure eighteen - Lymphangioleiomyomatosis (HRCT) - page 133
Figure nineteen - Lymphangioleiomyomatosis (CXR) - page 133
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APPENDIX TWO
Professor John Osborne: a Consultant Paediatrician and Honorary Senior Lecturer at 
the University of Bath. He has conducted research into Tuberous Sclerosis ( a 
significant cause of infantile spasms) since 1985, leading the team which located the 
TSC 1 gene. He was responsible for the follow-up and development assessment of 276 
infants in the UK study of ethamsylate for the prevention of intraventricular 
haemorrhage, which achieved a 97% follow-up rate.
Dr Richard Appleton: a Consultant Paediatric Neurologist in Liverpool with a special 
interest in epilepsy. He has conducted studies of vigabatrin in infantile spasms.
Dr Eleanor Hancock.
Dr Tony Johnson: is a statistician for the Medical Research Council in Cambridge and 
he has extensive experience of trials of epilepsy, although predominantly in older 
children and adults.
Dr Colin Kennedy: is Consultant Paediatric Neurologist in Southampton and was 
responsible for the multicentre study of post-haemorrhagic hydrocephalus in premature 
infants.
Dr Richard Newton: is a Consultant Paediatric Neurologist in Manchester and a 
member of the Cochrane Collaborative Group for Epilepsy. He has published a meta­
analysis of the treatment of febrile convulsions.
Dr F O’Callaghan: is Research Registrar in Tuberous Sclerosis to Prof. Osborne, and 
has recently won a Wellcome Research Epidemiology Training Fellowship to study 
Tuberous Sclerosis, based in Prof. Osborne’s department, with Dr C Martyn of 
Southampton University as joint supervisor.
Dr Christopher Verity: is a Consultant Paediatric Neurologist in Cambridge and has 
published on the epidemiology of epilepsy. He is currently Chairman of the British 
Paediatric Association’s Surveillance Unit.
Dr Lisa Vickers: is working for Prof. Osborne as a research co-ordinator on a one year 
pump-priming grant to establish this study of infantile spasms. She is a pharmacologist 
with expertise in research management.
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Please circle the appropriate number for questions 1-4
0 = no problem
1 = occurs less than twice a week
2 = occurs three or more times a week
1. Does your child take more than an hour to settle and finally fall asleep? 
Answer = 0 1 2
2. Does your child wake for more than a few minutes at night?
Answer = 0 1 2
3. Do you have to get up to attend to your child at night?
Answer = 0 1 2
4. Do you take your child into your bed at night?
Answer = 0 1 2
5. At what time is your child put to bed?
6. Is your child in nappies? yes / no
7. We would like to participate in this study yes/no
8. We would be able to obtain a 48 hour urine collection yes/no
9. We would be able to obtain a urine sample approx. every 4 hours yes/no
Signature Date
SLEEP DIARY
WEEKS 1 & 2  
(No treatment)















































































































WEEKS 3 & 4 
(Treatment A +  B)
Give melatonin capsules half an hour 
Before time put to bed
















































































































WEEKS 5 & 6 
(No treatment)
















































































































WEEKS 7 & 8 
(Treatment C + D)
Give melatonin capsules half an hour 
before time put to bed
































































































































































































































WEEKS 3 & 4 
(Treatment A + B )
Symbols:






































































































































































































































WEEKS 7& 8  
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GP's Information Sheet 
Patient's Information Sheet
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The United Kingdom Infantile Spasm Study
I N T R O D U C T I O N  T O  U K I S S
Thank you fo r partic ipating in UKISS. This is tw o  studies in one and is 
aim ing to  answer several im portan t questions.
The Epidem iology Study  aims to  give a reliable estimate o f the incidence 
o f in fan tile  spasms in the UK and to  define im portan t characteristics o f 
ch ild re n  w ith  in fa n t ile  spasms. W e 'll be lo o k in g  a t age a t onset, 
predisposing conditions and underlying aetiology, and clinical features o f 
the  spasms. We w ou ld  also like to  ge t a descrip tion  o f response to  
trea tm en t in infants w ho are not enrolled in the  drug tria l.
The m ost im p o rta n t co m ponen t o f th e  s tudy is the  R an d o m ised  
C o n tro lled  Trial o f synthetic ACTH (Synacthen Depot), prednisolone 
(Prednesol) and vigabatrin  (Sabril) in infants aged between 2 and 12 
months. This randomised contro lled tria l is im portan t because it is large 
enough to  provide reliable estimates o f trea tm en t and adverse effects 
and w ill be looking at tw o  o ther im portan t outcomes: EEG im provem ent 
and neurodevelopm ental progress.
The Sum m ary Sheet and F low  D iagram  give overviews o f the  study 
structure. The A ction Plan  shows which forms to  complete at each stage 
o f the study. The Protocol gives a fu lle r description o f the study, its aims, 
and its design. Please do not hesitate to  contact us if you have any questions 
or concerns. We look fo rw ard  to  hearing from  you.
The P atien t  and D octor In fo rm atio n  Sheets  are designed as a resource 
fo r use before consent is obtained and fo r reference at any po in t during 
the  tria l.
Much o f the in fo rm ation  about the progress o f the  child w ill be obtained 
from  a Patient's D iary
We have tried  to  keep the am ount o f w ork required o f the clinician to  a 
m inim um , bu t we appreciate th a t it is still a good deal o f extra w ork  fo r 
you. We assure you th a t we are extrem ely g ra te fu l fo r  the  tim e  and 
com m itm ent th a t you are devoting to  the study. Every enrolling hospital 
w ill be acknowledged in the paper if ed itoria l policy allows this, and on a 
website otherwise.
The United Kingdom Infantile Spasm Study
T R I A L  S U M M A R Y
Epidemiology
INCLUDE ALL CASES (of any  a g e )  o f  n ew ly  d ia g n o s e d  in fan t i le  spasm s  (IS)
Drug trial
Inclusion criteria: all n e w  clinical d ia g n o se s  o f  IS w i th  se izu re  o n s e t  b e t w e e n  2 c o m p le t e d  c a le n d a r  
m o n th s  a n d  1 y ea r  o f  a g e .  R a n d o m ise  w i th in  72 hours .  (EEG o r  v id e o  EEG is e s sen t ia l  un less  u n a b le  
t o  a r r a n g e  w i th in  72 h o u rs  a n d  y o u r  n o rm a l  p rac t ice  w o u ld  b e  t o  s t a r t  t r e a t m e n t  w i t h o u t  EEG.)
Eligible fo r  e n t ry  
in to  d r u g  trial
v ig a b a t r in  (Sabril)
S tero ids
t e t r a c o s a c t r i n  (S ynac then  D epo t)
p r e d n i s o lo n e  (P redneso l)
Drug doses: vigabatrin  50 m g /k g /d a y  orally  in 2 d iv id e d  d o se s  fo r  2 d o se s  t h e n  100 m g /k g /
day, b u t  if n o  s e izu re  c o n t ro l  a f t e r  96 h o u rs  (ie a f t e r  6 f u r th e r  doses)  t h e n  
150 m g /k g /d a y  in 2 d iv ided  d o se s  
prednisolone 10 m g orally  6 h o u r ly  ( re g a rd le s s  o f  w e ig h t )  fo r  2 w eeks :  
inc rease  t o  20 m g  8 h ou r ly  if n o  se izu re  c o n t ro l  a t  7 days 
Synacthen Depot 0.5 m g  IM o n  a lte rn a te  days fo r  2 w eeks :
if n o  se izu re  co n t ro l  a t  7 days, in c re ase  t o  0 .75 m g  o n  a lte rn a te  days
Exclusion criteria:
(i) K n o w n  o r  su sp e c te d  tu b e r o u s  sclerosis a t  r a n d o m is a t io n  (see p ro to co l  fo r  cr iteria)
(ii) In fa n ts  p rev iously  t r e a t e d  w i th  v ig a b a t r in  o r  s te ro id s  w i th in  28 days  o f  d ia g n o s is  o f  IS 
(Hi) C o n t ra in d ic a t io n  t o  p re d n iso lo n e ,  te t r a c o s a c t r i n  o r  v ig a b a t r in
(iv) Lethal o r  p o te n t ia l ly  le tha l  o t h e r  c o n d i t io n
(v) P rev ious t r e a t m e n t  fo r  IS
(vi) Inabil i ty  o f  p a r e n t /g u a r d i a n  t o  g ive in fo rm e d  c o n s e n t
(vii) E xpec ted  t o  leave t h e  UK w ith in  1 m o n th  o f  r a n d o m is a t io n
(viii) Inabil ity  o f  p a r e n t /g u a r d i a n  t o  k n o w  t o  n e a r e s t  w h o le  day  t im e  o f  ce ssa t io n  o f  se izu res  
(ix) E n ro lm e n t  in c o n c u r re n t  tr ia l  likely t o  a f f e c t  o u t c o m e  o f  IS
Outcomes:
Prim ary outcome:
(i) n u m b e r  o f  p a t i e n t s  ac h iev ing  c o m p le t e  ce ssa t ion  o f  se izu res  fo r  48  h o u rs  w i th in  14 days o f  
s t a r t in g  t r e a t m e n t
Secondary outcomes:
(ii) d e v e lo p m e n ta l  p ro g re ss  by 14 m o n th s  o f  a g e
(7/7) R e d u c t io n  o f  n u m b e r  o f  spasm s  in tw o - w e e k  p e r io d
(iv) R e lapse  ra te s
(v) O th e r  se iz u re  ty p e s  a n d  f r e q u e n c y  a t  14 m o n th s  o f  a g e
(vi) R eso lu t io n  o f  h y p s a r rh y th m ia  by 14 days
UKISS Trial C e n tre  
The C hild ren 's  C e n tre  
Royal U n ite d  H ospita l 




Tel/Fax 01225 824206 
Tel 01225 824490
See Protocol fo r  con firm a tion  a n d  m ore  d e t^ M
The United Kingdom Infantile Spasm Study
A CLINICAL DIAGNOSIS OF INFANTILE SPASMS 
made by a consultant or his/her deputy
Are any exclusion criteria met? —  Y E S — i
NO





Unable to get EEG 
within 72 hours









Is it your usual 
practice to  start 
trea tm ent before 













4s (see Action 




Consent Obtained Consent Refused
I I
(see Action Plan 3) (see Action Plan 4)
The United Kingdom Infantile Spasm Study





RCT (see Protocol 
section 1); 
no  exclusion 
criteria for RCT (see 
Protocol section 2); 
paren ts consent to  




1 com plete Consent 
Check List
j* com plete Consent 
Form A with parents
•co m p le te  Form 1, 
then phone Trial 
Centre for 
random isation
• com plete Form 2
'•a rra n g e  trea tm en t to  
be given and counsel 
parents in use of 
Patient's Diary
• return photocopies of 
the above form s to  the 
Trial C entre
• i f  taking blood during 
treatment period, 
please obtain sample 
for DNA analysis 
(see Form 5)
patient meets 
inclusion criteria for 
RCT; no exclusion 
criteria for 
RCT bu t EEG not 
ob tained within 72 
hours; parents 
w ould consent to  
random isation and 
inclusion in trial.
patient has a clear 
exclusion criterion;




parents or clinician 
are not happy for 
child to be included
in RCT but are happy 
to  consent to  
Epidemiology Study
or
other, such as unable 
to  a rrange EEG in 
time, or forgot to  
randomise
parents do not 
consent to inclusion 
in RCT or
Epidemiology Study






• after 14 days of 
treatm ent, com plete 
Form 4
1 check pages D3 to  D6 
of Patient's Diary
• return photocopies of 
Forms 4 & 5 and






1 after 28 days o f  • a t each 3-m onthly 
treatment, check page: follow-up, check 
D8 of Patient's Diary appropriate  General
1 return photocopy of I [!ro.9res.sf s^ et *rom 
page D8 to Trial Patients D.ary
C entre [• com plete Form(s) 6
• s e n d  photocopies of 
i these  to  Trial Centre
> com plete Consent 
Form B with parents
» com plete Form 1
• com plete Form 3
» return photocopies of 
forms to  Trial Centre
* counsel paren ts in use 
of Patient's Diary
1 i f  taking blood during 
treatment period, 
please obtain sample 
Tor DNA analysis (see 
Form 5)
1 com plete Form 1 and 
return photocopy to 
Trial C entre
• after 14 days of 
treatm ent, com plete 
Form 4
• check pages D3 to D6 
of Patient's Diary
return photocopies of 
Forms 4 & 5 and
pages D3 to  D6 to 
Trial Centre
1 after 28 days o f 
treatment, check 
page D8 of 
Patient's Diary
1 return photocopy of 
page D8 to  Trial 
Centre
12 to 14 month 
Follow-up
when child is 12 to 14 
months old, com plete 
Form 7
• check remaining pages 
of Patient's Diary
• send photocopies of 
Form 7 and remaining 
Patient's Diary pages 
to  Trial Centre
• when child is 12 
to 14 months old, 
com plete Form 7
• check remaining 
pages of Patient's 
Diary
• send photocopies 
of Form 7 and 
remaining 
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The United Kingdom Infantile Spasm Study
Doctors’ informat
Infantile spasms (IS), also known as West syndrome were first described by Dr. West in 1841 who gave an account of them 
occurring in his own 4 month old son. They are a refractory seizure disorder with a high risk of a poor prognosis, including 
intractable epilepsy and severe developmental delay. The condition is relatively common with an incidence which may be as 
high as 1 in 2500 births. There is an association with a number of disorders. Some of the disorders, such as cerebral palsy or 
Down syndrome are known at the  disease onset, whilst others, such as Tuberous Sclerosis or neuronal migration disorders are 
discovered on investigation after the  onset of spasms. However in a significant number of cases the  aetiology remains unknown 
(i.e. idiopathic).
Two treatments are currently in widespread use i.e. vigabatrin and steroids. Steroids are either administered as ACTH or 
prednisolone. Steroids have been used in the  trea tm ent of seizure disorders since the  late 1950's. They undoubtedly have a 
significant effect in reducing seizure frequency but side effects such as increased appetite, irritability and hypertension are 
common. There is no clear evidence about whether ACTH is preferable to  prednisolone. The effectiveness of trea tm ent has 
almost exclusively been measured in terms of reduction of seizure frequency and not in terms of improved psychomotor 
outcome. Vigabatrin has also recently been shown to  reduce seizure frequency in patients with infantile spasms. Its side-effect 
profile appears better than tha t of steroids has been. It is gaining acceptance, although there are recent reports which suggest 
tha t  it might affect visual fields in some adults. However it is not known w hether  it is better than steroids in treating infantile 
spasms and we don 't  know if either trea tm ent might improve developmental outcome.
This trial will compare steroids and vigabatrin in the  treatm ent of infantile spasms. It will assess outcome primarily in terms 
of reduction of seizure frequency and secondarily in terms of psychomotor development.
Trial design
UKISS is a national, multicentre, randomised, parallel-group open clinical trial. Patients will be allocated to one of two 
trea tm ent groups:
1. Vigabatrin (50mg/kg increasing to  a maximum of 150mg/kg per day)
2. Steroids. As ACTH gel is not available in the  UK, we have substituted Synacthen Depot. Give either Synacthen Depot 
(0.5mg on alternate days increasing to  0.75mg on alternate days if necessary) or Prednisolone (40mg increasing to  60mg 
per day if necessary).
Patients will be stratified before entry according to  sex, age and whether, at the  time of randomisation, there is identifiable 
prior risk of developmental delay. Exclusions include tuberous sclerosis, proven a t the time of randomisation.
Central randomisation will be by telephone call a t  which time the child will be registered into the  trial. We will collect 
baseline information and allocate initial treatment. The initial treatment period for all three groups will be two weeks. Responders 
are defined as those in whom there is a total cessation of seizures for at least 48 hours up to  and including the end of the  14th 
day of treatment.
Responders to  vigabatrin are recommended to  continue on a maintenance dose of the  drug until aged 1 2 - 1 4  months 
unless tha t is not your normal practice. Responders to  steroids ( Synacthen Depot or prednisolone ) will undergo a tapered 
withdrawal over 15 days, using prednisolone only. Responders who subsequently relapse will be treated  by increasing the  dose 
of vigabatrin to  a maximum of 150mg/kg/day or in the  case of steroids by giving a repeated dose. If this fails we recommend 
tha t  the alternative therapy is tried (i.e. vigabatrin if steroids fail and steroids if vigabatrin fails).
Please note th e  precautions listed in the manufacturer's data sheet for Synacthen Depot. Synacthen Depot should only be 
administered under medical supervision. Previous hypersensitivity reaction (localised or generalised) to ACTH, Synacthen or 
Synacthen Depot is a contraindication to  its use. It is also contraindicated in allergic disease. Hypersensitivity reactions generally 
occur within 30 minutes of administration (for which period direct observation of the  child is recommended). However, the 
Committee on Safety of Medicines has not received any reports of anaphylaxis in children less than 5 years of age. Avoid live 
vaccines durings the  period of treatment. Use with care in the  presence of renal insufficiency and hypertension.
All patients will be seen as deemed necessary by their own consultant, but this must include a visit at two weeks to  assess 
initial response to  therapy and thereafter a t 3 monthly intervals. Referring consultants will be asked to  fill in standardised 
progress report forms and send them back to the  trial centre in Bath after each of these consultations. The patient's psychomotor 
development will be assessed by a te lephone questionnaire administered by the  trial centre in Bath at 12 -14 months of age. 
Parents will be required to keep a diary until their child reaches 12-14 months of age. There should be a daily entry for 28 days 
after the start of trea tm ent and weekly after tha t  until the  12-14 month development assessment. In those children still having 
any form of seizure at 12-14 months, a daily entry will be obtained for the  final week.
If you have any questions or concerns, or would like any further information on this study please to  not hesitate to  contact:
The UKISS Trial Centre 
The Children's Centre 





Trial Centre Tel: 01225 824206
Randomisation Tel: 01225 824490 (8.30am to 6pm)
(answer machine 6pm to 8.30am) 
Fax: 01225 824206 or 01225 824212
24 hour number for hospital: 01225 428331
The United Kingdom Infantile Spasm Study
<3P’s information sheet
Infantile spasms (IS), also known as West syndrome were first described by Dr. West in 1841 who gave an account of them 
occurring in his own 4 month old son. They are a refractory seizure disorder with a high risk of a poor prognosis, including 
intractable epilepsy and severe developmental delay. The condition is relatively common with an incidence which may be as 
high as 1 in 2500 births. There is an association with a number of disorders. Some of the disorders, such as cerebral palsy or 
Down syndrome are known at the disease onset, whilst others, such as Tuberous Sclerosis or neuronal migration disorders are 
discovered on investigation after the onset of spasms. However in a significant number of cases the  aetiology remains unknown 
(i.e. idiopathic).
Two treatments are currently in widespread use i.e. vigabatrin and steroids. Steroids are either administered as ACTH or 
prednisolone. Steroids have been used in the  trea tm ent of seizure disorders since the  late 1950's. They undoubtedly have a 
significant effect in reducing seizure frequency but side effects such as increased appetite, irritability and hypertension are 
common. There is no clear evidence about w hether ACTH is preferable to  prednisolone. The effectiveness of trea tm ent has 
almost exclusively been measured in terms of reduction of seizure frequency and not in terms of improved psychomotor 
outcome. Vigabatrin has also recently been shown to  reduce seizure frequency in patients with infantile spasms. Its side-effect 
profile appears better than tha t  of steroids has been. It is gaining acceptance, although there are recent reports which suggest 
tha t  it might affect visual fields in some adults. However it is not known w hether it is better than steroids in treating infantile 
spasms and we don 't  know if either treatm ent might improve developmental outcome.
This trial will compare steroids and vigabatrin in the  trea tm ent of infantile spasms. It will assess outcome primarily in terms 
of reduction of seizure frequency and secondarily in terms of psychomotor development.
Trial design
UKISS is a national, multicentre, randomised, parallel-group open clinical trial. Patients will be allocated to one of tw o 
trea tm ent groups:
1. Vigabatrin (50mg/kg increasing to  a maximum of 150mg/kg per day)
2. Steroids. As ACTH gel is not available in the  UK, we have substituted Synacthen Depot. Give either Synacthen Depot 
(0.5mg on alternate days increasing to  0.75mg on alternate days if necessary) or Prednisolone (40mg increasing to  60mg 
per day if necessary).
Patients will be stratified before entry according to  sex, age and whether, a t  the  time of randomisation, there is identifiable 
prior risk of developmental delay. Exclusions include tuberous sclerosis, proven at the time of randomisation.
Central randomisation will be by te lephone call at which time the child will be registered into the trial. We will collect 
baseline information and allocate initial treatment. The initial treatment period for all three groups will be two weeks. Responders 
are defined as those in whom there is a total cessation of seizures for at least 48 hours up to  and including the  end of the  14th 
day of treatment.
Responders to  vigabatrin are recommended to  continue on a maintenance dose of the  drug until aged 1 2 - 1 4  months 
unless th a t  is not your normal practice. Responders to  steroids ( Synacthen Depot or prednisolone ) will undergo a tapered 
withdrawal over 15 days, using prednisolone only. Responders who subsequently relapse will be treated  by increasing the  dose 
of vigabatrin to  a maximum of 150mg/kg/day or in the  case of steroids by giving a repeated dose. If this fails we recommend 
tha t  the  alternative therapy is tried (i.e. vigabatrin if steroids fail and steroids if vigabatrin fails).
Please note the  precautions listed in the manufacturer's data sheet for Synacthen Depot. Synacthen Depot should only be 
administered under medical supervision. Previous hypersensitivity reaction (localised or generalised) to  ACTH, Synacthen or 
Synacthen Depot is a contraindication to  its use. It is also contraindicated in allergic disease. Hypersensitivity reactions generally 
occur within 30 minutes of administration (for which period direct observation of the child is recommended). However, the  
Committee on Safety of Medicines has not received any reports of anaphylaxis in children less than 5 years of age. Avoid live 
vaccines durings the  period of treatment.  Use with care in the  presence of renal insufficiency and hypertension.
All patients will be seen as deemed necessary by their own consultant, but this must include a visit at two weeks to  assess 
initial response to  therapy and thereafter a t  3 monthly intervals. Referring consultants will be asked to fill in standardised 
progress report forms and send them back to the  trial centre in Bath after each of these consultations. The patient's psychomotor 
development will be assessed by a te lephone questionnaire administered by the  trial centre in Bath at 12 -14 months of age. 
Parents will be required to  keep a diary until their child reaches 12 -14 months of age. There should be a daily entry for 28 days 
after the  start of trea tm en t and weekly after tha t  until the  12-14 month development assessment. In those children still having 
any form of seizure at 12 -14 months, a daily entry will be obtained for the  final week.
If you have any questions or concerns, or would like any further information on this study please to  not hesitate to  contact:
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park 
BATH BA13NG
Trial Centre Tel: 01225 824206
Randomisation Tel: 01225 824490 (8.30am to 6pm)
(answer machine 6pm to 8.30am) 
Fax: 01225 824206 or 01225 824212
24 hour number for hospital: 01225 428331
Please send this sheet to the patient's general practitioner
UKISS/GPIF/1/399
The United Kingdom In fantile  Spasm Study
Patient’s information sheet
W e w o u ld  like t o  invite  you  t o  p a r t i c ip a te  in a re se a rch  s tu d y  w h ich  aim s t o  f ind  t h e  m o s t  e f fec t iv e  w a y  o f  
t r e a t i n g  in fa n t i le  spasm s. Your d o c to r  will h av e  g iven  you  so m e  in f o rm a t io n  a b o u t  in fan t i le  spasm s. T h ese  a re  
a t y p e  o f  f i t  (or se izu re  or  convu ls ion  o r  epilepsy)  w h ich  occur  in b a b ie s  o r  y o u n g  in fan ts .  They a r e  n o t  very 
c o m m o n  a n d  a r e  o f t e n  difficult  t o  t r e a t .
T he  fits cons is t  o f  r e p e a t e d  a t ta c k s  o f  s u d d e n  b r ie f  m o v e m e n ts .  T he  a rm s  m ay  b e  t h r o w n  in t h e  air  a n d  t h e n  
b r o u g h t  back  like a cu d d le .  T he  child o f t e n  b e n d s  d o u b le  b u t  m ay  je rk  bac k w ard s .  O f te n  lots o f  th e s e  fits occur  
o n e  a f t e r  a n o t h e r  - w h ich  w e  call a b a tc h  o f  fits. T h e re  is t h e n  a g a p  w i th  n o rm a l  ac tivity  b e f o r e  t h e  n e x t  b a tch .  
O ccasionally  t h e  fits m ay  occur  individually. You m a y  n o t ic e  t h a t  t h e y  h a p p e n  m o r e  o f t e n  a t  ce r ta in  t im es ,  fo r  
e x a m p le ,  w h e n  y o u r  child is w a k in g  u p  o r  w h e n  h e /sh e  is t i r e d .
It is o f t e n  d iff icu lt  t o  realise t h a t  t h e  m o v e m e n t s  a re  fits. It m ay  s e e m  as if y o u r  child h a d  colic o r  a n o rm a l  
s ta r t le  reflex. It is t h e r e f o r e  h e lp fu l  fo r  t h e  d o c to rs  a n d  n u rses  t o  se e  a n  a t tac k .  Your child will n e e d  a n  EEG (this 
m ay  h a v e  h a p p e n e d  a lready) .  An EEG m e a s u re s  t h e  elec trica l activ ity  o f  t h e  b ra in .  You will g o  w i th  y o u r  child t o  
a specia l q u i e t  ro o m .  A te ch n ic ia n  will stick discs t o  y o u r  child's h e a d .  It d o e s  n o t  h u r t .  Leads co m in g  o u t  f ro m  
t h e  discs will t h e n  m e a s u r e  t h e  e lectrica l ac tivity  o f  t h e  b ra in .  You will h av e  t o  w a s h  y o u r  child's ha i r  a f te rw a rd s .
S o m e t im e s  in fa n t i le  spasm s occur a n d  w e  d o n ' t  k n o w  why, b u t  o f t e n  t h e r e  is a cause .  To f ind  t h e  c a u se  w e  will 
e x a m in e  y o u r  child  a n d  d o  tes ts .  T hese  te s ts  m ay  b e  d o n e  ev e n  if y o u r  child d o e s  n o t  e n t e r  t h e  study.
1. W e  will look  in you r  child's eyes  w i th  a specia l l igh t  (an  o p h th a lm o s c o p e ) .  W e o f t e n  use  eye  d ro p s  
w h ich  m a k e  t h e  pupils  b ig g e r  t o  m a k e  th is  easier.
2. W e will look  a t  y o u r  child's skin w i th  a specia l u l t ra v io le t  light.  This is c o m p le te ly  harm less .
3. W e will d o  a scan o f  t h e  bra in ,  w h ich  m ay  r e q u i r e  a s h o r t  a n a e s th e t i c .
4. W e will t a k e  a u r in e  sam ple .
5. W e  will a lso  t a k e  a s a m p le  o f  b lo o d .  The g e n e s  w e  in h e r i t  f ro m  o u r  p a r e n t s  d e t e r m in e  h o w  w e
g r o w  a n d  d ev e lo p .  S o m e t im e s  g e n e s  also  ca u se  m ed ica l  c o n d i t io n s  a n d  illnesses. W e w o u ld  like t o  
f ind  o u t  if in fan t i le  spasm s a r e  an  illness c a u se d  by g e n e s .  To d o  th is  w e  will n e e d  t o  se n d  a small 
a m o u n t  o f  b lo o d  to  a l a b o ra to r y  in L ondon  w h e r e  o u r  c o l le a g u e s  will e x t ra c t  t h e  g e n e t i c  m a te r ia l  
f ro m  t h e  b lo o d .  Any g e n e t ic  m a te r ia l  w e  e x t r a c t  f ro m  y o u r  child's b lo o d  will on ly  be  used  fo r  th is  
s tu d y  bu t,  in line w ith  r e c o m m e n d a t io n s  o f  t h e  Royal College o f  Patho logists ,  h u m a n  DNA e x t ra c te d  
f ro m  b lo o d  sam p les  will b e  k e p t  p e r m a n e n t l y  a t  t h e  l a b o ra to r y  in L ondon .
6. S o m e  b lo o d  m ay  also b e  t a k e n  t o  m e a s u r e  s te ro id  levels.
O n ce  w e  a r e  su re  t h a t  th e s e  a r e  in fan t i le  spasm s w e  h a v e  t o  s ta r t  t r e a t m e n t .  W e  d o n ' t  k n o w  t h a t  it is im p o r t a n t  
t h a t  w e  s t a r t  t h e  m ed ic ines  as quickly as possib le , b u t  in case  it is im p o r t a n t  w e  will s ta r t  t h e  t r e a t m e n t  as so o n  
as w e  a re  c e r ta in  t h a t  y o u r  child n e e d s  t r e a t m e n t .
S o m e t im e s  w h e n  th e s e  fits s t a r t  y o u r  child 's d e v e lo p m e n t  m ay  s to p  o r  you  m ay  f ind  t h a t  th e y  f o r g e t  t h in g s  t h a t  
th e y  h av e  a l r e a d y  le a rn t .  Your d o c to r  will ta lk  t o  y ou  in m o r e  d e ta i l  a b o u t  th is  as it varies  g re a t ly  b e t w e e n  
ch i ld ren .
O n e  o f  t h e  m o s t  d ifficu lt  p ro b le m s  w i th  in fan t i le  spasm s is t h e  t r e a t m e n t .  In t h e  p a s t  a n t i -e p i le p t ic  d ru g s  h av e  
n o t  b e e n  very  g o o d  a t  s to p p in g  th e s e  ty p e s  o f  fits. So in s te a d  d i f f e r e n t  ty p e s  o f  s te ro id  ( t r e a t m e n t  by m o u th  o r  
in jection) h a v e  b e e n  used. S tero ids  will s to p  t h e  spa sm s  in ju s t  o v e r  ha l f  o f  p a t ie n t s .  U n fo r tu n a te ly  t h e  fits can  
c o m e  back. O n e  n e w  an t i -e p i le p t ic  d r u g  is n o w  av a i la b le  w h ich  m ay  b e  g o o d  a t  s to p p in g  t h e  fits. It is ca lled  
v ig a b a tr in .  W e  n e e d  t o  k n o w  if v ig a b a t r in  o r  o n e  o f  t h e  s te ro id s  is t h e  bes t  t r e a t m e n t .
Co n t  i n u e d o y ^ ^ ^ s
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W e w o u ld  like t o  ask y o u  to  t a k e  p a r t  in th is  s tu d y  t o  f ind  o u t  w h ich  o f  t h e  t r e a t m e n t s  is bes t .  If w e  k n e w  w hich  
w a s  best,  w e  w o u ld  n o t  b e  d o in g  t h e  study. If fo r  an y  r e a so n  y ou  w o u ld  p re fe r  n o t  t o  t a k e  p a r t  in t h e  s tu d y  w e  
will r e sp e c t  t h a t  dec is ion  a n d  t h e  ca re  t h a t  y o u r  child receives will n o t  b e  a f f e c te d .
If you  d e c id e  t o  t a k e  p a r t  in th is  s tu d y  y o u r  child will g iven  o n e  o f  t h e  fo l lo w in g  t h r e e  d rugs .
1. S y n a c th e n  D e p o t .  This is g iven  by in jec t ion  o n  a l t e r n a t e  days  fo r  t w o  w ee k s .  It te lls  y o u r  child's 
o w n  b o d y  t o  m a k e  m o r e  n a tu ra l  s te ro id s  t h a n  usual.
2. P re d n iso lo n e .  This is a t y p e  o f  n a tu ra l  s te ro id  w h ich  is t a k e n  by m o u th  3 o r  4  t im e s  a day  fo r  t w o  
w ee k s .
3. V ig ab a tr in .  This is an  a n t i -e p i le p t ic  d ru g  w h ich  is t a k e n  by m o u th  2 t im e s  a d a y  f o r  t w o  w eeks .
Your child will receive  o n e  o f  th e s e  d ru g s  fo r  tw o  w ee k s .  A f te r  2 w e e k s  y o u r  child will b e  s e e n  by y o u r  docto r .  
If t h e  fits h a v e  s to p p e d  t h e n  y o u r  child will:
•  if o n  v ig a b a tr in ,  c o n t in u e  o n  w i th  t h e  t r e a t m e n t  until t h e y  a r e  a b o u t  12 -14 m o n th s  o ld  if t h a t  is you r  
d o c to r 's  n o rm a l  p rac tice .
•  if o n  s y n a c th e n  d e p o t  o r  p re d n iso lo n e ,  b e  g iven  o ral p r e d n i s o lo n e  fo r  15 m o r e  days a t  a lo w e r  dose .
A f te r  2 w ee k s ,  if t h e  spasm s  h a v e  n o t  s t o p p e d  y o u r  child will b e  c h a n g e d  t o  a d i f f e r e n t  t r e a t m e n t  t o  see  if t h a t  
helps.
Your child will b e  se e n  by y o u r  d o c to r  a t  leas t  every  t h r e e  m o n th s  (m o re  o f t e n  if necessary)  t o  check  p rog ress .  
If t h e r e  a re  p ro b le m s  w i th  t h e  spasm s o r  t h e  m e d ic in e  p le a se  te ll y o u r  doc to r .
W h e n  y o u r  child  is a b o u t  12 -14 m o n th s  o f  a g e  t h e n  w e  will c o n ta c t  y ou  by p h o n e  t o  check  o n  y o u r  child 's 
p rog ress .  This will t a k e  b e t w e e n  15 a n d  30 m in u te s  t o  c o m p le te .
D uring  t h e  s tu d y  w e  will also  ask y ou  to  fill in a diary. This will t a k e  ju s t  a c o u p le  o f  m in u te s  a day. W e will ask 
you  t o  m a rk  if y o u r  child has  h a d  an y  fits t h a t  day  o r  an y  o t h e r  illness. W e will ask you  t o  r e tu r n  t h e  d iary  a t  t h e  
e n d  o f  t h e  study, b u t  y ou  m ay  k e e p  a copy  if you  w a n t .  It will b e  a p e r m a n e n t  rec o rd  o f  y o u r  child 's p rog ress .
If w e  d o  n o t  d o  th is  s tu d y  w e  will n e v e r  lea rn  w h ich  t r e a t m e n t  is bes t .  If w e  k n e w  n o w  w h ic h  t r e a t m e n t  w as  
be s t  t h e n  w e  w o u ld  n o t  b e  d o in g  t h e  study. It will t a k e  all, o r  n ea r ly  all, o f  t h e  ch i ld ren  in t h e  UK t o  a g r e e  t o  t h e  
s tu d y  fo r  a b o u t  18 m o n th s  b e f o r e  w e  e x p e c t  t o  k n o w  w h ich  is t h e  b e s t  t r e a t m e n t .  T h e n  w e  can  give t h e  b es t  
t r e a t m e n t  t o  all ch i ld ren  w i th  in fan t i le  spasm s. This is t h e  usual w a y  d o c to rs  s tu d y  d r u g s  t o  se e  w h ich  o n e s  a re  
bes t.
The in f o rm a t io n  co l lec ted  o n  y o u r  child will b e  k e p t  by t h e  d o c to rs  in c h a r g e  o f  t h e  s tudy. T hey  will k e e p  it s a fe  
in locked  f il ing  cab ine ts .  S o m e  in f o rm a t io n  will b e  k e p t  o n  c o m p u te r :  it will b e  p r o t e c t e d  by a s e c re t  p as sw o rd .
If you  w a n t  t o  ask a b o u t  t h e  in f o rm a t io n  o r  t o  ask a n y  o t h e r  q u e s t io n s  ask y o u r  local specia list .  W e will se n d  
y ou  a n e w s  le t t e r  every  f e w  m o n th s ,  th is  will tell you  h o w  t h e  s tu d y  is g o in g .
If y o u  n e e d  to ,  you  can  c o n ta c t  y o u r  specialist:
His / Her n a m e  is: ....................................................................................................................................
Address:......... ....................................................................................................................................
T e l e p h o n e  No: ................................................................................................................
If y ou  n e e d  t o  you  can  also c o n ta c t  t h e  d o c t o r  in c h a r g e  o f  t h e  s tudy:
Prof J. O s b o rn e  
T he  UKISS Trial C e n tre  
T he Child ren 's  C e n tre  
Royal U n ited  Hospital 
C o m b e  Park 
BATH BA1 3NG
Tel: 01225  824206  b u t  p le a s e  ta lk  to  y o u r  lo c a l s p e c ia l is t  f ir s t .
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The United Kingdom In fantile  Spasm Study
Patient information sheet — Prednisolone
D ear  p a r e n t  /  g u a r d ia n ,
T h a n k  y ou  fo r  p a r t i c ip a t in g  in t h e  UKISS study. Your child m ay  b e  c h o s e n  t o  rece ive  p re d n is o lo n e  e i th e r  as th e i r  
f irst d r u g  in th is  s tu d y  o r  b e c a u s e  v ig a b a tr in  d id n o t  s to p  t h e i r  spasm s. H opefu lly  th is  in fo rm a t io n  s h e e t  will 
a n s w e r  a n y  q u e s t io n s  you  h av e  a b o u t  p r e d n is o lo n e  a n d  its use. If y o u  h a v e  an y  o t h e r  q u e s t io n s  o r  t h e r e  is 
an y th in g  t h a t  y ou  d o  n o t  u n d e r s t a n d  ask y o u r  d o c to r  now .
W hat is prednisolone?
P re d n iso lo n e  is t h e  chem ica l  n a m e  fo r  a ty p e  o f  s te ro id  t h a t  o u r  b o d ie s  p r o d u c e  natura lly .  It is also 
a v a i la b le  as a m ed ic in e .  It is m a d e  by a d r u g  c o m p a n y  (Glaxo) w h o  call t h e i r  b r a n d  o f  t h e  d r u g  P redneso l 
(in t h e  s a m e  w a y  t h a t  N estle  call t h e i r  c o f fe e  Nescafe).
How do I give it?
It co m e s  in t a b l e t  fo rm .  Each small p ink  t a b l e t  c o n ta in s  5m g  p re d n is o lo n e .  It is t a k e n  by m o u th  e i th e r  3 o r  
4 t im e s  a day. T hey  can  e i th e r  b e  c ru sh e d  a n d  sp r ink led  o n  f o o d  o r  can  b e  d isso lved  in w a t e r  (or squash).
They  m ay  b e  t a k e n  b e fo re ,  d u r in g  o r  a f t e r  meals .
How much do I give?
For t h e  first w e e k  o f  t r e a t m e n t  you  will g ive 10m g f o u r  t im e s  a d ay  (2 t a b le t s  f o u r  t im e s  a day). If a t  t h e  
e n d  o f  t h e  firs t  w e e k  y o u r  child's spasm s h a v e  n o t  s to p p e d  t h e n  y o u r  d o c to r  will te ll you  t o  inc rease  t h e  
d o s e  t o  2 0 m g  t h r e e  t im e s  a d ay  (4 t a b le t s  t h r e e  t im e s  a day). A f te r  t h e  t w o  w e e k s  you  will n e e d  to  r e d u c e  
t h e  d o se  o f  p re d n is o lo n e .  Your d o c to r  will exp la in  h o w  t o  d o  th is .  The a m o u n t  o f  m e d ic in e  n e e d e d  d o e s  
n o t  d e p e n d  on  y o u r  child 's w e ig h t  o r  ag e .
If t h e  spasm s s ta r t  a g a in  you  d o c to r  m ay  ask you  t o  r e p e a t  t h e  c o u rse  o f  s te ro ids .
If y o u r  child acc id en ta l ly  ta k e s  t o o  m uch  P redneso l ,  te ll y o u r  d o c t o r  im m e d ia te ly  o r  g o  t o  y o u r  n e a r e s t  
ca sua lty  d e p a r t m e n t .
If y ou  f o r g e t  t o  g ive  a d o se  g ive a n o t h e r  as so o n  as y ou  r e m e m b e r ,  un less  it is a lm o s t  t im e  fo r  th e i r  n ex t  
d ose ,  t h e n  g o  o n  as b e fo re .
Are there any side e f fec ts?
As w ith  all m e d ic in es  so m e  side e ffec ts  m a y  occur. T he  m o s t  c o m m o n  s ide  e f fec ts  o f  p r e d n i s o lo n e  a re  
irri tabili ty  a n d  c h a n g e s  in s leep in g .  T hese  will im p ro v e  o n c e  t h e  s te ro id s  a r e  s to p p e d .
Your d o c to r  ( e i th e r  y o u r  GP o r  a d o c to r  f ro m  t h e  hosp ita l)  will n e e d  t o  see  y o u r  child o n c e  a w e e k  t o  check  
t h e i r  b lo o d  p re s su re  a n d  urine.
B ecause  w e  on ly  u se  t h e  s te ro id s  fo r  a s h o r t  t im e ,  th e y  d o  n o t  c a u se  long  las t ing  effec ts .  For ex a m p le ,  y o u r  
child will n o t  s to p  g r o w in g  as an  e f fec t  o f  t h e  s te ro ids .
W hat do I do if my child has any side e ffects?
C o n ta c t  y o u r  d o c t o r  (GP) im m edia te ly .  H e/she will adv ise  y ou  o n  w h e t h e r  t o  c o n t in u e  t h e  p r e d n is o lo n e  o r  
w h e t h e r  y ou  n e e d  t o  s to p  t h e  p re d n iso lo n e .  If y ou  h a v e  t o  s to p  t h e  p r e d n i s o lo n e  you  m u s t  see  y o u r  
child 's p a e d ia t r i c ia n  as so o n  as possib le  so h e /sh e  can  g ive y ou  s o m e  d i f f e r e n t  m e d ic in e  t o  s to p  th e  
spasm s. You s h o u ld  also  w r i te  d o w n  t h e  p r o b le m  in y o u r  ' f i t  d ia ry ' .
W hat do I do if  my child becomes ill?
If y o u r  child b e c o m e s  unw ell  in an y  w a y  o r  if you  h a v e  an y  c o n c e rn s  you  s h o u ld  c o n ta c t  y o u r  d o c to r  (GP) 
im m ed ia te ly .  If y o u r  child d e v e lo p s  ch ick e n p o x  o r  is in c o n ta c t  w i th  a n o t h e r  child w h o  d e v e lo p s  
ch ick e n p o x  y ou  m u s t  c o n ta c t  y o u r  d o c to r  im m ed ia te ly .
Immunisations:
Your child s h o u ld  n o t  h av e  th e i r  im m u n isa t io n s  (vaccina tions,  jabs)  w hils t  t h e y  a r e  on  t h e i r  s te ro ids .  They
s h o u ld  h a v e  th e i r  im m u n isa t io n s  o n c e  th e y  h a v e  c o m p le te ly  f in ish e d  th e i r  co u rse  o f  s te ro id s .
UKISS/PDIF/1/399/P
The United Kingdom Infantile Spasm Study
Patient information sheet — Vigabatrin
Dear p a r e n t  /  g u a r d ia n ,
Thank y o u  f o r  p a r t i c ip a t in g  in t h e  UKISS study. Your child m ay  b e  c h o s e n  t o  rece ive  v ig a b a t r in  e i th e r  as th e i r  
first d ru g  in th is  s tu d y  o r  b e c a u s e  t h e  s te ro id  t r e a t m e n t  d id n o t  s to p  th e i r  spasm s. H opefu lly  th is  in fo rm a t io n  
sh e e t  will a n s w e r  a n y  q u e s t io n s  y ou  h av e  a b o u t  v ig a b a tr in  a n d  its use. If you  h a v e  any  o t h e r  q u e s t io n s  o r  t h e r e  
is a n / t h i n g  t h a t  y ou  d o  n o t  u n d e r s t a n d  t h e n  ask y o u r  d o c to r  now .
What is vigabatrin?
V igaoa tr in  is t h e  chem ica l  n a m e  o f  t h e  d ru g .  It is m a d e  by a d r u g  c o m p a n y  (H oechs t  M ario n  Roussel) w h o  
call th e i r  b r a n d  o f  t h e  d r u g  Sabril (in t h e  s a m e  w a y  t h a t  N estle  call t h e i r  c o f fe e  Nescafe).
How do I give it?
It com es in sache ts .  Each s a c h e t  c o n ta in s  500 m g  v ig a b a t r in  as a w h i t e  p o w d e r .  Do n o t  o p e n  t h e  s a c h e t  
until it is t im e  t o  g ive  t h e  m ed ic in e .  It is t a k e n  by m o u th  (orally) t w o  t im e s  a day. It can  b e  sp r ink led  o n  
fo o d  o r  d isso lved  in a d r in k  (for e x a m p le  w ate r ,  squash ,  milk, te a ) .  It m ay  b e  t a k e n  b e fo re ,  d u r in g  o r  a f t e r  
meals.
How much do I give?
Your d o c t o r  will w o rk  o u t  h o w  m uch  o f  t h e  m e d ic in e  y o u r  child has  t o  ta k e .  T he  a m o u n t  n e e d e d  d e p e n d s  
o n  how  m u c h  y o u r  child w e ig h s .  W e will bu ild  u p  t h e  a m o u n t  o f  v ig a b a t r in  y o u r  child t a k e s  o v e r  t h e  first 
t w o  days. A f t e r  f o u r  days  w e  m ay  inc rease  t h e  d o se  f u r th e r  if y o u r  child's spasm s h av e  n o t  s to p p e d .  It m ay  
also oe n ecessa ry  t o  inc rease  t h e  d o s e  la te r  in t h e  tr ia l if t h e  spasm s  s t a r t  a g a in  o r  as y o u r  child increases  
in w e igh t .  You d o  n o t  n e e d  t o  w o rry  a b o u t  this , y o u r  d o c to r  will w o rk  o u t  h o w  m u ch  m e d ic in e  is n e e d e d  
a n d  will te ll y o u  h o w  m u c h  t o  g ive t o  y o u r  child.
If your child a c c id en ta l ly  t a k e s  t o o  m uch  v ig a b a tr in ,  te ll y o u r  d o c to r  im m e d ia te ly  o r  g o  t o  y o u r  n e a r e s t  
casualty  d e p a r t m e n t .
If you f o r g e t  t o  g ive a d o s e  g ive a n o t h e r  as so o n  as you  r e m e m b e r ,  un less  it is a lm o s t  t im e  fo r  th e i r  n ex t  
d o s e  t h e n  g o  on  as b e fo re .
Are there any side e ffects?
As w t h  all m e d ic in es  s o m e  side e f fec ts  m ay  occur. T he  m o s t  c o m m o n  side e f f e c t  o f  v ig a b a t r in  is 
s leepiness. This usua lly  w e a r s  off  a f t e r  a f e w  days. O ccasionally  y o u r  child m ay  v o m it  (b e  sick). Recently, 
som e a d u l t s  t r e a t e d  w i th  v ig a b a t r in  h a v e  b e e n  f o u n d  t o  h a v e  visual f ield  d e fe c ts  (difficulty  in se e in g  
a ro u n d  t h e  e d g e  o f  t h e i r  n o rm a l  a r e a  o f  vision). This m ay  b e  m o r e  likely if t r e a t m e n t  c o n t in u e s  fo r  a long  
t im e  O th e r  s ide  e f fec ts  a r e  very rare .
What do I do if  my child has any side effects?
Contac t  y o u r  d o c to r  (GP) im m ed ia te ly .  H e/she will adv ise  y ou  o n  w h e t h e r  t o  c o n t in u e  t h e  v ig a b a t r in  o r  
w h e th e r  y ou  n e e d  t o  s to p  t h e  v ig a b a tr in .  If y ou  h av e  t o  s to p  t h e  v ig a b a t r in  y ou  m u s t  se e  y o u r  child 's 
p ae c ia t r ic ia n  as so o n  as possib le  so h e /sh e  can  g ive y ou  s o m e  d i f f e r e n t  m e d ic in e  t o  s to p  t h e  spasm s. You 
s h o u d  a lso  w r i te  d o w n  t h e  p r o b le m  in y o u r  'f i t  d ia ry ' .
What do I do if my child becomes ill?
If your child  b e c o m e s  u n w e ll  in an y  w a y  o r  if you  h a v e  any  co n c e rn s  y ou  s h o u ld  c o n ta c t  y o u r  d o c to r  (GP) 
im m ediate ly .
The United Kingdom Infantile Spasm Study
Patient Information Sheet - Synacthen Depot
D e a r  p a r e n t / g u a r d i a n ,
T h a n k  y o u  fo r  p a r t ic ip a t in g  in t h e  UKISS study. Your child m ay  b e  ch o sen  t o  rece ive  S y n a c th e n  D e p o t  e i th e r  as 
t h e i r  f irs t  d r u g  in th is  s tu d y  o r  b e c a u s e  v ig a b a tr in  d id n o t  s to p  th e i r  spasm s. H opefu lly  th is  in fo rm a t io n  s h e e t  
will a n s w e r  any  q u e s t io n s  y ou  h av e  a b o u t  S y n ac th en  D e p o t  a n d  its use. If y o u  h a v e  an y  o t h e r  q u e s t io n s  o r  t h e r e  
is a n y t h in g  t h a t  you  d o  n o t  u n d e r s t a n d  ask y o u r  d o c to r  now .
W hat is Synacthen Depot?
S y n a c th e n  D e p o t  is t h e  t r a d e  n a m e  fo r  a m a n u f a c tu r e d  m e d ic in e  w h ich  is a t y p e  o f  h o r m o n e  o u r  b od ie s  
p r o d u c e  n a tu ra l ly  (a t y p e  o f  a d r e n o c o r t ic o t ro p h ic  h o r m o n e ) .  This h o r m o n e  causes  t h e  p ro d u c t io n  o f  n a tu ra l  
s te ro id s  by t h e  body. It is m a d e  by a d r u g  c o m p a n y  w h o  call t h e i r  b r a n d  o f  t h e  d ru g  S y n ac th en  D e p o t  (in t h e  
s a m e  w a y  t h a t  N estle  call th e i r  co f fee  Nescafe).
How will i t  be given?
It is g iv e n  as  an  in t ra m u sc u la r  ( in to  t h e  m uscle - usually  t h e  t o p  o f  t h e  leg) in jection ,  o n  a l t e r n a t e  days by a 
t r a i n e d  m ed ica l  p e r so n  (your d o c to r  o r  nurse).
Are there  any side effects?
As w i th  all m ed ic ines  s o m e  side e f fec ts  m ay  occur. T he  m o s t  c o m m o n  s ide  e f fec ts  a re  irritabili ty  a n d  c h a n g e s  
in s le e p in g .  T hese  will im p ro v e  o n c e  t h e  s te ro id s  a r e  s to p p e d .
Your d o c t o r  will ask y ou  a b o u t  an y  k n o w n  a l le rg ie s  b e c a u s e  S y n a c th e n  D e p o t  can  u p s e t  ch i ld ren  w ith  
a l le rg ies .
Your d o c t o r  (e i th e r  y o u r  GP o r  a d o c to r  f ro m  t h e  hosp i ta l)  will n e e d  t o  see  y o u r  child o n c e  a w e e k  t o  check  
th e i r  b lo o d  p re ssu re  a n d  urine .
B ecause  w e  only  use  t h e  s te ro id s  fo r  a s h o r t  t im e ,  th e y  d o  n o t  c a u se  long  last ing  effec ts .  For ex a m p le ,  y o u r  
child will n o t  s to p  g r o w in g  as an  e f fec t  o f  t h e  s te ro ids .
W hat do I do if  my child has any side effects?
C o n ta c t  y o u r  d o c to r  (GP) im m edia te ly .  If you  h a v e  t o  s to p  t h e  S y n ac th en  D e p o t  you  m u s t  s e e  y o u r  child 's 
p a e d ia t r i c ia n  as so o n  as poss ib le  so h e /sh e  can  g ive you  s o m e  d i f f e r e n t  m e d ic in e  t o  try  t o  s to p  t h e  spasm s.
You sh o u ld  also  w r i te  d o w n  t h e  p r o b le m  in y o u r  'f i t  d ia ry '
W hat do I do if my child becomes ill?
If y o u r  child  b e c o m e s  u nw ell  in an y  w a y  o r  if you  h a v e  a n y  co n c e rn s  you  s h o u ld  c o n ta c t  y o u r  d o c to r  (GP) 
im m ed ia te ly .  If y o u r  child d e v e lo p s  c h ick e n p o x  o r  is in c o n ta c t  w i th  a n o t h e r  child w h o  d e v e lo p s  ch ick e n p o x  
y o u  m u s t  c o n ta c t  y o u r  d o c t o r  im m edia te ly .
Immunisations:
Your child  sh o u ld  n o t  h a v e  th e i r  im m u n isa t io n s  (vaccina tions,  jabs)  w h ils t  t h e y  a re  o n  th e i r  s te ro ids .  They 
s h o u ld  h a v e  th e i r  im m u n isa t io n s  o n c e  th e y  h a v e  c o m p le te ly  f in ish e d  t h e i r  c o u rse  o f  s te ro ids .
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Consent Check List for the UKISS Drug Trial
This check list must be com pleted prio r to  random isation and kept in this fo lde r 
C hild 's  full n a m e  (BLOCK CAPITALS):
D a t e  o f  b ir th :  Day/ M o n th /  Year/
Please tick ✓ ONE box on EACH line
1. Have you given th e  parents / guardians an oral explanation of th e  proposed research project?
2. Did y o u r  oral e x p la n a t io n  t o  t h e  p a r e n t s  /  g u a r d ia n s  inc lude:
•  t h a t  th is  is a r e se a rch  p ro je c t?
•  p a r t i c ip a t io n  is v o lu n ta r y ?
•  t h e  a im s o f  t h e  p r o je c t?
•  t h e  d u r a t i o n  o f  t h e  s u b je c t  in v o lv e m e n t?
•  t h e  n a t u r e  o f  t h e  d r u g s  b e in g  t e s t e d ?
•  t h a t  a re fusa l  t o  p a r t i c ip a te  m ay  b e  g iven  w i t h o u t  re a so n s  a n d  will n o t  a f fe c t  
t h e  ca re  w h ich  will b e  g iven  t o  t h e  child?
•  t h a t  t h e  su b je c t  m a y  b e  w i th d r a w n  f ro m  t h e  s tu d y  if t h e  in v e s t ig a t in g  
p a e d ia t r i c ia n  c o n s id e rs  th is  is necessary  in t h e  b e s t  in te re s ts  o f  t h e  child?
•  t h a t  p e r so n a l  in f o rm a t io n  m ay  b e  sc ru tin ised  by p ro p e r ly  a u th o r i s e d  p e o p le ,  
b u t  all p e r so n a l  in f o rm a t io n  will b e  t r e a t e d  as strictly c o n f id e n t ia l  a n d  will 
n o t  b e  m a d e  publicly av a i la b le ?
•  t h a t  t h e  in f o rm a t io n  g e n e r a t e d  by t h e  s tu d y  m ay  b e  p u b l is h e d  b u t  t h a t  no  
de ta i ls  will b e  d iv u lg e d  f ro m  w h ich  t h e  su b je c t  cou ld  b e  id e n t i f ie d ?
•  w h o m  t o  c o n ta c t  in a n  e m e r g e n c y ?
3- Have you  g iven  t h e  in f o rm a t io n  s h e e t  t o  t h e  p a r e n t s /g u a rd ia n s ?
4- H ave y ou  to ld  t h e  p a r e n t s /g u a r d i a n s  t h a t  t h e y  will b e  k e p t  in fo rm e d  o f  r e le v a n t  
in f o rm a t io n  w h ich  b e c o m e s  a v a i la b le  d u r in g  t h e  co u r se  o f  t h e  s tu d y ?
5- H ave y ou  a l lo w e d  t h e  p a r e n t s  / g u a r d ia n s  su ff ic ien t  t im e  t o  co n s id e r  t h e  m a t t e r  o n  t h e  
o w n ,  t o  discuss w i th  o th e r s  if w ish e d ,  o r  t o  ask y ou  q u e s t io n s ?
6. In y o u r  o p in io n ,  h a v e  t h e  p a r e n t s  /  g u a r d ia n s  u n d e r s to o d  a n d  c o n s e n te d  f o r  th e i r  child 
t o  t a k e  p a r t  in th is  r e se a rc h ?
N a m e  o f  in v e s t ig a to r  o b t a in in g  c o n s e n t
S ig n ed :  ....................................................................................................................
PRINT n a m e :  ................................................................................................... ................................................
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The United Kingdom In fantile  Spasm Study
FORM A: CONSENT FOR DRU TRIAL
CONSENT SY THE PARENT /  GUARDIAN
P a t ie n ts  full n a m e  (BLOCK CAPITALS):
D a te  o f  b ir th :  Day/ M o n th /  Year/
A ddress :
I hereby fu lly  and freely  consent to  a llow  my child to  participate in the UKISS tria l.
(P lease  tick /  a p p r o p r i a t e  boxes)
H ave y ou  r e a d  t h e  p a t i e n t  in f o rm a t io n  s h e e t?  Yes No
Have y ou  h a d  a n  o p p o r tu n i ty  t o  ask q u e s t io n s  a n d  discuss th is  s tu d y ?  Yes No □
Have y o u  rece ived  sa t is fac to ry  a n s w e rs  t o  all y o u r  q u e s t io n s ?  Yes ! No □
Have y ou  rece ived  e n o u g h  in f o rm a t io n  a b o u t  t h e  s tu d y ?  Yes No J
I a g r e e  t h a t  my g e n e r a l  p ra c t i t io n e r  a n d  hosp i ta l  c o n s u l t a n t  a r e  n o t i f ie d  o f  my child 's p a r t ic ip a t io n  in t h e  
tr ia l  a n d  t h a t  t h e y  m ay  re le ase  in f o rm a t io n  o n  my child 's p a s t  m ed ica l  history.
I u n d e r s t a n d  a n d  a c k n o w le d g e  t h a t  t h e  tr ia l  is d e s ig n e d  t o  p r o m o te  m ed ica l  k n o w le d g e .
I u n d e r s t a n d  t h a t  s o m e  in fo rm a t io n  will b e  k e p t  o n  c o m p u te r  in p a s sw o rd  p r o t e c t e d  files.
I u n d e r s t a n d  t h a t  I m ay  w i th d r a w  my c o n s e n t  a t  an y  s t a g e  in t h e  tr ia l.  I u n d e r s t a n d  t h a t  I d o  n o t  h a v e  to  
g ive  a r e a so n  fo r  w i th d r a w in g .  I u n d e r s t a n d  t h a t  th is  w o u ld  n o t  a f fe c t  t h e  ca re  t h a t  my child receives.
I a c k n o w le d g e  t h e  p u r p o s e  o f  t h e  trial a n d  t h e  risks involved f ro m  t h e  p ro c e d u re s  t h a t  m ay b e  u n d e r ta k e n .  
T h e  n a t u r e  a n d  p u r p o s e  o f  t h e  tr ia l  has  b e e n  g iven  t o  m e  in a n  in f o rm a t io n  s h e e t  a n d  has  b e e n  ex p la in e d  
t o  m e  by:
a n d  I h a v e  d iscussed  th e s e  m a t t e r s  w i th  h im/her.
S igned : Date :
N am e  (PRINT):
W itn ess  (signature):
N am e  (PRINT):
P a r e n t  / G u a rd ia n  (Please ring as appropria te)
D E C L A R A T I O N  S Y  T H E  I N V E S T I G A T O R  
I c o n f irm  t h a t  I h a v e  p r o v id e d  a n  in fo rm a t io n  s h e e t  a n d  e x p la in e d  t h e  n a t u r e  a n d  e f f e c t  o f  t h e  tr ia l  t o  t h e  
p a r e n t  /  g u a r d ia n  a n d  t h a t  c o n s e n t  has  b e e n  g iven  f ree ly  a n d  vo luntarily .
S igned :
N am e  (PRINT):
S ta tus : Hospita l n a m e :
I u n d e r s t a n d  t h a t  s o m e  in f o rm a t io n  will b e  k e p t  o n  c o m p u te r  in p a s sw o rd  p r o t e c t e d  files. 
P le a se  r e tu r n  a  p h o t o c o p y  o f  th is  fo r m  to :
U KISS/DC/1/399
T he UKISS Trial C e n tre  
T he  C h ild ren 's  C e n tre  
Royal U n i te d  Hospita l 
C o m b e  Park 
BATH BA1 3NG
01367
The Unit ed Kingdom In fantile  Spasm Study
FORM CONSENT FOR EPIDEMIOLOGY STUDY
CONSENT BY THE PARENT /  GUARDIAN
Patients  fu ll  n a m e  (BLOCK CAPITALS):
Date o f  b ir th :  Day/ M o n th /  Year/
Address:
I h a v e  c h o s e n  n ot t o  a l lo w  my child  t o  p a r t i c ip a te  in t h e  UKISS d r u g  tr ial.  H o w e v e r  in o r d e r  t o  a l lo w  t h e  
inves tiga to rs  t o  lea rn  m o r e  a b o u t  in fa n t i le  spa sm s  I a g r e e  t o  a l lo w  my clinician t o  g ive t h e  in v e s t ig a to rs  t h e  
fo l low ing  in f o rm a t io n  a b o u t  my child:
1. D e t a i l s  a b o u t  m y  c h i l d ’s  s p a s m s ,  f o r  e x a m p l e  w h a t  a g e  t h e y  
s t a r t e d ,  h o w  m a n y  o c c u r  in  a  d a y  a n d  w h i c h  m u s c l e s  t h e y  i n v o lv e .
2 .  D e t a i l s  a b o u t  m y  c h i l d ’s  d e v e l o p m e n t .
3 .  D e t a i l s  a b o u t  m y  c h i l d ’s  p a s t  m e d i c a l  h i s t o r y .
A-. D e t a i l s  a b o u t  m y  c h i l d ’s  e x a m i n a t i o n .
5 .  R e s u l t s  o f  a n y  t e s t s  p e r f o r m e d  o n  m y  c h i l d .
I u n d e r s ta n d  t h a t  I d o  n o t  h a v e  t o  c o n s e n t  t o  re le a s e  o f  th is  in f o rm a t io n  a n d  t h a t  if I d o  n o t  c o n s e n t  it will n o t  
a f f e c t  th?  c a re  t h a t  my child  receives.
I l in d g rs ta n d  t h a t  s o m e  in f o rm a t io n  will b e  k e p t  o n  c o m p u t e r  in p a s sw o rd  p r o t e c t e d  files.
S igned : P a re n t /G u a rd ia n
(d e le te  as a p p ro p r ia te )
N a m e  (PRINT): D ate :
W itn ess  (S igna tu re ) :
N am e  (PRINT):
DECLARATION SYTHE INVESTIGATOR
I c o n f i rn  t h a t  I h a v e  p r o v id e d  an  in f o r m a t io n  s h e e t  a n d  e x p la in e d  t h e  n a t u r e  a n d  e f f e c t  o f  t h e  tr ia l  t o  t h e  
p a r e n t  /g u a rd i a n  a n d  t h a t  c o n s e n t  h as  b e e n  g iv e n  f re e ly  a n d  voluntarily .
S igned:
N am e  (PRINT):
S ta tus :      -.......... .... ...................................... ...............................................................
Hospita l n a m e :
I u n d e r s a n d  t h a t  s o m e  in f o rm a t io n  will b e  k e p t  o n  c o m p u te r  in p a s sw o rd  p r o t e c t e d  files.
P lle a se re tu rn  a  p h o t o c o p y  o f  th i s  fo r m  to :  T he  UKISS Trial C e n tre
T he  C h ild ren 's  C e n tre  
Royal U n ite d  Hospita l 
C o m b e  Park 
BATH BA1 3NG
UKIISS/EC1/399
Tie United Kingdom In fantile  Spasm Study
01367
The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG 
Tel/Fax: 01225 824206
FORM ONE -  Notification
Y?u will need to  have this completed questionnaire available when you phone the randomisation centre for patient 
entry into the UKISS trial. This form should be completed even if the parents decline to  participate in the drug 
t ia l or the epidemiology study. We wish to  know how many patients have been excluded from this trial so th a t 
ws may compare our study population to  the whole population of infants with infantile spasms.
If in neither s tudy  (i.e. No Consent) please photocopy SOTH sides o f th is  form SEFORE use 
and Tick { / )  here [ J on photocopy
Telephone 0 1 2 2 5  5 2 4 2 0 6  for advice /  w ith q u eries 6 .3 0 a m  t o  6p m  w eek d ays
Today's d a t e :  Day/ M o n th /  Year/ Child's initials:
Child's d a t e  o f  b ir th :  Day/ M o n th /  Year/
1 D o c t o r s  d e - t a i l s
Name of consultant (PRINT): Name o f GP: .....................................................
Name o f enrolling doctor (PRINT): GP address:
G'ade of enrolling doctor (PRINT): ........................................  ...........................................................................
Hospital address(PRINT): ...........................
Hospital/Dept tel no: GP tel no.:
(if kn ow n )
2 .  E x c l u s i o n  c r i t e r i a  f o r  d r u g  - tr ia l  ( se e  protocol for d eta ils) Please tick [ / J  ONE box on EACH line 
P /ease complete EVEN if enrolment in Drug Trial is not being considered 
t  Is th e  patient aged  below  2 months? Yes No
•  Is th e  patient aged  over o n e  year? Yes No O
•  Is th e  patient known to  have or be at high risk of having tuberous sclerosis? Yes No □
•  Has th e  patient been treated  with vigabatrin or steroids in th e past 28 days? Yes No □
•  Is there any contraindication to  vigabatrin, prednisolone or Synacthen Depot? Yes No L ±
•  Has th e  patient previously been treated for infantile spasms? Yes No □
•  Does th e infant have a lethal or potentially lethal condition? YesL No □
•  Is th e  patient expected to  leave th e  UK within one m onth o f randomisation? Yes No □
•  Is th e  infant enrolled in a concurrent trial that either uses therapy that might 
affect th e outcom e m easures o f th e UKISS trial or on e that is tim e/effort
consum ing for the patients/guardians or th e  infants' medical practitioners? Yes No
•  Are th e  parents or guardian unable to  give informed, signed, consent? Yes No □
•  Are th e  parents or guardian unable to  know w hen th e spasms stop? Yes No □
(to th e  nearest w hole day)
If tfe  answer to  any of the above questions is YES, then the patient is exc luded from the drug 
tria, b u t please request consen t fo r  th e  E p idem io logy  S tudy and continue overleaf.
P l e a s e
UKISVR1/1399
01367
Please  tick  [ /  one b o x  o n  ea ch  line
3. Sex o f  p a t i e n t
4. Does t h e  child h a v e  a k n o w n  p ro v e n  c h r o m o s o m a l  a b n o r m a l i ty ?
5. Does t h e  child h a v e  a k n o w n  p ro v e n  s y n d r o m e ?
M ale  Fem ale
□  □  '
Yes □  No 
Yes No
6. Did th e  child have a diagnosis  o f  cerebral palsy m a d e  prior t o  th e  o n se t  of th e  spasms? Yes No
7. Did t h e  child h a v e  n e o n a ta l  e n c e p h a lo p a th y  w i th  se izu res?  Yes No
8. W as t h e  child a l re a d y  d ia g n o s e d  as h av in g  a b n o r m a l  d e v e lo p m e n t
b e f o r e  t h e  o n s e t  o f  sp a sm s  (this d iagnosis m u s t have  b een  m a d e  BEFORE th e  o n se t 
o f  spasms, b y  a d o c to r  or h ea lth  visitor)!  Yes No





10.C u r re n t  w e ig h t  ______ :_______ kg
If -this patient is -to be included in the O rug Trial, 
please c o m p lete Consent Form A
P le a se  r e tu r n  a p h o t o c o p y  o f  th is  fo r m  to :  The UKISS Trial C e n tre
The Child ren 's  C e n tre  
Royal U n ited  H ospita l 
C o m b e  Park 
BATH BA1 3NG
Thank you very much for your help
01367
T he Children's C entre  
Royal U n ited  H ospital 
C om b e Park 
Bath BA1 3NG  
Tel/Fax: 0 1 2 2 5  8 2 4 2 0 6
FORM TWO -  Enrolment in DRUG TRIAL
P a t i e n t ' s  d e t a i l s  
P a t ie n t 's  n a m e  (PRINT):
D a te  o f  b ir th :
H ospita l n u m b e r  
A ddress:
Day/ M o n th /  Y ear/
The United Kingdom In fantile  Spasm Study
H ospita l n a m e :
If the child is to  be entered into the drug tria l please phone the randomisation centre between 
3 .30 and 13.00 (Monday -  Friday) on Tel: 01225 324490 and then complete this form.
'
■ h h h
D ate  o f  r a n d o m is a t io n :  Day/ M o n th /  
Discussed w ith :
Y ear/ T ime o f  r a n d o m is a t i o n (24  h ou r clock)
a t  t h e  Trial C e n tre
1. E E G
a. Has a s t a n d a r d  EEG b e e n  p e r f o r m e d ?
If YES, w hat was th e  result? N orm al
H y p sa r rh y th m ia  
O th e r
please  specify:
b. Has a s le ep  EEG b e e n  p e r f o r m e d ?
If YES, w hat  was the  result? N orm al
H y p sa r rh y th m ia  
O th e r
p lease  specify:
c. Has a v id e o  EEG b e e n  p e r f o r m e d ?
If YES, w hat was the  result? N orm al
H y p sa r rh y th m ia  
O th e r
p lease  specify:
Please attach a photocopy o f any EEG report(s)
2 ! . D i a g n o s i s
Is t h e r e  a know n  underly ing diagnosis  o r  cause fo r  t h e  spasms? Yes □  No □










Yes No _ .
Yes ..... No
Yes No
u«is/R2/i/399 P l e a s e  tu rn  o v e r
01367
No D o n 't  k n o w
. No ___ D o n 't  k n o w
No D o n 't  k n o w
No D o n 't  k n o w
3 .  S i n c e  - t h e  o n s e t -  o f  " th e  s p a s m s
a. (i) Has t h e r e  b e e n  a r r e s t  o f  d e v e lo p m e n t?  Yes
(ii) If Yes, d id  th is  co inc ide  w i th  t h e  s t a r t  o f  t h e  spasm s?  Yes
b. (i) Has t h e i r  b e e n  reg ress io n  o f  d e v e lo p m e n t?  Yes
(ii) If Yes, d id  th is  co inc ide  w i th  t h e  s t a r t  o f  t h e  spasm s?  Yes
c. UKISS D e v e lo p m e n t  C h a r t
P lease  fill in th is  c h a r t  w h e n  t h e  child is e n t e r e d  in to  t h e  tr ial.  In o r d e r  t o  g e t  s o m e  in d ic a t io n  o f  
w h e t h e r  t h e r e  has  b e e n  a r r e s t  o f  d e v e lo p m e n t  o r  reg re ss io n  b e f o r e  t h e  o n s e t  o f  t r e a t m e n t ,  p le a se  
r e s p o n d  t o  t h e  q u e s t io n s  f o r  t h e  best ever developm ent t o  d a t e  (in t h e  c o lu m n  h e a d e d  'Best ev e r ')  
a n d  t h e  current developm ental a tta in m en t (in t h e  c o lu m n  h e a d e d  'C u rre n t ') .  (P lease  tick / )
Date o f assessment Day/ M o n th / Year/
Developm ental m ilestone Best ever Current
Hand regard: Does t h e  child fo cu s  o n  a n d  look  a t te n t iv e ly  a t  
t h e  h a n d s  a n d  f in g e rs?
Laugh: D oes t h e  child r e s p o n d  a t  t im e s  by la u g h in g  loudly  - 
a 'belly  la u g h '?
Play w ith  feet: Does t h e  child fo cu s  on ,  g rasp ,  a n d  play w ith  
t h e  f e e t ?
Grasps an object: Does t h e  child g r a s p  a small o b je c t  w i th in  
rea ch  w h e n  s i t t ing  w i th  s u p p o r t  (p a lm a r  g r a s p  is su ff ic ien t)?
Transfers an object: D oes t h e  child t r a n s f e r  a small o b je c t  
f ro m  o n e  h a n d  t o  a n o t h e r  d e l ib e ra te ly ?
Sits unsupported: Does t h e  child sit by itself  o n  a f la t  su rface?
Permanency: Does t h e  child k n o w  w h e r e  t o  look fo r  a n  o b je c t  
t h a t  has  fa l len  o u t  o f  v iew ?
Crawls: Can t h e  child craw l a r o u n d  o n  all fo u rs?
Gives an object: Does t h e  child h a n d  a n  o b je c t  t o  s o m e o n e  
o n  r e q u e s t  (w h e n  p r o m p te d  by g e s tu r e  a n d  voice)?
When compl et-dplease send a photocopy of this
form to  the Trial Centre:
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park 
BATH BA1 3NG
(as in Action Plan 1 or 2)
Thank you very muc
The United Kingdom In fan tile  Spasm Study
01367
The C hildren's C entre  
Royal U n ited  H ospital 
C om b e Park 
Bath BA1 3NG  
Tel/Fax: 0 1 2 2 5  8 2 4 2 0 6
FORM THREE -  Enrolment in EPIDEMIOLOGY STUDY
Please com plete  t h is  fo rm  fo r  A N Y  in fan t: d iagno sed  a s  having in fa n tile  s p a s m s  who has  
been exc luded  fo r  w h a te v e r  reason  fro m  th e  t r e a tm e n t  com ponent o f  t h is  s tu d y . The 
in fo rm a tio n  on t h is  fo rm  is  E S S E N T IA L  provided t h e  p a re n ts /g u a rd ia n s  have given 
c o n s e n t f o r  th e  ep idem io logy s tu d y .
E s s e n t i a l  i n f o r m a t i o n
P a t ie n t 's  n a m e  (PRINT): 
D a te  o f  b ir th :
Hospita l n u m b e r :  
Address(PRINT):
Day/ M o n th / Year/
Hospita l n a m e :
1.  R e a s o n  f o r  n o n - e n t r y  i n t o  d r u g  t r i a l  i f  o t h e r  t h a n  e x c l u s i o n :
a. N o n -p a r t ic ip a t in g  c e n t r e  Yes No
b. Unable to  ge t  EEG within 72 hours and you don 't  normally trea t  before EEG result known Yes No □
c. EEG a n d  s le ep  EEG n o r m a l
d. P a re n ts  /  g u a r d ia n s  d e c l in e d  t o  t a k e  p a r t
e. O th e r  (p lease  s ta te ) :  ...............................................................................................
2 .  N o  n - r a  n d  o  m  i s  e  d  t r e a t m e n t
a. W hich  d r u g  a r e  y ou  in te n d in g  t o  u se  as p r im a ry  t r e a t m e n t  o f  t h e  in fan t i le  spasm s?
Drug Total Daily D o s e ____________




b. Any c o m m e n t s  o n  i n t e n d e d  t r e a t m e n t :  
(p lease  s ta te ) :
c. P lease s t a te  d a te :  Day/ M o n th / .............................Y ear/.................................
a n d  a p p r o x im a te  t im e  ! (24  h ou r  clock) t h a t  th is  t r e a t m e n t  dec is ion  w a s  m a d e
P l e a s e
U K ISS/R 3/1/399/page 1
3 .  E E G
a. Has a standard EEG been performed?




b. Has a sleep EEG been performed?




c. Has a video EEG been performed?




Please attach a photocopy of any EEG report(s)
A . D i a g n o s i s



















No Don't know  
No □  Don't know  
No Don't know
If YES, please specify:
5 .  S i n c e  - t h e  o n s e t  o f  - t h e  s p a s m s
a. (i) Has there been arrest o f developm ent?
(ii) If YES, did this coincide with the start o f th e  spasms?
b. (i) Has their been regression o f developm ent?
(ii) If YES, did this coincide with th e start of the spasms?
c. UKISS D evelopm ent Chart
Please fill in this chart w hen th e child is entered into the trial. In order to  g e t  som e indication o f 
w hether there has been arrest o f developm ent or regression before th e  onset o f treatm ent, please  
respond to  th e  questions for th e best ever developm ent to  date (in th e  column headed 'Best ever') 
and th e current developm ental a tta in m en t (in the column headed 'Current'). (Please tick)
Date of assessment Day/ M onth/ Year/
No Don't know
Developm ental m ilestone Best ever Current
Hand regard: Does the child focus on and look attentively at 
th e hands and fingers?
Laugh: Does th e child respond at tim es by laughing loudly - a 'belly laugh'?
Play w ith  feet: Does th e child focus on, grasp, and play with th e feet?
Grasps an object: Does th e child grasp a small object within 
reach w hen sitting with support (palmar grasp is sufficient)?
Transfers an object: Does th e child transfer a small object 
from one hand to  another deliberately?
Sits unsupported: Does th e child sit by itself on a flat surface?
Permanency: Does th e child know w here to  look for an object 
that has fallen out o f view?
Crawls: Can th e  child crawl around on all fours?
Gives an object: Does th e child hand an object to  
som eon e on request (when prom pted by gesture and voice)?
Please return a p h o to c o p y  o f  this form  to: The UKISS Trial Centre
The Children's Centre 
Royal United Hospital 
Combe Park 
BATH BA1 3NG
U K IS S /R 3/1 /1298/page 2
01367
The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG
The United Kingdom In fantile  Spasm Study Tel/Fax: 01225 824206
FORM FOUR -  DRUG TRIAL & EPIDEMIOLOGY Assessment a t 14 Days
This form should be completed when the child is reviewed at the end of the initial two weeks of therapy. This 
assessment should take place as close to, but NOT BEFORE 14 completed days of the initial therapy.
D a te  o f  as se ssm en t:  
P a t i e n t  d e t a i l s :
Day/ M o n th / Year/
D a te  o f  b ir th : Day/ M o n th /  Year/
H H H M H I
1.  T h  e  s p a s m s
a. (i) A g e  a t  onset o f  t h e  spasms:
(ii) If YES, specify d a te :
(iii) If NO, is t h e  a g e  a c c u r a te  t o  t h e  n e a re s t :
b. D a te  o f  diagnosis o f  t h e  spasm s
Is t h e  ex a c t  d a t e  k n o w n ?  Yes No O
day /  m o n t h /  y ea r /
w e e k  m o n th  □
d ay  / m o n t h /  y ea r /
c. (i) Has the re  been complete cessation of spasms for 48 hours since commencing trea tm e n t?  Yes No □
(ii) If YES, date o f last spasm ? day /
d. W hat date did treatm ent com m ence? d ay /
e. (i) Has there been a relapse since?
(ii) If YES, have spasms stopped again for 48 hours ?
2 .  P r e g n a n e y
a. (i) W ere there any maternal problems/illnesses during pregnancy?
(ii) If YES, what w e re  they?
3 .  I 3 i r t h  h i s t o r y
a. Gestation at delivery: /40
b. (Please tick /  boxes) (i) vaginal (ii) forceps
(iv) planned section (v) emergency section (vi) breech
c. Birth w eight: grams
d. Apgars (if known): (i) @1 (ii)
e. Head circum ference at birth: \  cm
f. History o f neonatal problems
m o n t h /  yea r /






(iii) ventouse □  
(vii) cephalic □
@5 (iii) @10
A- . A n y  o t h e r  p a s t  m e d i c a l  i l l n e s s e s  /  o p e r a t i o n s
P l e a s e  tu rn  o v e r
UKISS/AS4/1/299/page 1
5 . A n y  p r e c e d i n g  f i t s  a n d  t h e i r  t r e a t m e n t
01367
0 .  A n y  f a m i l y  h i s t o r y  o f  e p i l e p s y  o r  r e l e v a n t  m e d i c a l  c o n d i t i o n s  
i n  f i r s t  d e g r e e  r e l a t i v e s .
(Please i nd i ca te  how many f i r s t  degree r e l a t i ves  a f f e c t e d / u n a f f e c t e d . )
7 .  D r u g  h i s t o r y
M edication betw een day 1 and day 14 (including m edication for infantile spasms):
(i) Drug (ii) Single dose (iii) No o f tim es given (iv) Days on which the
(e.g. bd, tds) drug w as given (eg days 1-7)
b.
Proposed changes after day 14 to  current m edication (if any) and reasons:
&.  C l i n i c a l l y  i m p o r t a n t *  a d v e r s e  e v e n t s
a. Have the parents/guardians reported any clinically important adverse events
(symptoms, illnesses or surgery) regardless of whether related to the treatment(s) given? Yes No
b. If Yes,please com plete th e details in th e  table below.
If you think that the adverse event is attributable to the trial drug, please place an asterisk (*) in the first box.
A d verse  e v e n t D a te  
o f  o n s e t
HosDitalisation A ctio n  ta k en __Cljjnical o u tc o m e







Any life -th re a te n in g  adverse event or any even t requ iring  w ith d ra w a l of 
treatm ent should be reported to  the Trial Centre IMMEDIATELY.
UKISS/AS4/1/399/page 2
P l e a s e  c o n t i n u e
01367
9 .  N e u r o l o g i c a l  a s s e s s m e n t
a. (i) W a s  t h e  n e u ro lo g ic a l  e x a m in a t io n  o f  t h e  in f a n t  n o rm a l?  Yes No
(ii) If NO, p le ase  d esc r ib e  a n y  f in d in g s  b e lo w  e .g .  h y p o to n ia ,  spasticity:
b. (i) W e r e  t h e  fu n d i  e x a m in e d  w i th  an  o p th a lm o s c o p e ?  





c. (i) W a s  a W o o d s  l igh t  e x a m in a t io n  p e r f o r m e d ?  
(ii) If YES, w e r e  t h e r e  an y  a b n o r m a l  f in d in g s?
Yes No
d. P lease  list any  o th e r  n e u r o c u ta n o u s  f in d in g s
e. (i) A re  t h e r e  an y  d y sm o rp h ic  f e a tu r e s ?  Yes LJ No □
(ii) If YES, p lease  list: ..................................................  ................................................................................
f. (i) Current w eight: * kg (ii) Current head (occipitofrontal) circumference: * cm
1 O.  3 l  o o d  p r e s s u r e
a. Has BP (either systolic or diastolic) risen above (Please tick: ^  one box only)? W 110/so ^ 12%o ^  No
b. Have antihypertensive drugs been started? Yes No
c. Did the drug treatment of infantile spasms have to be stopped as a result of the hypertension? Yes No □
1 1 .  U r i n e  a n a l y s i s
a. (i) Has urine analysis been perform ed? Yes No
(ii) If YES, was glycosuria recorded? Yes No
(iii) If YES, was any treatm ent required? Yes No
b. Did treatm ent have to  be stopped as a result o f  diabetes? Yes No L J
1 2 .  I n v e s t i g a t i o n s  p e r f o r m e d
Please indicate whether or not the following investigations have been performed on the patient. If they have then 
where possible please can you either enclose copies of the reports or fill in the result on this form. If they have not 
had the investigation, please indicate whether it is planned in the  fu ture or give the reason for it not being done.
a. (i) Was EEG perform ed at 14 days (the  tim e  o f  th is assessm ent)  Yes No □
(ii) If YES, Date:
(iii) Result (attach photocopy o f report if abnormal) Normal Hypsarrhythmia Other □
(iv) C o m m en ts ........................................................................  ...........................................................................
(v) If NOT done, is it planned for the future? Yes No O ;
(vi) If NOT planned, please specify reason:
b. (i) Was an MR I o f th e  brain perform ed? Yes L J  No □
(ii) If YES, result (a ttach p h o to c o p y  o f  rep o rt i f  abnorm al) Normal Abnormal
(iii) C om m en ts  .................................................................
(iv) If NOT done, is it planned for the future? Yes No □
(v) If NOT planned, please specify reason (e.g. CT done)
p i  e a s e  tu rn  o v e r
UKISS/AS4/1/299/page 3
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The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG 
Tel/Fax: 01225 824206
FORM 6(a) -  THREE MONTHLY ASSESSMENT FORM {DRUG TRIAL)
This form  should be completed when the child is reviewed THREE months after enrolment 
into the trial (unless preceded by final assessment).
P a t i e n t  d e t a i l s :
Name (BLOCK CAPITALS):
Date o f birth: Day/ M onth/ Year/
The United Kingdom In fantile  Spasm Study
Study number: Please now  put Study Number on next A ssessm ent Form
Today's date:







1 . E f f e c t  o f  t h e  t h e r a p y  o n  t h e  s p a s m s  ( n o t  o t h e r  s e i zu r e  t y p e s )
a. Has th e child had any spasms since th e  last assessm ent? Yes No
b. Have an / changes been m ade to  their treatm ent? Yes







Date: Day / M onth/
Result:
(Please attach a photocopy o f any abnormal result)
E p i l e p t i c  S e i z u r e s  
. Has th e :hiId had any other type o f epileptic seizure since last assessm ent?
D r u g  h i s t o r y  a t  t i m e  o f  t h i s  a s s e s s m e n t
(p lease r e c o r d  a II d r u g s  c u r r e n t l y  being t a k e n )
D rug (i) Total D aily D o se  (ii)
Year/
Normal O




P l e a s e  tu rn  o v e r
01367
5 .  C l i n i c a l l y  i m p o r t a n t ,  a d v e r s e  e v e n t s
a. Have the parents/guardians reported any clinically important adverse events (symptoms, illnesses or surgery) 
regardless o f w hether related to  the treatment(s) given?
NoYes
b. If Y es,please com plete th e details in th e tab le below .
(If you think that the adverse event is attributable to the trial drug, please place an asterisk (*) in the first box.)
A d verse  e v e n t D ate Hosoitalisation A ctio n  ta k e n Clinical o u t c o m e






0 .  I n v e s t i g a t i o n s  p e r f o r m e d  t o  f i n d  u n d e r l y i n g  c a u s e  
Have any further investigations been perform ed since the child's last review?






7 . A n y  o t h e r  c o m m e n t s
— .
PI e a s e  s an d  a p h o to c o p y  o f  t h is  c o m p le te d  fo rm  t o  t h e  
Tria l C e n tre  (a s  in A c t io n  P lan 1 o r  2 )
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park 
BATH BA1 3NG
Thank you very much for your help
UKISS/A S6a/1/1298
The United Kingdom In fan tile  Spasm Study
01367
The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG 
Tel/Fax: 01225 824206
FORM 8(b) -  THREE MONTHLY ASSESSMENT FORM TRIAL)
This form  should be completed when the child is reviewed SIX months after enrolment 
into the tria l (unless preceded by final assessment).
P a t i e n t  d e t a i l s :
N a m e  (BLOCK CAPITALS):
D a te  o f  b ir th :  Day/ M o n th /  Y ear/
Study number:
Today 's  d a t e :
D a te  o f  las t  A ssessm ent:
Please now  put Study Number on next A ssessm ent Form
Day/
Day/
M o n th /
M o n th /
Year/
Year/
1.  E f f e c t  o f  t h e  t h e r a p y  o n  t h e  s p a s m s  ( n o t  o t h e r  se i zu re  t y p e s )
a. Has t h e  child h a d  a n y  spasm s  since t h e  last a s s e s s m e n t?  Yes No
b.  H ave any  c h a n g e s  b e e n  m a d e  to  th e i r  t r e a t m e n t ?
c. If YES, p le a se  s t a t e  th o s e  c h a n g e s  a n d  w h e n  w e r e  t h e y  m a d e ?
Yes □  NolZ
B E G
A ny f u r th e r  EEG?
Date :
Result:
(P lease  a t t a c h  a p h o to c o p y  o f  an y  a b n o r m a l  result)
Day / M o n th / Y ear/
N orm al  □
3 .  E p i l e p t i c  S e i z u r e s
a. Has t h e  child h a d  a n y  o t h e r  t y p e  o f  ep i lep t ic  se izu re  since  last a s se s s m e n t?
4 - .  D r u g  h i s t o r y  a t  t i m e  o f  t h i s  a s s e s s m e n t
(p l ease  r e c o r d  al l  d r u g s  c u r r e n t l y  being t a k e n )









5 .  C l i n i c a l l y  i m p o r t a n t  a d v e r s e  e v e n t s
a. Have the parents/guardians reported any clinically important adverse events (symptoms, illnesses or surgery) 
regardless of w hether related to  the treatm ent(s) given?
Yes No
b. If Yes,please com plete th e  details in th e tab le  below.
(If you think that the adverse event is attributable to the trial drug, please place an asterisk (*) in the first box.)
A d verse  e v e n t
*
D a te  
o f  o n s e t









0 .  I n v e s t i g a t i o n s  p e r f o r m e d  t o  f i n d  u n d e r l y i n g  c a u s e  
Have any further investigations been perform ed since th e child's last review?






*7. A n y  o t h e r  c o m m e n t s
P le a s e  s en d  a p h o to c o p y  o f  t h is  c o m p le te d  fo rm  t o  th e  
Tria l C e n tre  (a s  in A c t io n  Plan 1 o r  2 )
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park 
BATH BA1 3NG
Thank you very much for your help
U KISS/A S6b/1/399
The United Kingdom In fan tile  Spasm Study
01367
The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG 
Tel/Fax: 01225 824206
FORM 6(c) — THREE MONTHLY ASSESSMENT FORM (DRUG TRIAL)
This form  should be completed when the child is reviewed NINE months after enrolment 
into the tria l (unless preceded by final assessment).
P a t i e n t  d e - t a i l s :
Name (BLOCK CAPITALS):
Date o f birth: Day/ M onth/ Year/






Date o f last Assessment:
1 . E f f e c t  o f  - t h e  - t h e r a p y  o n  - t h e  s p a s m s  ( n o t  o t h e r  se i zu re  t y p e s )
a. Has th e  child had any spasms since th e  last assessm ent? Yes No
b. Have any changes been made to  their treatm ent? Yes 









(Please attach a photocopy o f any abnormal result)
S e i z u r e s
. Has th e child had any other type o f  seizure since last assessm ent?
D r u g  h i s t o r y  a t  t i m e  o f  t h i s  a s s e s s m e n t
( p l ease  r e c o r d  al l  d r u g s  c u r r e n t l y  being t a k e n )
D rug (i) Total Daily D o se  (ii)
Year/............
Normal O




P l e a s e  turn  o v e r
01367
5 .  C l i n i c a l l y  i rr\ p  o  r t> a  n t ,  a d v e r s e  e v e n t s
a. Have the parents/guardians reported any clinically important adverse events (symptoms, illnesses or surgery),
regardless of w hether related to  the treatment(s) given?
Yes No
b. If Yes,please com plete th e  details in th e table below.
(If you think that the adverse event is attributable to the trial drug, please place an asterisk (*) in the first box.)
A d verse  e v e n t D ate Hospitalisation A ction  ta k en Clinical o u tc o m e







0 .  I n v e s t i g a t i o n s  p e r f o r m e d  t o  f i n d  u n d e r l y i n g  c a u s e  
Have a n y  further investigations been perform ed since th e  child's last review?





7 .  A n y  o t h e r  c o m m e n t s
.
P le a s e  s e n d  a  p h o to c o p y  o f  t h is  c o m p le te d  fo rm  t o  th e  
Tria l C e n tre  (a s  in A c t io n  P lan 1 o r  2 )
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park 
BATH BA1 3NG
Thank you very much for your help
UKISS/AS6c/1/399
The United Kingdom In fan tile  Spasm Study
01367
The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG 
Tel/Fax: 01225 824206
FORM SEVEN -  FINAL ASSESSMENT AT 12 T014 MONTHS OF AGE 
(Drug Trial and Epidemiology Study)
This form should be com pleted  w hen th e  child is reviewed b etw een  th e ages o f 12 and 14 months. 
P a tie n t  d e t a i l s :
Name (PRINT):





D a t e  o f  a s s e s s m e n t Day/ M onth/ Year/
1 . E f f e c t  o f  t h e  t h e r a p y  o n  t h e  s p a s m s  (not o ther  seizure types)
a. Has th e  child had any spasms since th e  last assessm ent?
b. Have any changes been m ade to  their treatm ent?
c. If YES, w hat w ere th ose changes and w hen w ere they made?
Yes p i  No 
Yes No
2 .  E E G ?
a. Any recent EEG?
b. Date: / and  Result: Normal
(Please attach a photocopy o f any abnormal result)
3 .  E p i l e p t i c  S e i z u r e s
a. Has the child had any other type of epileptic seizure since the last assessment?
Yes c i  No U  
□  Abnormal D
Yes L J  No □
b. If YES, please give the type of seizure, with approximate frequency and duration of each type
A-. C u r r e n t  d r u g  t r e a t m e n t  (please record all drugs currently being taken)




e   ..................
f ..................................
P l e a s e  tu rn  o v e r
UKISS/AS7/1/399
01367
5 .  C l i n i c a l l y  i m p o r t a n t  a d v e r s e  e v e n t s
a. Have the parents/guardians reported any clinically important adverse events (symptoms, illnesses or surgery) 
regardless of w hether related to  the treatment(s) given?
Yes No
b. If Yes,please com plete th e  details in th e  table below.
(If you think that the adverse event is attributable to the trial drug, please place an asterisk (*) in the first box.)
A d verse  e v e n t D a te  
o f  o n s e t










£ 3 . D e v e l o p m e n t a l  h i s t o r y  a t  t i m e  o f  t h i s  a s s e s s m e n t
In your opinion, is th e infant's developm ent appropriate for age? Yes No □
*7. N e u r o l o g i c a l  a s s e s s m e n t  ( e x c l u d i n g  d e v e l o p m e n t )
a. Is th e neurological exam ination o f th e  infant currently normal? Yes □  No P
b. If NO, please describe any positive findings below:
3 .  (i) C u rre n t w e ig h t: kg (ii) C u rre n t h e a d  ( o c c ip i to fr o n ta l)  c irc u m fe re n c e : c m
9 .  I n v e s t i g a t i o n s  p e r f o r m e d  t o  f i n d  u n d e r l y i n g  c a u s e  
Have any further investigations been  perform ed since th e child's last review?
Please list and give th e  results w here available





1 0 .  A n y  o t h e r  c o m m e n t s
11. I s  t h e r e  a k n o w n  u n d e r l y i n g  d i a g n o s i s / a e t i o l o g y  f o r  t h i s  p a t i e n t ’s  s p a s m s ?
Yes a No P
If YES, please com m ent: ....................................................................................................................................................
P le a se  s e n d  a  p h o to c o p y  o f  t h i s  c o m p le te d  fo rm , 
t o g e t h e r  w ith  t h e  rem ain ing p a g e s  o f  t h e  P a t ie n t ’s  D iary ; 
t o  t h e  Trial C e n tr e  (a s  in A c tio n  Plan 1, 2  o r  3 )
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park BATH BA1 3NG
ISS/A S 7/1/399 Thank you very much for your help
A p p e n d i x  1
The United Kingdom Infantile Spasm Study
T R I A L  
P R O T O C O L
PLEASE IVIOTE: As ACTH gel is not available in the UK, 
we have substituted Synacthen Depot.
Give 0 .5m g on a lte rna te  days (equ iva len t to  40 iu /day  o f ACTH) 
intramuscularly (regardless o f age or weight) fo r tw o weeks. If at the end of 
the first week seizure control has not been achieved then the dose should 
be further increased to 0.75mg on alternate days (equivalent to 60iu/day of 
ACTH) intramuscularly.
Before prescribing Synacthen Depot, please read the 
Doctor's Information Sheet.
S e p t e m b e r  1 9 9 8
Version 2 MREC Approved
UKISS/P/1/12 98
01367
5 .  Cl inical ly i m p o r t a n t  adverse  even t s
a. Have t h e  p a re n ts /g u a rd ia n s  r e p o r te d  any  clinically im p o r ta n t  adve rse  ev en ts  (symptoms, illnesses o r  surgery) 
regard less  o f  w h e t h e r  r e la te d  to  t h e  t r e a tm e n t( s )  g iven?
Yes No
b. If Y e s ,p le a s e  c o m p le t e  t h e  d e ta i l s  in t h e  t a b l e  be low .
(If you think that the adverse event is attributable to the trial drug, please place an asterisk (*) in the first box.)
A d verse  e v e n t D ate Hospitalisation A ction  ta k en C linical o u tc o m e
*








0 .  D e v e l o p m e n t a l  h i s t o r y  a t  t i m e  o f  t h i s  a s s e s s m e n t  
In y o u r  o p in io n ,  is the infant's developm ent appropriate for age? Yes
7 .  N e u r o l o g i c a l  a s s e s s m e n t  ( exc l udi ng d e v e l o p me n t )
a. Is t h e  n e u ro lo g ic a l  e x a m in a t io n  o f  t h e  in fa n t  cu r ren t ly  n o rm a l?  Yes □
b. If NO, p le a se  d esc r ib e  a n y  posit ive  f in d in g s  b e lo w :
No
No□
3 .  (i) C u rre n t w e ig h t: • kg (ii) C u rre n t h e a d  (o c c ip i to fr o n ta l)  c irc u m fe re n c e :  •
9 .  I n v e s t i g a t i o n s  p e r f o r m e d  t o  f i n d  u n d e r l y i n g  c a u s e  
H ave an y  f u r th e r  in v e s t ig a t io n s  b e e n  p e r f o r m e d  since t h e  child 's last rev iew ?







1 0 .  A n y  o t h e r  c o m m e n t s
11.  I s  t h e r e  a k n o w n  u n d e r l y i n g  d i a g n o s i s / a e t i o l o g y  f o r  t h i s  p a t i e n t ’s  s p a s m s ?
Yes No P
If YES, p lease  c o m m e n t :
P le a se  s e n d  a  p h o to c o p y  o f  th i s  c o m p le te d  form , 
t o g e t h e r  w ith  t h e  rem aining p a g e s  o f  th e  P a t ie n t ’s  Diary, 
t o  th e  Trial C e n tr e  (a s  in A c tio n  Plan 1, 2  o r  3 )
The UKISS Trial Centre 
The Children's Centre 
Royal United Hospital 
Combe Park BATH BA1 3NG
U K ISS/A S7/1/399 Thank you very much for your help
A p p e n d i x  1
The United Kingdom Infantile Spasm Study
T R I A L  
P R O T O C O L
PLEASE MOTE: As ACTH gel is not available in the UK, 
we have substituted Synacthen Depot.
Give 0.5mg on alternate days (equivalent to 40iu/day of ACTH) 
intramuscularly (regardless of age or weight) for two weeks. If at the end of 
the first week seizure control has not been achieved then the dose should 
be further increased to 0.75mg on alternate days (equivalent to 60iu/day of 
ACTH) intramuscularly.
Before prescribing Synacthen Depot, please read the 
Doctor's Information Sheet.
S e p t e m b e r  1 9 9 8
Version 2 MREC Approved
UKISS/P/1'1298
The United Kingdom Infantile Spasm Study
Trial C entre
The Children's Centre 
Royal United Hospital 
Combe Park 
Bath BA1 3NG 
Tel/Fax: 01225 824206
Trial S teer in g  C o m m ittee
In Bath: Prof J P Osborne (Chairman)
Dr S Edwards 
Dr E Hancock 
Dr A Lux 
Dr F O'Callaghan 
Also: Dr T Johnson (MRC, Cambridge)
Dr C Kennedy (Southampton)
Dr R Newton (Manchester)
Dr C Verity (Cambridge)
R A N D O M I S A T I O N
Telephone: 01225 824490 / Monday to  Friday between 
or by  Facsimile: 01225 824206[8 .30am and 6pm only
Please report all cases, even if not for randomisation
P r o t o c o l  C o n t e n t s
Protocol A1
Epidemiology A1
Notify all cases of infantile spasms A1
Drug trial A1
Inclusion criteria for drug trial A1











Following discharge, during the initial two week period A5
Responders and proposed treatment for relapse A5
Review at 2 weeks A5
Non - response at 2 weeks A6
Relapse after the initial two week period A6
Side effects A6
Subsequent follow up A6
Recruitment rate A6
Compliance A7
Likely rate of loss to follow-up A7
Post randomisation stratification A7
Post investigation diagnostic sub groups A7
Primary outcome measure A7
Secondary outcome measures
Analysis
The United Kingdom Infantile Spasm Study
P R O T O C O L
This is a pragmatic drug trial o f the current, most common treatments using the clinicians 
normal investigation plan.
E P I D E M I O L O G Y
NOTIFY ALL CASES OF INFANTILE SPASMS
Please notify all cases of infantile spasms to  the tria l centre even if you do not intend to 
recruit the individual patient, fo r whatever reason, into the trial. Any patient w ith  a 
clinical diagnosis o f infantile spasms should be included even if the EEG turns out to  be 
normal. This would include patients younger than 2 months or older than 1 year. It 
would be very helpful if all cases can be notified so tha t we know how representative 
our tria l population is compared to  the whole UK population. Brief clinical details w ill 
be requested.
In order to  carry out a capture-recapture analysis o f the UK population w ith IS (thus 
allowing a more complete ascertainment o f cases), we shall ask fo r information from 
pharmacists and EEG departments in collaborating hospitals. This information w ill be 
in itia ls, date o f birth and sex. The clinician will then be approached for pre-randomisation 
stratification data.
D R U G  T R I A L
1. INCLUSION CRITERIA FOR DRUG TRIAL
All infants shall be included of either sex aged at seizure onset between 2 completed 
calendar months and 1 year o f age (up to  but not including their first birthday) who are 
resident in the UK and who have a clinical diagnosis o f infantile spasms from any cause.
2. EXCLUSION CRITERIA FOR DRUG TRIAL
(i) Infants who are either known to  suffer from tuberous sclerosis (TSC) or who are 
at high risk i.e. a presumptive diagnosis o f tuberous sclerosis because of;
(a) known affected parent
(b) previously diagnosed cardiac rhabdomyoma
(c) hypomelanic macules, a forehead fibrous plaque or shagreen patch 
noted
(d) a retinal phakoma seen
(e) polycystic kidneys in the infant
We recommend tha t first line therapy in these infants should be vigabatrin (see later fo r 
dosage. Please inform tria l centre even though they w ill not be entered into the tria l)
(ii) Infants previously treated w ith  vigabatrin or steroids w ith in  28 days of the first 
diagnosis of infantile spasms.
(iii) Infants w ith  a contra-indication to  vigabatrin or steroids.
(iv) Infants w ith  a lethal or potentially lethal other condition.
(v) Previous treatm ent for infantile spasms.
(vi) Inability o f parents or guardians to  give informed, signed consent.
(vii) Infants expected to  leave the UK w ith in  one month o f randomisation.
(viii) Inability o f parents or guardians to  know when spasms stop - to  the nearest 
whole day.
(ix) Infants enrolled in a concurrent tria l tha t either uses therapy tha t m ight affect 
the outcome measures of the UKISS tria l or one tha t is tim e/effo rt consuming 
fo r the patients/guardians or the infants' medical practitioners.
All excluded infants should be reported to  the tria l centre.
3. CONSENT
The tria l should then be discussed w ith the parents or guardians and the ir consent 
requested fo r participation in the tria l. Please report any infants where consent is not 
obtained to  the tria l centre.
4. ELECTROENCEPHALOGRAM (EEG)
An EEG (or video EEG) should be obtained as quickly as possible so tha t treatm ent can 
start w ith in  72 hours o f diagnosis. Only if this is not possible and only if your normal 
practice is to  start treatm ent prior to  an EEG (or video EEG) may you randomise before 
an EEG (or video EEG) is obtained. If the EEG (or video EEG) is normal, a sleep EEG w ill 
be required prior to  randomisation, if this has not already occurred. If the sleep EEG is 
normal the child w ill be excluded from the drug tria l (unless already enrolled) but please 
report the exclusion to  the tria l centre fo r fu rther fo llow  up.
If there w ill be a delay o f more than 72 hours before the EEG (or video EEG) can be 
performed and it is not your normal practice to  start treatm ent prior to  EEG (or video 
EEG), the child w ill be excluded from the drug tria l (but please report the exclusion to 
the tria l centre fo r further fo llow  up).
5. PRE-RANDOMISATION
Prior to  entry into the study the children w ill be stratified fo r randomisation by three 
variables:
(1) By gender: male, female
(2) By age: 60 to  119 days
120 to  179 days 
180 to  239 days 
240 days and over
(3) By diagnosis know n a t  tim e o f  random isation  (Yes / No).
A: a proven chromosomal abnormality 
B: a proven syndrome diagnosis
C: a diagnosis o f cerebral palsy made before the onset o f the 
infantile spasms 
D: a diagnosis o f neonatal encephalopathy w ith  seizures
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E: a diagnosis of delayed development having already been made 
before the onset of the spasms. The diagnosis should have 
been made by either a medical practitioner or a health visitor, 
and must have been made before the onset o f the spasms.
Stratification is being done not to  provide definitive groups fo r subanalysis but to  balance 
the treatm ent groups w ith respect to  factors which are identifiable at randomisation 
and which m ight affect our outcome measures.
6. RANDOMISATION
This w ill involve central randomisation by telephone call which w ill register the child 
into the trial, report base-line information and allocate initial treatment using the method 
of minimisation balancing over three factors.
7. TREATMENT GROUPS
All children eligible for the tria l w ill then be randomised into tw o treatm ent groups:
(1) Vigabatrin
(2) "Steroids"
All patients randomised to receive steroids w ill undergo a second randomisation at that 
time to  either Synacthen Depot or prednisolone.
The only pharmacological intervention, fo r the infantile spasms, in the first tw o  weeks 
w ill be the use of the drug to  which each patient has been randomised.
8. INITIAL TREATMENT
This w ill be a period of tw o weeks during which the child w ill receive the drug to  which 
they are allocated as monotherapy. It is the local doctor's responsibility to  read the 
manufacturer's drug data sheet before prescribing the fo llow ing drugs:
Vigabatrin
Give 50mg/kg/day orally in tw o divided doses fo r 24 hours (i.e. a to ta l o f 2 doses). 
Then increase to  100mg/kg/day orally in tw o  divided doses in all patients.
If at 96 hours seizure control has not been achieved then the dose should be 
further increased to 150mg/kg/day orally in tw o divided doses.
They then continue on this dose (100 or 150mg/kg/day) until the tim e of the ir 
final developmental assessment around 12 -14 months o f age unless no response 
or relapse occurs (see below), or this is not your normal practice.
ACTH — USE SYNACTHEN DEPOT
As ACTH is not available in the UK, we have substituted Synacthen Depot. Give
0.5mg on alternate days (equivalent to  40iu/day o f ACTH) intram usclarly 
(regardless of age or weight) fo r tw o weeks. If at the end of the first week 
seizure control has not been achieved then the dose should be fu rthe r increased 
to  0.75mg on alternate days (equivalent to  60iu/day of ACTH) intramuscularly. 
This group will then tail on oral prednisolone over 15 days. Those on 0.5mg on 
alternate days o f Synacthen Depot w ill receive 30mg of oral prednisolone fo r 5 
days, then 20mg fo r 5 days then 10mg fo r 5 days and then stop. Those on 0.75mg 
of alternate days o f Synacthen Depot w ill receive 40mg of oral prednisolone for 
5 days then 20mg fo r 5 days and then 10mg fo r 5 days and then stop. 
Prednisolone
Give 10mg q.d.s. orally (regardless of age or weight) fo r tw o  weeks.
If at the end o f the first week seizure control has not been achieved the dose 
should be increased to  20mg t.d.s. orally.
This group will then tail on oral prednisolone over 15 days. Those on 40mg w ill 
reduce to  30mg fo r 5 days, then 20mg fo r 5 days then 10mg fo r five days and 
stop. Those on 60mg w ill reduce to  40mg fo r 5 days then 20 mg fo r 5 days then 
10mg fo r 5 days then stop.
9. INVESTIGATIONS
(a) An investigation of the child's development w ill be made by history. A t enrolment 
the clinician w ill be asked to  record the best development ever made on history 
by the child. It w ill not be necessary to  record the age at which this performance 
was made. They w ill then be asked to  record the current development achieved.
(b) As part o f normal practice in the investigation o f infants w ith infantile spasms, 
we assume the fo llow ing investigations w ill be undertaken:
1. MRI or CT of the brain
2. Urine metabolic screen fo r amino acids
3. Ophthalmoscopy (either direct or indirect)
4. Ultraviolet light examination (Woods light)
The results o f these tests should be forwarded to  the tria l centre. If fo r any reason one 
or more of these tests is not completed the reason should be stated.
(c) The fo llo w ing  tests may be considered appropria te in some cases and, if 
performed, the results o f these and any other tests should be forwarded to  the 
tria l centre.
1. Urea and electrolytes
2. Liver function tests
3. Chromosomes





9. Pyridoxine response - if pyridoxine is to  be given we would recommend 
tha t pyridoxine is given one month after the start of the tria l (after both 
the randomised treatm ent and first alternate treatm ent have been given 
in a child who continues fitting ).
(d) When venesection is performed fo r any clinical reason during the course of the 
infants illness, please take a blood sample fo r DNA analysis (bottle, form  and 
addressed sample box included in patient pack). A subgroup of those on steroids 
w ill have blood taken to  measure cortisol levels.
10. INITIAL OBSERVATIONS
The patient w ill be admitted if necessary fo r clinical confirm ation of the diagnosis o f 
in fantile  spasms. If commencing steroid treatm ent, the patient w ill preferably be 
detained in hospital fo r 48 hours in order to  have the ir blood pressure checked twice a 
day fo r tw o days and to  have a urine analysis fo r glucose performed before discharge.
11. AT ENROLMENT
At enrolment the parents/guardians w ill be given the ir copy o f a 'f i t  diary'. Its use, and 
how to  complete it, must be explained and fu lly understood. In addition the importance 
o f this diary to interpreting the results o f the tria l should be explained. Details of the
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child's name, date of birth, address, NHS number, tria l number, consultant and general 
practitioner should be completed. In addition we w ill ask all parents/guardians fo r a 
th ird  party address (e.g. a grandparent) so tha t if they move and we lose contact w ith  
them we can try and track them through this th ird party.
As a minimum, the parents/guardians w ill be expected to  make a once daily entry fo r 
the first 4 weeks of the tria l and a once weekly entry thereafter, until the time o f the 
final developmental assessment (12 -14 months), w ith  a final 7 day daily entry fo r those 
still having seizures. They should bring the diary w ith them to  all clinic appointments 
and they may use the diary to  record more detailed information if the lead clinician so 
wishes.
12. BEFORE DISCHARGE
Before discharge please arrange fo r a fo llow  up EEG as close to  14 days after the start of 
treatm ent as possible. Please also see the child in out-patients as close to  14 days after 
the start o f treatment as possible (but not less than 14 days after the start o f treatment).
13. FOLLOWING DISCHARGE, DURING THE INITIAL TWO WEEK PERIOD
Once the patient is discharged from hospital, if on steroids the blood pressure and 
urine analysis fo r glucose should be performed weekly whilst treatm ent continues, until 
the dose is reduced when this may be om itted if problems have not already been 
detected.
14. RESPONDERS A ND  PROPOSED TREATMENT FOR RELAPSE
Responders: are those in whom there is to ta l cessation of spasms for at least 48 hours 
up to  and including the end of the 14th day o f treatment.
Relapse: a single spasm in a responder constitutes a relapse.
If a child relapses w ith in  the initial 2 week period then the lead clinician would be 
expected to  increase the dose of the initial therapy up to the maximum recommended 
dose as per protocol.
If for any reason the lead clinician felt that it was not in the child's best interest to increase 
the dose of initial therapy (for example side effects experienced) then he should inform the 
trial centre as soon as possible, preferably but not necessarily before changing therapy.
15. REVIEW AT 2 WEEKS
Please review the patient as close to  14 days after the start o f treatm ent as possible but 
not less than 14 days after the start o f treatment.
The patient should be seen in order to  confirm their progress and to  complete the brief 
standardised progress report form. If the infant has responded the patient w ill continue 
on the same therapy as above.
16. NON - RESPONSE AT 2 WEEKS
The trial w ill be analysed by intention to treat at randomisation. However, in order to 
minimise the effects of a multitude o f different subsequent treatments, we will ask, but not 
require, clinicians to change to the alternative treatment if the primary treatment fails.
If a response has not occurred after 2 weeks, we expect the lead clinician to  change to 
the alternative therapy i.e. either steroids after vigabatrin (the lead clinician to  choose 
which steroid -  Synacthen Depot or prednisolone) or vigabatrin after steroids. This 
alternative treatm ent w ill continue fo r the th ird  and fourth  weeks (a fu ll 14 days) at the 
same dose as recommended fo r the first tw o  weeks.
If the lead clinician does not feel tha t this treatm ent is in the child's best interest they 
may change to  a treatm ent of his/her own choice, w ithou t violating the tria l protocol, 
but they should notify the tria l centre o f this change in treatm ent plan using the 14 day 
standard report form.
If both treatments fail, the clinician will be left to  choose the most appropriate treatment.
17. RELAPSE AFTER THE INITIAL TWO WEEK PERIOD
The lead clinician may choose his/her own treatment, but we suggest; if the child relapses 
after the initial tw o week period either: If on vigabatrin increase the dose in parallel 
w ith the child's weight gain (if increase is more than 1 kg) or if on 100mg/kg/day increase 
to  150mg/kg/day; If on steroids repeat the course once even if tailing. If these measures 
fail after a fu ll 14 days treatm ent change to  the alternative therapy i.e. either steroids 
(Synacthen Depot or prednisolone) after vigabatrin, or vigabatrin after steroids.
18. SIDE EFFECTS
Should an in fan t suffer unacceptable side effects then the trea tm ent should be 
discontinued and the tria l centre informed immediately. The lead clinician may choose 
his own alternative treatment but we suggest, the lead clinician change to  the alternative 
therapy i.e. either steroids (Synacthen Depot or prednisolone) a fte r vigabatrin, or 
vigabatrin after steroids.
19. SUBSEQUENT FOLLOW UP
1. All enrolled infants should be seen at 3 monthly intervals as a minimum although 
we realise tha t many w ill be seen more often because of the ir clinical need. The 
lead clinician w ill be asked to  fill in a brief progress report form  to  send back to 
the tria l centre in Bath at each 3 monthly visit until the 12-14 month assessment.
2. Psychomotor development w ill also be assessed using a telephone questionnaire 
based on the "Vineland Adaptive Behaviour Scales" (see Section 26). This w ill 
be done by a trained researcher who w ill be based in Bath when the infant is 
between 12 and 14 months of age.
20. RECRUITMENT RATE
This is a national study and it is hoped to  recruit all new cases of infantile spasms in the 
United Kingdom occurring w ith in the study period. Papers dealing w ith the epidemiology 
of infantile spasms put the incidence between 1 in 2380 and 1 in 6250 births. The average 
UK birth rate is approximately 800,000 per year. Therefore, it should be possible to 
recruit between 130 and 340 new cases per year. Taking into account exclusions, 
recruitment should be completed w ith in 18 months.
We intend to  drive recruitment actively and have already sought to  recruit one paediatric 
neurologist from each old health region to  help promote the study. The tria l centre w ill 
take responsibility fo r ethics committee approval fo r each district in the UK and w ill 
recruit one paediatrician from each district to  help promote the study. We w ill provide 
coasters and Post-it notes printed w ith contact arrangements at the commencement of
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the  tria l. A newsletter will be sent out to  all recruiting clinicians and all promoters every 
tw o  months.
We w ili notify all EEG departments o f the tria l w ith  coasters, post-its and newsletters 
and ask them to remind clinicians of the trial whenever a request is made for an EEG in 
a child w ith possible infantile spasms, or whenever hypsarrhythmia is found.
21. COMPLIANCE
This is a serious disorder w ith profound sequelae. The motivation fo r clinicians and 
parents of patients to  participate in treatm ent is high. The clinical workload to  be 
imposed on attending physicians is little  more than constitutes good clinical practice. 
(The workload to  be imposed on parents is small.) The administrative work w ill be kept 
to  a minimum. We w ill not collect unessential data and the trial centre w ill be responsible 
fo r documentation and fo r submissions to  ethics committees.
22. LIKELY RATE OF LOSS TO FOLLOW UP
Loss to  fo llow-up should be small. Patients known to  be likely to  move outside the 
country during the tria l period w ill be excluded at entry. As this is a national study, 
movement w ith in  the UK should not lead to  loss o f contact. Patient's NHS number, 
general practitioner and a th ird party address (e.g. grandparents) w ill be recorded on 
entry to  the tria l thus making it easier to  keep track of patients who move.
23. POST RANDOMISATION STRATIFICATION
There w ill be post-randomisation stratification fo r potential confounding variables not 
accounted fo r in pre-randomisation. These include EEG appearance (i.e. hypsarrhythmia 
vs atypical vs normal awake, normal asleep) and diagnostic sub-groups (i.e. cerebral 
dysgenesis on cranial scanning, chromosomal abnormalities or other syndromes and 
other diagnosis such as metabolic disease).
Social factors w ill include birth order and maternal age at school leaving.
24. POST INVESTIGATION DIAGNOSTIC SUB GROUPS
It may be possible to  see if any trends in outcome are repeated w ith in  subgroups of the 
tria l population.
The largest subgroup should be infants where development was delayed (as shown by 
pre-randomisation stratification data and, separately, by development history).
Smaller subgroups, e.g. those diagnosed w ith  cerebral palsy on clinical examination, 
cerebral dysgenesis on cranial imaging, normal awake and asleep EEGs, are unlikely to 
be large enough fo r separate analysis. However, the data w ill be examined in case 
there is a dramatic difference in outcome, or a consistent trend.
25. PRIMARY OUTCOME MEASURE
The primary outcome measure w ill be the number o f patients who achieve complete 
cessation of spasms fo r at least 48 hours up to  and including the end of the 14th day of 
treatment.
2 6 .  S E C O N D A R Y  OUTCOM E M E A SU R E S
1. Time taken to  complete cessation o f all spasms fo r at least 48 hours.
2. Partial response i.e. those patients tha t have a reduction in the number of spasms 
during the tw o week period.
3. Relapse rates.
4. Other seizure types and frequency at 14 months, in those still having seizures.
5. Resolution of hypsarrhythmia at 14 days.
6. Developmental progress at 12 -14 months of age. This w ill allow at least 2 months 
o f recovery fo llo w in g  trea tm en t and is an age at which some language 
development has occurred. It is believed that delaying the assessment to  a greater 
age w ill give little  advantage and would have the disadvantage of increasing 
the impact of environmental factors.
The Vineland Adaptive Behaviour Scales have been developed and validated in the U.S.A. 
to measure "adaptive behaviour" defined as the performance of the daily activities 
required fo r personal and social sufficiency. It concentrates on the usual response, not 
the best response to  any task. It has been validated in greater detail on larger numbers 
of children (3000) and has been used in the U.K. fo r other developmental fo llow-up 
studies. It achieves construct validity, content validity and has been compared to other 
scales in both normal and handicapped children. It has been shown to  have internal 
consistency, test-retest and interrater reliability. It has been designed to minimise the 
influence of physical handicap.
The Vineland has four domains (communication, daily living skills, socialization and motor 
skills) and these combine to  give an Adaptive Behaviour Composite: each of these has a 
standard score of 100 w ith  a standard deviation of 15 and each can be expressed as an 
age equivalent (developmental age).
The Vineland scales can easily be adapted to  be performed as a parental questionnaire 
that can be administered over the phone.
27. ANALYSIS
Assuming recruitment o f 250 children over the 18 month period, w ith  approximately 
125 randomised to  vigabatrin and 125 to  "steroids" and, assuming approximately 50% 
will achieve cessation of seizures in the "steroid" group, the tria l w ill have 90% power 
to detect an improvement in cessation of seizures to  70% in the vigabatrin group.
We are aware tha t the pattern of developmental age in the tw o groups may be bimodal. 
A direct comparison o f the developmental age (total score and subsets) o f the tw o  
groups w ill be undertaken, but we w ill also determine the proportion of individuals in 
each group whose development is one, tw o  and three standard deviations below the 
mean fo r the Vineland.
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PATIENT’S  
D I A R Y
Name:
Address:
S tu d y  number:
Your co n su lta n t d o c to r ’s  team  can be conX^acX^ed 
by phoning 
and asking for
N O TE TO DOCTOR: P le a se  p h o to co p y  co m p leted  
p a g es  before p ostin g  and keep original for yourself. The 
original will be needed if th e  cop ies are lo s t  in th e  p o s t
In tr o d u c tio n  t o  t h e  P a t ie n t ’s  D iary
Thank you for agreeing to  take  p a r t in th e  UKISS s tu d y  which will help us find
o u t more about infantile spasm s. This diary will be a record o f  your child’s  spasm s
and o th er im portant information.
How to  use your diary — for the first 2 weeks
1. Please fill in your child's n a m e  and address  on  t h e  fron t  o f  this  diary. Please m ake  
sure th a t  your d o c to r  fills in t h e  s tudy n u m b er  and  h o w  t o  c o n ta c t  him or her.
2. Please fill in your child 's n a m e and s tu d y  n u m b er  on  EACH PAGE o f  this diary.
3. Please fill in p a g e s  D3 t o  D5 and  start p a g e  D6 a s  soon as you are g iven  t h e  diary, 
w h ich  m ust b e  b e fo r e  your child starts t r e a tm e n t .
4. During t h e  first t w o  w e e k s  o f  t r e a tm e n t  w e  n e e d  t o  k n o w  w h a t  h a p p e n s  t o  your  
child's spasms. Please fill in t h e  deta ils  a b o u t  t h e  n u m b er  o f  b a tch es  and th e  n u m ber  
o f  spasm s per batch as best  you  can. Please w rite  'none' if your child has n o  spasm s  
on a particular day. W e w a n t  to  f ind o u t  w h e n  t h e  spasm s stop . W e also w a n t  to  
k n o w  if t h e  spasm s c o m e  back.
5. W e are in terested  in s ide e f fec ts  or p rob lem s w ith  t h e  trea tm en t;  th in g s  such as 
vom it in g ,  rashes, or excessive  s leep in ess .
6. W e h ave  left  room  for  you  to  w r ite  deta ils  a b o u t  o th e r  illnesses th a t  your child may  
h ave  and a n yth in g  e lse  th a t  y ou  th ink  m ig h t  b e  im portant.  Please w rite  as m uch as 
you  like.
7. At t h e  en d  o f  t h e  first t w o  w e e k s  o f  t r e a tm e n t  y o u  will b e  s e e in g  your d o cto r  again .  
This sh ou ld  b e  as c lose  t o  14 days after  t h e  start o f  t r e a tm e n t  as possib le  - but n ot  
less th a n  14 d ays .  A t th is  visit, p le a s e  ask  y o u r  d o c t o r  t o  p h o t o c o p y  p a g e s  
D3f D4, D5, and  D6 o f  this  diary and  th e n  forw ard  th e m  t o  us.
8. R em em ber: it is im p o rta n t th a t  YOUR CHILD'S NAME AND STUDY NUMBER 
ARE ON EACH PAGE. Please check this n ow .
9. If y ou r  ch ild  h as o n ly  o n e  sp a sm  a t a t im e  and  never  has b a tch es  o f  spasms, 
p lease  ta k e  g rea t  care w h e n  filling in t h e  ta b le s  on  t h e  fo l lo w in g  p a g es .  Put th e  
nu m b er  o f  s in g le  spasm s occuring during o n e  day (m id n igh t  t o  m idn ight)  in th e  
co lu m n  h e a d e d  "number o f batches" and c h a n g e  t h e  w o rd  "batches" in this  
h e a d in g  t o  "spasms". The correct resp on se  t o  t h e  q u es t io n  "maximum (largest) 
number o f spasms in one batch this day" w o u ld  b e  "one".
Thank yo u  fo r  helping u s To g e t  th i s  in form ation
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Questionnaire for infantile spasms
Fiease fill o u t pages D3, D4 and D5 a s  soon a s  you can. This will give us useful 
information about your child’s  illness before th e  trea tm en t started . Your doctor  
will ask to  see  th is when h e /sh e  next se e s  you. If you do n o t understand any o f  
th e  questions then  ask  your doctor.
Y o u r  c h i ld 's  n a m e :
D a t e  o f  B ir th :  /  /  ( d a y / m o n t h / y e a r )
NHS n u m b e r  (if known).................. _....................... •............._........ ...........
P le a s e  g iv e  us  t h e  n a m e  a n d  a d d r e s s  o f  a f r i e n d ,  o r  s o m e o n e  in y o u r  fam ily ,  w h o  w o u l d  
b e  a b l e  t o  f o r w a r d  l e t t e r s  t o  y o u  if y o u  m o v e  h o u s e  o r  if w e  d o  n o t  k n o w  w h e r e  y o u  a r e .
N a m e :   „..... ............................. .................................................................
A d d r e s s :  .........................................................................................................................................................................
GENERAL DESCRIPTION OF SPASMS
1. Please tell us w h a t  h a p p e n s  w h e n  your child has a spasm  (please use your own words).
2. Do the spasms ever occur one at a time or do they occur in batches (ie several at one time)? 
(Please tick ( / )  o n e  o f  th e  fo llow ing) 
only  o n e  spasm  at a t im e  
only  in b a tch es  o f  spasm s
s o m e t im e s  o n e  spasm  at a t im e ,  and s o m e t im e s  b a tch es
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HOW OFTEN IS YOUR CHILD HAVING INFANTILE SPASMS?
A batch of spasms is when two or more spasms occur in a short space of time.
3. Number of BATCHES occurring in one day ...
On average, h o w  m any BATCHES occur in a period lasting from m idnight o n e  day to  
m idnight th e  fo llow in g  day? Please tick ( / )  b e lo w  for an a v era g e  day during th e  past 
w eek , or since t h e  spasms b egan  if this is less th an  7 days ago . (please tick (S) one)
5 or fewer IZ j 6 to 10I J 11 to 20 21 to 40 More than 4 0 __]
A gain , but fo r  th e  w o r s t  day, h o w  m any BATCHES occur in a period lasting from  
m id n ig h t  o n e  day t o  m id n ig h t  t h e  n ex t  day? Please tick ( / )  b e lo w  for  t h e  w o r s t  day  
(ie t h e  day w ith  t h e  m ost  batches) during th e  past w e e k ,  (please tick (S) one)
5 or fewer1 Zl 6 to 10 i 11 to 20 21 to 40 More than 40 }
Again, but for  th e  b est day, h o w  m any BATCHES occur in a period lasting from midnight  
o n e  day to  m idnight o f  th e  next day? Please tick ( / )  b e lo w  for th e  b e st  day (ie th e  day  
w ith  th e  smallest num ber o f  batches) during th e  past w eek . (If th e  spasms started less 
than  7 days ago , only include days after th e  spasms started.) (please tick (S) one)
5 or fewer 6 to l0  ] 11 to 2o\ 21to40 Morethan40' ’
4. Number of SPASMS occurring during any one batch
During th e  past w e e k  (or since t h e  spasm s started  if this  is less th an  7 days ago),  
h o w  m any spasm s occurred, on  a v era g e , during o n e  batch? (please tick ( /)  one)
5 or fewer 6 to 10 11 to 20 21 to 40 41 to 80 More than 80
During th e  past w e e k ,  w h a t  is t h e  MAXIMUM (la rg est)  n u m b er o f  sp a sm s th a t  
have  occurred during o n e  batch? (please tick (S) one)
5 or fewer [ 6 to 10 11 to 20 21 to 401 41 to 80 More than 80 □
During t h e  past w e e k  (or since t h e  spasm s s tarted  if th is  is less th a n  7 days ago) ,  w h a t  
is t h e  MINIMUM (sm a lle st)  n u m b er  o f  sp a sm s th a t  h ave  occurred during o n e  
batch? (please tick (S) one)
5 or fewer I I 6 to 10! I 11 to 20 \ 21 to 40 41 to 80 More than 80 !
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Child’s  Name: UKISS Study Number:
M ovem ents o f  th e  b o d y  during  an a ttack
5. T h e  s p a s m  invo lves  t h e  f o l lo w in g  m o v em e n ts  o f  parts o f  th e  body. (Please record the 
direction of the f a s t e s t  or strongest movement) (please tick (S) 'Yes' or 'No')
T h e  h ea d  m o v i n g  f o r w a r d s  
T h e  h ead  m o v i n g  b a c k w a r d s  
T h e  e y e s  m o v i n g  s i d e w a y s  
if Yes,
T h e  trunk ( b o d y )  m o v i n g  f o r w a r d s  
T h e  trunk ( b o d y )  m o v i n g  b a c k w a r d s  
T h e  arm s
if Yes, L ef t  a r m  o n ly  or r i g h t  a r m  o n ly  
T h e  a r m s  b e n d  in t o w a r d s  t h e  c h e s t  
T h e  a r m s  a r e  f l u n g  o u t ,  a w a y  f r o m  t h e  b o d y  
T h e  le g s
if Yes, L ef t  le g  o n ly  or r i g h t  le g  o n ly  
Leg(s) b e n d  a n d  a r e  b r o u g h t  u p  t o  t h e  b o d y  
Leg(s) s t r a i g h t e n  o u t ,  a w a y  f r o m  t h e  b o d y
Timing of spasms
6. D o  t h e  s p a s m s  o c c u r  a t  a n y  p a r t i c u l a r  t i m e ?
if Yes, (please tick (S) one or more) 
m o r n i n g  a f t e r n o o n  J
o t h e r  □  please specify:__________
Y e s : N o  □
Yes N o  □  
Yes N o  □  
To o n e  s id e  o n ly  L or t o  b o t h  s id e s  g
Yes □  N o  □  
Y es E ll  N o  □  
Yes □  N o  o  
or b o t h  a r m s  □  
Y e s '  _ i  N o  □  
Yes N o  
Yes N o  □  
or b o t h  l e g s  □  
Y es N o  □  
Yes □  N o  □
e v e n i n g □
Yes □  N o  
n i g h t - t i m e  □
H a v e  y o u  n o t i c e d  a n y t h i n g  t h a t  s e t s  t h e  s p a s m s  o f f ?  
if Yes Please specify: __________________
Yes [ J/VoLJ
a n d  d o e s  it  t r i g g e r  t h e  s p a s m  ...
a l w a y s  a: u s u a l ly  □  s o m e t i m e s  □ (please tick(S)one)
01367
Child’sN am e: UKISS S tu d y  Number:
INITIAL TREATMENT
Name of treatment:.....................................................................................................
Please use this page of your diary to keep a daily record of your child's spasms during 
the first two weeks of the study.
D ate  tr e a tm e n t  started : /  /  YOU MUST FILL IN THIS DATE
DAILY Number o f batches* in a day. 
(m idnight to  midnight)
Maximum (largest) number 
o f spasms in o n e  batch this day




















* (or number of single spasms if they do not occur in batches)
Please record in the table b e lo w  anything else that you think may be important for 
the doctors running the trial to know: for example, unusual reactions that may be caused







Please ask your doctor to photocopy pages D3 to D6 when they are completed and he/ 
she will post the photocopy to us.
CHECKED BY Dr.i ,_____ „_______       on: /  /
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How to use your diary — after the first two weeks o f the study
1. Please fill out the diary d aily  for a further two weeks.
2. For all children in the study, we will then need to keep a w e e k ly  record of progress 
until the time of the final study assessment at between 12 and 14 months of age.
3. Each time you visit your doctor, please let them see the diary. This will give you a 
chance to discuss it with them. Your doctor will send photocopies of the completed 
pages to us.
4. We will ask you to write down the number and type of fits for a week (7 days) after 
your child's first birthday. We want to know if your child continues to have spasms or 
develops any other form of fits.
I f  you would like to keep a copy o f this diary, please ask your doctor to provide
you with a photocopy. Helshe w ill keep the original at the end o f the study.
01367
Child’sName: UKISS Study Number:
SECOND TWO-WEEK PERIOD:
Name of treatment:....................................................................................................
Please use this page of the diary to keep a daily record of your child's spasms during the 
second two-week period of the study.______________________________________
D ate  2n d  tr e a tm e n t  started : /  /  YOU MUST FILL IN THIS DATE
if your child has started a second t rea tm en t
DAILY Number o f batches* in a day. 
(m idnight to  midnight)
Maximum (largest) number 
o f spasm s in on e  batch this day




















* (or number of single spasms if they do not occur in batches)
Please record in the table b e lo w  anything else that you think may be important for 
the doctors running the trial to know: for example, unusual reactions that may be caused 







Please ask your doctor to photocopy this page at the end of two weeks and he/she will 
post the photocopy to us.
CHECKED BY Dr.: on: / /
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Child’s  Name: UKISS S tu d y  Number:
GENERAL PROGRESS:
Once your child has finished the two (or four) weeks of treatment, please fill in the 
diary below once w eekly until they have their final study assessment at between 12 
and 14 months of age. Please record the number of batches during the worst day that 
week and the number of spasms in the longest batch during that week. As before, 
record in the second table any information that you think will be useful for the doctors 
conducting the study to know about____________ __________________________
WEEKLY Number o f batches* during th e worst 
day (m idnight to  midnight) o f this w eek
Maximum (largest) number 
















* (or number of single spasms if they do not occur in batches)
Please record in the table b e lo w  anything else that you think may be important for 
the doctors running the trial to know: for example, unusual reactions that may be caused 











Child’s  Name: UKISS S tu d y  Number:
GENERAL PROGRESS (continuation sheet)
If you have completed the table on page D9, please fill in the diary below once w eekly  
until your child has their final study assessment at between 12 and 14 months of age. 
Please record the number of batches during the worst day that week and the number 
of spasms in the longest batch during that week.
WEEKLY Number o f batches* during th e  worst 
day (m idnight to  midnight) o f  this w eek
Maximum (largest) number 


















* (or number of single spasms if they do not occur in batches)
Please record in the table be low  anything else that you think may be important for 
the doctors running the trial to know: for example, unusual reactions that may be caused 







Please ask your doctor to photocopy this page at the next visit and he/she will post the 
photocopy to us.
CHECKED BY Dr.: on: /  /
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01367
Child’s  Name: UKISS S tu d y  Number:
CONTINUING FITS
Please complete this page after your child's 1st birthday.
Please make a d a ily  en try  fo r  o n e  w e e k . Please fill in the types of fits that your child 
is having and the number they have each day. If they are having more than one type of 
fit, please record the number of each type that they are having. If you are not sure what 
type of fits your child is having you should ask your doctor.








or My child has not had any f it (epileptic seizure or spasm) during the past week. □
Signed:
Thank you very much for all your help.
If you have any questions about the stu dy please contact your 
consultant doctor’s  team by telephoning the number 
on the front of this diary.
The UKISS Trial Centre 
The Children's Centre
Royal United Hospital
